fluorouracil has been researched along with Cancer of Esophagus in 1848 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this phase II prospective study, we compared the efficacy and toxicity of DP (docetaxel and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens with concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcinoma (ESCC) and analyzed the 5-year overall survival (OS) and progression free survival (PFS)." | 9.69 | Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial. ( Chen, B; Hu, Y; Jiang, H; Li, Q; Makelike, K; Xi, M; Zhu, Y, 2023) |
| "This phase II trial aimed to assess the safety and efficacy of paclitaxel in combination with cisplatin and 5-fluorouracil (TPF) induction chemotherapy followed by surgery for locally advanced borderline-resectable esophageal squamous cell carcinoma (BR-ESCC)." | 9.51 | Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial. ( Fong, WP; Hu, M; Hu, Y; Li, Q; Li, Y; Ren, C; Tan, Q; Wang, D; Wang, Z; Wu, J; Yang, H, 2022) |
| "Transient receptor potential vanilloid 2 (TRPV2) was previously shown to play an important role in the maintenance of cancer stem cells, and its specific inhibitor, tranilast, also has potential as a targeted therapeutic agent for esophageal squamous cell carcinoma (ESCC)." | 9.34 | Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast in advanced esophageal squamous cell carcinoma: Phase I/II study (TNAC). ( Arita, T; Fujiwara, H; Ikoma, H; Konishi, H; Kosuga, T; Kubota, T; Kudou, M; Kuriu, Y; Morimura, R; Okamoto, K; Otsuji, E; Shimizu, H; Shiozaki, A; Yamamoto, Y, 2020) |
| "Apatinib mesylate combined with chemotherapy for the treatment of patients with gastroesophageal junction adenocarcinoma was safe and effective, with improved survival benefit compared with control." | 9.30 | Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. ( Chen, J; Hua, Z; Lu, B; Lu, C; Qu, C; Sun, Z; Tong, R; Zhang, J, 2019) |
| "This phase II trial evaluated the efficacy of cisplatin and fluorouracil (CF)-based combination neoadjuvant chemotherapy on the outcome of patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC)." | 9.24 | Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). ( Doki, Y; Fujitani, K; Hirao, M; Kimura, Y; Kobayashi, K; Makino, T; Miyata, H; Mori, M; Motoori, M; Satoh, T; Shiraishi, O; Tamura, S; Yamasaki, M; Yano, M; Yasuda, T, 2017) |
| "Based upon preclinical data showing synergy with mTOR inhibition and platinum chemotherapy, this study explores the safety and tolerability of combining everolimus with mFOLFOX6 for patients with metastatic gastroesophageal adenocarcinoma." | 9.22 | Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma. ( Chao, J; Chung, S; Chung, V; Fakih, MG; Frankel, P; Koehler, S; Lau, SC; Leong, L; Lim, D; Luevanos, E; Ruel, N; Yeon, C, 2016) |
| "A combination of cetuximab plus pemetrexed was marginally effective and well tolerated in patients with advanced esophageal squamous cell carcinoma as the second-line treatment." | 9.20 | Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. ( Han, Y; Shang, M; Shi, SB; Tian, J; Xu, J, 2015) |
| "This phase II trial aimed to evaluate the efficacy and safety of docetaxel, cisplatin, and fluorouracil (DCF) combination in neoadjuvant setting in patients with locally advanced gastric adenocarcinoma." | 9.19 | Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. ( Abali, H; Bostanci, B; Civelek, B; Oguz, D; Oksuzoglu, B; Ozdemir, N; Vural, M; Yalcin, B; Yalcin, S; Zengin, N, 2014) |
| " We evaluated the safety, tolerability, and efficacy of the combination capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas." | 9.17 | A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. ( Altomare, I; Arrowood, CC; Bendell, JC; Blobe, GC; Brady, JC; Conkling, P; Cushman, SM; Favaro, J; Hsu, SD; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Uronis, HE; Zafar, SY, 2013) |
| "We performed a phase II trial of docetaxel in combination with capecitabine to evaluate the antitumor response, toxicity, and survival in pre-treated patients with advanced esophageal squamous cell carcinoma." | 9.17 | Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma. ( Li, X; Lin, S; Lin, W; Lin, Y; Wang, H, 2013) |
| "To evaluate the safety and tolerability of two different weekly doses of the fully humanized epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab combined with high-dose 5-fluorouracil, leucovorin and cisplatin (PLF) in the first-line treatment of patients with EGFR-positive advanced gastric and esophagogastric adenocarcinomas." | 9.17 | Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. ( Heeger, S; Lüpfert, C; Przyborek, M; Schleucher, N; Trarbach, T; Vanhoefer, U, 2013) |
| "This randomized clinical study was to assess and compare the efficacy and safety of two chemoradiotherapy (cisplatin + 5-fluorouracil + radiotherapy and cisplatin + docetaxel + radiotherapy) regimens in patients with unresectable local advanced oesophageal squamous cell carcinoma." | 9.16 | Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. ( Chen, H; Zhang, T; Zhao, T, 2012) |
| "This prospective multicentre phase II trial assessed the feasibility and efficacy of perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in patients with gastro-oesophageal adenocarcinoma." | 9.16 | Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. ( Arnold, D; Bichev, D; Breithaupt, K; Daum, S; Florschütz, A; Gahn, B; Glanemann, M; Hofheinz, RD; Kneba, M; Kretzschmar, A; Mantovani-Löffler, L; Reichardt, P; Schlattmann, P; Schumacher, G; Thuss-Patience, PC, 2012) |
| "To compare the efficacy and feasibility of neoadjuvant chemoradiotherapy with docetaxel plus cisplatin or with cisplatin plus fluorouracil in the treatment of local advanced esophageal squamous cell carcinoma." | 9.16 | [Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma]. ( Chen, MY; Chen, Z; Luo, JC; Wei, L; Wu, S, 2012) |
| "Previously untreated patients with metastatic gastroesophageal adenocarcinoma received bevacizumab 10 mg/kg, docetaxel 40 mg/m², fluorouracil 400 mg/m², leucovorin 400 mg/m² on day 1, fluorouracil 1,000 mg/m²/d × 2 days intravenous continuous infusion beginning on day 1, and cisplatin 40 mg/m² on day 3." | 9.15 | Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. ( Capanu, M; Ilson, DH; Jhawer, M; Kelsen, DP; Lefkowitz, RA; Robinson, E; Shah, MA, 2011) |
| "Patients with clinically staged II or III esophageal adenocarcinoma received oxaliplatin 85 mg/m(2) on days 1, 15, and 29; protracted-infusion fluorouracil (PI-FU) 180 mg/m(2)/d on days 8 through 43; and external-beam radiation therapy (EBRT) 5 days a week at 1." | 9.15 | S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. ( Benedetti, JK; Billingsley, KG; Blanke, CD; Bohanes, PO; Corless, CL; Danenberg, KD; Gold, PJ; Goldman, BH; Iqbal, S; Leichman, LP; Lenz, HJ; Thomas, CR, 2011) |
| "We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia." | 9.14 | A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. ( Drew, PA; Jamieson, GG; Liu, JF; Wu, TC; Zhu, GJ, 2009) |
| "Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile." | 9.14 | Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. ( Ajani, JA; Bodoky, G; Falcon, S; Garin, A; Gorbunova, V; Lang, I; Lichinitser, M; Moiseyenko, V; Rodriguez, W; Vynnychenko, I, 2010) |
| "The regimen of docetaxel and capecitabine is a well-tolerated, easily administered and active outpatient regimen for advanced gastric and GE adenocarcinoma." | 9.14 | A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. ( Hantel, A; Hwang, J; Javle, M; Khorana, AA; Kiefer, G; Lo, SS; Rajasenan, K; Ramanathan, RK; Schmotzer, A; Shayne, M; Simon, S; Wang, H, 2010) |
| "Patients with histologically confirmed metastatic or locally advanced adenocarcinoma of the stomach or gastroesophageal junction received docetaxel 25 mg/m2 and oxaliplatin 50 mg/m2 on days 1 and 8 with capecitabine 625 mg/m2 twice daily from day 1-14, in 21-day cycles." | 9.14 | Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. ( Aggarwal, S; Goel, G; Jauhri, M; Negi, A, 2010) |
| "We aimed to establish the superiority (or noninferiority if superiority was not achieved) in terms of time to progression (TTP) of irinotecan/5-fluorouracil (IF) over cisplatin/5-fluorouracil (CF) in chemonaive patients with adenocarcinoma of the stomach/esophagogastric junction." | 9.13 | Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. ( Barone, C; Bugat, R; Cisar, L; Dank, M; Goker, E; Peschel, C; Valvere, V; Wang, K; Wenczl, M; Yalcin, S; Zaluski, J, 2008) |
| "Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil 2600 mg/m(2) as a 24-h infusion in combination with docetaxel 50 mg/m(2) (FLOT) on day 1 every 2 weeks." | 9.13 | Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Clemens, MR; Fritz, M; Hartmann, JT; Hofheinz, R; Homann, N; Jäger, E; Mahlberg, R; Pauligk, C; Probst, S; Rethwisch, V; Seipelt, G; Sievert, M; Stoehlmacher, J, 2008) |
| "Patients with previously untreated advanced adenocarcinoma of the stomach or esophagogastric junction were randomly assigned to receive either fluorouracil 2,600 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2), and oxaliplatin 85 mg/m(2) (FLO) every 2 weeks or fluorouracil 2,000 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2) weekly, and cisplatin 50 mg/m(2) every 2 weeks (FLP)." | 9.13 | Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Bokemeyer, C; Derigs, HG; Grossmann, J; Hartmann, JT; Hegewisch-Becker, S; Hofheinz, R; Hollerbach, S; Homann, N; Jäger, E; Knuth, A; Pauligk, C; Probst, S; Rethwisch, V; Schmalenberg, H; Schuch, G; Seipelt, G; Stoehlmacher, J; Wilhelm, G, 2008) |
| "Oxaliplatin and capecitabine in combination demonstrates activity in metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia." | 9.12 | Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Fitch, TR; Foster, NR; Jatoi, A; Knost, JA; Murphy, BR; Nikcevich, DA; Rowland, KM, 2006) |
| "Previous studies suggest that the combination of docetaxel and capecitabine are worthy of further testing in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction." | 9.12 | Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK, 2006) |
| "We investigated 2-weekly intravenous irinotecan combined with oral capecitabine in patients with advanced gastroesophageal adenocarcinoma." | 9.12 | A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. ( Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C, 2006) |
| "The aim of this study was to evaluate the activity and safety of 5-fluorouracil (5-FU)/leucovorin (LV) and irinotecan as first- or second-line treatment in patients with advanced gastric adenocarcinoma." | 9.12 | Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma. ( Chrysanthopoulos, C; Gerolymos, MK; Iconomou, G; Kalofonos, HP; Kontogeorgou, E; Koutras, AK; Makatsoris, T; Tsiata, E; Vourli, G, 2007) |
| "In this phase II randomized study, untreated patients with confirmed advanced gastric or gastroesophageal adenocarcinoma received either DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2 on day 1, and fluorouracil 750 mg/m2/d as continuous infusion on days 1 to 5) or DC (docetaxel 85 mg/m2 and cisplatin 75 mg/m2 on day 1) every 3 weeks." | 9.11 | Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. ( Ajani, JA; Assadourian, S; Cabral Filho, S; Chao, Y; Fodor, MB; Majlis, A; Moiseyenko, VM; Tjulandin, SA; Van Cutsem, E, 2005) |
| "The purpose of this study was to evaluate the dose-limiting toxicity (DLT) and maximum tolerated dose of capecitabine when used in combination with epirubicin and cisplatin (ECC) in patients with oesophageal or gastric adenocarcinoma." | 9.10 | A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ( Blackie, R; Evans, TR; Fullarton, GM; McDonald, AC; McInnes, A; Morrison, R; Paul, J; Pentheroudakis, G; Raby, N; Soukop, M, 2002) |
| "The present study was conducted to evaluate the effect of allopurinol spray on stomatitis induced by chemotherapy for esophageal cancer." | 9.10 | [The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs]. ( Fujii, E; Hanawa, T; Ito, A, 2002) |
| "To reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in patients with advanced gastro-oesophageal adenocarcinoma." | 9.09 | Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma. ( Dunlop, DJ; Eatock, MM; Lim, KC; Pentheroudakis, G; Soukop, M, 2001) |
| "The primary purpose of this study was to explore the short-term efficacy of different cisplatin and fluorouracil-based chemotherapy regimens in the treatment of patients with esophagogastric junctional adenocarcinoma (EGJA) using a network meta-analysis (NMA)." | 8.95 | A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma. ( Hu, JH; Song, DJ; Wang, C; Xie, SP; Xu, ZL, 2017) |
| "Docetaxel + cisplatin + 5-fluorouracil (DCF) therapy, a frequently prescribed regimen for esophageal cancer, is associated with a high risk of febrile neutropenia (FN)." | 8.31 | Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy. ( Kawasaki, K; Nara, K; Sato, Y; Seto, Y; Suzuki, H; Takada, T; Toriumi, T; Yagi, K; Yamamoto, T, 2023) |
| "In Japan, standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) includes preoperative chemotherapy with fluorouracil plus cisplatin followed by esophagectomy." | 8.12 | Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy. ( Demachi, K; Fujita, T; Fujiwara, H; Kojima, T; Kotani, D; Okunaka, M; Sakashita, S; Yoshino, T, 2022) |
| " The current study aimed to retrospectively investigate neoadjuvant radiotherapy with cisplatin and 5-fluorouracil (CF-RT) and radiotherapy with docetaxel and CF (DCF-RT) and compare their treatment outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC)." | 8.12 | Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma. ( Arigami, T; Kurahara, H; Matsushita, D; Mori, S; Nakajo, A; Noda, M; Ohtsuka, T; Sasaki, K; Shimonosono, M; Tsuruda, Y; Uchikado, Y, 2022) |
| "Salvage concurrent chemoradiotherapy (60 Gy in 30 fractions) with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy was an effective and safe treatment for locoregional recurrence after curative resection of esophageal squamous cell carcinoma, especially in those approaching a complete response." | 8.12 | Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma. ( Akimoto, T; Daiko, H; Fujita, T; Fujiwara, H; Hojo, H; Ito, R; Kojima, T; Nakamura, N; Nakamura, Y; Sunakawa, H; Yano, T; Yoshino, T, 2022) |
| "The inclusion criteria were as follows: (1) oesophageal squamous cell carcinoma, (2) a schedule to receive three courses of induction chemotherapy (docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, 5-fluorouracil 750 mg/m2 days 1-5, every 3 weeks), (3) stage IB-III, (4) 20-75 years old, (5) 0-1 performance status, (6) preserved organ functions and (7) written informed consent." | 8.02 | A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. ( Ando, T; Fujii, H; Hamamoto, Y; Hara, H; Hosokawa, A; Ishikawa, H; Katada, C; Koizumi, W; Kojima, T; Muto, M; Nakajima, TE; Sakamoto, Y; Sugawara, M; Tahara, M; Watanabe, A, 2021) |
| "This study documents the clinical efficacy and toxicity of S-1 and paclitaxel (S1/PTX) in patients with unresectable or postoperative recurrent esophageal squamous cell carcinoma (ESCC) who had been previously treated with fluorouracil (5FU), cisplatin, and docetaxel." | 7.88 | A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy. ( Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y, 2018) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic agent used to treat a variety of gastric cancers including oesophageal squamous cell carcinoma (OSCC), for which the 5-year mortality rate exceeds 85%." | 7.88 | Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB, 2018) |
| "5-Fluorouracil (5-FU) is used for the clinical treatment of esophageal squamous cell carcinomas (ESCCs), yet it also induces chemoresistant cancer cells during treatment, which leads to the failure of the therapy." | 7.85 | A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics. ( Chen, Z; Ge, J; Jiang, H; Li, X; Ma, Q; Shi, Y; Wang, J; Wang, M; Wang, Z; Zhang, C, 2017) |
| "Previous Japanese trials of the docetaxel, cisplatin, and 5-fluorouracil regimen for oesophageal cancer have demonstrated that a large proportion of patients also develop grade IV neutropenia." | 7.85 | Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen. ( Miwa, Y; Naito, M; Shimamoto, C; Yamamoto, T, 2017) |
| " This study was aimed to compare the differences in pathologic response and survival between docetaxel/cisplatin and fluorouracil/cisplatin as neoadjuvant CRT in locally advanced esophageal squamous cell carcinoma (SCC)." | 7.85 | Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. ( Fu, JH; Li, Y; Liu, MZ; Liu, SL; Xi, M; Yang, YD; Zhang, L; Zhang, P, 2017) |
| "The anticancer efficacy of docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy has been reported to be better than that of conventional regimens for advanced or relapsed esophageal squamous cell carcinoma (ESCC), and may become a standard therapy for this disease." | 7.85 | Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. ( Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y, 2017) |
| "Docetaxel, cisplatin and fluorouracil (DCF) is a candidate neoadjuvant chemotherapy (NAC) regimen for esophageal squamous cell carcinoma (ESCC)." | 7.85 | The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. ( Baba, H; Baba, Y; Hiyoshi, Y; Kurashige, J; Sakamoto, Y; Watanabe, M; Yoshida, N, 2017) |
| "To retrospectively evaluate the efficacy and toxicity of definitive concurrent chemoradiotherapy (dCRT) with cisplatinum/paclitaxel versus cisplatinum/5-fluorouracil in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who received nonsurgical treatment." | 7.83 | Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients. ( Guo, J; Han, X; Hu, G; Liu, L; Tang, N; Wang, Y; Wang, Z; Zhang, Q, 2016) |
| "Two estrogen receptor (ER)-positive esophageal adenocarcinoma cell lines (OE-19 and OE-33) were treated with combinations of tamoxifen, cisplatin and 5-fluorouracil (5-FU)." | 7.83 | Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells. ( Astill, DS; Bastian, I; Ding, GQ; Due, SL; Hussey, DJ; Sukocheva, OA; Vat, L; Watson, DI, 2016) |
| "To investigate the effects of nimotuzumab (h-R3) with cisplatin (DDP) or fluorouracil (5-FU) on human esophageal squamous cell carcinoma (ESCC) EC1 cells." | 7.81 | Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells. ( Huo, XQ; Ji, YH; Li, GJ; Li, WW; Lu, P; Mu, YL; Wu, JQ; Yang, XY, 2015) |
| "Definitive chemoradiotherapy (CRT) with 5-fluorouracil (5-FU) and cisplatin (CDDP) is one of the standard therapies for esophageal squamous cell carcinoma (ESCC); however, inter-individual variations in clinical outcomes have yet to be investigated." | 7.80 | Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Azuma, T; Hirai, M; Kuwahara, A; Miki, I; Minegaki, T; Nakamura, T; Nishiguchi, K; Okuno, T; Omatsu, H; Sakaeda, T; Tamura, T; Yamamori, M, 2014) |
| " In this study, 49 Japanese patients with esophageal squamous cell carcinoma (ESCC) were followed up for 5 years after treatment with a definitive 5-fluorouracil (5-FU)/cisplatin (CDDP)-based chemoradiotherapy (CRT), and the effects of genotypes of vascular endothelial growth factor (VEGF) were retrospectively revaluated in terms of prediction of long-term survival." | 7.78 | VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Kuwahara, A; Manabe, Y; Miki, I; Nakamura, T; Nishiguchi, K; Okuno, T; Sakaeda, T; Tamura, T; Yamamori, M, 2012) |
| "The aim of this retrospective study was to evaluate the efficacy and safety of weekly high-dose 5-fluorouracil (5-FU)/folinic acid (FA) as 24-h infusion (AIO regimen) plus irinotecan in patients with histologically proven metastatic gastroesophageal adenocarcinoma (UICC stage IV)." | 7.77 | Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b ( Albrecht, H; Boxberger, F; Busse, D; Golcher, H; Hahn, EG; Hohenberger, W; Janka, R; Konturek, PC; Koucky, K; Männlein, G; Neurath, MF; Ostermeier, N; Reulbach, U; Schildberg, C; Siebler, J; Wein, A; Wolff, K, 2011) |
| "We report an elderly patient with esophageal adenocarcinoma in whom a complete response (CR) was obtained by chemoradiotherapy using daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU." | 7.75 | [A case of elderly esophageal adenocarcinoma successfully treated with daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation]. ( Furuta, T; Futami, H; Hamaya, Y; Ikuma, M; Iwaizumi, M; Kodaira, C; Muramatsu, A; Nishino, M; Osawa, S; Sugimoto, K; Takagaki, K; Yamada, T; Yoshida, K, 2009) |
| "A 72-year-old patient with esophageal carcinoma developed a severe hand-foot syndrome during second-line therapy with the oral fluoropyrimidine capecitabine." | 7.74 | [Hand-foot syndrome with capecitabine therapy]. ( Hengge, UR; Marini, A, 2007) |
| "Hyperammonemia or hyperammonemic leukoencephalopathy sometimes occurs as an adverse event after 5-fluorouracil (5-FU) chemotherapy." | 7.74 | The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases. ( Asakage, T; Kikuta, S; Kubota, A; Nakao, K; Sugasawa, M, 2008) |
| "5-Fluorouracil (5-FU) is a key drug in the treatment of esophageal squamous cell carcinoma (ESCC)." | 7.74 | Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines. ( Ando, T; Fujii, Y; Ishiguro, H; Katada, T; Kimura, M; Kuwabara, Y; Mitsui, A; Mori, R; Ogawa, R; Sugito, N, 2008) |
| "We reported two cases of retroperitoneal hematoma in patients who received a combination of anticoagulant therapy and 5-fluorouracil (5-FU)." | 7.73 | Two cases of retroperitoneal hematoma caused by combination of anticoagulant therapy and 5-fluorouracil. ( Furutani, K; Furutani, S; Kashihara, K; Minato, M; Morita, N; Murase, T; Nishitani, H; Otsuka, H; Tagashira, H; Tsujikawa, T; Yoneda, K, 2005) |
| "Retrospectively, we analysed 23 consecutive patients who were treated with epirubicin, cisplatin and oral capecitabine for inoperable or metastatic oesophagogastric adenocarcinoma during 2002 and 2003." | 7.73 | Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma. ( Boot, H; Corporaal, S; Legdeur, MC; Russel, MG; Smit, WM; van der Palen, J, 2006) |
| " We report two cases of NM from breast carcinoma and a third with esophageal carcinoma, which responded to treatment with capecitabine, an oral prodrug for 5-flurouracil." | 7.72 | Response of neoplastic meningitis from solid tumors to oral capecitabine. ( Giglio, P; Groves, MD; Tremont-Lukats, IW, 2003) |
| "We report a case of double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin." | 7.69 | [A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin]. ( Akiyama, S; Hibi, K; Ito, K; Kasai, Y; Kondo, K; Nonami, T; Takagi, H, 1995) |
| "We reviewed our results with chemotherapy for adenocarcinoma of the esophagus or gastroesophageal junction tumors in patients treated with 5-fluorouracil, Adriamycin, and mitomycin C (FAM) regimen as developed by MacDonald and colleagues for adenocarcinoma of the stomach." | 7.69 | 5-Fluorouracil, adriamycin, and mitomycin C in adenocarcinoma of the esophagus or gastroesophageal junction tumors. ( Allred, C; Khansur, T; Tavassoli, M, 1994) |
| "After a loading dose of 4 x 90 mg folinic acid orally, a continuous infusion of 5-fluorouracil 500 mg/sqm/day for 5 days with concommitant folinic acid 6 x 60 mg/day orally, was administered to 29 consecutive patients with metastatic adenocarcinoma of the esophagus or esophagogastric junction area." | 7.69 | 5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. ( Kok, TC; Splinter, TA; van der Gaast, A, 1996) |
| "We have evaluated the effect of 5-fluorouracil 600 mg/m2, doxorubicin ('Adriamycin') 40 mg/m2, and Mitomycin-C 4 mg/m2 (FAM) in two groups of patients with adenocarcinoma of the oesophagus, as either a preoperative or primary treatment." | 7.68 | A phase II study of 5-fluorouracil, adriamycin and mitomycin-C in adenocarcinoma of the oesophagus. ( Allen, SM; Cullen, MH; Matthews, HR; Steel, A; Walker, SJ, 1991) |
| "Fifteen patients with potentially resectable adenocarcinoma of the esophagus were treated with two cycles of preoperative chemotherapy with 5-fluorouracil (5-FU) and cisplatin (DDP)." | 7.68 | A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus. ( Bromberg, C; Carey, RW; Choi, NC; Grillo, HC; Hilgenberg, AD; Logan, DL; Mathisen, DJ; Wain, JC, 1991) |
| "Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy." | 6.94 | Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. ( Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D, 2020) |
| "Febrile neutropenia was observed in 20 (21." | 6.90 | Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil. ( Ohkura, Y; Udagawa, H; Ueno, M, 2019) |
| "Paclitaxel is an active agent against oesophageal cancer and it has been proved as a potent radiation sensitiser." | 6.87 | Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2). ( Ai, D; Badakhshi, H; Cao, J; Chen, Y; Deng, J; Fan, J; Fan, M; Huang, G; Li, J; Li, L; Li, Y; Lin, Q; Liu, Q; Luo, H; Ren, W; Wei, S; Wu, K; Yang, H; Ye, J; Zhang, J; Zhao, K; Zhao, W; Zheng, X; Zhou, J; Zhu, H; Zhu, Z, 2018) |
| "4%) and renal adverse events (all grades: CS, 18." | 6.78 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013) |
| " Toxic effects were graded according to NCI-CTC version 3." | 6.78 | The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. ( Abdel-Latif, RM; Anter, AH, 2013) |
| "Hyperammonemia is a rare adverse event of 5-FU." | 6.66 | [Hyperammonemia with Disturbance of Consciousness during 5-FU plus Nedaplatin Therapy for Esophageal Cancer-A Case Report]. ( Hirakawa, T; Hirata, K; Iwauchi, T; Kurihara, S; Matsutani, S; Miyamoto, H; Morimoto, J; Nagashima, D; Okada, T; Takeuchi, K; Tanaka, H; Tsujio, G; Uchima, Y; Yamagata, S, 2020) |
| "Forty-six patients with cT4b esophageal cancer, including borderline cT4b lesions, were eligible." | 5.72 | Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil. ( Ihara, K; Kikuchi, M; Kojima, K; Kubo, T; Morita, S; Muroi, H; Nakagawa, M; Nakajima, M; Nakamura, T; Takise, S; Yamaguchi, S, 2022) |
| "Data from OGSG1003, a randomized phase-II trial comparing two regimens of neoadjuvant chemotherapy, cisplatin and fluorouracil plus Adriamycin and cisplatin and fluorouracil plus docetaxel, for locally advanced esophageal squamous cell carcinoma were used." | 5.69 | The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003. ( Aoyama, S; Doki, Y; Fujitani, K; Hamakawa, T; Hirao, M; Kimura, Y; Makino, T; Miyata, H; Motoori, M; Shiraishi, O; Sugimura, K; Takeno, A; Tanaka, K; Yamasaki, M; Yamashita, K; Yano, M; Yasuda, T, 2023) |
| " In this phase II prospective study, we compared the efficacy and toxicity of DP (docetaxel and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens with concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcinoma (ESCC) and analyzed the 5-year overall survival (OS) and progression free survival (PFS)." | 5.69 | Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial. ( Chen, B; Hu, Y; Jiang, H; Li, Q; Makelike, K; Xi, M; Zhu, Y, 2023) |
| "Severe neutropenia is dose-limiting toxicity of docetaxel and it is well known to be frequently occurred during DCF chemotherapy." | 5.56 | ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. ( Daiko, H; Demachi, K; Fujii, S; Itoh, K; Kawasaki, T; Kojima, T; Matsuzawa, H; Mochizuki, N; Nomura, H; Tsuji, D; Yano, T, 2020) |
| "Trifluridine/tipiracil monotherapy is feasible and shows modest activity in patients with refractory esophageal squamous cell carcinoma." | 5.51 | Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study. ( Hara, H; Hironaka, S; Horimatsu, T; Ishihara, R; Kasai, H; Kato, K; Kawaguchi, A; Kikuchi, O; Kojima, T; Mori, Y; Mukai, K; Muto, M; Tada, H; Tsushima, T; Uozumi, R, 2022) |
| "Fluorouracil (FU), platinum (PT), and taxane (TAX) therapy was the standard chemotherapy for esophageal squamous cell carcinoma (ESCC) before the era of anti-programmed death-1 antibodies." | 5.51 | A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404). ( Hirota, M; Kawada, J; Kawakami, H; Kii, T; Kurokawa, Y; Matsuyama, J; Nomura, M; Ohta, T; Sakai, D; Satoh, T; Shimokawa, T; Tsujinaka, T, 2022) |
| "The perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin plus docetaxel (FLOT) was recommended by the Chinese Society of Clinical Oncology Guidelines for gastric cancer (2018 edition) for patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (class IIA)." | 5.51 | Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma. ( Jia, SJ; Liu, Q; Song, LY; Wang, C; Zeng, H; Zeng, X, 2022) |
| "This phase II trial aimed to assess the safety and efficacy of paclitaxel in combination with cisplatin and 5-fluorouracil (TPF) induction chemotherapy followed by surgery for locally advanced borderline-resectable esophageal squamous cell carcinoma (BR-ESCC)." | 5.51 | Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial. ( Fong, WP; Hu, M; Hu, Y; Li, Q; Li, Y; Ren, C; Tan, Q; Wang, D; Wang, Z; Wu, J; Yang, H, 2022) |
| "Oesophageal squamous cell carcinoma (ESCC) is the sixth most common cause of cancer-associated death in the world and novel therapeutic alternatives are urgently warranted." | 5.43 | Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway. ( Bai, L; Chen, DL; Chen, LZ; Ju, HQ; Lu, YX; Mo, HY; Sheng, H; Wang, DS; Wang, F; Wu, QN; Xie, D; Xu, RH; Yu, HE; Yun, JP; Zeng, ZL, 2016) |
| " Oxaliplatin in combination with intravenous 5-FU plus leucovorin (LV; modified [m]FOLFOX6) or capecitabine (XELOX) improves tolerability compared with 5-FU/cisplatin regimen." | 5.42 | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. ( André, T; Bachet, JB; Chibaudel, B; Cohen, R; de Gramont, A; Hentic, O; Louvet, C; Samalin, E; Soularue, É; Tournigand, C; Zaanan, A, 2015) |
| "A 78-year-old man with Stage III esophageal cancer was referred to our hospital." | 5.42 | [A Case of Severe Bradycardia Induced by Combination Chemotherapy with Cisplatin and 5-Fluorouracil]. ( Kawamori, H; Kusunoki, N; Nakajima, T; Ohno, M; Takase, S; Yamazaki, Y, 2015) |
| "Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2) tyrosine kinase domains." | 5.39 | Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models. ( Bachman, KE; Fei, M; Greshock, J; Hou, W; Liu, L; Liu, P; Moon, H; Qin, X; Wang, H; Ye, BC; Zang, CY; Zhang, P; Zhu, X, 2013) |
| "Histological examinations revealed squamous cell carcinoma." | 5.37 | [A case of advanced esophageal cancer with multiple liver metastases accompanying poorly general conditions and serious liver dysfunctions, successfully treated using concurrent radiotherapy and chemotherapy with low-dose nedaplatin and 5-fluorouracil]. ( Fukui, T; Itoh, Y; Kawada, S; Takeda, H; Yoshioka, T, 2011) |
| "The most commonly used schedules are 5-FU in combination with CDDP with or without epirubicin (ECF) or docetaxel (TCF) in treatment of MGA patients (pts), independently of HER status." | 5.37 | Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. ( Abbas, F; Adenis, A; Afchain, P; Aparicio, T; Bécouarn, Y; Bouché, O; Desseigne, F; Dorval, E; Edeline, J; Guimbaud, R; Kramar, A; Mitry, E; Romano, O; Samalin, E; Thézenas, S; Ychou, M, 2011) |
| "In Japan, esophagectomy after two courses of 5-fluorouracil plus cisplatin is regarded a standard strategy for treating stage II or III esophageal squamous cell carcinoma (ESCC)." | 5.34 | An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus. ( Hattori, N; Hayashi, M; Iwata, N; Kanda, M; Kodera, Y; Koike, M; Nakayama, G; Omae, K; Shimizu, D; Tanaka, C; Yamada, S, 2020) |
| "Transient receptor potential vanilloid 2 (TRPV2) was previously shown to play an important role in the maintenance of cancer stem cells, and its specific inhibitor, tranilast, also has potential as a targeted therapeutic agent for esophageal squamous cell carcinoma (ESCC)." | 5.34 | Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast in advanced esophageal squamous cell carcinoma: Phase I/II study (TNAC). ( Arita, T; Fujiwara, H; Ikoma, H; Konishi, H; Kosuga, T; Kubota, T; Kudou, M; Kuriu, Y; Morimura, R; Okamoto, K; Otsuji, E; Shimizu, H; Shiozaki, A; Yamamoto, Y, 2020) |
| "Under the diagnosis of multiple lung metastases, the patient was hospitalized and received intensive chemotherapy with docetaxel 40 mg/week (day 1), 5-fluorouracil 500 mg/day (days 1-5), cisplatin 10 mg/day (days 1-5)." | 5.33 | A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy. ( Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T, 2006) |
| "Type 1 undifferentiated carcinoma (non-small cell type) was detected in the middle of the thoracic esophagus in August 1999." | 5.32 | [Complete remission of esophageal undifferentiated carcinoma with nedaplatin and 5-FU chemotherapy and endoesophageal brachytherapy]. ( Iwashige, M; Kikuchi, H; Kumada, K; Midorikawa, T; Nagasaki, H; Nemoto, H; Sanada, Y; Takeuchi, S; Takizawa, K; Tate, G; Yagi, H; Yoshizawa, Y, 2003) |
| "Apatinib mesylate combined with chemotherapy for the treatment of patients with gastroesophageal junction adenocarcinoma was safe and effective, with improved survival benefit compared with control." | 5.30 | Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. ( Chen, J; Hua, Z; Lu, B; Lu, C; Qu, C; Sun, Z; Tong, R; Zhang, J, 2019) |
| "5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens." | 5.30 | Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. ( Ahmad, M; Aziz, SA; Iqbal, K; Jalal, S; Mohi-ud-Din, K; Tramboo, NA, 1998) |
| "Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2." | 5.28 | Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. ( Coia, LR; Engstrom, PF; Hanks, GE; Paul, AR; Stafford, PM, 1991) |
| "Of the 31 patients with stomach cancer who were evaluable for response and had had no previous chemotherapy, 12 (39%) achieved complete or partial remission." | 5.26 | Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas. ( Bennetts, RW; Heifetz, LJ; Jones, RD; Karlin, DA; Mahal, PS; Stroehlein, JR, 1982) |
| "Patients with untreated metastatic adenocarcinoma of the stomach, gastroesophageal junction, or distal esophagus received mFOLFOX6 (leucovorin 400 mg/m, fluorouracil 400 mg/m bolus and 2400 mg/m continuous infusion over 46 h, oxaliplatin 85 mg/m) and bevacizumab (10 mg/kg) every 2 weeks until disease progression or intolerance." | 5.24 | Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma. ( Deng, Y; Doddamane, I; Fischbach, NA; Hochster, HS; Karimeddini, D; Kortmansky, JS; Lacy, J; Li, J; Stein, S; Yao, X; Zhang, Y, 2017) |
| "This phase II trial evaluated the efficacy of cisplatin and fluorouracil (CF)-based combination neoadjuvant chemotherapy on the outcome of patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC)." | 5.24 | Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). ( Doki, Y; Fujitani, K; Hirao, M; Kimura, Y; Kobayashi, K; Makino, T; Miyata, H; Mori, M; Motoori, M; Satoh, T; Shiraishi, O; Tamura, S; Yamasaki, M; Yano, M; Yasuda, T, 2017) |
| "Based upon preclinical data showing synergy with mTOR inhibition and platinum chemotherapy, this study explores the safety and tolerability of combining everolimus with mFOLFOX6 for patients with metastatic gastroesophageal adenocarcinoma." | 5.22 | Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma. ( Chao, J; Chung, S; Chung, V; Fakih, MG; Frankel, P; Koehler, S; Lau, SC; Leong, L; Lim, D; Luevanos, E; Ruel, N; Yeon, C, 2016) |
| "Docetaxel is active in esophagogastric junction (EGJ) adenocarcinoma, and DCF (docetaxel/cisplatin/5-fluorouracil) has shown good results in the neoadjuvant setting." | 5.22 | A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma. ( Al-Fakeeh, A; Al-Ruzug, I; Alcindor, T; Doerksen, T; Ferri, L; Mulla, N; Santos, F, 2016) |
| "Patients more than 18 years of age with gastric adenocarcinoma were randomized 1:1 to capecitabine-cisplatin plus either bevacizumab or placebo." | 5.20 | Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). ( Bu, L; Chen, L; Dai, G; Li, J; Liu, Y; Pan, H; Piao, Y; Qin, S; Shen, L; Shu, Y; Wang, J; Wang, L; Xu, J; Xu, R; Yang, Z; Yu, S, 2015) |
| "A combination of cetuximab plus pemetrexed was marginally effective and well tolerated in patients with advanced esophageal squamous cell carcinoma as the second-line treatment." | 5.20 | Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. ( Han, Y; Shang, M; Shi, SB; Tian, J; Xu, J, 2015) |
| "The aim of the study was to compare efficacy and safety of first-line palliative chemotherapy with (EOX) epirubicin/oxaliplatin/capecitabine and (mDCF) docetaxel/cisplatin/5FU/leucovorin regimens for untreated advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma." | 5.20 | Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. ( Budzynski, A; Fijorek, K; Konopka, K; Krzemieniecki, K; Lazar, A; Matlok, M; Ochenduszko, S; Pedziwiatr, M; Puskulluoglu, M; Sinczak-Kuta, A; Urbanczyk, K, 2015) |
| "Patients with previously untreated thoracic AEC who had T4 tumors or M1 lymph node metastasis (M1 LYM), or both, received intravenous infusions of docetaxel (35 mg/m(2)) and cisplatin (40 mg/m(2)) on day 1 and a continuous intravenous infusion of 5-fluorouracil (400 mg/m(2)/day) on days 1 to 5, every 2 weeks, plus concurrent radiation." | 5.19 | Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). ( Azuma, M; Hayakawa, K; Higuchi, K; Ishido, K; Ishiyama, H; Katada, C; Katada, N; Koizumi, W; Komori, S; Sasaki, T; Tanabe, S, 2014) |
| "This phase II trial aimed to evaluate the efficacy and safety of docetaxel, cisplatin, and fluorouracil (DCF) combination in neoadjuvant setting in patients with locally advanced gastric adenocarcinoma." | 5.19 | Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. ( Abali, H; Bostanci, B; Civelek, B; Oguz, D; Oksuzoglu, B; Ozdemir, N; Vural, M; Yalcin, B; Yalcin, S; Zengin, N, 2014) |
| " We evaluated the safety, tolerability, and efficacy of the combination capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas." | 5.17 | A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. ( Altomare, I; Arrowood, CC; Bendell, JC; Blobe, GC; Brady, JC; Conkling, P; Cushman, SM; Favaro, J; Hsu, SD; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Uronis, HE; Zafar, SY, 2013) |
| "We performed a phase II trial of docetaxel in combination with capecitabine to evaluate the antitumor response, toxicity, and survival in pre-treated patients with advanced esophageal squamous cell carcinoma." | 5.17 | Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma. ( Li, X; Lin, S; Lin, W; Lin, Y; Wang, H, 2013) |
| "To evaluate the safety and tolerability of two different weekly doses of the fully humanized epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab combined with high-dose 5-fluorouracil, leucovorin and cisplatin (PLF) in the first-line treatment of patients with EGFR-positive advanced gastric and esophagogastric adenocarcinomas." | 5.17 | Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. ( Heeger, S; Lüpfert, C; Przyborek, M; Schleucher, N; Trarbach, T; Vanhoefer, U, 2013) |
| "Patients with localized, operable gastric or gastroesophageal adenocarcinoma received two cycles of induction chemotherapy of fluorouracil, docetaxel, and cisplatin (TPF) followed by 45 Gy of radiation and concurrent fluorouracil plus docetaxel then surgery for nonmetastatic patients." | 5.17 | Docetaxel-based preoperative chemoradiation in localized gastric cancer: impact of pathological complete response on patient outcome. ( Abd-Allah, D; El-Shazly, W; Khedr, G; Rostom, Y; Zaghloul, H, 2013) |
| "Patients with metastatic gastric, gastro-oesophageal junction, or distal oesophageal adenocarcinoma were randomized 1:1:1 to CX (cisplatin 80 mg/m(2) IV Q3W; capecitabine 1000 mg/m(2) P." | 5.17 | Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. ( Adewoye, AH; Bampton, CL; Bass, MB; Bodoky, G; Eatock, MM; Nanayakkara, N; Strickland, AH; Sun, YN; Swieboda-Sadlej, A; Tebbutt, NC; Valladares-Ayerbes, M; Van Cutsem, E; Zhong, ZD, 2013) |
| "This randomized clinical study was to assess and compare the efficacy and safety of two chemoradiotherapy (cisplatin + 5-fluorouracil + radiotherapy and cisplatin + docetaxel + radiotherapy) regimens in patients with unresectable local advanced oesophageal squamous cell carcinoma." | 5.16 | Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. ( Chen, H; Zhang, T; Zhao, T, 2012) |
| "This prospective multicentre phase II trial assessed the feasibility and efficacy of perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in patients with gastro-oesophageal adenocarcinoma." | 5.16 | Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. ( Arnold, D; Bichev, D; Breithaupt, K; Daum, S; Florschütz, A; Gahn, B; Glanemann, M; Hofheinz, RD; Kneba, M; Kretzschmar, A; Mantovani-Löffler, L; Reichardt, P; Schlattmann, P; Schumacher, G; Thuss-Patience, PC, 2012) |
| "To compare the efficacy and feasibility of neoadjuvant chemoradiotherapy with docetaxel plus cisplatin or with cisplatin plus fluorouracil in the treatment of local advanced esophageal squamous cell carcinoma." | 5.16 | [Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma]. ( Chen, MY; Chen, Z; Luo, JC; Wei, L; Wu, S, 2012) |
| "Previously untreated patients with metastatic gastroesophageal adenocarcinoma received bevacizumab 10 mg/kg, docetaxel 40 mg/m², fluorouracil 400 mg/m², leucovorin 400 mg/m² on day 1, fluorouracil 1,000 mg/m²/d × 2 days intravenous continuous infusion beginning on day 1, and cisplatin 40 mg/m² on day 3." | 5.15 | Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. ( Capanu, M; Ilson, DH; Jhawer, M; Kelsen, DP; Lefkowitz, RA; Robinson, E; Shah, MA, 2011) |
| "Patients with clinically staged II or III esophageal adenocarcinoma received oxaliplatin 85 mg/m(2) on days 1, 15, and 29; protracted-infusion fluorouracil (PI-FU) 180 mg/m(2)/d on days 8 through 43; and external-beam radiation therapy (EBRT) 5 days a week at 1." | 5.15 | S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. ( Benedetti, JK; Billingsley, KG; Blanke, CD; Bohanes, PO; Corless, CL; Danenberg, KD; Gold, PJ; Goldman, BH; Iqbal, S; Leichman, LP; Lenz, HJ; Thomas, CR, 2011) |
| "In this prospective pilot study, we assessed the efficacy and safety of the FOLFIRI regimen (irinotecan 180 mg/m², leucovorin 200 mg/m² d1 followed by bolus 400 mg/m² 5-fluorouracil (5-FU) and by a 46-h 2400 mg/m² 5-FU infusion, every 2 weeks) in patients with advanced esophageal or junctional adenocarcinoma." | 5.15 | FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study. ( Bourgeois, V; Ferte, C; Hebbar, M; Ladrat, L; Lindet, C; Mariette, C; Peugniez, C; Romano, O; Triboulet, JP, 2011) |
| "We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia." | 5.14 | A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. ( Drew, PA; Jamieson, GG; Liu, JF; Wu, TC; Zhu, GJ, 2009) |
| "Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile." | 5.14 | Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. ( Ajani, JA; Bodoky, G; Falcon, S; Garin, A; Gorbunova, V; Lang, I; Lichinitser, M; Moiseyenko, V; Rodriguez, W; Vynnychenko, I, 2010) |
| "Accumulating data indicate that docetaxel plus cisplatin and 5-fluorouracil has certain effect on advanced gastric or gastro-oesophageal junction adenocarcinoma." | 5.14 | A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma. ( Guo, JF; Nie, XY; Peng, J; Wang, B; Wu, F; Xing, H; Zhang, B; Zhu, GY, 2010) |
| "The regimen of docetaxel and capecitabine is a well-tolerated, easily administered and active outpatient regimen for advanced gastric and GE adenocarcinoma." | 5.14 | A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. ( Hantel, A; Hwang, J; Javle, M; Khorana, AA; Kiefer, G; Lo, SS; Rajasenan, K; Ramanathan, RK; Schmotzer, A; Shayne, M; Simon, S; Wang, H, 2010) |
| "Patients with histologically confirmed metastatic or locally advanced adenocarcinoma of the stomach or gastroesophageal junction received docetaxel 25 mg/m2 and oxaliplatin 50 mg/m2 on days 1 and 8 with capecitabine 625 mg/m2 twice daily from day 1-14, in 21-day cycles." | 5.14 | Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. ( Aggarwal, S; Goel, G; Jauhri, M; Negi, A, 2010) |
| "We aimed to establish the superiority (or noninferiority if superiority was not achieved) in terms of time to progression (TTP) of irinotecan/5-fluorouracil (IF) over cisplatin/5-fluorouracil (CF) in chemonaive patients with adenocarcinoma of the stomach/esophagogastric junction." | 5.13 | Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. ( Barone, C; Bugat, R; Cisar, L; Dank, M; Goker, E; Peschel, C; Valvere, V; Wang, K; Wenczl, M; Yalcin, S; Zaluski, J, 2008) |
| "Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil 2600 mg/m(2) as a 24-h infusion in combination with docetaxel 50 mg/m(2) (FLOT) on day 1 every 2 weeks." | 5.13 | Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Clemens, MR; Fritz, M; Hartmann, JT; Hofheinz, R; Homann, N; Jäger, E; Mahlberg, R; Pauligk, C; Probst, S; Rethwisch, V; Seipelt, G; Sievert, M; Stoehlmacher, J, 2008) |
| "Patients with previously untreated advanced adenocarcinoma of the stomach or esophagogastric junction were randomly assigned to receive either fluorouracil 2,600 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2), and oxaliplatin 85 mg/m(2) (FLO) every 2 weeks or fluorouracil 2,000 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2) weekly, and cisplatin 50 mg/m(2) every 2 weeks (FLP)." | 5.13 | Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Bokemeyer, C; Derigs, HG; Grossmann, J; Hartmann, JT; Hegewisch-Becker, S; Hofheinz, R; Hollerbach, S; Homann, N; Jäger, E; Knuth, A; Pauligk, C; Probst, S; Rethwisch, V; Schmalenberg, H; Schuch, G; Seipelt, G; Stoehlmacher, J; Wilhelm, G, 2008) |
| "Oxaliplatin and capecitabine in combination demonstrates activity in metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia." | 5.12 | Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Fitch, TR; Foster, NR; Jatoi, A; Knost, JA; Murphy, BR; Nikcevich, DA; Rowland, KM, 2006) |
| "Previous studies suggest that the combination of docetaxel and capecitabine are worthy of further testing in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction." | 5.12 | Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK, 2006) |
| "We investigated 2-weekly intravenous irinotecan combined with oral capecitabine in patients with advanced gastroesophageal adenocarcinoma." | 5.12 | A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. ( Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C, 2006) |
| "A regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) improves survival among patients with incurable locally advanced or metastatic gastric adenocarcinoma." | 5.12 | Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. ( Allum, WH; Chua, YJ; Cunningham, D; Falk, SJ; Iveson, TJ; Langley, RE; Lofts, FJ; Nicolson, M; Scarffe, JH; Smith, DB; Stenning, SP; Thompson, JN; Van de Velde, CJ; Verma, M; Weeden, S, 2006) |
| "Patients with squamous cell carcinoma or adenocarcinoma of the esophagus initially received capecitabine, carboplatin, and paclitaxel with RT (1." | 5.12 | A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. ( Bendell, JC; Blobe, GC; Czito, BG; D'Amico, TA; Fernando, NH; Harpole, DH; Honeycutt, W; Hurwitz, HI; Kelsey, CR; Morse, MA; Willett, CG; Yu, D, 2007) |
| "The aim of this study was to evaluate the activity and safety of 5-fluorouracil (5-FU)/leucovorin (LV) and irinotecan as first- or second-line treatment in patients with advanced gastric adenocarcinoma." | 5.12 | Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma. ( Chrysanthopoulos, C; Gerolymos, MK; Iconomou, G; Kalofonos, HP; Kontogeorgou, E; Koutras, AK; Makatsoris, T; Tsiata, E; Vourli, G, 2007) |
| "Cumulative gastrointestinal toxicities and neutropenia were the DLTs of docetaxel, capecitabine, and carboplatin." | 5.11 | Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. ( Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY, 2005) |
| "In this phase II randomized study, untreated patients with confirmed advanced gastric or gastroesophageal adenocarcinoma received either DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2 on day 1, and fluorouracil 750 mg/m2/d as continuous infusion on days 1 to 5) or DC (docetaxel 85 mg/m2 and cisplatin 75 mg/m2 on day 1) every 3 weeks." | 5.11 | Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. ( Ajani, JA; Assadourian, S; Cabral Filho, S; Chao, Y; Fodor, MB; Majlis, A; Moiseyenko, VM; Tjulandin, SA; Van Cutsem, E, 2005) |
| "The purpose of this study was to evaluate the dose-limiting toxicity (DLT) and maximum tolerated dose of capecitabine when used in combination with epirubicin and cisplatin (ECC) in patients with oesophageal or gastric adenocarcinoma." | 5.10 | A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ( Blackie, R; Evans, TR; Fullarton, GM; McDonald, AC; McInnes, A; Morrison, R; Paul, J; Pentheroudakis, G; Raby, N; Soukop, M, 2002) |
| "The present study was conducted to evaluate the effect of allopurinol spray on stomatitis induced by chemotherapy for esophageal cancer." | 5.10 | [The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs]. ( Fujii, E; Hanawa, T; Ito, A, 2002) |
| "The efficacy of a new chemotherapeutic combination consisting of Cis-diammineglycolatoplatinum (Nedaplatin), a derivative of cisplatin (CDDP), and 5-fluorouracil (5FU) was evaluated in patients with advanced esophageal carcinomas." | 5.09 | A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers. ( Gamoh, M; Ishibashi, S; Ishioka, C; Kanamaru, R; Kato, S; Murakawa, Y; Shibata, H; Shimodaira, H; Shineha, R; Suzuki, T; Yoshioka, T, 1999) |
| "Forty-four patients with carcinoma of the esophagus or gastroesophageal junction were prospectively entered into a phase II trial of preoperative 5-fluorouracil, cisplatin, and interferon alfa with concurrent external beam radiotherapy before esophagectomy." | 5.09 | Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma. ( Gooding, WE; Lew, JI; Posner, MC; Ribeiro, U; Safatle-Ribeiro, AV, 2001) |
| "To reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in patients with advanced gastro-oesophageal adenocarcinoma." | 5.09 | Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma. ( Dunlop, DJ; Eatock, MM; Lim, KC; Pentheroudakis, G; Soukop, M, 2001) |
| "These studies demonstrate that the concurrent addition of modest dose cisplatin and infusional dose fluorouracil to radiation in the definitive, preoperative, and palliative settings contribute to high rates of durable dysphagia-free survival, with overall survival comparable to (and possibly better than) the chemoradiation arm of the recently reported Intergroup Study, but at the cost of less morbidity." | 5.08 | Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. ( Ackland, SP; Burmeister, BH; Denham, JW; Devitt, P; Gill, PG; Hamilton, CS; Jamieson, GG; Lamb, DS; O'Brien, M; Yeoh, E, 1995) |
| "Eighteen patients with esophageal carcinoma (16 adenocarcinoma, two squamous cell carcinoma) were treated with two cycles of induction chemotherapy consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 (3-hour infusion), cisplatin 20 mg/m2/d x 4 days, and 5-fluorouracil 1 g/m2/d (continuous infusion x 4 days) separated by a 28-day interval before surgical resection." | 5.08 | Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. ( Belani, CP; Day, R; Ferson, PF; Keenan, RJ; Kim, R; Landreaneau, RJ; Lembersky, B; Luketich, JD; Posner, M; Ramanathan, RK; Seeger, J, 1997) |
| "Preoperative chemotherapy with a combination of cisplatin and fluorouracil did not improve overall survival among patients with epidermoid cancer or adenocarcinoma of the esophagus." | 5.08 | Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. ( Ajani, J; Estes, N; Ginsberg, R; Gunderson, L; Haller, DG; Kelsen, DP; Kocha, W; Minsky, BD; Mortimer, J; Pajak, TF; Roth, JA; Sheahan, DG, 1998) |
| "This phase III prospective, randomized, and stratified trial was undertaken to evaluate the efficacy of four courses of combined fluorouracil (1000 mg per square meter of body-surface area daily for four days) and cisplatin (75 mg per square meter on the first day) plus 5000 cGy of radiation therapy, as compared with 6400 cGy of radiation therapy alone, in patients with squamous-cell carcinoma or adenocarcinoma of the thoracic esophagus." | 5.07 | Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. ( al-Sarraf, M; Brindle, J; Byhardt, R; Cooper, J; Davis, L; Emami, B; Herskovic, A; Leichman, L; Martz, K; Vaitkevicius, V, 1992) |
| "The primary purpose of this study was to explore the short-term efficacy of different cisplatin and fluorouracil-based chemotherapy regimens in the treatment of patients with esophagogastric junctional adenocarcinoma (EGJA) using a network meta-analysis (NMA)." | 4.95 | A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma. ( Hu, JH; Song, DJ; Wang, C; Xie, SP; Xu, ZL, 2017) |
| " In patients with metastatic or locally advanced/recurrent gastric or gastro-oesophageal junction adenocarcinoma, the median time to tumour progression was significantly prolonged with 3-week cycles of intravenous (IV) docetaxel plus cisplatin and fluorouracil (5-fluorouracil) compared with 4-week cycles of IV cisplatin plus IV fluorouracil (5." | 4.84 | Docetaxel: in gastric cancer. ( Deeks, ED; Scott, LJ, 2007) |
| "The combination of cisplatin and continuous-infusion 5-fluorouracil is the standard regimen for the treatment of both squamous cell carcinoma and adenocarcinoma." | 4.81 | [Chemotherapy for the patients with esophageal cancer]. ( Ando, N; Shih, CH, 2002) |
| "At this juncture in the development of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), knowledge about the agent's pharmacologic behavior and clinical antitumor activity in less common neoplasms is being elucidated." | 4.79 | Paclitaxel pharmacology and other tumor types. ( Rowinsky, EK, 1997) |
| " From October 1985 to October 1987, 43 patients with local-regional esophageal cancer (adenocarcinoma in 21, squamous cell in 22) were treated with cisplatin, vinblastine, and 5-fluorouracil chemotherapy concurrent with 4,500 cGy radiation therapy for 21 days before transhiatal esophagectomy 3 weeks later." | 4.78 | Chemotherapy and radiation therapy before transhiatal esophagectomy for esophageal carcinoma. ( Bromberg, J; Forastiere, AA; Orringer, MB; Perez-Tamayo, C; Takasugi, BJ; Urba, S, 1990) |
| "We aimed to evaluate the efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy over cisplatin and 5-fluorouracil (CF) in patients with surgically resectable advanced esophageal squamous cell carcinoma (ESCC), using real-world data from 85 esophageal centers." | 4.31 | Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan. ( Doki, Y; Kakeji, Y; Kawakubo, H; Kitagawa, Y; Matsuda, S; Muto, M; Okamura, A; Okui, J; Takemura, R; Takeuchi, H; Watanabe, M, 2023) |
| "The standard preoperative treatment for resectable locally advanced esophageal squamous cell carcinoma (LAESCC) in Japan is docetaxel, cisplatin (CDDP), and 5-fluorouracil." | 4.31 | Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin. ( Daiko, H; Hashimoto, T; Hirose, T; Honma, Y; Ikeda, G; Ishiyama, K; Itoyama, M; Kadono, T; Kato, K; Oguma, J; Ohara, A; Sekine, S; Yamamoto, S; Yokoyama, K, 2023) |
| "There is limited real-world data on the efficacy of 2-weekly cycles of docetaxel, oxaliplatin, leucovorin, and fluorouracil (FLOT) compared to epirubicin, oxaliplatin, and capecitabine (EOX) as perioperative therapy in esophagogastric adenocarcinomas (EGAC)." | 4.31 | Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis. ( Bhandare, M; Bhargava, P; Booma, N; Chaudhari, V; Chaugule, D; Das, S; Kannan, S; Kapoor, A; Mantri, A; Ostwal, V; Ramaswamy, A; Shrikhande, SV; Srinivas, S, 2023) |
| "This study aimed to clarify the impact of the average relative dose intensity (RDI) of neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-NAC) for resectable locally advanced esophageal squamous cell carcinoma (ESCC)." | 4.31 | Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients. ( Hiraki, Y; Imano, M; Kato, H; Momose, K; Shinkai, M; Shiraishi, O; Yasuda, A; Yasuda, T, 2023) |
| "Docetaxel + cisplatin + 5-fluorouracil (DCF) therapy, a frequently prescribed regimen for esophageal cancer, is associated with a high risk of febrile neutropenia (FN)." | 4.31 | Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy. ( Kawasaki, K; Nara, K; Sato, Y; Seto, Y; Suzuki, H; Takada, T; Toriumi, T; Yagi, K; Yamamoto, T, 2023) |
| "Hyperammonemia induced by 5-fluorouracil(5-FU)is known as a rare adverse event, but there are few reports of hyperammonemia occurring during FP(5-FU plus CDDP)treatment for esophageal cancer." | 4.31 | [A Case of Esophageal Cancer with Consciousness Disorder Due to Hyperammonemia during FP Treatment]. ( Chiba, T; Hayashi, M; Iseki, H; Matsui, T; Miura, T; Noguchi, N; Ryotokuji, T; Tsunemi, A; Yamasaki, Y; Yokosuka, T, 2023) |
| "In Japan, standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) includes preoperative chemotherapy with fluorouracil plus cisplatin followed by esophagectomy." | 4.12 | Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy. ( Demachi, K; Fujita, T; Fujiwara, H; Kojima, T; Kotani, D; Okunaka, M; Sakashita, S; Yoshino, T, 2022) |
| "Docetaxel, cisplatin, and 5-fluorouracil (DCF) have high response rates, but severe neutropenia is frequently observed." | 4.12 | Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer. ( Daiko, H; Demachi, K; Fujii, S; Itoh, K; Kawasaki, T; Kojima, T; Nomura, H; Tsuji, D; Ueno, S; Yano, T, 2022) |
| "Perioperative FLOT (fluorouracil plus leucovorin, oxaliplatin, and docetaxel) chemotherapy is a recent regimen used to treat resectable oesophagogastric (OG) adenocarcinoma, associated with improved overall survival versus earlier chemotherapy strategies." | 4.12 | Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study. ( Allum, WH; Bhogal, RH; Chau, I; Chaudry, A; Cunningham, D; Fribbens, C; Gerlinger, M; Kumar, S; Malietzis, G; Moussa, O; Rao, S; Starling, N; Watkins, D, 2022) |
| " The current study aimed to retrospectively investigate neoadjuvant radiotherapy with cisplatin and 5-fluorouracil (CF-RT) and radiotherapy with docetaxel and CF (DCF-RT) and compare their treatment outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC)." | 4.12 | Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma. ( Arigami, T; Kurahara, H; Matsushita, D; Mori, S; Nakajo, A; Noda, M; Ohtsuka, T; Sasaki, K; Shimonosono, M; Tsuruda, Y; Uchikado, Y, 2022) |
| "Salvage concurrent chemoradiotherapy (60 Gy in 30 fractions) with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy was an effective and safe treatment for locoregional recurrence after curative resection of esophageal squamous cell carcinoma, especially in those approaching a complete response." | 4.12 | Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma. ( Akimoto, T; Daiko, H; Fujita, T; Fujiwara, H; Hojo, H; Ito, R; Kojima, T; Nakamura, N; Nakamura, Y; Sunakawa, H; Yano, T; Yoshino, T, 2022) |
| "The inclusion criteria were as follows: (1) oesophageal squamous cell carcinoma, (2) a schedule to receive three courses of induction chemotherapy (docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, 5-fluorouracil 750 mg/m2 days 1-5, every 3 weeks), (3) stage IB-III, (4) 20-75 years old, (5) 0-1 performance status, (6) preserved organ functions and (7) written informed consent." | 4.02 | A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. ( Ando, T; Fujii, H; Hamamoto, Y; Hara, H; Hosokawa, A; Ishikawa, H; Katada, C; Koizumi, W; Kojima, T; Muto, M; Nakajima, TE; Sakamoto, Y; Sugawara, M; Tahara, M; Watanabe, A, 2021) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic agent commonly used to treat esophageal squamous cell carcinoma (ESCC), but acquisition of chemoresistance frequently occurs and the underlying mechanisms are not fully understood." | 3.91 | MicroRNA-338-5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id-1. ( Chan, KT; Chan, KW; Cheung, ALM; Cui, D; Guan, XY; Han, L; Lam, AKY; Law, SYK; Lee, NPY; Li, B; Ma, S; Qin, YR; Tsao, SW; Xu, WW; Zhu, Y, 2019) |
| " The phytochemical curcumin is a potential treatment for Esophageal Squamous Cell Carcinoma (ESCC)." | 3.91 | Tetrahydrocurcumin, Curcumin, and 5-Fluorouracil Effects on Human Esophageal Carcinoma Cells. ( Geusz, ME; Jamasbi, RJ; Pendleton, EG, 2019) |
| " Here, we report the case of a successfully treated patient with thoracic esophageal cancer who had esophageal perforation during docetaxel, cisplatin, and 5-fluorouracil chemotherapy." | 3.91 | Successful Stenting Followed by Surgery for Perforated Esophageal Cancer Due to Chemotherapy. ( Doki, Y; Kobayashi, T; Makino, T; Mori, M; Tanaka, K; Yamasaki, M, 2019) |
| "Platinum plus 5-fluorouracil (FP) is a first-line regimen of palliative chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma (RM-ESCC)." | 3.91 | S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma. ( Boku, N; Hirano, H; Honma, Y; Ito, T; Iwasa, S; Kato, K; Okita, N; Shoji, H; Takashima, A, 2019) |
| "This study documents the clinical efficacy and toxicity of S-1 and paclitaxel (S1/PTX) in patients with unresectable or postoperative recurrent esophageal squamous cell carcinoma (ESCC) who had been previously treated with fluorouracil (5FU), cisplatin, and docetaxel." | 3.88 | A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy. ( Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y, 2018) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic agent used to treat a variety of gastric cancers including oesophageal squamous cell carcinoma (OSCC), for which the 5-year mortality rate exceeds 85%." | 3.88 | Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB, 2018) |
| "Neoadjuvant chemotherapy (NAC) involving two cycles of cisplatin plus fluorouracil is recommended in Japan as a standard treatment for resectable, locally advanced esophageal squamous cell carcinoma (ESCC)." | 3.88 | Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma. ( Fujiwara, Y; Gyobu, K; Hashiba, R; Ihara, T; Kishida, S; Lee, S; Naka, R; Nishiyama, M; Osugi, H; Takemura, M, 2018) |
| "Perioperative epirubicin, cisplatin and 5-FU or capecitabine (ECF/X) chemotherapy is recognised as a standard of care for patients with resectable gastroesophageal adenocarcinoma; however, there is limited evidence regarding its use in older patients." | 3.88 | Perioperative ECX chemotherapy in older adults with gastroesophageal adenocarcinoma. ( Hepworth, R; Smith, E; Tin, AW; Wadd, N; Walker, J; Wilson, D, 2018) |
| "5-Fluorouracil (5-FU) is used for the clinical treatment of esophageal squamous cell carcinomas (ESCCs), yet it also induces chemoresistant cancer cells during treatment, which leads to the failure of the therapy." | 3.85 | A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics. ( Chen, Z; Ge, J; Jiang, H; Li, X; Ma, Q; Shi, Y; Wang, J; Wang, M; Wang, Z; Zhang, C, 2017) |
| "Previous Japanese trials of the docetaxel, cisplatin, and 5-fluorouracil regimen for oesophageal cancer have demonstrated that a large proportion of patients also develop grade IV neutropenia." | 3.85 | Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen. ( Miwa, Y; Naito, M; Shimamoto, C; Yamamoto, T, 2017) |
| " This study was aimed to compare the differences in pathologic response and survival between docetaxel/cisplatin and fluorouracil/cisplatin as neoadjuvant CRT in locally advanced esophageal squamous cell carcinoma (SCC)." | 3.85 | Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. ( Fu, JH; Li, Y; Liu, MZ; Liu, SL; Xi, M; Yang, YD; Zhang, L; Zhang, P, 2017) |
| "The anticancer efficacy of docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy has been reported to be better than that of conventional regimens for advanced or relapsed esophageal squamous cell carcinoma (ESCC), and may become a standard therapy for this disease." | 3.85 | Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. ( Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y, 2017) |
| "Docetaxel, cisplatin and fluorouracil (DCF) is a candidate neoadjuvant chemotherapy (NAC) regimen for esophageal squamous cell carcinoma (ESCC)." | 3.85 | The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. ( Baba, H; Baba, Y; Hiyoshi, Y; Kurashige, J; Sakamoto, Y; Watanabe, M; Yoshida, N, 2017) |
| " We found that fluorouracil (5-FU)-resistant esophageal squamous cell carcinoma cell lines, established through exposure to increasing concentrations of 5-FU, showed upregulation of Id1, IGF2, and E2F1." | 3.83 | Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance. ( Chan, KT; Chan, KW; Cheung, AL; Guan, XY; He, QY; Law, S; Lee, NP; Li, B; Li, YY; Qin, YR; Tam, PY; Tsao, SW; Xu, WW; Yuen, HF, 2016) |
| " We sought to evaluate the pharmacokinetics of cisplatin and 5-fluorouracil in plasma and peritoneal dialysate in a patient being treated for esophageal adenocarcinoma." | 3.83 | A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. ( Beumer, JH; Eads, JR; Holleran, JL; Meropol, NJ; Negrea, L; Strychor, S, 2016) |
| "Although combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil demonstrates high response rates in esophageal squamous cell carcinoma, patients treated with docetaxel, cisplatin and 5-fluorouracil frequently experience acute kidney injury." | 3.83 | Plasma ghrelin levels as a predictor of adverse renal events due to cisplatin-based chemotherapy in patients with esophageal cancer. ( Doki, Y; Kurokawa, Y; Makino, T; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M; Yanagimoto, Y, 2016) |
| "To retrospectively evaluate the efficacy and toxicity of definitive concurrent chemoradiotherapy (dCRT) with cisplatinum/paclitaxel versus cisplatinum/5-fluorouracil in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who received nonsurgical treatment." | 3.83 | Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients. ( Guo, J; Han, X; Hu, G; Liu, L; Tang, N; Wang, Y; Wang, Z; Zhang, Q, 2016) |
| "Two estrogen receptor (ER)-positive esophageal adenocarcinoma cell lines (OE-19 and OE-33) were treated with combinations of tamoxifen, cisplatin and 5-fluorouracil (5-FU)." | 3.83 | Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells. ( Astill, DS; Bastian, I; Ding, GQ; Due, SL; Hussey, DJ; Sukocheva, OA; Vat, L; Watson, DI, 2016) |
| "Perioperative chemotherapy with 5-fluorouracil and cisplatin, with or without epirubicin, improves overall survival in resectable gastroesophageal junction and gastric adenocarcinoma." | 3.83 | Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. ( Afchain, P; Aparicio, T; Artru, P; Bachet, JB; Baumgaertner, I; Benallaoua, M; Boige, V; Boubaya, M; Coriat, R; des Guetz, G; Lecaille, C; Locher, C; Mary, F; Samalin, E; Tougeron, D; Zaanan, A, 2016) |
| "Patients with locally advanced (cT3 or N+) esophageal and esophagogastric junction adenocarcinoma undergoing neoadjuvant TCF [Taxotere, cisplatin 5-fluorouracil (5-FU)], ECF (epirubicin, cisplatin, 5-FU), or FLOT (docetaxel, oxaliplatin, leucovorin, and 5-FU) at the McGill University Health Center from March 2007 to September 2012 were identified from a prospective database." | 3.81 | Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided? ( Alcindor, T; Asselah, J; Cools-Lartigue, J; Eckert, E; Ferri, LE; Jones, D; Rousseau, M; Spicer, J; Vanhuyse, M; Zourikian, T, 2015) |
| "To investigate the effects of nimotuzumab (h-R3) with cisplatin (DDP) or fluorouracil (5-FU) on human esophageal squamous cell carcinoma (ESCC) EC1 cells." | 3.81 | Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells. ( Huo, XQ; Ji, YH; Li, GJ; Li, WW; Lu, P; Mu, YL; Wu, JQ; Yang, XY, 2015) |
| "Perioperative chemotherapy with epirubicin, cisplatin and 5-fluorouracil (5-FU) (ECF)-like regimens is the European standard for patients with adenocarcinoma of the gastroesophageal junction (GEJ) or gastric body (GaCa) stage UICC II/III (staged according to the Union for International Cancer Control)." | 3.81 | High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma. ( Bichev, D; Breithaupt, K; Daum, S; Dogan, Y; Schmidt, SC; Thuss-Patience, PC; Treese, C; von Winterfeld, M, 2015) |
| " We examined the effects of celecoxib, a COX-2 inhibitor, in enhancing the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma (ESCC) by reducing the COX-2 activity." | 3.80 | A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. ( Akanuma, N; Akutsu, Y; Hanari, N; Hoshino, I; Hu, X; Isozaki, Y; Komatsu-Akimoto, A; Matsubara, H; Mori, M; Mutallip, M; Qin, W; Yusup, G, 2014) |
| "Definitive chemoradiotherapy (CRT) with 5-fluorouracil (5-FU) and cisplatin (CDDP) is one of the standard therapies for esophageal squamous cell carcinoma (ESCC); however, inter-individual variations in clinical outcomes have yet to be investigated." | 3.80 | Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Azuma, T; Hirai, M; Kuwahara, A; Miki, I; Minegaki, T; Nakamura, T; Nishiguchi, K; Okuno, T; Omatsu, H; Sakaeda, T; Tamura, T; Yamamori, M, 2014) |
| "Our clinical study indicates esophageal adenocarcinoma patients on metformin had a better treatment response than those without metformin." | 3.80 | Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. ( Ajani, JA; Chen, Q; Honjo, S; Johnson, RL; Scott, AW; Skinner, HD; Song, S; Stroehlein, J, 2014) |
| "We report our experience with 2 male patients (71 and 74 years old, respectively) with advanced esophageal cancer who exhibited pulmonary embolism during treatment with neoadjuvant chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5- FU)." | 3.80 | [Pulmonary embolism in esophageal cancer patients receiving neoadjuvant chemotherapy with CDDP and 5-FU]. ( Fujiwara, H; Ichikawa, D; Ikoma, H; Kitagawa, M; Komatsu, S; Konishi, H; Kuriu, Y; Murayama, Y; Nakanishi, M; Okamoto, K; Otsuji, E; Sakakura, C; Shiozaki, A, 2014) |
| " Surgery Division of Verona University, 155 consecutive patients with locally advanced esophageal cancers (90 SCC, 65 adenocarcinoma) were treated with a single protocol of neoadjuvant CRT (docetaxel, cisplatin, and 5-fluorouracil with 50." | 3.79 | Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center. ( Casella, F; de Manzoni, G; Giacopuzzi, S; Pasini, F; Verlato, G; Weindelmayer, J; Zanoni, A; Zhao, E, 2013) |
| "The aim of this study was to determine the pathological complete remission (pCR) rate, and its relationship to clinical outcome, in patients with adenocarcinoma of the stomach or oesophagogastric junction receiving preoperative 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) every 2 weeks." | 3.78 | Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. ( Al-Batran, SE; Altmannsberger, HM; Atmaca, A; Bruch, HP; Homann, N; Jäger, E; Luley, K; Noack, F; Pauligk, C; Werner Kraus, T, 2012) |
| " In this study, 49 Japanese patients with esophageal squamous cell carcinoma (ESCC) were followed up for 5 years after treatment with a definitive 5-fluorouracil (5-FU)/cisplatin (CDDP)-based chemoradiotherapy (CRT), and the effects of genotypes of vascular endothelial growth factor (VEGF) were retrospectively revaluated in terms of prediction of long-term survival." | 3.78 | VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Kuwahara, A; Manabe, Y; Miki, I; Nakamura, T; Nishiguchi, K; Okuno, T; Sakaeda, T; Tamura, T; Yamamori, M, 2012) |
| " Two of the patients could not be treated with 5-FU any more because they had developed a myocardial ischemia, which was most likely caused by fluorouracil." | 3.78 | 5-FU-induced cardiac toxicity--an underestimated problem in radiooncology? ( Hautmann, MG; Kölbl, O; Steger, F, 2012) |
| "Fifty-six patients with squamous cell carcinomas of the esophagus were treated between April 1989 and September 1993 in the Centre Hospitalier Universitaire in Brest, France with two courses of preoperative concomitant radiochemotherapy, separated by a 2-week interval, and followed by surgery (each course 18." | 3.78 | Preoperative concomitant radiochemotherapy in squamous cell carcinoma of the esophagus: results of a study of 56 patients. ( Labat, JP; Lozac'h, P; Lucas, B; Malhaire, JP; Simon, H; Topart, P; Volant, A, 1996) |
| "Cisplatin-/5-fluorouracil-resistant oesophageal squamous cell carcinoma (SCC) and adenocarcinoma (EAC) cell lines were established, and the impact of ectopic upregulation of miR-106a and miR-148a on response to both drugs was assessed." | 3.77 | Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. ( Haier, J; Hummel, R; Hussey, DJ; Kist, J; Michael, MZ; Smith, C; Watson, DI, 2011) |
| "The aim of this retrospective study was to evaluate the efficacy and safety of weekly high-dose 5-fluorouracil (5-FU)/folinic acid (FA) as 24-h infusion (AIO regimen) plus irinotecan in patients with histologically proven metastatic gastroesophageal adenocarcinoma (UICC stage IV)." | 3.77 | Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b ( Albrecht, H; Boxberger, F; Busse, D; Golcher, H; Hahn, EG; Hohenberger, W; Janka, R; Konturek, PC; Koucky, K; Männlein, G; Neurath, MF; Ostermeier, N; Reulbach, U; Schildberg, C; Siebler, J; Wein, A; Wolff, K, 2011) |
| "Palliative chemoradiotherapy using 5-fluorouracil plus cisplatin combined with concurrent 40 Gy irradiation effectively improved the symptom of dysphagia in Stage IVB esophageal cancer with acceptable toxicity and favorable survival." | 3.77 | Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. ( Doi, T; Fuse, N; Ikeda, E; Kaneko, K; Kojima, T; Minashi, K; Nihei, K; Ohtsu, A; Onozawa, M; Tahara, M; Yano, T; Yoshino, T, 2011) |
| "The clinical course of 122 patients with Barrett's carcinoma, who all underwent a neoadjuvant chemotherapy with cisplatin, five fluorouracil and leucovorin and following oesophagectomy, was reviewed." | 3.77 | The amount of neoadjuvant chemotherapy for Barrett's carcinoma does not correlate with long-term survival. ( Friess, H; Knoefel, WT; Schauer, M; Theisen, J, 2011) |
| "Current and proposed trials in esophageal cancer have changed their focus accordingly to meet this new treatment challenge." | 3.77 | The use of mitomycin in esophageal cancer. ( Coia, LR, 1993) |
| " In the first phase III study, the ToGA trial, HER2-positive patients with advanced gastroesophageal and gastric adenocarcinoma were randomized to receive 5-fluorouracil/capecitabine and cisplatin either alone or in combination with trastuzumab." | 3.76 | Targeted HER2 treatment in advanced gastric cancer. ( Jørgensen, JT, 2010) |
| "Epirubicin, cisplatin or 5-fluorouracil was administered to severe combined immune-deficient mice bearing OE19 oesophageal adenocarcinoma xenografts." | 3.76 | Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. ( Appleyard, V; Baker, L; Exon, D; Kelly, P; Lamont, D; Murray, K; Paulin, F; Suttie, S; Thompson, A, 2010) |
| "The aim of this study was to determine whether pretherapeutic protein expression levels of the excision repair cross-complementing (ERCC1) enzyme, thymidylate synthetase (TS), multidrug-resistance protein 1 (MRP-1) and P-glycoprotein (P-gp) are associated with tumour response to cisplatin and fluorouracil (5-FU)-based neoadjuvant chemotherapy in oesophageal adenocarcinomas." | 3.76 | High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. ( Becker, K; Feith, M; Hofler, H; Langer, R; Lordick, F; Ott, K; Specht, K, 2010) |
| "One hundred fifty-six patients with locally advanced or metastatic esophageal adenocarcinoma received neoadjuvant chemotherapy with cisplatin, 5-fluorouracil, and leucovorin followed by resection." | 3.76 | Interleukin-10 and -12 predict chemotherapy-associated toxicity in esophageal adenocarcinoma. ( Friess, H; Holzmann, B; Knoefel, WT; Peiper, M; Schauer, MC; Theisen, J, 2010) |
| "We report an elderly patient with esophageal adenocarcinoma in whom a complete response (CR) was obtained by chemoradiotherapy using daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU." | 3.75 | [A case of elderly esophageal adenocarcinoma successfully treated with daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation]. ( Furuta, T; Futami, H; Hamaya, Y; Ikuma, M; Iwaizumi, M; Kodaira, C; Muramatsu, A; Nishino, M; Osawa, S; Sugimoto, K; Takagaki, K; Yamada, T; Yoshida, K, 2009) |
| "A 72-year-old patient with esophageal carcinoma developed a severe hand-foot syndrome during second-line therapy with the oral fluoropyrimidine capecitabine." | 3.74 | [Hand-foot syndrome with capecitabine therapy]. ( Hengge, UR; Marini, A, 2007) |
| "Hyperammonemia or hyperammonemic leukoencephalopathy sometimes occurs as an adverse event after 5-fluorouracil (5-FU) chemotherapy." | 3.74 | The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases. ( Asakage, T; Kikuta, S; Kubota, A; Nakao, K; Sugasawa, M, 2008) |
| "5-Fluorouracil (5-FU) is a key drug in the treatment of esophageal squamous cell carcinoma (ESCC)." | 3.74 | Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines. ( Ando, T; Fujii, Y; Ishiguro, H; Katada, T; Kimura, M; Kuwabara, Y; Mitsui, A; Mori, R; Ogawa, R; Sugito, N, 2008) |
| "We reported two cases of retroperitoneal hematoma in patients who received a combination of anticoagulant therapy and 5-fluorouracil (5-FU)." | 3.73 | Two cases of retroperitoneal hematoma caused by combination of anticoagulant therapy and 5-fluorouracil. ( Furutani, K; Furutani, S; Kashihara, K; Minato, M; Morita, N; Murase, T; Nishitani, H; Otsuka, H; Tagashira, H; Tsujikawa, T; Yoneda, K, 2005) |
| "To test the hypothesis that TS3'UTR polymorphisms predict outcomes in 146 Caucasian patients with esophageal adenocarcinoma treated with preoperative 5-fluorouracil-based chemoradiation." | 3.73 | Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. ( Ajani, JA; Correa, AM; Cox, JD; Komaki, R; Liao, Z; Liu, H; Roth, JA; Swisher, SG; Wang, L; Wei, Q; Wu, TT, 2006) |
| "Retrospectively, we analysed 23 consecutive patients who were treated with epirubicin, cisplatin and oral capecitabine for inoperable or metastatic oesophagogastric adenocarcinoma during 2002 and 2003." | 3.73 | Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma. ( Boot, H; Corporaal, S; Legdeur, MC; Russel, MG; Smit, WM; van der Palen, J, 2006) |
| " We report two cases of NM from breast carcinoma and a third with esophageal carcinoma, which responded to treatment with capecitabine, an oral prodrug for 5-flurouracil." | 3.72 | Response of neoplastic meningitis from solid tumors to oral capecitabine. ( Giglio, P; Groves, MD; Tremont-Lukats, IW, 2003) |
| "Resection specimens from 47 cases of oesophageal adenocarcinoma treated with preoperative 5-fluorouracil/cisplatin and radiotherapy were reviewed." | 3.71 | A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. ( Dunne, B; Griffin, M; Kelly, A; Mulligan, E; Reynolds, JV, 2001) |
| "Despite its significant toxicity for esophageal fistula, this concurrent CT-RT protocol of protracted 5-fluorouracil infusion and cisplatin appears feasible and effective for T4 esophageal cancer with or without fistulas." | 3.71 | Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. ( Kanamori, S; Nakamatsu, K; Nishimura, Y; Shigeoka, H; Suzuki, M; Yagyu, Y, 2002) |
| "Epirubicin, cisplatin and continuous 5-fluorouracil (5-FU) infusion (ECF) has been reported to result in high clinical response rates in advanced gastro-oesophageal adenocarcinoma and is currently the 'gold standard' chemotherapy regimen for this tumour site." | 3.70 | Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma. ( Banerji, U; Geh, JI; Glynne-Jones, R; Harrison, RA; Kwok, QS; Livingstone, JI; Mitchell, IC; Townsend, ER, 2000) |
| "We report a case of double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin." | 3.69 | [A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin]. ( Akiyama, S; Hibi, K; Ito, K; Kasai, Y; Kondo, K; Nonami, T; Takagi, H, 1995) |
| " Here we have examined human gastric/esophageal adenocarcinoma cell lines for p53 mutational status, chemosensitivity to 5-fluorouracil, mitomycin C, and cis-dichlorodiammineplatinum(II), alteration in p53 levels following exposure of cells to these drugs, and the mechanisms involved in regulating p53 levels." | 3.69 | The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. ( Albino, AP; Altorki, NK; Blundell, ML; de Oliveira, AR; Kelsen, DP; Lai, L; Loganzo, F; Maslak, P; Nabeya, Y; Schwartz, GK, 1995) |
| "Thirty-two patients with resectable (clinical stage IIa, n = 17; IIb, n = 1; III, n = 14) squamous cell cancer (n = 15) or adenocarcinoma (n = 17) were treated with neoadjuvant chemotherapy (cisplatin, 5-fluorouracil, leukovorin), resection, and postoperative chemoradiotherapy (hydroxyurea, 5-fluorouracil; 50-66 Gy)." | 3.69 | Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction. ( Drinkard, LC; Ferguson, MK; Haraf, DJ; Hoffman, PC; Reeder, LB; Vokes, EE, 1995) |
| "We reviewed our results with chemotherapy for adenocarcinoma of the esophagus or gastroesophageal junction tumors in patients treated with 5-fluorouracil, Adriamycin, and mitomycin C (FAM) regimen as developed by MacDonald and colleagues for adenocarcinoma of the stomach." | 3.69 | 5-Fluorouracil, adriamycin, and mitomycin C in adenocarcinoma of the esophagus or gastroesophageal junction tumors. ( Allred, C; Khansur, T; Tavassoli, M, 1994) |
| " To improve local control and decrease metastases, a 7-month regimen was used with standard-dose radiotherapy (RT), cisplatin (DDP), and continuous infusion (CI) 5-fluorouracil (5-FU) in patients with locoregional squamous/adenocarcinoma of the esophagus." | 3.69 | Chemoradiotherapy of esophageal carcinoma. ( Cummings, G; Gaspar, LE; Herskovic, AM; Khanuja, PS; Kinzie, JL; Kraut, MJ; Lattin, PB; Poplin, EA; Steiger, Z; Vaitkevicius, VK, 1994) |
| "After a loading dose of 4 x 90 mg folinic acid orally, a continuous infusion of 5-fluorouracil 500 mg/sqm/day for 5 days with concommitant folinic acid 6 x 60 mg/day orally, was administered to 29 consecutive patients with metastatic adenocarcinoma of the esophagus or esophagogastric junction area." | 3.69 | 5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. ( Kok, TC; Splinter, TA; van der Gaast, A, 1996) |
| " We report on a clinical deterioration, yet near-complete pathological and radiological response to a combination of cisplatin and fluorouracil in a patient with locally-advanced gastric adenocarcinoma." | 3.69 | Paradoxical clinical deterioration despite near-complete pathological response to neoadjuvant chemotherapy for locally advanced gastro-oesophageal adenocarcinoma. ( Crellin, A; Guillou, PJ; Hassan, S; Macadam, R; Reynolds, JV; Sadek, SA; Somers, SS; Windsor, AC, 1995) |
| "Between December 1988 and August 1992, 68 patients with adenocarcinoma (n = 39) and squamous carcinoma (n = 29) of the esophagus were entered prospectively in a treatment protocol to receive two cycles of cisplatin, 5-fluorouracil, etoposide, leucovorin, and 3,000 cGy of radiation to the involved esophagus and adjacent mediastinum, followed by resection." | 3.68 | Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma. ( Adkins, RB; Hoff, SJ; Johnson, DH; Merrill, WH; Murray, MJ; Sawyers, JL; Stewart, JR, 1993) |
| "Of 13 patients with adenocarcinoma treated with 5-fluorouracil, adriamycin, and mitomycin (FAM), nine showed minor histological changes compared with 14 control cases." | 3.68 | Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy. ( Allen, SM; Darnton, SJ; Edwards, CW; Matthews, HR, 1993) |
| "Forty-three patients with locoregional squamous cell carcinoma or adenocarcinoma of the esophagus or cardia were treated with fluorouracil (5-FU), cisplatin, and bolus vinblastine concurrent with radiation administered over 21 days." | 3.68 | Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. ( Forastiere, AA; Orringer, MB; Perez-Tamayo, C; Urba, SG; Zahurak, M, 1993) |
| "A 63-year-old male had undergone combination chemotherapy including adriamycin, cisplatin, mitomycin C, 5-fluorouracil and vindesine for six months for double cancer of esophagus and stomach." | 3.68 | [Chemotherapy-associated hemolytic uremic syndrome--a case report]. ( Kanamaru, R; Kikuchi, H, 1992) |
| "From October 1986 to January 1991, 47 patients with esophageal cancer (29 squamous, 18 adenocarcinoma) were treated with simultaneous radiotherapy (3000 or 3600 cGy) and chemotherapy (infusional 5-fluorouracil, cisplatin) delivered during a 5-week period." | 3.68 | Preoperative chemotherapy and radiotherapy for esophageal carcinoma. ( Andrus, CH; Baue, AE; Johnson, FE; Naunheim, KS; Petruska, P; Roy, TS; Schlueter, JM, 1992) |
| "We have evaluated the effect of 5-fluorouracil 600 mg/m2, doxorubicin ('Adriamycin') 40 mg/m2, and Mitomycin-C 4 mg/m2 (FAM) in two groups of patients with adenocarcinoma of the oesophagus, as either a preoperative or primary treatment." | 3.68 | A phase II study of 5-fluorouracil, adriamycin and mitomycin-C in adenocarcinoma of the oesophagus. ( Allen, SM; Cullen, MH; Matthews, HR; Steel, A; Walker, SJ, 1991) |
| "Fifteen patients with potentially resectable adenocarcinoma of the esophagus were treated with two cycles of preoperative chemotherapy with 5-fluorouracil (5-FU) and cisplatin (DDP)." | 3.68 | A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus. ( Bromberg, C; Carey, RW; Choi, NC; Grillo, HC; Hilgenberg, AD; Logan, DL; Mathisen, DJ; Wain, JC, 1991) |
| "Thirty-five consecutive patients with resectable adenocarcinoma of the esophagus or gastroesophageal junction were treated with two preoperative and three or four postoperative chemotherapy courses consisting of etoposide, fluorouracil, and cisplatin (EFP) to evaluate the rate of curative resection, clinical and pathologic response, toxic effects, and survival." | 3.68 | Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. ( Abbruzzese, JL; Ajani, JA; DeCaro, L; Jackson, DE; Levin, B; McMurtrey, M; Mountain, C; Rich, TA; Roth, JA; Ryan, B, 1990) |
| "The watery diarrhea-hypokalemia-achlorhydria syndrome associated with ectopic secretion of vasoactive intestinal peptide has only been conclusively documented with tumors originating in the pancreas or sympathetic chain." | 3.67 | Watery diarrhea-hypokalemia-achlorhydria syndrome and carcinoma of the esophagus. ( Douglas, MC; Hurley, R; Kalnins, R; Moran, L; Shulkes, A; Smallwood, RA; Watson, KJ, 1985) |
| "Between January 1981 and December 1986, 20 patients with adenocarcinoma of the esophagus and gastroesophageal junction were entered into a prospective study involving combined radiation therapy and chemotherapy (5-fluorouracil [5-FU] and mitomycin) as primary management." | 3.67 | Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction. ( Coia, LR; Engstrom, PF; Paul, AR, 1988) |
| "The cytotoxic effects of three anticancer drugs, methotrexate (MTX), 5-fluorouracil (5-Fu) and oridonin (Rub A), were investigated using a human gastric adenocarcinoma cell line (MGc80-3) and a human esophageal cancer cell line (CaEs-17) by means of colony-forming assay, dye exclusion test, measurement of incorporation of 3H-thymidine into DNA and examination of mitotic index." | 3.67 | [Comparison of in vitro assays for the cytotoxic effect of anticancer drugs]. ( Li, PY; Li, XT; Lin, C, 1986) |
| "We herein investigated the association between early tumor shrinkage (ETS) and depth of response (DpR) and clinical outcomes in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil (bDCF) using data from the JCOG0807, a phase I/II trial of bDCF as first-line chemotherapy for metastatic esophageal cancer." | 3.30 | Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807. ( Chin, K; Doki, Y; Fujitani, K; Fushiki, K; Hironaka, S; Kato, K; Kitagawa, Y; Kojima, T; Kusaba, H; Matsushita, H; Mizusawa, J; Okuno, T; Seki, S; Tomori, A; Tsubosa, Y; Tsushima, T; Ura, T, 2023) |
| "Esophageal cancer has one of the poorest prognoses among all cancer types, due to the propensity for an early spread through the lymphatics and the difficulty to perform surgical treatment." | 3.30 | Updates of perioperative multidisciplinary treatment for surgically resectable esophageal cancer. ( Kawakubo, H; Kitagawa, Y; Matsuda, S; Takeuchi, M; Tsuji, T, 2023) |
| " Currently, no trials have investigated the impact of perioperative immunotherapy in combination with chemotherapy for resectable gastric or GEJ adenocarcinoma." | 3.11 | Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). ( Brachet, PE; Castera-Tellier, M; Clarisse, B; Corbinais, S; Dorbeau, M; Dos Santos, M; Galais, MP; Guilloit, JM; Le Gallic, C; Leconte, A; Lequesne, J; Parzy, A; Poulain, L; Varatharajah, S; Vaur, D; Weiswald, LB, 2022) |
| "Our aim was to establish if presence of circulating tumor cells (CTCs) predicted worse outcome in patients with non-metastatic esophageal cancer undergoing tri-modality therapy." | 3.11 | Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial. ( Allan, AL; Bierer, J; Dar, AR; Fortin, D; Frechette, E; Inculet, RI; Law, J; Lewis, D; Lowes, LE; Malthaner, RA; Palma, DA; Raphael, J; Rodrigues, GB; Sanatani, M; Vincent, MD; Warner, A; Yaremko, BP; Younus, J; Yu, E, 2022) |
| " All cases of reported adverse events were recorded and analyzed." | 3.11 | Safety and efficacy of the FLOT regimen in the Polish population - an analysis of the prospective trial. ( Jóźwiak, M; Kolasińska-Ćwikła, A; Marcisz-Grzanka, K; Olesiński, T; Pałucki, J; Samsel, R; Sułkowska, U; Wieszczy, P; Winiarek, M; Wyrwicz, LS, 2022) |
| "Oral mucositis (OM) is an unpleasant adverse event in patients receiving chemotherapy." | 3.01 | Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial-EPOC 2 (JFMC49-1601-C5). ( Baba, H; Emi, Y; Hamai, Y; Hihara, J; Kitagawa, Y; Kunisaki, C; Maehara, Y; Matsubara, H; Morita, S; Nagano, H; Nakashima, Y; Oki, E; Otsuji, E; Saeki, H; Takeuchi, H; Tanaka, Y; Tomizuka, K; Ueno, T; Yoshida, K, 2021) |
| "First-line therapy for advanced oesophageal cancer is currently limited to fluoropyrimidine plus platinum-based chemotherapy." | 3.01 | Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. ( Adenis, A; Antunes, L; Bhagia, P; Cho, BC; Doi, T; Enzinger, P; Fountzilas, C; Goekkurt, E; Hara, H; Kato, K; Kim, SB; Kojima, T; Li, SH; Li, Z; Liu, Q; Mansoor, W; Maqueda, MA; Metges, JP; Oliden, VC; Shah, MA; Shah, S; Shen, L; Sun, JM; Sunpaweravong, P; Tsuji, A, 2021) |
| "Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy." | 2.94 | Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. ( Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D, 2020) |
| " Evaluation of pharmacogenomically dosed perioperative gFOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and UGT1A1 genotype-directed irinotecan) to optimize efficacy while limiting toxic effects may have value." | 2.94 | Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. ( Allen, K; Alpert, L; Catenacci, DVT; Chase, L; de Wilton Marsh, R; Ferguson, MK; Gordon, B; Hart, J; Karrison, T; Kindler, HL; Kipping-Johnson, K; Liao, CY; Lomnicki, S; Markevicius, U; Maron, SB; Moore, K; Narula, S; Peterson, B; Polite, BN; Posner, MC; Prachand, VN; Racette, C; Rampurwala, MM; Roggin, KK; Setia, N; Siddiqui, UD; Turaga, K; Xiao, SY, 2020) |
| "Advanced unresectable gastroesophageal cancers continue to confer a dismal patient prognosis." | 2.94 | Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. ( Ajani, JA; Blum Murphy, M; Palmer, M; Rogers, JE; Trail, A; Xiao, L, 2020) |
| " However, the current guidelines fail to recommend an optimal dosing schedule of pegfilgrastim along with the DCF regimen to prevent FN." | 2.90 | Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study. ( Dohi, O; Fujiwara, H; Ishikawa, T; Itoh, Y; Kamada, K; Konishi, H; Naito, Y; Okayama, T; Shiozaki, A; Takagi, T; Teramukai, S; Uchiyama, K; Yasuda, T; Yoshida, N, 2019) |
| "The proportion of elderly patients in esophageal cancer is now growing, but there is a lack of evidence in term of treatment standard for this group of patients, which is what we aim to obtain through this prospective phase III study." | 2.90 | A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. ( Chang, X; Chen, J; Deng, L; Ge, X; Han, C; Li, C; Liang, J; Lin, Y; Ni, W; Pang, Q; Sun, X; Wang, L; Wang, P; Wang, W; Wang, X; Xiao, Z; Zhang, W; Zhao, Y; Zhou, Z, 2019) |
| "10-20% of patients with gastric cancer (GC) have HER2+ tumors." | 2.90 | EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction aden ( Caballero, C; Cats, A; Elme, A; Grabsch, HI; Kang, YK; Lordick, F; Marreaud, S; Martens, U; Mauer, M; Moehler, MH; Mueller, L; Rha, SY; Thuss-Patience, P; Tokunaga, M; Wagner, AD, 2019) |
| "Febrile neutropenia was observed in 20 (21." | 2.90 | Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil. ( Ohkura, Y; Udagawa, H; Ueno, M, 2019) |
| "Paclitaxel is an active agent against oesophageal cancer and it has been proved as a potent radiation sensitiser." | 2.87 | Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2). ( Ai, D; Badakhshi, H; Cao, J; Chen, Y; Deng, J; Fan, J; Fan, M; Huang, G; Li, J; Li, L; Li, Y; Lin, Q; Liu, Q; Luo, H; Ren, W; Wei, S; Wu, K; Yang, H; Ye, J; Zhang, J; Zhao, K; Zhao, W; Zheng, X; Zhou, J; Zhu, H; Zhu, Z, 2018) |
| "We conducted a prospective study in esophageal cancer patients who received nCT (n = 126) or nCRT (n = 141) prior to surgery." | 2.84 | Impact of neoadjuvant chemotherapy and chemoradiotherapy on postoperative cardiopulmonary complications in patients with esophageal cancer. ( Zhang, H; Zhang, Z, 2017) |
| "This phase I/II study was designed to determine the maximum tolerated dose of tivantinib in combination with standard dose FOLFOX for the treatment of patients with advanced solid tumors and to evaluate the safety and efficacy of this combination for patients with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach." | 2.84 | A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach. ( Bendell, J; Flores, M; Hemphill, B; Kurkjian, C; Pant, S; Patel, M; Thompson, D, 2017) |
| "Esophageal stenosis was identified as a candidate stratification factor for randomized trials of unresectable LAESCC patients." | 2.84 | Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303). ( Ando, N; Fukuda, H; Igaki, H; Ishikura, S; Katayama, H; Kato, H; Kato, K; Kawano, T; Kimura, Y; Kitagawa, Y; Kojima, T; Kosugi, S; Nakamura, K; Okabe, H; Okuno, T; Shinoda, M; Toh, Y; Tsubosa, Y; Wakabayashi, M, 2017) |
| " The aim of this study was to investigate the effects of synbiotics in esophageal cancer patients receiving neoadjuvant chemotherapy on the intestinal microbiota and the adverse events of chemotherapy." | 2.84 | Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. ( Akita, H; Asahara, T; Fujiwara, Y; Gotoh, K; Ishikawa, O; Kobayashi, S; Miyata, H; Miyoshi, N; Motoori, M; Nomoto, K; Noura, S; Ohue, M; Omori, T; Saito, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M, 2017) |
| "For these patients with metastatic esophageal cancer, chemotherapy is generally indicated." | 2.84 | Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus. ( Hayata, K; Iwahashi, M; Katsuda, M; Matsumura, S; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H, 2017) |
| " Patients received once-daily vandetanib (planned dosing levels of 100, 200, and 300 mg) with concomitant daily radiotherapy (1." | 2.84 | Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. ( Astsaturov, IA; Berger, AC; Boland, PM; Burtness, BA; Cheng, JD; Cohen, SJ; Cooper, HS; Davey, M; Lebenthal, A; Meyer, JE; Neuman, T; Olszanski, AJ; Scott, WJ, 2017) |
| " However, the safety and efficacy of nimotuzumab combined with chemotherapy in locally advanced or metastatic esophageal cancer patients remain unclear." | 2.84 | Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer. ( Han, X; Lu, N; Pan, Y; Xu, J, 2017) |
| "The prognosis of esophageal cancer patients is still unsatisfactory." | 2.82 | Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma. ( Matsuhashi, N; Miyazaki, T; Okumura, N; Tanahashi, T; Tanaka, Y; Yamada, A; Yamaguchi, K; Yoshida, K, 2016) |
| " This phase II study investigated the feasibility, safety and efficacy of radiation dose escalation using simultaneous modulated accelerated radiotherapy (SMART) combined with chemotherapy in 60 EC patients." | 2.82 | Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer: a phase II study. ( Chang, D; Chen, C; Chen, J; Chen, Z; Guo, H; Guo, L; Huang, R; Li, D; Lin, K; Zhai, T; Zhang, W; Zhou, M, 2016) |
| "Fifty-five patients with esophageal cancer were enrolled." | 2.82 | Early Response of Esophageal Cancer to Neoadjuvant Chemotherapy with Docetaxel-Cisplatin-5-Fluorouracil Represents Sensitivity: A Phase II Study. ( Aiba, K; Arakawa, Y; Ishibashi, Y; Matsumoto, A; Mitsumori, N; Nishikawa, K; Omura, N; Sakuyama, T; Tanaka, Y; Tanishima, Y; Yanaga, K; Yuda, M, 2016) |
| "Esophageal stenosis was the only significant risk factor for esophageal fistula formation both in univariate (P = 0." | 2.82 | Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer: A Supplementary Analysis of JCOG0303. ( Fukuda, H; Honma, Y; Igaki, H; Kato, K; Kitagawa, Y; Mizusawa, J; Nakamura, K; Shinoda, M; Sudo, K; Tsubosa, Y; Tsushima, T, 2016) |
| "In advanced refractory esophagogastric cancer patients, monotherapy with SUN was associated with good tolerability but limited tumor response." | 2.82 | Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. ( Al-Batran, SE; Galle, PR; Gepfner-Tuma, I; Hegewisch-Becker, S; Kanzler, S; Koenig, J; Kullmann, F; Maderer, A; Moehler, M; Otte, M; Rafiyan, MR; Ruessel, J; Schimanski, CC; Schmoll, HJ; Schollenberger, L; Siveke, JT; Thuss-Patience, PC; von Weikersthal, LF; Weißinger, F; Weusmann, J; Wilke, H, 2016) |
| "Fourteen patients with esophageal cancer enrolled in this dose escalation study to determine the RD for a phase III trial." | 2.80 | Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer. ( Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T, 2015) |
| "Neoadjuvant therapy for cancer of the esophagus or gastroesophageal (GE)-junction is well established." | 2.80 | Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial. ( Alexandersson von Döbeln, G; Kalman, S; Lund, M; Lundell, L; Nilsson, M; Tsai, JA; Winter, R, 2015) |
| "Patients with esophageal squamous cell carcinoma were treated with escalating radiation dose of 4 levels, with a simultaneous integrated boost (SIB) to the pre-treatment 50% SUVmax area of the primary tumor." | 2.80 | Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18)FDG-PET/CT for esophageal cancer. ( Cai, XW; Feng, W; Fu, XL; Liu, Q; Yao, ZF; Yu, W; Zhang, Q; Zhang, YJ; Zhu, ZF, 2015) |
| "This multicenter trial included esophageal cancer patients with clinical T4 disease and/or unresectable regional lymph node metastasis." | 2.80 | Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). ( Ando, N; Fukuda, H; Ishikura, S; Kato, H; Kato, K; Kawano, T; Kimura, Y; Kosugi, S; Minashi, K; Nakamura, K; Okabe, H; Shinoda, M; Toh, Y; Tsubosa, Y, 2015) |
| " We have developed a 2-weekly docetaxel combined with CF regimen and conducted a Phase I/II trial for metastatic or recurrent esophageal cancer (JCOG0807)." | 2.80 | A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods o ( Chin, K; Fukuda, H; Hironaka, S; Kataoka, K; Katayama, H; Kato, K; Kii, T; Kitagawa, Y; Mizusawa, J; Shibuya, Y; Tsubosa, Y; Tsushima, T, 2015) |
| "Thirty-four patients with unresectable esophageal cancer were enrolled and received DNF therapy." | 2.80 | Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer. ( Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Saito, K; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T, 2015) |
| " Adverse events, treatment response and follow-up data were collected." | 2.80 | Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer. ( Li, QL; Qiu, MQ; Wang, T; Yang, JS, 2015) |
| "The data from two phase III trials for oesophageal cancer were used." | 2.80 | Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer. ( Ando, N; Fukuda, H; Hayashi, K; Igaki, H; Kataoka, K; Kato, K; Kitagawa, Y; Mizusawa, J; Nakamura, K; Ozawa, S, 2015) |
| "Patient survival in esophageal cancer (EC) remains poor." | 2.80 | A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer. ( Hayashi, T; Hirakawa, M; Hori, M; Kato, J; Kobune, M; Miyanishi, K; Nakata, K; Ohnuma, H; Okagawa, Y; Osuga, T; Sagawa, T; Sakata, K; Sato, T; Sato, Y; Someya, M; Takayama, T; Takimoto, R, 2015) |
| " Median values for AUC, Cmax, and Cmin were lower in patients with progressive disease (PD) than other response categories, although the 1." | 2.79 | Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. ( Cosson, VF; Lehle, M; Lum, BL; Ng, VW, 2014) |
| " This study was conducted as a phase I clinical trial of multiple-peptide vaccine therapy combined with CRT on patients with unresectable ESCC." | 2.79 | Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. ( Fukushima, R; Horikawa, M; Iinuma, H; Ikeda, T; Ikeda, Y; Inaba, T; Inoue, T; Matsutani, N; Nakamura, Y; Ogawa, E; Okinaga, K; Takeda, K; Tamura, J; Tsunoda, T; Yoshida, K, 2014) |
| "A database of esophageal cancer was queried for nonmetastatic patients with adenocarcinoma treated between 2000 and 2011 with CRT." | 2.79 | Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus. ( Almhanna, K; Freilich, J; Fulp, WJ; Hoffe, SE; Karl, RC; Meredith, K; Shridhar, R; Yue, B, 2014) |
| " Patients received 2-weekly docetaxel (30 mg/m(2) [dose level (DL)1] or 40 mg/m(2) [DL2] with a 3 + 3 design in phase I, on days 1 and 15) in combination with fixed-dose CF (80 mg/m(2) cisplatin, day 1; 800 mg/m(2) fluorouracil, days 1-5) repeated every 4 weeks." | 2.79 | Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). ( Chin, K; Doki, Y; Fujitani, K; Hironaka, S; Kato, K; Kii, T; Kitagawa, Y; Kojima, T; Kusaba, H; Matsushita, H; Mizusawa, J; Nakamura, T; Okuno, T; Seki, S; Taira, K; Taniki, T; Tomori, A; Tsubosa, Y; Tsushima, T; Ura, T, 2014) |
| "Fluorouracil and cisplatin have been used most frequently as neoadjuvant therapy for esophageal cancer." | 2.79 | The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study. ( Ba-Ssalamah, A; Hejna, M; Kandioler, D; Kappel, S; Kührer, I; Mittlböck, M; Pluschnig, U; Schoppmann, SF; Wolf, B; Wrba, F; Zacherl, J; Zwrtek, R, 2014) |
| "An analysis of surgically resected esophageal cancer patients after nCRT was performed to determine an association between the number of LNs resected and survival." | 2.78 | Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. ( Almhanna, K; Chuong, MD; Hoffe, SE; Karl, RC; Meredith, K; Shridhar, R; Weber, JM, 2013) |
| "4%) and renal adverse events (all grades: CS, 18." | 2.78 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013) |
| "To evaluate the efficacy and safety of trastuzumab in combination with chemotherapy versus chemotherapy alone in the first-line treatment of HER-2-positive advanced gastric or gastro-oesophageal junction cancer." | 2.78 | [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport]. ( Feng, FY; Guan, ZZ; Jiao, SC; Jin, YN; Li, J; Pan, LX; Qin, SK; Shen, L; Tao, M; Wang, JJ; Wang, LW; Wang, YJ; Xu, JM; Yu, SY; Zheng, LZ, 2013) |
| "Fourteen patients with esophageal cancer were enrolled and received DNF combination therapy at different dose levels according to the treatment and examination plan." | 2.78 | Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer. ( Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T, 2013) |
| " Toxic effects were graded according to NCI-CTC version 3." | 2.78 | The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. ( Abdel-Latif, RM; Anter, AH, 2013) |
| "Squamous cell carcinoma is the main histological subtype of esophageal cancer in the east Asia." | 2.78 | A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus. ( Chang, J; Ji, D; Li, W; Peng, W; Wang, H; Wang, J; Wu, X; Yu, H, 2013) |
| "pCR was achieved in 67% of squamous cell carcinoma." | 2.77 | Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. ( Balagué, C; Bellmunt, J; Conill, C; Gallego, R; Iglesias, M; Martín-Richard, M; Maurel, J; Momblan, D; Montagut, C; Pera, M; Pétriz, L; Reig, A, 2012) |
| "The Trastuzumab for Gastric Cancer (ToGA) study is the first international trial to include Japanese patients with human epidermal growth factor 2 (HER2) positive advanced/metastatic gastric or gastroesophageal junction cancer." | 2.77 | Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. ( Abe, T; Baba, E; Boku, N; Hamamoto, Y; Hatake, K; Miyata, Y; Nishina, T; Ohashi, Y; Ohtsu, A; Omuro, Y; Sasaki, Y; Satoh, A; Satoh, T; Sawaki, A; Takiuchi, H; Tamura, T; Yamaguchi, K, 2012) |
| "This study included 7 patients with esophageal cancer." | 2.77 | Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer. ( Aoki, Y; Emi, M; Hamai, Y; Hihara, J; Kenjo, M; Murakami, Y; Okada, M, 2012) |
| "In this study, patients with oesophageal cancer were divided into two group: one with neoadjuvant therapy and the other without neoadjuvant therapy." | 2.77 | The effect of neoadjuvant chemoradiotherapy on airway colonization and postoperative respiratory complications in patients undergoing oesophagectomy for oesophageal cancer. ( Asnaashari, A; Bagheri, R; Ghazvini, K; RajabiMashhadi, MT; Sahebi, MA; Zahediyan, A, 2012) |
| "Patients with stage II and III esophageal cancer were enrolled." | 2.77 | Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. ( Chak, A; Chang, KJ; Hanna, N; Pinto, H; Reid, T; Senzer, N; Soetikno, R; Swisher, S, 2012) |
| "The objective of this study was to review the outcomes of recombinant human endostatin combined with chemoradiotherapy (CRT) as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma (SCC) of the oesophagus." | 2.77 | Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus. ( Dai, N; Gu, X; Li, M; Qing, Y; Wang, D; Zhang, Z; Zhong, Z, 2012) |
| " The purpose of the present study was to update the results of radiotherapy combined with nedaplatin and 5-fluorouracil (5-FU) for postoperative loco-regional recurrent esophageal cancer." | 2.77 | Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study. ( Abe, K; Ishikawa, Y; Jingu, K; Kubozono, M; Matsushita, H; Nemoto, K; Shirata, Y; Sugawara, T; Takahashi, C; Takeda, K; Tanabe, T; Umezawa, R; Yamamoto, T, 2012) |
| "Response to anticancer therapy is believed to be directly related to the concentration of the anticancer drug in the tumor itself." | 2.76 | Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. ( de Bruijn, P; Ghobadi Moghaddam-Helmantel, IM; Konings, IR; Loos, WJ; Mathijssen, RH; Sleijfer, S; van Dam, LM; Verweij, J; Wiemer, EA, 2011) |
| "Advanced esophageal cancer with widespread metastasis to lymph nodes or other organs is difficult to treat and has an extremely poor prognosis." | 2.76 | Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. ( Aoki, T; Hoshino, S; Ogata, T; Osaka, Y; Shinohara, M; Takagi, Y; Tsuchida, A, 2011) |
| " Toxicity from DCF therapy was grade 3 or 4 emergent adverse events (77." | 2.76 | [Evaluation of efficacy and safety of first-line docetaxel/cisplatin/5-FU combined therapy for advanced esophageal cancer]. ( Ehara, K; Hasebe, S; Hayashi, M; Ito, T; Kinoshita, Y; Minowa, M; Ogawa, M; Takebayashi, K; Udagawa, H; Ueno, M, 2011) |
| "Esophageal squamous cell carcinoma (ESCC) is refractory to current therapeutic regimens and more effective therapies are imperative." | 2.76 | Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. ( Doki, Y; Miyata, H; Mori, M; Motoori, M; Peng, YF; Shiozaki, H; Shiraishi, O; Tanaka, K; Yamasaki, M; Yano, M; Yasuda, T, 2011) |
| "To evaluate the efficacy of late accelerated hyperfractionated conformal radiotherapy (LACF) combined with capecitabine on esophageal carcinoma." | 2.76 | [Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma]. ( Feng, XZ; Han, JQ; Sheng, W, 2011) |
| "To determine the maximum tolerated dose of oblimersen, an antisense oligonucleotide directed to the Bcl-2 mRNA, in combination with cisplatin and 5-flourouracil in patients with advanced gastric and esophageal carcinoma." | 2.75 | A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma. ( Christos, P; Kaubisch, A; Ocean, AJ; Raab, R; Ramirez, M; Sparano, JA; Vinciguerra, V, 2010) |
| "Grade 3 neutropenia was seen in seven patients and grade 4 in one patient." | 2.75 | Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. ( Egashira, H; Fujiwara, J; Honda, M; Izumi, Y; Kato, T; Miura, A; Monma, K; Nemoto, T; Ryotokuji, T, 2010) |
| "To investigate the therapeutical effect and side-effect of docetaxel combined with cisplatin (DDP) on the treatment of local advanced esophageal cancer with concomitant radiation therapy." | 2.75 | [Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy]. ( Gu, XW; Pan, YK; Xu, X; Zhang, TR; Zhao, T, 2010) |
| "Fourteen patients with localised oesophageal cancer suitable for curative chemoradiation therapy registered on the study." | 2.74 | A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer. ( Burmeister, BH; Burmeister, EA; Cox, S; D'Arcy, N; Harvey, JA; Smithers, BM; Thomson, DB; Walpole, ET, 2009) |
| "Eighteen patients with esophageal cancer were enrolled on the study." | 2.74 | Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study. ( Ahn, BM; Chae, YS; Jeon, SW; Kim, JC; Kim, JG; Lee, EB; Lee, SJ; Moon, JH; Park, IK; Sohn, SK, 2009) |
| "Protracted low-dose concurrent chemotherapy combined with radiation has been proposed for enhanced treatment results for esophageal cancer." | 2.74 | Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma. ( Furuta, T; Hamaya, Y; Ikuma, M; Iwaizumi, M; Kanaoka, S; Kodaira, C; Kosugi, T; Nishino, M; Osawa, S; Sugimoto, K; Takagaki, K; Takayanagi, Y; Terai, T; Yamada, T; Yamade, M; Yoshida, K, 2009) |
| "Patients with advanced esophageal squamous cell carcinoma receive neoadjuvant chemotherapy or chemoradiotherapy to improve survival, but benefits are observed only in those with histologic response." | 2.73 | Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. ( Doki, Y; Fujiwara, Y; Fukunaga, H; Hatazawa, J; Higuchi, I; Miyata, H; Monden, M; Takiguchi, S; Tatsumi, M; Yano, M; Yasuda, T, 2008) |
| " However, their optimal dosage and efficacy when combined with concurrent radiotherapy as neoadjuvant treatment are unknown." | 2.73 | Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. ( Brücher, B; Geinitz, H; Höfler, H; Lordick, F; Lorenzen, S; Molls, M; Ott, K; Peschel, C; Riera, J; Roethling, N; Schuster, T; Siewert, JR; Zimmermann, F, 2008) |
| "Forty-four patients with esophageal squamous cell carcinoma (ESCC) were randomized into two groups." | 2.73 | [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer]. ( Chen, K; Gao, XS; Lin, Q; Qiao, XY; Wang, YD; Zhou, ZG, 2008) |
| "Celecoxib was given daily during CRT at one of five doses (200 mg bd to 600 mg bd)." | 2.73 | A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. ( Biagi, J; Dawson, SJ; Foo, KF; Hui, A; Jefford, M; Leong, T; Michael, M; Milner, AD; Ngan, SY; Thomas, RJ; Zalcberg, JR, 2007) |
| "The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma." | 2.73 | Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). ( Berardi, R; Cascinu, S; Ceccarelli, C; Di Fabio, F; Funaioli, C; Giannetta, L; Giaquinta, S; Longobardi, C; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL; Siena, S, 2007) |
| "First-line chemotherapy for 32 advanced squamous cell carcinomas of the esophagus is not effective, and early recurrences after chemotherapy were examined." | 2.73 | [Evaluation of docetaxel, CDDP and 5-FU combined therapy as second-line chemotherapy for esophagus cancer]. ( Aoyama, N; Minamide, J; Oota, Y; Takada, K, 2007) |
| "Patients with local/regional oesophageal cancer with adequate functional status should not be excluded from potentially curative treatment based on age alone." | 2.73 | Combined modality chemoradiation in elderly oesophageal cancer patients. ( Anderson, SE; Bains, M; Hummer, A; Ilson, DH; Kelsen, D; Minsky, BD, 2007) |
| "For patients with localized esophageal cancer, whether or not preoperative chemotherapy is administered, only an R0 resection results in substantial long-term survival." | 2.73 | Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. ( Ajani, JA; Estes, NC; Gunderson, LL; Haller, DG; Kelsen, DP; Kocha, W; Minsky, BD; Mortimer, J; Roth, JA; Willett, CG; Winter, KA, 2007) |
| "This study assessed the clinical activity and safety of twice-weekly paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin (TP-HDFL) in patients with recurrent or metastatic esophageal squamous cell carcinoma." | 2.73 | Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. ( Cheng, AL; Hsu, C; Hsu, CH; Hsu, WL; Lin, CC; Tsai, YC; Yang, CH; Yeh, KH, 2007) |
| "Eight patients had esophageal cancer and 9 had gastric cancer." | 2.73 | A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. ( Akerman, P; Evans, D; Jean, M; Kennedy, T; Millis, R; Miner, T; Safran, H, 2007) |
| "All patients had histologically proven squamous cell carcinoma of the esophagus." | 2.73 | A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. ( Cho, EY; Hong, YS; Im, YH; Kang, WK; Kim, HS; Kim, K; Kim, MJ; Lee, HR; Lee, J; Park, K; Shim, YM, 2008) |
| " Nearly all patients (94%) suffered at least one grade 3 or worse adverse event, including 3 treatment-related deaths." | 2.73 | Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). ( Alberts, SR; Fitch, TR; Foster, NR; Jatoi, A; Lair, BS; Martenson, JA; McLeod, HL; Moore, DF; Nichols, F; Tschetter, LK, 2007) |
| "Patients with stage I or II esophageal cancer received preoperative radiation therapy (28-30 daily 1." | 2.73 | Acute respiratory disease syndrome with preoperative chronomodulated chemoradiotherapy in patients with esophageal cancer. Early termination of a phase I trial. ( Adenis, A; Lartigau, E; Mariette, C; Mirabel, X; Sarrazin, T; Triboulet, JP, 2008) |
| "50 patients with squamous cell carcinoma (90%) or adenocarcinoma and mostly advanced tumor stage were treated (82% T3/T4 and 70% N1)." | 2.73 | Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. ( Brunner, TB; Grabenbauer, GG; Melzner, W; Rupp, A; Sauer, R, 2008) |
| "Our data suggest that esophageal cancers with activated NF-kappaB have aggressive clinical biology and poor treatment outcome." | 2.72 | Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. ( Aggarwal, BB; Ajani, JA; Chao, KS; Ensor, J; Hittelman, WN; Izzo, JG; Lee, JH; Liao, Z; Luthra, R; Malhotra, U; Swisher, SG; Wu, TT, 2006) |
| "Multimodality therapy for esophageal cancer holds promise for improving outcome in this lethal disease." | 2.72 | Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. ( Beard, M; Cheng, JD; Freedman, G; Goldberg, M; Henry, LR; Konski, A; McLaughlin, S; Meropol, NJ; Scott, W; Watts, P; Weiner, LM, 2006) |
| " Thus, the recommended dosing schedule is level 2." | 2.72 | A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer. ( Abe, S; Araki, H; Hareyama, M; Iyama, S; Kato, J; Miyanishi, K; Murase, K; Nagakura, H; Niitsu, Y; Okamoto, T; Sagawa, T; Sato, T; Sato, Y; Takayama, T; Takimoto, R, 2006) |
| " The purpose of the present study was to evaluate the effectiveness and safety of radiotherapy combined with nedaplatin and 5-FU for postoperative locoregional (excluding hematogenous metastasis) recurrent esophageal cancer." | 2.72 | Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer. ( Jingu, K; Matsushita, H; Nakata, E; Nemoto, K; Ogawa, Y; Sugawara, T; Takahashi, C; Takai, Y; Yamada, S, 2006) |
| " The authors evaluated G17DT vaccination given with cisplatin plus 5-fluorouracil for the treatment gastric adenocarcinoma." | 2.72 | An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. ( Ajani, JA; Baker, J; Eduljee, A; Hecht, JR; Ho, L; Michaeli, D; Oortgiesen, M, 2006) |
| "Multimodal treatment of esophageal cancer showed promising results, although not significant, in terms of survival and disease progression for patients achieving a complete pathologic response." | 2.71 | Preoperative chemoradiotherapy in cancer of the thoracic esophagus. ( Baccarani, U; Bresadola, F; Bresadola, V; Buffoli, A; Cartei, G; Cedolini, C; Fongione, S; Iop, A; Sacco, C; Signor, M; Terrosu, G; Uzzau, A; Vigevani, E, 2003) |
| "Ninety-two patients with esophageal cancer (65 with adenocarcinoma and 27 with squamous cell carcinoma) were treated in two sequential protocols of preoperative chemoradiotherapy." | 2.71 | Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. ( Burtness, B; Forastiere, AA; Heath, EI; Heitmiller, R; Kleinberg, L; Knisely, JP; Salem, R; Zahurak, M, 2003) |
| "The median dysphagia free time was 9." | 2.71 | A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus. ( Glynne-Jones, R; Goodchild, K; Harney, J; Hoskin, PJ; Phillips, H; Saunders, MI, 2003) |
| "5-FU/irinotecan is a valuable regimen for second-line treatment in 5-FU/platinum-resistant O-G carcinoma." | 2.71 | Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. ( Assersohn, L; Brown, G; Cunningham, D; Hill, ME; Norman, AR; Oates, J; Ward, C; Waters, JS, 2004) |
| " A study was conducted of a novel treatment, EMR combined with CRT, for patients with superficial esophageal carcinoma." | 2.71 | EMR combined with chemoradiotherapy: a novel treatment for superficial esophageal squamous-cell carcinoma. ( Asaka, M; Fujita, M; Hosokawa, M; Kato, M; Nakagawa, S; Shimizu, Y; Tsukagoshi, H; Yamamoto, J, 2004) |
| "The paclitaxel dose was started at 75 mg/m(2) (n = 7) and escalated to 125 mg/m(2) (n = 5), at which point, dose-limiting toxicities occurred." | 2.71 | Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. ( Ancukiewicz, M; Choi, N; Donahue, D; Lynch, T; Mathisen, D; Park, SD; Wain, J; Wright, C, 2004) |
| "Patients with previously untreated esophageal cancer were eligible if they had performance status 0-1, were 75 years or younger and had adequate organ function." | 2.71 | Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer. ( Fujitani, K; Hirao, M; Tsujinaka, T, 2004) |
| "Dysphagia was measured at the beginning and completion of treatment and at monthly intervals until death, using a modified DeMeester (4-point) score." | 2.71 | Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. ( Beller, E; Bessell, JR; Burmeister, BH; Burmeister, E; Doyle, L; Gotley, DC; Harvey, JA; Martin, I; Smithers, BM; Thomas, J; Thomson, DB; Walpole, ET, 2004) |
| "Patients with locally advanced squamous cell carcinoma of the esophagus, who respond to preoperative neoadjuvant combined radiochemotherapy, seem to have more benefit from subsequent resection than non-responding patients." | 2.71 | Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. ( Brücher, BL; Busch, R; Dittler, HJ; Fink, U; Molls, M; Sarbia, M; Siewert, JR; Stein, HJ; Werner, M; Zimmermann, F, 2004) |
| " This study was to compare effects and toxicities of intratumoral H101 injection combined with cisplatin plus 5-fluorouracil (PF) regimen or adriamycin plus 5-fluorouracil (AF) regimen versus PF or AF regimen alone in treating patients with head and neck or esophagus squamous cell cancer." | 2.71 | [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. ( Chang, JH; Chen, JC; Chen, ZC; Fan, QX; Guan, ZZ; Hu, XH; Huang, JJ; Jiang, WQ; Liu, JW; Lu, JW; Wang, HQ; Wu, GH; Xia, ZJ; Zhang, L; Zhang, Y; Zheng, X; Zhou, QH, 2004) |
| "Esophageal cancer has a poor prognosis." | 2.71 | [Phase I study of the combination of nedaplatin (NED), adriamycin (ADM), and 5-fluorouracil (5-FU) (NAF) for treatment of unresectable advanced esophageal cancer]. ( Fujitani, K; Hirao, M; Tsujinaka, T, 2005) |
| "Celecoxib (Celebrex) was administered at 200 mg orally twice daily beginning on day 1 until surgery and then at 400 mg orally twice daily until disease progression or unexpected toxicities, or for a maximum of 5 years." | 2.71 | Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. ( Ansari, R; Fineberg, N; Fox, E; Govindan, R; Hanna, N; Helft, P; Kesler, K; Mantravadi, P; McLeod, H; Stoner, C, 2004) |
| "5-Fluorouracil 225 mg/m2 was delivered as a continuous infusion on days 1 through 38." | 2.71 | Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification. ( Bader, SB; Louie, J; Molendyk, J; Phillips, M; Regan, J; Ross, HJ; Ruzich, J; Seligman, M; Seung, SK; Skokan, L; Smith, JW; Soo, E, 2004) |
| "Patients with locally advanced squamous cell carcinoma (SCC) of the esophagus were randomly allocated to either induction chemotherapy followed by chemoradiotherapy (40 Gy) followed by surgery (arm A), or the same induction chemotherapy followed by chemoradiotherapy (at least 65 Gy) without surgery (arm B)." | 2.71 | Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. ( Budach, W; Franke, C; Klump, B; Lehmann, N; Meyer, HJ; Schmitt, G; Schmitt, M; Seeber, S; Stahl, M; Stuschke, M; Teichmann, R; Walz, MK; Wilke, H, 2005) |
| "To define the maximum-tolerated dose of oxaliplatin given with cisplatin, protacted 96-h infusion of fluorouracil, and radiotherapy for patients with advanced esophageal cancer." | 2.71 | Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma. ( Cervantes, A; Chirivella, I; Conill, C; Gallego, R; Manzano, H; Marfa, X; Martin-Richard, M; Maurel, J; Pera, M; Salazar, R, 2005) |
| "Forty-three patients with a T4 esophageal cancer were enrolled in a prospective study in which each patient decided for themselves a treatment arm, CRT-followed-by-esophagectomy or esophagectomy-followed-by-CRT." | 2.71 | Prospective non-randomized trial comparing esophagectomy-followed-by-chemoradiotherapy versus chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers. ( Fujita, H; Hayabuchi, N; Inutsuka, H; Sasahara, H; Shirouzu, K; Sueyoshi, S; Suzuki, G; Tanaka, T; Tanaka, Y, 2005) |
| "Patients with either adenocarcinoma or squamous cell carcinoma of the esophagus could enroll; however, patients could not have received prior chemotherapy for metastatic disease." | 2.71 | A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. ( Ahuja, H; Bailey, H; Berlin, JD; Hansen, R; Jumonville, A; Kim, K; McFarland, T; Morgan-Meadows, S; Mulkerin, D; Saphner, T; Thomas, JP, 2005) |
| "For locally advanced esophageal cancer, the combination of esophagectomy, post-operative CCRT with weekly cisplatin and systemic adjuvant chemotherapy is well tolerated and effective." | 2.71 | Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy. ( Chang, CC; Chen, CC; Chen, MJ; Chen, YJ; Huang, CJ; Hung, SK; Liu, HC; Lu, LH; Tai, CJ; Tzen, CY, 2005) |
| "This study analyzed the impact on long-term results of an increase in the dosage of an induction chemoradiotherapy protocol for squamous cell carcinoma (SCC) of the thoracic esophagus." | 2.71 | Induction chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus: impact of increased dosage on long-term results. ( Bernini, M; Cordiano, C; de Manzoni, G; Grandinetti, A; Laterza, E; Pasini, F; Pedrazzani, C; Ruzzenente, A; Tomezzoli, A; Zerman, G, 2005) |
| "Thirty patients with squamous cell carcinoma of the esophagus received CRT followed by surgery." | 2.71 | Chemoradiotherapy for T3 and T4 squamous cell carcinoma of the esophagus using low-dose FP and radiation: a preliminary report. ( Fujiwara, M; Fujiwara, Y; Inoue, T; Kamikonya, N; Koishi, K; Kojima, S; Nakagawa, K; Nakao, K; Nishiwaki, M; Yagyu, R; Yamamura, T; Yoshikawa, R, 2005) |
| "From 1991 to 1997, 83 consecutive esophageal cancer patients underwent surgical exploration after completion of two cycles of cisplatin and 5-fluorouracil chemotherapy regimens, either in pulse or in continuous infusion cycles." | 2.70 | The clinical efficacy of neoadjuvant chemotherapy in squamous esophageal cancer: a prospective nonrandomized study of pulse and continuous-infusion regimens with Cisplatin and 5-Fluorouracil. ( Chan, AC; Chung, SC; Griffith, JF; Lam, CC; Lam, YH; Lau, JY; Lee, DW; Leung, SF; Ng, EK, 2002) |
| "33 had squamous carcinoma and 7 adenocarcinoma; 15 were male; the locoregional metastatic ratio was 1:39; median ECOG performance status was 2 (range 1-3)." | 2.70 | A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma. ( Ajarim, D; Al Fadda, M; Bazarbashi, S; El Weshi, A; Ezzat, A; Memon, M; Pai, C; Rahal, M; Raja, MA, 2002) |
| " This phase I study was designed to find the maximum tolerated dose (MTD) of weekly cisplatin in combination with standard doses of gemcitabine (1,000 mg/m(2), 30 min) and 5-FU (750 mg/m(2), 24 h)/folinic acid (200 mg/m(2), 30 min)." | 2.70 | Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer. ( Arnold, D; Hoepffner, N; Kern, M; Neuhaus, P; Oettle, H; Riess, H; Settmacher, U, 2002) |
| "We evaluated the clinical effect of 5-FU and low-dose Cisplatin (LFP) therapy alone and LFP therapy combined with radiation therapy in patients with advanced or recurrent esophageal cancer." | 2.70 | [Preliminary clinical evaluation of continuous infusion of 5-FU and low-dose Cisplatin (LFP) therapy alone and combined with radiation therapy for treatment of advanced or recurrent esophageal cancer]. ( Horimi, T; Itoh, S; Morita, S; Ohnishi, T; Takamatsu, M; Tsuji, A, 2002) |
| "Thirty-seven patients with cT4 squamous cell carcinoma of the thoracic esophagus were enrolled in this study." | 2.70 | Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. ( Aoki, K; Iijima, S; Ikeda, K; Ishida, K; Iwaya, T; Kimura, Y; Koeda, K; Maesawa, C; Nakamura, R; Ogasawara, S; Saito, K; Sato, N; Uesugi, N, 2001) |
| "Weight gain was observed in 48% of patients, and dysphagia improved in 76%." | 2.70 | Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. ( Artru, P; Baujat, B; Carola, E; de Gramont, A; Krulik, M; Louvet, C; Mabro, M; Maindrault, F; Taïeb, J; Tournigand, C, 2002) |
| "Postoperative complications were reported in 146 (41%) CS and 161 (42%) S patients." | 2.70 | Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. ( , 2002) |
| "To identify a dose and schedule of oxaliplatin (OXP) to be safely administered in combination with protracted-infusion (PI) fluorouracil (5-FU) and external-beam radiation therapy (XRT) for patients with primary esophageal carcinoma (EC)." | 2.70 | Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. ( Berdzik, J; Bodnar, L; Douglass, H; Greco, W; Khushalani, NI; Klippenstein, D; Leichman, CG; Leichman, L; Litwin, A; Nava, E; Nava, H; Pendyala, L; Proulx, G; Smith, J; Smith, P, 2002) |
| "Thirteen patients with esophageal cancer were randomly placed in either a control or a glutamine group." | 2.69 | Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer. ( Fujita, H; Matsui, M; Shirouzu, K; Shirouzu, Y; Yamana, H; Yoshida, S, 1998) |
| "Paclitaxel is an important new agent in the treatment of esophageal carcinoma, and further evaluation of this agent in combination chemotherapy is warranted." | 2.69 | Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. ( Ajani, J; Bhalla, K; Donegan, J; Forastiere, A; Huang, Y; Ilson, DH; Kelsen, DP; Martin, L; Patel, P; Pazdur, R; Reed, C, 1998) |
| " To clarify the pharmacokinetic differences according to the administration schedules of cisplatin, we compared three different administration schedules of cisplatin such as single short-term infusion, daily short-term infusion and daily continuous infusion in combination with 5-fluorouracil." | 2.69 | Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. ( Ikeda, K; Ishida, K; Iwaya, T; Kawamura, H; Koeda, K; Maesawa, C; Saito, K; Sato, N; Takagane, A; Takiyama, I; Terashima, M; Yoshinari, H, 1998) |
| "Squamous cell cancer of the esophagus is the most common cancer among black South African males, and 60% of patients present with localized inoperable disease." | 2.69 | A randomized study of radiotherapy alone versus radiotherapy plus 5-fluorouracil and platinum in patients with inoperable, locally advanced squamous cancer of the esophagus. ( Burger, W; Falkson, CI; Falkson, G; Nel, JS; Schoeman, L; Slabber, CF, 1998) |
| "Since the prognosis of patients with T4 squamous cell carcinoma (SCC) of the esophagus is extremely poor, an effective multimodal treatment needs to be established." | 2.69 | Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. ( Doki, Y; Inoue, M; Inoue, T; Monden, M; Shiozaki, H; Tanaka, E; Tsujinaka, T; Yamamoto, M; Yano, M, 1999) |
| "The cases with esophageal cancer, stomach cancer, pancreatic cancer, hepatocellular carcinoma or colonic cancer co-existing with their inoperable lesion(s) were considered in this chemotherapy." | 2.69 | [Biochemical modulation of 5-FU--effect of low dose CDDP]. ( Denno, R; Hirata, K; Kimura, H; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Tsuji, A; Yamamitsu, S, 1999) |
| "Two of 13 patients with squamous cell carcinoma (SCC) had a complete response (CR), but one died of pneumonia after 9 months while still in CR, and the other still in CR after more than 5 years." | 2.69 | Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma. ( Bjarnason, GA; Cripps, C; Fields, AL; Goel, R; Hrincu, A; Jensen, JL; Kerr, IA; Khoo, KE; Warner, E, 1999) |
| "The aim of this study was to clarify whether preoperative chemotherapy caused adverse effects on the perioperative course of patients undergoing esophagectomy." | 2.69 | Does preoperative chemotherapy cause adverse effects on the perioperative course of patients undergoing esophagectomy for carcinoma? ( Aikou, T; Baba, M; Fukumoto, T; Kusano, C; Nakano, S; Natsugoe, S; Shimada, M; Shirao, K, 1999) |
| "Paclitaxel and cisplatin were administered as postoperative adjuvant therapy." | 2.69 | Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. ( Burtness, BA; Canto, MI; Forastiere, AA; Heath, EI; Heitmiller, RF; Kaufman, HS; Kleinberg, L; Knisely, JP; Olukayode, K; Salem, R; Talamini, MA; Topazian, M; Wu, TT; Yang, SC, 2000) |
| "From 1992 to 1998, 34 of 131 total esophageal cancer patients were designated stage III (16 T3N1, 9 T4N0, 9 T4N1) and medically fit to enter a combined modality protocol with continuous infusion 5-fluorouracil (CIS-FU, 300 to 600 mg/m2/day), high-dose external beam irradiation (60 Gy), and interval esophagectomy." | 2.69 | Aggressive multimodality therapy for stage III esophageal cancer: a phase I/II study. ( Alexander, EP; Harmon, J; Lipman, T; Wadleigh, R, 2000) |
| "This paclitaxel-based treatment regimen for locoregionally advanced esophageal cancer produced increased toxicity with no improvement in results when compared with our previous 5-FU experience." | 2.69 | Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. ( Adelstein, DJ; Ciezki, J; DeCamp, M; Dumot, JA; Larto, MA; Rice, TW; Rybicki, LA; Saxton, J; Vargo, JJ; Zuccaro, G, 2000) |
| "Between 1994 and 1997, 22 patients with dysphagia from advanced incurable esophageal cancer were enrolled in a phase I/II prospective study to assess the palliative benefit and toxicity of a short course of radiotherapy with chemotherapy." | 2.69 | A prospective trial of short-course radiotherapy plus chemotherapy for palliation of dysphagia from advanced esophageal cancer. ( Hayter, CR; Huff-Winters, C; Paszat, L; Schulze, K; Shelley, WE; Youssef, YM, 2000) |
| "To determine the dose-limiting toxicity of CPT-11 in combination with oxaliplatin, and the maximal tolerated dose (MTD) and the recommended dose (RD) of CPT-11 using an every two weeks schedule." | 2.69 | Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. ( Cvitkovic, E; Di Palma, M; Goldwasser, F; Gross-Goupil, M; Marceau-Suissa, J; Misset, JL; Tigaud, JM; Wasserman, E; Yovine, A, 2000) |
| " However, in combination with radiation therapy, this regimen is tolerable when the primary goal is palliation of dysphagia near the end of life." | 2.68 | Split-course accelerated radiation therapy combined with carboplatin and 5-fluorouracil for palliation of metastatic or unresectable carcinoma of the esophagus. ( Turrisi, AT; Urba, SG, 1995) |
| "Conventional treatment of esophageal cancer with surgery or radiation alone has afforded few long-term survivors." | 2.68 | Preoperative chemoradiotherapy for locoregional esophageal cancer: preliminary report. ( Chang, HS; Choi, EK; Kim, SB; Kim, SH; Kim, SW; Lee, JS; Lee, JW; Lee, KH; Song, HY; Suh, CW, 1995) |
| "The histology was squamous cell carcinoma in 44 patients and adenocarcinoma in 3 patients with esophagus cancer." | 2.68 | Chemotherapy rapidly alternating with twice-a-day accelerated radiation therapy in carcinomas involving the hypopharynx or esophagus: an update. ( Beattie, E; Malamud, S; Nussbaum, M; Vikram, B; Yu, L; Yudelman, I, 1995) |
| "Six patients (21%) had residual cancer in the resected specimen, either at the primary site or--more often--in adjacent lymph nodes." | 2.68 | Treating esophageal cancer with a combination of chemotherapy, radiation, and excision. ( Bates, DM; Clyde, JC; Garcia, JM; Girvin, GW; Lin, PH; Matsumoto, GH, 1995) |
| "5-fluorouracil, 750 mg m-2, was administered via continuous 5-day infusion beginning day 1 and weekly thereafter; interferon, 10 mu subcutaneously, was administered three times per week beginning day 1 and sargramostin, 5 micrograms kg-1, was administered on days without 5-fluorouracil." | 2.68 | Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer. ( Beitler, JJ; Fell, S; Haynes, H; Levine, BA; Rozenblit, A; Wadler, S; Wolf, E, 1995) |
| "From January 1990 to April 1993, 60 oesophageal cancer patients were enrolled in a protocol of non-surgical treatment that consisted of induction chemotherapy followed by concurrent chemoradiotherapy." | 2.68 | Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer. ( Aman, E; Barugel, M; Blajman, C; Carraro, S; Fiorini, A; Giglio, R; Gonzalez, G; Jarentchuk, A; Kneitschel, R; Milano, C; Nadal, J; Navigante, A; Pennella, E; Roca, E; Santarelli, MT; Sardi, M, 1996) |
| "Since 1984, 373 patients with oesophageal cancer have been treated on three prospective, but unrandomised, protocols involving radiation with concurrent cisplatin and infusional fluorouracil." | 2.68 | Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG) ( Burmeister, BH; Denham, JW; Hamilton, CS; Joseph, DJ; Lamb, DS; O'Brien, P; Spry, NA; Walker, QJ; Yeoh, E, 1996) |
| " Recommendations are made concerning initial dosing, dose reductions and delays to minimize adverse patient outcomes from myelosuppression." | 2.68 | Concurrent chemoradiation for oesophageal cancer: factors influencing myelotoxicity. ( Burmeister, BH; Denham, JW; Lamb, DS; MacKean, J, 1996) |
| "Twenty-five patients with esophageal cancer were treated in a phase I pilot protocol consisting of initial esophagectomy with gastroesophagostomy and subsequent combined chemotherapy and radiation." | 2.68 | Integration of surgery in multimodality therapy for esophageal cancer. ( Doolas, A; Ebie, N; Griem, K; Hartsell, W; Kang, HJ; Millikan, K; Murthy, AK; Recine, DC; Taylor, S, 1997) |
| "Thirteen patients with advanced squamous cell carcinoma of the esophagus were treated with 1,000 mg/m2/day 5-fluorouracil days 1-5 continuously and 100 mg/m2 cisplatin on day 1." | 2.68 | Sequential chemotherapy and radiotherapy for squamous cell esophageal carcinoma. ( Davis, EB; Hussain, MA; Krasnow, SH; Lunzer, S; Sharma, D; Wadleigh, RG, 1997) |
| "The response rate was 56." | 2.68 | [Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors--nationwide questionnaire survey]. ( Aiba, K; Araki, H; Chung, Y; Hirata, K; Saji, S; Sasaki, K; Shirasaka, T; Sowa, M; Tanaka, M; Toge, T; Wada, H; Yamamitsu, S; Yasumoto, K, 1997) |
| "Forty patients with esophageal cancer were treated in a phase I and II trial of induction chemotherapy (cisplatin, 5-fluorouracil, and paclitaxel) at three dosage levels (75, 125, and 100 mg/m2) and concurrent hyperfractionated radiotherapy (45 Gy to the mediastinum, 58." | 2.68 | Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. ( Carey, RW; Choi, NC; Grillo, HC; Grossbard, ML; Lynch, TJ; Mathisen, DJ; Moncure, AC; Wain, JC; Wright, CD, 1997) |
| "Locally advanced esophageal cancer is rarely operable and has a dismal prognosis." | 2.68 | First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up. ( Ancona, E; Bonavina, L; Castoro, C; Chiarion-Sileni, V; Merigliano, S; Peracchia, A; Ruol, A; Santi, S, 1997) |
| "Patients with localized esophageal cancer also received radiation therapy beginning on day 1 (1." | 2.68 | Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial. ( Greco, FA; Hainsworth, JD; Meluch, AA, 1997) |
| "The paclitaxel dose levels were 25 mg/m2 in four patients, 40 mg/m2 in five patients, 60 mg/m2 in nine patients, and paclitaxel 50 mg/m2 with 5-FU reduced to 200 mg/m2 in nine patients." | 2.68 | Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. ( Coia, LR; Colarusso, P; Dresler, C; Goldberg, M; Weiner, LM, 1997) |
| "FLEP is an active combination for oesophageal cancer, especially when used preoperatively in LAD." | 2.67 | 5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus. ( Achterrath, W; Berger, M; Berns, T; Fink, U; Harstrick, A; Knipp, H; Meyer, HJ; Preusser, P; Stahl, M; Wilke, H, 1994) |
| "Thirteen patients had squamous cell carcinoma and 8 adenocarcinoma." | 2.67 | Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon. ( Fell, S; Haynes, H; Kaleya, R; Katz, HJ; Rozenblit, A; Wadler, S; Wiernik, PH, 1993) |
| "A prospective randomized trial in 64 esophageal cancer patients was conducted from 1986 to 1989." | 2.67 | [Randomized trial of combined chemotherapy including high dose cisplatin and radiotherapy for esophageal cancer]. ( Zhou, JC, 1991) |
| "Significant improvement in dysphagia was recorded in 76% patients with complete response in 47 cases ranging from 6 to 27 months." | 2.67 | The role of intraluminal radiotherapy and concurrent 5-fluorouracil infusion in the management of carcinoma esophagus: a pilot study. ( Desai, PB; Deshpande, R; Dinshaw, KA; Malliat, MK; Pendse, AM; Sharma, V; Telang, CS; Vege, SS, 1991) |
| "Eight patients with untreated squamous cell carcinoma of the esophagus accompanying distant metastases who were treated by one to five cycles of chemotherapy consisting of Cisplatin and 120 hour infusion of 5-Fluorouracil were reported." | 2.67 | [Combined radiotherapy and pre-radiation chemotherapy with cisplatin and 5-fluorouracil for advanced esophageal carcinoma. I. Clinical evaluation in cases with distant metastases]. ( Sueyama, H, 1990) |
| "Hyperammonemia is a rare adverse event of 5-FU." | 2.66 | [Hyperammonemia with Disturbance of Consciousness during 5-FU plus Nedaplatin Therapy for Esophageal Cancer-A Case Report]. ( Hirakawa, T; Hirata, K; Iwauchi, T; Kurihara, S; Matsutani, S; Miyamoto, H; Morimoto, J; Nagashima, D; Okada, T; Takeuchi, K; Tanaka, H; Tsujio, G; Uchima, Y; Yamagata, S, 2020) |
| "By histology, 22 cases were squamous cell carcinoma, 1 adenocarcinoma and 2 squamous adenocarcinoma." | 2.66 | [Preoperative chemotherapy of esophageal cancer]. ( Wang, ZY, 1986) |
| " day 1, 2, 23 and 24) was applied with the same schedule and dosage of radiation." | 2.65 | The value of two combined chemoradiotherapy approaches in the treatment of inoperable esophageal cancer. ( Dujmović, I; Kolarić, K; Roth, A, 1984) |
| "According to the Trastuzumab for Gastric Cancer (ToGA) study, trastuzumab plus cisplatin and capecitabine/5-fluorouracil (5-FU) is standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced oesophagogastric cancer." | 2.58 | Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis. ( Creemers, A; de Waal, L; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH, 2018) |
| "Approximately 20% of patients with cancer of the stomach or gastro-oesophageal junction (GOJ) present with resectable disease." | 2.55 | The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. ( Cartwright, E; Cunningham, D, 2017) |
| "The predominant histological types of esophageal cancer are adenocarcinoma and squamous cell carcinoma." | 2.55 | Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma. ( Baba, H; Baba, Y; Maehara, Y; Nakashima, Y; Oki, E; Saeki, H; Shigaki, H; Watanabe, M; Yoshida, N, 2017) |
| "In the UK, the standard of care for esophageal cancer has generally combined surgery with neoadjuvant chemotherapy, with definitive chemoradiotherapy (dCRT) being reserved for certain subgroups." | 2.52 | Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature. ( Cook, N; Gilligan, D; Hategan, M; Hindmarsh, A; Prewett, S; Qian, W, 2015) |
| "Esophageal cancer is thought to be the most malignant neoplasm due to its biological aggressiveness." | 2.52 | Chemoradiotherapy and surgery for T4 esophageal cancer in Japan. ( Akutsu, Y; Matsubara, H, 2015) |
| "In the West, where esophageal cancer occurs more frequently than gastric cancer, a phase III trial (the CROSS trial) demonstrated the efficacy of preoperative chemoradiotherapy using carboplatin plus paclitaxel for patients with esophageal or EGJ cancer." | 2.52 | [Adjuvant treatment for esophagogastric junction cancer]. ( Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M, 2015) |
| "When paclitaxel plus platinum was compared with platinum plus 5-fluorouracil, the hazard ratios (95% CrI) in the entire, squamous cell carcinoma, and adenocarcinoma population were 0." | 2.52 | Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer. ( Hsu, CH; Huang, TC; Lin, CC; Tu, YK, 2015) |
| "One of them was well differentiated tubular adenocarcinoma which occupied in mucosal layer." | 2.52 | Resection of a Submucosal Tumor-Like Superficial Carcinoma in Middle Thoracic Esophagus Concomitant with Mucosal Adenocarcinoma and Submucosal Squamous Cell Carcinoma: A Case Report and Review of Literature. ( Chino, O; Kazuno, A; Kumaki, N; Makuuchi, H; Ozawa, S; Sakai, I; Shimada, H; Tamayama, T; Yamamoto, S; Yasuda, S, 2015) |
| "The treatment for esophageal squamous cell carcinoma (SCC) depends on its etiology." | 2.49 | Treatment options for esophageal squamous cell carcinoma. ( Kato, H; Nakajima, M, 2013) |
| "Esophageal carcinosarcoma is a rare malignant tumor." | 2.49 | [Esophageal carcinosarcoma treated with surgery and chemoradiotherapy-a report of 4 cases]. ( Fujiwara, H; Ichikawa, D; Ikoma, H; Komatsu, S; Konishi, H; Kubota, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Okamoto, K; Otsuji, E; Sakakura, C; Shimizu, H; Shiozaki, A; Takemoto, K, 2013) |
| "For cT2 N0 esophageal cancer patients, the benefit of neoadjuvant therapy is still unclear." | 2.48 | Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging. ( Brock, MV; Franco, N; Hooker, CM; How, R; Hulbert, A; Lee, S; Prevas, H; Shin, J; Yang, SC; Zhang, JQ, 2012) |
| "Studies that included patients with metastases at enrollment were excluded." | 2.48 | Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis. ( Cai, XH; Ge, L; Lei, C; Wang, HJ; Yin, D; Zhang, GQ; Zhu, JF, 2012) |
| "Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug." | 2.45 | The role of capecitabine in the management of tumors of the digestive system. ( Gennatas, C; Gennatas, S; Michalaki, V, 2009) |
| "The optimal management of locoregional esophageal cancer is controversial." | 2.44 | Combined-modality therapy for esophageal and gastroesophageal junction cancers. ( Gibson, MK; Yoon, HH, 2007) |
| "Gemcitabine is a well-tolerated anti-tumour drug with broad-spectrum activity." | 2.44 | [Gemcitabine and digestive carcinomas]. ( André, T; Blanchard, P; Huguet, F, 2007) |
| " Dosing of S-1 is different between Western and Asian populations due to differences in metabolism by CYP2A6." | 2.44 | Medical treatment for advanced gastroesophageal adenocarcinoma. ( Ajani, JA; Cen, P, 2007) |
| "Colorectal cancers have been the first cancers to benefit from an efficient anti-angiogenic treatment, represented by bevacizumab, which has been approved for first-line metastatic treatment in combination with reference chemotherapies and which is under study in the adjuvant setting." | 2.44 | [Angiogenesis targeting in gastro-intestinal cancers]. ( Meric, JB, 2007) |
| "Recently in esophageal cancer, radiation therapy has been more frequently combined with other modalities including chemotherapy and surgery." | 2.43 | [The role of radiotherapy in the management of esophageal cancer]. ( Badzio, A; Jassem, J; Serkies, K, 2005) |
| "Esophageal cancer is the ninth most common malignancy in the world and the seventh leading cause of death in American men." | 2.43 | Docetaxel in the treatment of esophageal cancer. ( Bubis, JA; Dragnev, KH; Rigas, JR, 2005) |
| "Capecitabine is a novel, orally administered fluoropyrimidine carbamate that has been approved for adjuvant treatment in patients with Stage III colon cancer, first-line metastatic colorectal cancer, and metastatic breast cancer, both as a single agent (for patients who are resistant to paclitaxel and anthracyclines) and in combination with docetaxel (after failure on anthracycline-based therapy)." | 2.43 | Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. ( Ajani, J, 2006) |
| "Formerly the treatment of gastrointestinal cancers was exclusively surgical." | 2.43 | [Progress in the treatment of gastrointestinal cancers due to introduction of neoadjuvant concept]. ( Cseke, L; Esik, O; Horváth Ors, P; Kalmár, K; Papp, A; Yousuf, AF, 2006) |
| "In advanced pancreatic cancer, oxaliplatin has been found to be clinically effective in phase II trials in which it was combined with either 5-fluorouracil (5-FU) or gemcitabine, the current standard chemotherapy for this disease." | 2.42 | The role of oxaliplatin in the management of upper gastrointestinal tract malignancies. ( Scheithauer, W; Van Cutsem, E, 2003) |
| "Since mucosal (T1a) esophageal cancer is well controlled by endoscopic treatment, chemoradiotherapy (CRTx) is not indicated." | 2.42 | [Chemoradiotherapy for esophageal cancer]. ( Fujita, H; Hayabuchi, N; Matono, S; Sasahara, H; Shirouzu, K; Sueyoshi, S; Suzuki, G; Tanaka, T; Yamana, H, 2003) |
| "Capecitabine is an oral 5-fluorouracil (5-FU) prodrug that is more convenient than using infusional 5-FU, appears to have a similar therapeutic profile, and can be combined with daily irradiation." | 2.42 | COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas. ( Rich, TA; Shepard, R, 2003) |
| "However, since esophageal cancer can hardly be cured by definitive chemotherapy alone, chemotherapy plays an important role in the multimodality therapy for esophageal cancer." | 2.42 | [Chemotherapy for esophageal cancer]. ( Nabeya, Y; Ochiai, T, 2003) |
| "Among the gastrointestinal cancers, esophageal cancer is supposed to be relatively sensitive to both radiotherapy and chemotherapy." | 2.41 | [Progress of postoperative adjuvant therapies for esophageal cancer]. ( Gotoh, M; Kogure, M; Terashima, M, 2002) |
| "We report here a very rare case of chronic myeloid leukemia (CML) with a minor bcr-abl transcript, which developed following long-term chemotherapy with fluorouracil for esophageal carcinoma." | 2.41 | A case of chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma. ( Dan, K; Hanawa, H; Inokuchi, K; Nakamura, H; Tajika, K; Tamura, H; Yamaguchi, H, 2000) |
| "Irinotecan (Camptosar) has shown activity in several solid tumor malignancies, including gastric and pancreatic cancer." | 2.41 | Irinotecan in esophageal cancer. ( Enzinger, PC; Ilson, DH, 2000) |
| "On the other hand, as esophageal cancer is treated mainly by surgery in Japan, CRT is applied in patients with tumors invading adjacent organs, and a high pathological complete response rate is reported in some neoadjuvant studies." | 2.41 | [Chemoradiation therapy for esophageal cancer]. ( Hirakawa, K; Kubo, N; Matsumura, Y; Ohira, M; Yamashita, Y; Yamazaki, M, 2002) |
| "Salvage surgery for the T4 esophageal cancer following downstaging by neoadjuvant chemo-radiotherapy has become to be available." | 2.40 | [Salvage surgery for the T4 esophageal cancer following downstaging by neoadjuvant chemoradiotherapy]. ( Ando, N; Kitagawa, Y; Kitajima, M; Ozawa, S; Takeuchi, H, 1997) |
| "Advanced esophageal cancer, which invades into neighboring organs are classified as T4 esophageal cancer." | 2.40 | [Esophagectomy combined resection of invaded neighboring organs for T4 esophageal carcinoma]. ( Ayabe, H, 1997) |
| "Paclitaxel was well tolerated." | 2.40 | Treatment of patients with upper gastrointestinal carcinomas. ( Ajani, JA, 1997) |
| "Eighty percent of the patients had squamous cell carcinoma and 20% had adenocarcinoma." | 2.39 | Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. ( Bates, BA; Bernard, SA; Detterbeck, FC; Qaqish, BF; Tepper, JE, 1996) |
| "However, in gastric cancer, 5-FU/FA and 5-FU/IFN seem to induce higher complete and overall remission rates in advanced gastric cancer compared with 5-FU alone." | 2.38 | Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer. ( Achterrath, W; Fink, U; Harstrick, A; Knipp, H; Köhne-Wömpner, CH; Meyer, HJ; Preusser, P; Schmoll, HJ; Stahl, M; Wilke, H, 1992) |
| "Thirteen patients with previously untreated advanced squamous cell carcinoma of the esophagus were treated with pre-radiation chemotherapy followed by radiation therapy." | 2.38 | [Combined radiotherapy and pre-radiation chemotherapy with cisplatin and 5-fluorouracil for advanced esophageal carcinoma. II. Clinical evaluation in cases with higher than T2 stage]. ( Sueyama, H, 1990) |
| " The advantages of chemoradiotherapy in esophageal cancer could be summarized as follows: higher response rate (60-80%), higher proportion of complete responses (up to 45%), longer remission duration, lower radiation dosage (3,200-4,000 cGy) and consequently better tolerance of treatment (less morbidity)." | 2.37 | Combination of cytostatics and radiation--a new trend in the treatment of inoperable esophageal cancer. ( Kolarić, K, 1985) |
| "The prognostic impact of postoperative anastomotic leakage (AL) and pneumonia on survival was evaluated." | 1.91 | Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers. ( Doki, Y; Kakeji, Y; Kawakubo, H; Kitagawa, Y; Matsuda, S; Muto, M; Okamura, A; Okui, J; Takemura, R; Takeuchi, H; Watanabe, M, 2023) |
| "In patients with esophageal cancer, muscle loss induced by neoadjuvant therapy before esophagectomy is correlated with poor prognosis." | 1.91 | Risk Factors for Muscle Loss During Neoadjuvant Therapy for Esophageal Cancer. ( Ebata, T; Fukaya, M; Miyata, K; Shimizu, D; Sugita, S, 2023) |
| "Interestingly, patients with gastroesophageal cancer benefitted more from this therapy." | 1.91 | Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort. ( Brossart, P; Feldmann, G; Gonzalez-Carmona, MA; Jafari, A; Kalff, JC; Köksal, M; Lingohr, P; Mahn, R; Mańczak, A; Möhring, C; Monin, MB; Sadeghlar, F; Sarria, GR; Sommer, N; Strassburg, CP; Timotheou, A; Toma, M; Zhou, T, 2023) |
| "In preoperative chemotherapy for esophageal cancer, the incidence of hematological toxicity was significantly higher in patients with low skeletal muscle mass." | 1.72 | [Effect of Biweekly-DCF Neoadjuvant Chemotherapy on Skeletal Muscle Mass of Esophageal Cancer Patients]. ( Fujii, H; Hatanaka, Y; Imai, T; Mase, J; Matsuhashi, N; Ojio, H; Okumura, N; Sato, Y; Suetsugu, T; Takahashi, T; Tanaka, Y; Yoshida, K, 2022) |
| "In patients with esophageal cancer, oxaliplatin appears to have a lower risk of SIADH than cisplatin, suggesting that oxaliplatin can be a therapeutic option for patients with esophageal cancer who are at high risk of SIADH." | 1.72 | Folinic Acid, Fluorouracil, and Oxaliplatin Therapy for Recurrent Esophageal Cancer with Syndrome of Inadequate Antidiuretic Hormone Secretion (SIADH) After Preoperative Cisplatin/5-Fluorouracil Therapy. ( Abe, T; Futai, R; Hayashi, H; Iemoto, T; Inoue, Y; Morikawa, T; Ose, T; Sanuki, T; Sasaki, A; Yoshie, T, 2022) |
| "DCF-RT for advanced cervical esophageal cancer could achieve a favorable prognosis with larynx preservation." | 1.72 | Definitive Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil for Advanced Cervical Esophageal Cancer: A Medium-Term Outcome. ( Akaishi, R; Ando, R; Fukutomi, T; Horie, Y; Kamei, T; Okamoto, H; Ozawa, Y; Sato, C; Shinozaki, Y; Takahashi, K; Taniyama, Y; Unno, M, 2022) |
| "However, patients with esophageal cancer and PD-L1 CPS ≥ 10 may gain the most LYs from initial PPF treatment." | 1.72 | Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis. ( Ding, D; Liu, K; Peng, L; Zhou, Y; Zhu, Y, 2022) |
| "The esophagus has no serosa; therefore, esophageal cancer may quickly invade its adjacent organs." | 1.72 | Efficacy of thoracotomy and thoracoscopic-assisted esophageal surgery in conversion and salvage surgeries: a retrospective study. ( Gunji, H; Hoshino, I; Kurosaki, T; Kuwayama, N; Nabeya, Y; Soda, H; Takayama, W; Takiguchi, N; Tonooka, T, 2022) |
| "Forty-six patients with cT4b esophageal cancer, including borderline cT4b lesions, were eligible." | 1.72 | Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil. ( Ihara, K; Kikuchi, M; Kojima, K; Kubo, T; Morita, S; Muroi, H; Nakagawa, M; Nakajima, M; Nakamura, T; Takise, S; Yamaguchi, S, 2022) |
| "He was diagnosed with unresectable esophageal cancer with multiple lung metastases(cStage Ⅳb)and gastric cancer(L, Gre, T3N+M0, cStage Ⅲ)." | 1.72 | [A Case of Perforation of Unresectable Esophageal Cancer during Nivolumab Therapy]. ( Hashimoto, K; Kubota, Y; Nagayama, S; Nakahara, H; Nakamura, S; Shimomatsuya, T, 2022) |
| "To compare the chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) and continuous infusion 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) protocols administered in distal esophageal and gastroesophageal junction (GEJ) tumors in terms of effectiveness and toxicity." | 1.62 | CROSS or FLOT in Distal Esophageal and Gastroesophageal Cancer. ( Ates, O; Cakmak Oksuzoglu, OB; Karadag, I; Karakaya, S, 2021) |
| "Oesophageal cancer is categorised among the most fatal cancers across the world with a mortality ranking of sixth position." | 1.62 | Rare presentation of subglottic soft-tissue swelling following FOLFOX therapy in a patient with metastatic oesophageal cancer. ( Govero, AB; Kukhon, FR; Sanghavi, DK; Yarrarapu, SNS, 2021) |
| "Niclosamide is an FDA‑approved anthelmintic drug, and may elicit antineoplastic effects through direct STAT3 inhibition, which has been revealed in numerous human cancer cells." | 1.56 | Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents. ( Chen, YK; Hsu, YJ; Lee, MC; Lin, BR, 2020) |
| "Three patients (25%) developed anastomotic leakage." | 1.56 | Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer. ( Fujiwara, T; Hashimoto, M; Katsui, K; Maeda, N; Nishizaki, M; Noma, K; Sakurama, K; Shirakawa, Y; Tanabe, S, 2020) |
| "Currently, no disease recurrence, dysphagia, or respiratory symptoms have been reported at 13 months after initiating chemoradiotherapy." | 1.56 | Adaptive radiotherapy in locally advanced esophageal cancer with atelectasis: a case report. ( Fujii, K; Mizowaki, T; Sakanaka, K, 2020) |
| "We demonstrated in this study that dose escalation using IMRT in combination with platin-based chemotherapy as a definitive treatment for esophageal carcinoma is safe and results in higher loco-regional and control survival when compared to previously reported data." | 1.56 | Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients. ( Carrère, N; Dalmasso, C; Guimbaud, R; Izar, F; Lusque, A; Modesto, A; Moyal, E; Rives, M; Vieillevigne, L, 2020) |
| "Patients with esophageal cancer treated with dCRT between January 2004 and November 2016 were included in this retrospective analysis." | 1.56 | Definitive chemoradiotherapy for squamous cell carcinoma of the esophagus: outcomes for borderline-resectable disease. ( Ishikura, S; Kondo, T; Miyakawa, A; Murai, T; Ozawa, Y; Shibamoto, Y; Sugie, C; Yanagi, T, 2020) |
| "Among patients with esophageal cancer who received treatment with curative intention, cisplatin-fluorouracil was associated with better survival compared to carboplatin-fluorouracil, while patients with gastroesophageal junction cancer who were treated with cisplatin-fluorouracil had worse survival compared to fluorouracil-oxaliplatin." | 1.56 | Survival of esophageal and gastric cancer patients with adjuvant and palliative chemotherapy-a retrospective analysis of a register-based patient cohort. ( Ebrahim, F; Ekheden, I; Henriksson, R; Ólafsdóttir, H; Raaschou, P; Wettermark, B; Ye, W, 2020) |
| "The patient was diagnosed with advanced esophageal cancer, Mt, type 2, cT2N2M0, stage Ⅱ." | 1.56 | [A Case of Local Remnant Esophageal Cancer after Chemotherapy Getting Complete Response by Radiotherapy]. ( Iwasaki, K; Katsumata, K; Makuuchi, Y; Nagakawa, Y; Osaka, Y; Ota, Y; Sato, S; Seshimo, A; Suda, T; Tachibana, S; Takahashi, K; Tsuchida, A; Watanabe, T, 2020) |
| "Esophageal cancer is increasingly common and carries a poor prognosis." | 1.56 | Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis. ( Bateman, A; Byrne, JP; Grace, BL; Iveson, T; Jackson, A; Kelly, JJ; Noble, F; Pucher, PH; Rahman, SA; Rees, C; Underwood, TJ; Walker, RC, 2020) |
| "Severe neutropenia is dose-limiting toxicity of docetaxel and it is well known to be frequently occurred during DCF chemotherapy." | 1.56 | ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. ( Daiko, H; Demachi, K; Fujii, S; Itoh, K; Kawasaki, T; Kojima, T; Matsuzawa, H; Mochizuki, N; Nomura, H; Tsuji, D; Yano, T, 2020) |
| "Definitive chemoradiotherapy(CRT)for esophageal cancer is the standard treatment and alternative to surgery." | 1.56 | [Tolerability of Definitive Chemoradiotherapy in Elderly Patients with Esophageal Cancer]. ( Asagi, A; Hamamoto, Y; Hasebe, A; Hino, K; Hori, S; Inoue, T; Kajiwara, T; Kataoka, M; Nadano, S; Nakasya, A; Nishide, N; Nishina, T; Sakaguchi, C; Tanimizu, M; Terao, T; Yoshimatsu, M, 2020) |
| "She was diagnosed with esophageal cancer (cT3N2M0, stage III)." | 1.56 | A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy. ( Asano, T; Fujiki, K; Furumoto, Y; Hayakawa, Y; Horiuchi, T; Kobayashi, K; Matsumoto, T; Matsuoka, M; Misumi, Y; Miura, N; Nozaka, T; Sakamoto, N, 2020) |
| " We evaluated the relationships between the dysphagia score at diagnosis and clinicopathological factors, including DCF therapy-related adverse events, tumor response, and survival." | 1.51 | Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer. ( Doki, Y; Hagi, T; Kimura, Y; Makino, T; Mori, M; Motoori, M; Nishida, N; Sakai, D; Satoh, T; Tanaka, K; Yamasaki, M, 2019) |
| "Oropharyngeal and esophageal squamous cell carcinomas, especially the latter, are a lethal disease, featuring intratumoral cancer cell heterogeneity and therapy resistance." | 1.51 | Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells. ( Arigami, T; Avadhani, NG; Bass, AJ; Basu, D; Chandramouleeswaran, PM; Diehl, JA; Doki, Y; Ginsberg, GG; Giroux, V; Hara, T; Kasagi, Y; Kijima, T; Kikuchi, O; Kita, Y; Klein-Szanto, AJ; Mori, M; Muir, AB; Muto, M; Naganuma, S; Nakagawa, H; Natsugoe, S; Ohashi, S; Omoto, I; Rustgi, AK; Sahu, V; Sasaki, K; Shimonosono, M; Shinden, Y; Tanaka, K; Uchikado, Y; Whelan, KA, 2019) |
| "Oral mucositis is an important adverse effect of chemotherapy, and its severity, frequency, and impact on patient quality of life should not be underestimated." | 1.51 | Oral cryotherapy for prophylaxis of oral mucositis caused by docetaxel, cisplatin, and fluorouracil chemotherapy for esophageal cancer. ( Fushida, S; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Tajima, H; Takamura, H; Terai, S; Yamaguchi, T, 2019) |
| "The incidence of elderly patients with esophageal cancer (OC) is increasing as the population ages." | 1.51 | Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers. ( Hu, Y; Huang, C; Li, Q; Liu, H; Liu, M; Yuan, Y; Zhang, W; Zhu, Y, 2019) |
| "To investigate the relationship between treatment-related lymphopenia and pathologic response to neoadjuvant chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC)." | 1.51 | Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy. ( Hu, Y; Li, Q; Liu, M; Liu, S; Xi, M; Yang, H; Zhao, L; Zhou, S, 2019) |
| "We report the case of a long-term esophageal cancer survivor treated by esophageal bypass operation for ERF after chemoradiotherapy (CRT)." | 1.51 | Long-term Esophageal Cancer Survivor Treated by Bypass for Esophagobronchial Fistula After Chemoradiotherapy: A Case Report. ( Emi, M; Hamai, Y; Ibuki, Y; Miyata, Y; Ohsawa, M; Okada, M, 2019) |
| "Long-term outcomes of older esophageal cancer patients (70 y and above) selected for treatment with neoadjuvant chemoradiotherapy followed by surgery or definitive chemoradiotherapy were comparable with the outcomes of their younger counterparts." | 1.48 | Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer. ( Aleman, BMP; Grootscholten, C; Sikorska, K; Snaebjornsson, P; van der Kaaij, RT; van Dieren, JM; van Sandick, JW; van Werkhoven, E; Voncken, FEM, 2018) |
| "Esophageal cancer is a common malignant tumor worldwide." | 1.48 | α-solanine enhances the chemosensitivity of esophageal cancer cells by inducing microRNA‑138 expression. ( Du, X; Li, M; Liu, K; Sun, Q; Wang, L; Wang, Y; Wu, J; Zang, W; Zhao, G, 2018) |
| "Myocardial metastasis for esophageal squamous cell carcinoma(ESCC)is relatively rare and it is diagnosed as a part of widespread metastasis in the terminal stage." | 1.48 | [A Case of Myocardial Metastasis of Esophageal Squamous Cell Carcinoma]. ( Akaishi, T; Hakamada, K; Mitsuhashi, Y; Muroya, T; Sato, K; Suzuki, T; Tsuruta, S; Umemura, K; Umetsu, S; Wajima, N; Wakasa, Y; Yachi, T; Yoshida, T, 2018) |
| "Esophageal fistula was observed in 28 patients (24%)." | 1.48 | Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study. ( Fukutomi, A; Hamauchi, S; Kawakami, T; Kito, Y; Machida, N; Ogawa, H; Omae, K; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T; Yoshida, Y, 2018) |
| "DCF-R treatment for advanced cervical esophageal cancer could be completed by the careful administration; although a strong blood toxicity might occur, this treatment may provide the chance to obtain favorable prognosis with larynx preservation." | 1.48 | Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer. ( Heishi, T; Ishida, H; Ito, K; Kamei, T; Konno-Kumagai, T; Maruyama, S; Okamoto, H; Onodera, Y; Sakurai, T; Sato, C; Taniyama, Y; Teshima, J, 2018) |
| "The change in the dysphagia score from before to after treatment was assessed, and NSFS was evaluated." | 1.48 | Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia. ( Karasawa, K; Kawamoto, T; Nihei, K; Sasai, K, 2018) |
| "Esophageal squamous cell carcinoma (ESCC) exhibits good reactivity to chemoradiation therapy (CRT)." | 1.48 | Correlation between high FBXW7 expression in pretreatment biopsy specimens and good response to chemoradiation therapy in patients with locally advanced esophageal cancer: A retrospective study. ( Baatar, S; Gombodorj, N; Kumakura, Y; Kuriyama, K; Kuwano, H; Miyazaki, T; Nishiyama, M; Sakai, M; Shirabe, K; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T; Yoshida, T, 2018) |
| " The dosage to planning treatment volume was 60 Gy in 30 fractions." | 1.46 | Clinical outcome of definitive radiation therapy for superficial esophageal cancer. ( Abe, T; Itoh, M; Itoh, Y; Kodaira, T; Koide, Y; Makita, C; Muro, K; Naganawa, S; Niwa, Y; Tachibana, H; Tajika, M; Tomita, N, 2017) |
| " Nephrotoxicity that developed within 14 days following CDDP administration was evaluated in accordance with Common Terminology Criteria for Adverse Events ver." | 1.46 | Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study. ( Enokiya, T; Ikemura, K; Ishinaga, H; Iwamoto, T; Katayama, N; Mizuno, T; Muraki, Y; Oda, H; Okamoto, A; Okuda, M; Oshima, K; Takeuchi, K, 2017) |
| "Esophageal squamous cell carcinoma (ESCC) is the second common cancer in Henan province and is well-known for aggressiveness and dismal prognosis." | 1.46 | All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma. ( Cui, H; Li, D; Li, N; Li, S; Lian, J; Lu, T; Lu, Y; Sang, L; Wang, Y; Yu, JJ; Zhang, L; Zheng, X, 2017) |
| "Based on our findings, thoracoscopic esophagectomy is safe and effective for locally advanced EC, even after NAC." | 1.46 | Safety and feasibility of thoracoscopic esophagectomy after neoadjuvant chemotherapy for esophageal cancer. ( Fujiwara, Y; Gyobu, K; Hashiba, R; Kishida, S; Lee, S; Osugi, H; Takemura, M, 2017) |
| "Esophageal squamous cell carcinoma (ESCC) accounts for 80% of all esophageal cancers worldwide." | 1.46 | EGFR Expression in Patients with Esophageal Squamous Cell Carcinoma and its Association with Pathologic Response to Preoperative Chemoradiotherapy: A Study in Northeastern Iran. ( Abdollahi, A; Aledavoud, SA; Anvari, A; Anvari, K; Forghani, MN; Ghaffarzadegan, K; Memar, B; Seilanian Toussi, M; Shahidsales, S; Sima, HR, 2017) |
| "Esophageal cancer is the eighth most common cancer worldwide." | 1.46 | Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience. ( Chen, Y; Hao, D; He, C; Liu, J; Wang, J; Wang, W; Wu, X; Xing, W; Yang, Y, 2017) |
| "Most patients had esophageal cancer (97%) with SCC histology (91%)." | 1.46 | Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers. ( Hiranyatheb, P; Jiarpinitnun, C; Ngamphaiboon, N; Pattaranutaporn, P; Sirachainun, E; Supsamutchai, C; Tamtai, A; Unwanatham, N, 2017) |
| "To diagnose esophageal cancer at an earlier stage, and to improve the effect of anticancer therapy would improve the therapeutic efficacy." | 1.46 | Nano Let‑7b sensitization of eliminating esophageal cancer stem‑like cells is dependent on blockade of Wnt activation of symmetric division. ( Du, N; Li, X; Liang, R; Liu, J; Pang, Y; Ren, H; Sun, X; Tang, SC; Xu, C; Zhang, B; Zhang, J; Zhang, Y, 2017) |
| "We diagnosed unresectable advanced esophageal cancer(cT3N4M0, cStage IV a)." | 1.46 | [A Case of Advanced Esophageal Cancer Successfully Treated with DCF Chemotherapy Followed by Conversion Surgery]. ( Kobayashi, K; Miki, H; Okada, K; Takeoka, T, 2017) |
| "We evaluated esophageal cancer patients treated between 2006 and 2014 with preoperative IMRT chemoradiation to a dose of 50." | 1.46 | Dose escalated neoadjuvant chemoradiotherapy with dose-painting intensity-modulated radiation therapy and improved pathologic complete response in locally advanced esophageal cancer. ( Abuodeh, Y; Almhanna, K; Fontaine, JP; Frakes, JM; Hoffe, SE; Meredith, KL; Naghavi, AO; Pimiento, JM; Shridhar, R; Venkat, PS, 2017) |
| "Esophageal squamous cell carcinoma is a highly aggressive neoplasm and the sixth leading cause of global cancer-related death; the 5-year survival rate for esophageal cancer is only about 20%-25% for all stages." | 1.46 | Low-dose hyperthermia enhances the antitumor effects of chemotherapy in squamous cell carcinoma. ( Akutsu, Y; Hanari, N; Hu, X; Kano, M; Matsubara, H; Matsumoto, Y; Murakam, K; Otsuta, R; Qin, W; Suganami, A; Suito, H; Takahashi, M; Tamura, Y; Usui, A, 2017) |
| "107 gastro-esophageal cancer patients were retrospectively analyzed." | 1.46 | Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer. ( Borro, M; Botticelli, A; Cerbelli, B; Gentile, G; Lionetto, L; Marchetti, L; Marchetti, P; Mazzotti, E; Mazzuca, F; Onesti, EC; Romiti, A; Simmaco, M, 2017) |
| "Twenty esophageal cancer patients receiving chemotherapy with 5-fluorouracil plus cisplatin were assigned randomly to one of the following two groups: (1) receiving elemental diet with Elental (one pack per day) for 14 days and (2) not receiving Elental during chemotherapy." | 1.46 | A prospective study of nutritional supplementation for preventing oral mucositis in cancer patients receiving chemotherapy. ( Hoshino, A; Kawada, K; Kawano, T; Miyawaki, Y; Nagai, K; Nakajima, Y; Nishikage, T; Okada, T; Ryotokuji, T; Tokairin, Y, 2017) |
| "50 patients with advanced esophageal cancer were treated with a continuous infusion of CF, 5-FU, and CDDP, and the short-term effects, adverse reactions, and survival periods after treatment were analyzed." | 1.46 | Continuous infusion of a large dose of CF (folinic acid) and 5-FU combined with CDDP in the treatment of advanced esophageal cancer. ( Cai, HX; Zhu, ZA; Zhu, ZQ, 2017) |
| "For patients with operable esophagogastric cancer, peri-operative chemotherapy confers a significant overall survival benefit compared to surgery alone, however only 30-40% of patients demonstrate histopathological response." | 1.46 | The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery. ( Bowman, CR; Dorrington, MS; Kaye, P; Madhusudan, S; Mumtaz, E; Pang, V; Parsons, SL; Reece-Smith, AM; Saunders, JH; Soomro, I, 2017) |
| "Type of esophageal cancer was adenocarcinoma in 213 patients (80%) and squamous cell carcinoma in 46 patients (17%)." | 1.43 | Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience. ( Bhatia, S; Martenson, JA; Miller, RC; Quevedo, JF; Schomas, DA; Sio, TT; Stauder, MC; Wilson, ZC, 2016) |
| "Watson and Ogilvie dysphagia scores were used to assess dysphagia, while appetite was assessed by the Edmonton Assessment System Visual analogue scale-appetite questionnaire." | 1.43 | Relief of dysphagia during neoadjuvant treatment for cancer of the esophagus or gastroesophageal junction. ( Ericson, J; Friesland, S; Kumagai, K; Lindblad, M; Lundell, L; Nilsson, M; Rouvelas, I; Sunde, B; Tsai, JA; Wang, N, 2016) |
| "Esophageal squamous cell carcinoma (ESCC) contains genomic alterations of undefined clinical significance." | 1.43 | Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China. ( Bi, Y; Chen, X; Chen, Y; Cheng, C; Cheng, X; Cui, H; Cui, Y; Guo, J; Guo, S; Hu, X; Jia, J; Jia, Z; Kong, P; Li, G; Li, H; Li, Q; Li, Y; Liang, J; Liu, H; Liu, J; Qian, Y; Shi, R; Song, B; Wang, C; Wang, F; Wang, J; Wang, T; Xi, Y; Xu, E; Yan, T; Yang, B; Yang, J; Zhan, Q; Zhang, L; Zhang, Y; Zhao, Z; Zhou, Y, 2016) |
| "Patients with early and advanced esophageal cancer and relapsed esophageal cancer after radical surgery were included." | 1.43 | Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer. ( Haga, A; Kiritoshi, T; Nakagawa, K; Ohtomo, K; Okuma, K; Takenaka, R; Yamashita, H, 2016) |
| "Differentially expressed in squamous cell carcinoma 1 (DESC1), which belongs to the Type II transmembrane serine protease family, was frequently downregulated in ESCC." | 1.43 | DESC1, a novel tumor suppressor, sensitizes cells to apoptosis by downregulating the EGFR/AKT pathway in esophageal squamous cell carcinoma. ( Cal, S; Dai, W; Ip, JC; Ko, JM; Lung, ML; Ng, HY; Yu, VZ, 2016) |
| "Successful treatment of oesophageal cancer is hampered by recurrent drug resistant disease." | 1.43 | MiR-193b promotes autophagy and non-apoptotic cell death in oesophageal cancer cells. ( Boersma, AW; McKenna, SL; Nyhan, MJ; O'Donovan, TR; Wiemer, EA, 2016) |
| "Information about 406 consecutive esophageal cancer patients with resectable disease who underwent surgery with neoadjuvant chemotherapy consisting of cisplatin plus 5-fluorouracil or who underwent definitive CRT was reviewed." | 1.43 | Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis. ( Abe, T; Andoh, M; Kadowaki, S; Kodaira, T; Komori, A; Masuishi, T; Muro, K; Muto, M; Narita, Y; Niwa, Y; Nomura, M; Oze, I; Tachibana, H; Tajika, M; Taniguchi, H; Uemura, N; Ura, T, 2016) |
| "In advanced esophageal cancer patients, standard treatment involves chemoradiotherapy and surgery." | 1.43 | Herpes simplex virus-1 encephalitis induced by chemoradiotherapy and steroids in an esophageal cancer patient: a case report. ( Imoto, H; Kiyozaki, H; Obitsu, T; Rikiyama, T; Saito, M; Takata, O; Taniyama, Y, 2016) |
| "Oesophageal cancer is a highly aggressive disease with about 50% of patients presenting with advanced or metastatic disease at initial diagnosis." | 1.43 | Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review. ( Bai, L; Cheng, Z; Dai, G; Han, Z; Liang, P; Liu, F; Tan, S; Yu, J; Yu, X; Zhou, F, 2016) |
| "Patients with resectable oesophageal cancer are treated with neoadjuvant chemoradiotherapy (nCRT) followed by surgery within 3-8 weeks." | 1.43 | Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma. ( Creemers, GJ; Kathiravetpillai, N; Koëter, M; Luyer, MD; Nieuwenhuijzen, GA; Rutten, HJ; van der Sangen, MJ, 2016) |
| "Oesophageal squamous cell carcinoma (ESCC) is the sixth most common cause of cancer-associated death in the world and novel therapeutic alternatives are urgently warranted." | 1.43 | Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway. ( Bai, L; Chen, DL; Chen, LZ; Ju, HQ; Lu, YX; Mo, HY; Sheng, H; Wang, DS; Wang, F; Wu, QN; Xie, D; Xu, RH; Yu, HE; Yun, JP; Zeng, ZL, 2016) |
| "Neoadjuvant chemotherapy(NAC)for esophageal cancer is standard in Japan." | 1.43 | [Pathological Complete Response in 3 Patients with Esophageal Cancer Treated with Neoadjuvant Chemoradiation Therapy]. ( Katayanagi, S; Kawachi, S; Makuuchi, Y; Osakabe, H; Shigoka, M; Sumi, T, 2016) |
| "Esophageal neuroendocrine carcinoma is relatively rare and the prognosis is poor owing to its aggressive malignancy." | 1.43 | [A Case of Neuroendocrine Carcinoma of the Esophagus Treated with Neoadjuvant Chemotherapy Comprising 5-Fluorouracil plus Cisplatin]. ( Akaishi, T; Akasaka, H; Hakamada, K; Hasebe, T; Mitsuhashi, Y; Muroya, T; Sato, K; Wajima, N; Yachi, T; Yakoshi, Y, 2016) |
| "Indications for surgery for esophageal cancer often do not include cases with SCLN metastasis because the latter is considered distant metastasis." | 1.42 | Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. ( Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M, 2015) |
| "We aimed to identify esophageal squamous cell carcinoma (ESCC) stem-like cells, the epigenetic mechanism and identify novel biomarkers for targeting ESCC CSCs." | 1.42 | Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity. ( Chen, X; Gao, Q; Huang, L; Li, F; Li, J; Li, S; Ping, Y; Wang, D; Wang, L; Yang, L; Yue, D; Zhang, T; Zhang, Y, 2015) |
| "Sarcopenia is a significant predictor of DLT in oesophago-gastric cancer patients undergoing neo-adjuvant chemotherapy." | 1.42 | Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. ( Brammer, K; Catton, JA; James, EJ; Parsons, SL; Randhawa, N; Tan, BH; Welch, NT, 2015) |
| " Oxaliplatin in combination with intravenous 5-FU plus leucovorin (LV; modified [m]FOLFOX6) or capecitabine (XELOX) improves tolerability compared with 5-FU/cisplatin regimen." | 1.42 | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. ( André, T; Bachet, JB; Chibaudel, B; Cohen, R; de Gramont, A; Hentic, O; Louvet, C; Samalin, E; Soularue, É; Tournigand, C; Zaanan, A, 2015) |
| "All patients had squamous cell carcinoma." | 1.42 | Long-term results of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer (T1bN0M0). ( Doi, Y; Kenjo, M; Kimura, T; Murakami, Y; Nagata, Y; Nishibuchi, I; Okabe, T; Takahashi, I, 2015) |
| "025) in the toxic group (n = 12) compared to the non-toxic group (n = 19)." | 1.42 | Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study. ( Bowen, JM; Game, PA; Hussey, DJ; Irvine, T; Karapetis, CS; Keefe, DM; Kristaly, K; Smith, L; Tan, H; Thompson, SK; Tsykin, A; Watson, DI; White, I, 2015) |
| "For patients with locoregional recurrence(s), image fusion was performed between radiotherapy planning CT and follow-up CT(s)." | 1.42 | Tumor recurrence and in-field control after multimodality treatment of locally advanced esophageal cancer. ( Boterberg, T; Ceelen, W; Pattyn, P; Thoen, H; Van Daele, E, 2015) |
| "Currently, esophageal cancer is rarely curable, and herein, a paclitaxel or 5-fluorouracil/esophageal stent combination (PTX or 5-FU/stent) was used to provide a new approach to treat this cancer." | 1.42 | Paclitaxel or 5-fluorouracil/esophageal stent combinations as a novel approach for the treatment of esophageal cancer. ( Chen, W; Guo, S; Li, J; Liu, J; Shen, Y; Wang, Z; Wu, K, 2015) |
| "Esophageal cancer is most frequently treated with platinum-based chemoradiotherapy (CRT)." | 1.42 | Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer. ( Emi, M; Hamai, Y; Hihara, J; Kenjo, M; Murakami, Y; Nagata, Y; Okada, M, 2015) |
| "Aortic pseudoaneurysm formation subsequent to concurrent chemoradiotherapy (CCRT) for esophageal cancer patient with esophageal metallic stent insertion is a rare condition." | 1.42 | Aortic pseudoaneurysm formation following concurrent chemoradiotherapy and metallic stent insertion in a patient with esophageal cancer. ( Chang, MH; Chung, CS; Hou, PY; Hsieh, CH; Huang, CC; Liu, CY; Shueng, PW; Teng, CJ, 2015) |
| "Information about 209 esophageal cancer patients with stage III or T3 disease, who underwent NAC consisting of CF with or without docetaxel, was reviewed." | 1.42 | Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. ( Abe, T; Andoh, M; Ishihara, M; Kadowaki, S; Kawai, R; Komori, A; Masuishi, T; Muro, K; Muto, M; Narita, Y; Niwa, Y; Nomura, M; Oze, I; Tajika, M; Tanaka, T; Taniguchi, H; Uemura, N; Ura, T, 2015) |
| "A 63 year-woman was diagnosed with esophageal cancer (Mt." | 1.42 | [A Successfully Treated Case of Central Venous Catheter-Related Suppurative Thrombophlebitis of the Right Jugular Vein to the Superior Vena Cava Associated with Esophageal Cancer]. ( Komai, H; Kon, M; Nakai, K; Yamada, M; Yamamichi, K; Yoshioka, K, 2015) |
| "This retrospective study on early and locally advanced esophageal cancer was conducted to evaluate locoregional failure and its impact on survival by comparing involved field radiotherapy (IFRT) with elective nodal irradiation (ENI) in combination with concurrent chemotherapy." | 1.42 | Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers: a single institutional retrospective study. ( Imae, T; Nakagawa, K; Ohtomo, K; Okuma, K; Omori, M; Takenaka, R; Yamashita, H, 2015) |
| "Esophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancies of the digestive tract in East Asian countries." | 1.42 | Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma. ( Ban, X; Guan, XY; Li, L; Li, XD; Li, Y; Xie, D; Yang, H; Yun, J; Zeng, TT; Zhang, BZ; Zhou, Y, 2015) |
| "Lobaplatin plus 5-Fu combined with concurrent radiotherapy is safe and effective in treating patients with middle-advanced stage esophageal cancer." | 1.42 | Clinical Study on Lobaplatin Combined with 5-Fu and Concurrent Radiotherapy in Treating Patients with Inoperable Esophageal Cancer. ( Huang, JZ; Jia, XJ, 2015) |
| "Three months after the operation, recurrences in the upper abdominal multiple para-aortic lymph nodes were detected." | 1.42 | [A Case of Early Recurrence after Esophagectomy for Cancer Following Neoadjuvant Chemotherapy Resulting in a Complete Response of the Primary Lesion]. ( Arimitsu, H; Chibana, T; Hironaka, S; Ikeda, A; Ishige, F; Kainuma, O; Kobayashi, R; Nabeya, Y; Nagata, M; Saito, H; Soda, H; Takiguchi, N; Tonooka, T; Yamamoto, H; Yanagibashi, H, 2015) |
| "We report a case of far-advanced esophageal cancer in which induction chemotherapy followed by chemoradiotherapy achieved complete remission." | 1.42 | [Complete Response in Far-Advanced Esophageal Cancer Treated with Induction Chemotherapy Followed by Definitive Chemoradiotherapy]. ( Aga, K; Harada, H; Kaburagi, T; Koizumi, W; Matsumoto, H; Sakata, M; Seki, H; Shimada, A; Watanabe, H; Yasui, N, 2015) |
| "A PPC was defined as pneumonia or acute respiratory distress syndrome within 30 days after surgery." | 1.42 | Serum Transforming Growth Factor-β1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy. ( Chang, DT; Cheng, JC; Hsu, CH; Hsu, FM; Huang, PM; Koong, AC; Lee, JM; Lu, SL; Tsai, CL; Wu, JK, 2015) |
| "A 78-year-old man with Stage III esophageal cancer was referred to our hospital." | 1.42 | [A Case of Severe Bradycardia Induced by Combination Chemotherapy with Cisplatin and 5-Fluorouracil]. ( Kawamori, H; Kusunoki, N; Nakajima, T; Ohno, M; Takase, S; Yamazaki, Y, 2015) |
| "We report a case of regional recurrence of esophageal cancer after curative esophagectomy." | 1.42 | [A Case of Salvage Chemoradiotherapy for Regional Recurrence after Curative Esophagectomy]. ( Imanishi, T; Kakeji, Y; Kanaji, S; Kanemitsu, K; Nakamura, T; Okuno, T; Sumi, Y; Suzuki, S; Yamamoto, M; Yamashita, K, 2015) |
| "After 4 weeks, dysphagia scores improved by at least 1 point in 67% of patients in group 1 versus 93% in group 2 (p=0." | 1.40 | Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer. ( Archambeaud, I; Landi, B; Lepère, C; Lièvre, A; Mitry, E; Rougier, P; Touchefeu, Y, 2014) |
| "However, the number of long-term esophageal cancer survivors has been increasing due to advances in early detection and therapy." | 1.40 | Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer. ( Dasanu, CA; Nandy, N, 2014) |
| "Human esophageal cancer tissue microarray was analyzed for overexpression of IGF-II and its correlation with that of Id1 and phosphorylated AKT (p-AKT)." | 1.40 | Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy. ( Chan, KW; Cheung, AL; He, QY; Li, B; Li, YY; Ludwig, DL; Novosyadlyy, R; Tsao, SW, 2014) |
| "DCF has strong antitumor activity for esophageal cancer and may confer survival benefits when used as preoperative chemotherapy." | 1.40 | Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer. ( Baba, H; Baba, Y; Ishimoto, T; Iwagami, S; Iwatsuki, M; Nagai, Y; Watanabe, M; Yoshida, N, 2014) |
| "Acute toxic leukoencephalopathy (ATL) is a rare adverse effect of 5-Fluorouracil (5-FU) chemotherapeutic agent." | 1.40 | 5-FU induced acute toxic leukoencephalopathy: early recognition and reversibility on DWI-MRI. ( Azeemuddin, M; Maheen Anwar, SS; Mubarak, F; Sajjad, Z, 2014) |
| "Postoperative complications were graded according to the Clavien-Dindo classification." | 1.40 | Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy. ( Baba, H; Baba, Y; Ida, S; Imamura, Y; Ishimoto, T; Iwagami, S; Karashima, R; Miyamoto, Y; Sakamoto, Y; Watanabe, M; Yoshida, N, 2014) |
| "Secondary surgery of metastasized gastric cancer may be justified in selected cases without progression under induction chemotherapy." | 1.40 | Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy. ( Friess, HM; Novotny, AR; Reim, D; Schuhmacher, C, 2014) |
| "Esophageal squamous cell carcinoma (ESCC) patients with regional lymph node metastases have poor prognosis after surgery." | 1.40 | Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma? ( Feng, Q; Gao, S; He, J; Huang, J; Jiang, Y; Liu, Y; Lyu, X; Mao, Y; Shao, K; Wang, J, 2014) |
| "However, the esophageal cancer recurred, and subtotal esophagectomy was performed in January 2011." | 1.40 | [A case of esophageal squamous cell carcinoma with an adenocarcinoma component that dedifferentiated after chemotherapy]. ( Kigawa, G; Matsubara, T; Matsumiya, A; Mizukami, H; Nemoto, H; Saito, M; Tanaka, J; Tate, G; Umemoto, T, 2014) |
| " The aim of the present study was to investigate the inhibitive effects of puerarin combined with 5‑fluorouracil (5‑FU) on Eca‑109 esophageal cancer cells in vitro and in vivo." | 1.40 | Synergistic effects of puerarin combined with 5-fluorouracil on esophageal cancer. ( Dong, WG; Guo, XF; Song, J; Wang, J; Yang, ZR; Zhang, JX, 2014) |
| "Esophageal cancer is the sixth most common cause of cancer-related deaths worldwide." | 1.40 | Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. ( Cheung, AL; Guan, XY; Law, S; Li, B; Li, J; Qin, YR; Tsao, SW; Xu, WW; Zhang, LY, 2014) |
| "Two patients presented with brain metastases, while one demonstrated lymphangitic spread to lungs." | 1.40 | A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. ( Calkins, SM; Cinar, P; Kelley, RK; Venook, AP, 2014) |
| "Esophageal carcinosarcoma is a rare malignant esophageal neoplasm consisting of both carcinomatous and sarcomatous elements, with an incidence of 0." | 1.40 | A case of metachronous development of esophageal squamous cell carcinoma in the patient with esophageal carcinosarcoma. ( Cha, RR; Ha, CY; Jung, WT; Kim, HJ; Kim, TH; Ko, GH; Oh, HW, 2014) |
| "Esophageal obstruction prior to CCRT, residual tumor according to the first follow-up endoscopy, and poor follow-up computed tomography responses were significantly associated with locoregional failure." | 1.40 | Local control may be the key in improving treatment outcomes of esophageal squamous cell carcinoma undergoing concurrent chemoradiation. ( Kim, HW; Kim, JH; Kim, JW; Lee, CG; Lee, IJ; Lee, YC; Park, H; Park, JJ; Youn, YH, 2014) |
| "A man in his 60s was diagnosed with esophageal cancer (T3, N0, StageII) and treated with 5-fluorouracil and cisplatin as neoadjuvant chemotherapy (NAC)." | 1.40 | [A case of pneumatosis cystoides intestinalis after neoadjuvant chemotherapy for esophageal cancer]. ( Akasaka, H; Hakamada, K; Ichinohe, D; Kimura, A; Kubo, N; Okano, K; Sakuraba, S; Shimada, T; Wajima, N; Yamana, D, 2014) |
| "Operable patients with locally advanced esophageal cancer (clinically staged T3 N0-1 M0) were enrolled in this prospective study." | 1.39 | Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. ( Duhamel, A; Huglo, D; Mariette, C; Mirabel, X; Petyt, G; Piessen, G, 2013) |
| "He had squamous cell carcinoma diagnosed by biopsy specimens, found in the esophagogastric junction by esophagogastroduodenoscopy." | 1.39 | [A case of squamous cell carcinoma of the esophagogastric junction with bulky no.7-metastatic node successfully treatedby chemoradiation followed by surgery]. ( Koide, N; Miyagawa, S; Shinoda, A; Suzuki, A; Takeuchi, D; Yoshizawa, J, 2013) |
| "Ninety-five patients with esophageal cancer were retrospectively analyzed." | 1.39 | Endoscopic ultrasound in staging esophageal cancer after neoadjuvant chemotherapy--results of a multicenter cohort analysis. ( Domagk, D; Domschke, W; Heinzow, HS; Kucharzik, T; Meister, T; Seifert, H; Tsepetonidis, S; Wolters, H, 2013) |
| "We retrospectively analyzed esophageal squamous cell carcinoma (SCC) patients with e-CR after nCRT between 1999 and 2006." | 1.39 | Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy. ( Chang, HK; Chang, WC; Chao, YK; Chiu, CT; Liu, YH; Tseng, CK; Wan, YL; Wen, YW, 2013) |
| "The survival rates of esophageal cancer treated with DCRT in North West of Iran is poor; therefore, early detection and improved treatment methods, with clinical trials are a high priority." | 1.39 | Survival in patients treated with definitive chemo- radiotherapy for non-metastatic esophageal cancer in north- west iran. ( Ghojazadeh, M; Jangjoo, AG; Mirinezhad, SK; Mohammadzadeh, M; Naseri, AR; Nasiri, B; Seyednezhad, F; Somi, MH, 2013) |
| "Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2) tyrosine kinase domains." | 1.39 | Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models. ( Bachman, KE; Fei, M; Greshock, J; Hou, W; Liu, L; Liu, P; Moon, H; Qin, X; Wang, H; Ye, BC; Zang, CY; Zhang, P; Zhu, X, 2013) |
| "We retrospectively studied 276 esophageal cancer patients treated with nCRT and surgery between 2002 and 2008." | 1.39 | Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome? ( Chan, SC; Chang, HK; Chao, YK; Chen, WH; Chiu, CH; Liu, YH; Tseng, CK, 2013) |
| "DNA from 143 esophageal cancer patients, 63 receiving neoadjuvant therapy and 80 receiving primary surgery, was analyzed for the following polymorphisms: the GSTM1 null, GSTT1 null, and GSTP1 Ile105Val (rs16953) in glutathione S-transferase (GST) family, 2 in thymidylate synthase (TS) gene, and the ERCC1 Asn118Asn (rs11615), ERCC1 C8092A (rs3212986), XPD/ERCC2 Asp312Asn (rs1799793), and XPD/ERCC2 Lys751Gln (rs13181) of the nucleotide excision repair pathway." | 1.39 | ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy. ( Alfieri, R; Amadori, A; Ancona, E; Basso, D; Boldrin, E; Cagol, M; Castoro, C; Cavallin, F; Rumiato, E; Ruol, A; Saggioro, D, 2013) |
| "Most (90%) patients with brain metastases were diagnosed within 24 months of surgery." | 1.39 | Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. ( Ajani, JA; Bhutani, MS; Blum, MA; Campagna, MC; Correa, AM; Hofstetter, WL; Komaki, R; Lee, JH; Maru, DM; Rice, DC; Skinner, H; Sudo, K; Swisher, S; Taketa, T; Wadhwa, R; Weston, B, 2013) |
| "Here, we examined 95 patients with oesophageal cancer who received 5-fluorouracil and cisplatin (FP) to determine whether nephrotoxicity was affected by SLC22A2 808G>T polymorphism." | 1.39 | Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies. ( Hinai, Y; Miura, M; Motoyama, S; Niioka, T, 2013) |
| "To investigate the inhibitory effects of sinomenine (SIN) combined with 5-fluorouracil (5-FU) on esophageal carcinoma in vitro and in vivo." | 1.39 | Cooperative inhibitory effect of sinomenine combined with 5-fluorouracil on esophageal carcinoma. ( Dong, WG; Guo, XF; Qiu, S; Song, J; Wang, J; Yang, ZR; Zhang, JX, 2013) |
| "We treated 53 thoracic esophageal cancer patients who underwent surgery following neoadjuvant chemotherapy between January 2010 and December 2012." | 1.39 | [Current status of neoadjuvant chemotherapy for advanced esophageal cancer]. ( Fujiwara, T; Katsube, R; Maeda, N; Noma, K; Ohara, T; Sakurama, K; Shirakawa, Y; Tanabe, S, 2013) |
| "Although squamous cell carcinoma was diagnosed by biopsy of the SMT-like tumor in the gastric cardia, gastric involvement was suspected via metastasis to the perigastric lymph nodes or direct invasion of the gastric wall by the ESCC, because the primary lesion of ESCC could not be identified during the examinations." | 1.39 | [A case of esophageal squamous cell carcinoma with submucosal tumor-like tumor due to direct invasion of the gastric wall]. ( Fujiwara, H; Ichikawa, D; Ikoma, H; Komatsu, S; Konishi, H; Kubota, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Nako, Y; Okamoto, K; Otsuji, E; Sakakura, C; Shiozaki, A, 2013) |
| "He was diagnosed as having esophageal cancer( Mt, type 3, cT3, cN2, cM0, cStage III)." | 1.39 | [A case of cytomegalovirus colitis during chemotherapy for esophageal cancer]. ( Hazama, S; Kanekiyo, S; Kitahara, M; Oka, M; Takeda, S; Ueno, T; Watanabe, Y; Yamamoto, T; Yoshino, S, 2013) |
| "By this stage of esophageal cancer, surgery, although very invasive, is the standard radical therapy for the patients." | 1.39 | Clinical outcome of endoscopic mucosal resection for esophageal squamous cell cancer invading muscularis mucosa and submucosal layer. ( Kameda, Y; Ohkawa, S; Tamai, S; Yoshii, T, 2013) |
| "A 57-year-old male with lower esophageal cancer underwent subtotal esophagectomy with lymphadenectomy." | 1.39 | Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case. ( Fujiwara, H; Ichikawa, D; Iitaka, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Sonoyama, T, 2013) |
| "All patients had histologically proven squamous cell carcinoma." | 1.39 | Results of chemoradiotherapy for stage I esophageal cancer in medically inoperable patients compared with results in operable patients. ( Ariga, H; Jingu, K; Matsushita, H; Miyata, G; Narazaki, K; Nemoto, K; Onodera, K; Sugawara, T; Takeda, K; Umezawa, R; Yamada, S, 2013) |
| " CRT combined with 5-fluorouracil (5-FU) and cisplatin (CDDP) was administered to all patients." | 1.39 | Treatment strategy for superficial pharyngeal squamous cell carcinoma synchronously combined with esophageal cancer. ( Hayashi, R; Ikematsu, H; Ito, M; Kaneko, K; Kojima, T; Minashi, K; Ohtsu, A; Onozawa, M; Oono, Y; Satake, H; Yajima, Y; Yano, T; Yoda, Y, 2013) |
| "Twenty patients with esophageal cancer were treated with trimodal therapy (CRT plus surgery) and underwent [(18)F]FDG-PET/CT scans both before (pre-CRT) and after (post-CRT) CRT." | 1.39 | Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. ( Chen, W; D'Souza, WD; Feigenberg, S; Kim, G; Kligerman, S; Lu, M; Lu, W; Suntharalingam, M; Tan, S, 2013) |
| "To assess the outcome of esophageal cancer according to therapeutic strategy." | 1.39 | [Esophageal cancer: outcome according to therapeutic strategy]. ( Capitain, O; Cellier, P; Denis, F; Girault, S; Hamy, A; Mahé, MA; Mesgouez-Nebout, N; Paumier, A; Poirier, AL; Rousseau, D, 2013) |
| "Patients who had squamous cell carcinoma (SCC) or adenocarcinoma (AC) were treated in four referral centers in the north-east Netherlands with definitive chemoradiotherapy (dCRT) or radiotherapy (dRT) between 1996 and 2008." | 1.39 | Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands. ( Beukema, JC; Burgerhof, JG; Hospers, GA; Langendijk, JA; Muijs, CT; Mul, VE; Muller, K; Paardekooper, G; Plukker, JT; Smit, JK; Timmer, PR; van Dijk, BA; Woutersen, D, 2013) |
| "Patients with stage IVA esophageal cancer treated with chemoradiotherapy between April 2003 and March 2009 were evaluated." | 1.39 | Outcomes of patients with stage IVA esophageal cancer (Japanese classification) treated with definitive chemoradiotherapy. ( Anbai, A; Hashimoto, M; Jin, M; Koga, M; Motoyama, S; Shibata, H, 2013) |
| "TE13 human esophageal squamous cell carcinoma cells were transfected with a COX-2 constitutive expression vector, and stable transfectants overexpressing COX-2 were established." | 1.39 | COX-2 overexpression Induced by gene transfer reduces sensitivity of TE13 esophageal carcinoma cells to 5-fluorouracil and cisplatin. ( Fujiwara, H; Furutani, A; Ichikawa, D; Komatsu, S; Kubota, T; Ochiai, T; Okamoto, K; Okamura, H; Okamura, S; Otsuji, E; Sakakura, C; Shiozaki, A; Takahashi, Y; Todo, M; Umehara, S; Yoneda, M; Yoshimoto, T, 2013) |
| " SERMS are a safe and effective intervention in dysphagic patients undergoing neoadjuvant chemotherapy for esophageal cancer." | 1.38 | Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer. ( Gilani, SQ; Jain, PK; Pellen, MG; Razack, A; Sabri, S, 2012) |
| "A total of 139 esophageal cancer patients treated with CCRT (cisplatin-based chemotherapy combined with 40 Gy of irradiation) and subsequent esophagectomy were recruited at the National Taiwan University Hospital between 1997 and 2008." | 1.38 | Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer. ( Chen, PC; Chen, SK; Chen, YC; Chuang, EY; Hsiao, CK; Lai, LC; Lee, JM; Lee, YC; Tsai, MH; Yang, PW, 2012) |
| "Eighteen patients with esophageal squamous cell carcinoma with and without neoadjuvant chemotherapy were analyzed using immunohistochemical methods for human leukocyte antigen (HLA) class I heavy chain, CD4-, CD8-, and Foxp3-positive cell infiltration." | 1.38 | The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma. ( Hirano, S; Kondo, S; Miyamoto, M; Shichinohe, T; Tsuchikawa, T; Yamamura, Y, 2012) |
| "We examined the sensitivity of three oesophageal cancer cell lines to 5-fluorouracil (5-FU) alone and in combination with the BH3 mimetic HA14-1." | 1.38 | The BH3 mimetic HA14-1 enhances 5-fluorouracil-induced autophagy and type II cell death in oesophageal cancer cells. ( Crowley, LC; Elzinga, B; McKenna, SL; Nyhan, MJ; O'Donovan, TR; O'Sullivan, GC, 2012) |
| "Concurrent chemoradiotherapy for esophageal cancer impairs LVF from an early treatment stage." | 1.38 | Acute cardiac impairment associated with concurrent chemoradiotherapy for esophageal cancer: magnetic resonance evaluation. ( Hatakenaka, M; Higo, T; Honda, H; Kamitani, T; Matsuo, Y; Nagao, M; Nakamura, K; Nishikawa, K; Nonoshita, T; Setoguchi, T; Shioyama, Y; Yabuuchi, H; Yonezawa, M, 2012) |
| "Curcumin was more effective than p65 siRNA in vitro and in vivo." | 1.38 | Comparison of the effect of p65 siRNA and curcumin in promoting apoptosis in esophageal squamous cell carcinoma cells and in nude mice. ( Jiang, Y; Tian, F; Tian, W; Zhang, C; Zhang, X, 2012) |
| "Tegafur is a 5-fluorouracil (5-FU) prodrug widely used outside the United States to treat colorectal cancer as well as cancers of the head and neck." | 1.38 | Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. ( Hurwitz, HI; McManus, TJ; Peer, CJ; Petros, WP, 2012) |
| " Boosted high dosing to metastatic lymph nodes can increase the relapse-free survival rate." | 1.38 | Efficacy analysis of simplified intensity-modulated radiotherapy with high or conventional dose and concurrent chemotherapy for patients with neck and upper thoracic esophageal carcinoma. ( Chen, XF; Han, JH; Li, T; Yu, CH; Zhou, K; Zhu, WG, 2012) |
| "The treatment results for cT4 esophageal cancer were examined in 81 patients who received definitive CRT [radiation 50-70 Gy, cisplatin and 5-fluorouracil; group I] and 19 patients who underwent esophagectomy after preoperative CRT [40Gy, Group II]." | 1.38 | Clinical significance of chemoradiotherapy and surgical resection for cT4 esophageal cancer. ( Ikeda, Y; Maehara, S; Maehara, Y; Minami, K; Morita, M; Ohgaki, K; Okamura, T; Saeki, H; Sakaguchi, Y; Sugiyama, M; Toh, Y; Uehara, S, 2012) |
| "HAI can be a treatment of choice for esophageal cancer when metastasis is limited to the liver." | 1.38 | [Multimodality therapy containing hepatic arterial infusion chemotherapy for liver metastasis of esophageal cancer-a case report]. ( Hasegawa, H; Ikebe, M; Kitamura, M; Saitoh, G, 2012) |
| "In patients with cervical oesophageal cancer 35 of 55 (64%) underwent oesophageal resection or pharyngo-laryngectomy." | 1.38 | [The role of neoadjuvant therapy in the treatment of locally advanced squamous cell cancer of the cervical oesophagus]. ( Bellyei, S; Cseke, L; Farkas, R; Horváth, OP; Márton, S; Papp, A; Pavlovics, G; Potó, L; Varga, G, 2012) |
| "Between 1997 and 2007, 94 patients with esophageal cancer were treated with chemoradiation in our institute." | 1.37 | Chemoradiation for esophageal cancer: institutional experience with three different regimens. ( Aleman, BM; Boot, H; Cats, A; Courrech Staal, EF; Jansen, EP; van Coevorden, F; van Sandick, JW; van Velthuysen, ML, 2011) |
| "Fatigue was a prominent long-lasting symptom in these patients." | 1.37 | Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer. ( Aarstad, AK; Aarstad, HJ; Hjermstad, MJ; Hurmuzlu, M; Viste, A, 2011) |
| "All of the patients had squamous cell carcinoma." | 1.37 | Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. ( Ahn, SD; Choi, EK; Kim, JH; Kim, SB; Lee, SW; Lee, YS; Park, JW; Park, SI; Song, SY; Yoon, SM, 2011) |
| "A diagnosis of acute leukoencephalopathy was reached based on these findings." | 1.37 | Early detection of 5-FU-induced acute leukoencephalopathy on diffusion-weighted MRI. ( Akitake, R; Chiba, T; Ezoe, Y; Horimatsu, T; Miyamoto, S; Muto, M; Nakamura, F, 2011) |
| "Chemoradiotherapy (CRT) for esophageal cancer is disadvantageous because of a high locoregional failure rate." | 1.37 | Submucosal tumor appearance is a useful endoscopic predictor of early primary-site recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma. ( Horimatsu, T; Ishikura, S; Minashi, K; Muto, M; Nihei, K; Ohtsu, A; Onozawa, M; Taku, K; Tu, CH; Yano, T; Yoshida, S, 2011) |
| "Three patients (20%) had grade 3-4 dysphagia in weeks 3-4 and were continued on intravenous fluids and pain medications." | 1.37 | Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer. ( Ad, VB; Bar-Ad, V; Both, S; Hwang, WT; Metz, J; O'Dwyer, P; Plastaras, J; Thukral, A, 2011) |
| "Obesity is a risk factor for the development of esophageal malignancy." | 1.37 | Esophageal adenocarcinoma after laparoscopic gastric band placement for obesity. ( Mathew, J; Odell, JA; Stauffer, JA, 2011) |
| "A cohort of 148 patients with esophageal cancer received cisplatin-based CCRT (concurrently combined with 40 Gy irradiation) and subsequent esophagectomy." | 1.37 | Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery. ( Chen, JS; Cheng, JC; Chuang, TH; Hsu, CH; Hsu, HH; Huang, PM; Kuo, SW; Lee, JM; Lee, YC; Lin, CC; Shun, CT; Wang, YH; Wu, MT; Yang, PW; Yang, SY, 2011) |
| "Forty-one patients with newly diagnosed esophageal cancer treated with combined radiochemotherapy were included in this study." | 1.37 | Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. ( Albarghach, N; Corcos, L; Hatt, M; Le Rest, CC; Metges, JP; Pradier, O; Tixier, F; Visvikis, D, 2011) |
| " Despite widespread concern about the successful performance of this procedure following neoadjuvant chemoradiotherapy (NACR) treatment, we hypothesized that safe and effective MIE could be performed in this setting." | 1.37 | Minimally invasive esophagectomy is safe and effective following neoadjuvant chemoradiation therapy. ( Ben-David, K; Cendan, JC; Grobmyer, SR; Hochwald, SN; Rossidis, G; Sarosi, GA; Zlotecki, RA, 2011) |
| "Histological examinations revealed squamous cell carcinoma." | 1.37 | [A case of advanced esophageal cancer with multiple liver metastases accompanying poorly general conditions and serious liver dysfunctions, successfully treated using concurrent radiotherapy and chemotherapy with low-dose nedaplatin and 5-fluorouracil]. ( Fukui, T; Itoh, Y; Kawada, S; Takeda, H; Yoshioka, T, 2011) |
| "The most commonly used schedules are 5-FU in combination with CDDP with or without epirubicin (ECF) or docetaxel (TCF) in treatment of MGA patients (pts), independently of HER status." | 1.37 | Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. ( Abbas, F; Adenis, A; Afchain, P; Aparicio, T; Bécouarn, Y; Bouché, O; Desseigne, F; Dorval, E; Edeline, J; Guimbaud, R; Kramar, A; Mitry, E; Romano, O; Samalin, E; Thézenas, S; Ychou, M, 2011) |
| "CR to CRT for the esophageal cancer and CR to chemotherapy for the gastric cancer were achieved." | 1.37 | Complete response to chemoradiotherapy in a patient with synchronous double gastric and esophageal cancer. ( Fujii, M; Funada, T; Kaiga, T; Kanamori, N; Kochi, M; Mihara, Y; Takayama, T; Tamegai, H; Watanabe, M; Yoshida, N, 2011) |
| "Tissue samples from esophageal cancer were obtained from all 25 patients by biopsy before concurrent CRT, and semiquantitative analyses of HIF-1α expression were performed using immunohistochemical staining." | 1.37 | Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy. ( Chiba, I; Morioka, T; Murayama, S; Nishimaki, T; Ogawa, K; Shimoji, H; Takamatsu, R; Tamaki, W; Yoshimi, N, 2011) |
| "Postoperative recurrence or distant metastasis was observed in 7/10 of FP patients and 5/12 of DCF patients." | 1.37 | Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. ( Abe, T; Hatooka, S; Kondo, C; Mizota, A; Muro, K; Nomura, M; Shinoda, M; Shitara, K; Takahari, D; Ura, T; Yatabe, Y; Yokota, T, 2011) |
| "Here, Japanese patients with esophageal squamous cell carcinoma (ESCC) were followed up for 5 years after treatment with a definitive 5-FU/cisplatin (CDDP)-based chemoradiotherapy (CRT), and the association between prognosis and the plasma concentration of 5-FU was evaluated." | 1.37 | Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Kadoyama, K; Kuwahara, A; Miki, I; Nakamura, T; Nishiguchi, K; Okuno, T; Omatsu, H; Sakaeda, T; Tamura, T; Yamamori, M, 2011) |
| "Stomatitis is a side effect caused frequently by chemotherapy in patients with esophageal cancer, but a standard treatment for it has not been established." | 1.37 | [Elental prevented and reduced oral mucositis during chemotherapy in patients esophageal cancer]. ( Fukui, T; Itoh, Y; Kawada, S; Orihara, M; Takeda, H; Yoshioka, T; Yoshizawa, K, 2011) |
| "A total of 104 patients with advanced esophageal cancer received 2 courses of NAF-chemotherapy between February 2003 and March 2010." | 1.37 | [Efficacy of combined chemotherapy with nedaplatin, adriamycin, and 5-FU (NAF), and clinical factors affecting its effect in patients with advanced esophageal cancer]. ( Fujitani, K; Hasegawa, H; Hirao, M; Mita, E; Nakazuru, S; Tsujinaka, T, 2011) |
| "In cases of highly advanced esophageal cancer, a long-term follow-up should be performed." | 1.37 | [A case of advanced esophageal cancer patient surviving more than 7 years treated with chemoradiotherapy]. ( Hakamada, K; Kawasaki, H; Kubo, N; Maruyama, M; Miyamoto, K; Takahashi, K; Wajima, N, 2011) |
| "CASE 2: A 58-year-old man with thoracic esophageal cancer, T3N2M0, cStage III, underwent NAC with 5-FU/CDDP." | 1.37 | [Two cases of complete response of primary esophageal carcinoma treated with 5-FU/CDDP as neoadjuvant chemotherapy]. ( Hakamada, K; Kawasaki, H; Kubo, N; Maruyama, M; Miyamoto, K; Ogasawara, H; Takahashi, K; Wajima, N, 2011) |
| "Patients who had clinical Stage I-IVA esophageal cancer and received definitive CRT between 2001 and 2007 were retrospectively analyzed." | 1.36 | Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. ( Higashino, K; Iishi, H; Imai, A; Ishihara, R; Nishiyama, K; Sugimoto, N; Takeuchi, Y; Tatsuta, M; Uedo, N; Yamamoto, S; Yano, M, 2010) |
| "Esophageal squamous cell carcinoma (ESCC) exhibits abnormalities in epidermal growth factor receptor (EGFR) gene." | 1.36 | EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. ( Hirayama, Y; Imawari, M; Kagawa, N; Kaneko, K; Katagiri, A; Kogo, M; Konishi, K; Kubota, Y; Kumekawa, Y; Kushima, M; Makino, R; Muramoto, T; Nozawa, H; Ohmori, T; Ohtsu, A; Oyama, T, 2010) |
| "In patients with advanced gastric and esophageal cancer who were not candidates for every-3-week DCF, a weekly formulation of DCF demonstrated modest activity with minimal hematologic toxicity, suggesting that weekly DCF is a reasonable treatment option for such patients." | 1.36 | Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. ( Abbruzzese, JL; Ajani, J; Ho, L; Jhamb, J; Kazmi, SM; Lin, E; Overman, MJ; Phan, A; Yao, JC, 2010) |
| "Using a comprehensive esophageal cancer database, we identified patients who underwent esophagectomy between 1994 and 2008." | 1.36 | Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. ( Hoffe, S; Karl, R; Kelley, S; Marcovalerio, M; McLoughlin, J; Meredith, KL; Shah, N; Siegel, EM; Turaga, KK; Weber, JM, 2010) |
| "GX15-070 induced autophagy in esophagus cancer cell line EC9706 and osteosarcoma cancer cell line U2OS." | 1.36 | The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. ( Cao, Q; Chen, Q; Cheng, C; Jin, Y; Pan, J; Verstovsek, S, 2010) |
| "Patients with deeply invading (T3-T4) oesophageal cancers usually receive chemoradiotherapy with or without surgery." | 1.36 | Pre- and post-therapy nodal status equally affects survival of patients with oesophageal squamous cell carcinoma receiving preoperative chemoradiation. ( Doki, Y; Fujiwara, Y; Miyata, H; Mori, M; Nakajima, K; Takiguchi, S; Yamasaki, M, 2010) |
| " However, the optimal dosage of chemoradiotherapy and the treatment strategy for esophageal cancer in patients with Fanconi anemia remain unclear, and outcomes are generally extremely poor." | 1.36 | Successful treatment of esophageal squamous cell carcinoma in a patient with Fanconi anemia. ( Hirashima, Y; Hosoya, Y; Jinbu, Y; Lefor, A; Muroi, K; Nakazawa, M; Nokubi, M; Yamaguti, T; Yasuda, Y, 2010) |
| "Interestingly, rare balanced chromosomal abnormalities were observed in the present cases, thus providing new insights into the leukemogenesis of therapy-related leukemia." | 1.36 | Therapy-related leukemia following chemoradiotherapy for esophageal cancer. ( Ise, M; Kumagai, K; Mimura, N; Nagata, M; Sakai, C; Takagi, T; Tsujimura, H, 2010) |
| "298 patients with inoperable cancer of the esophagus were identified (16." | 1.36 | Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. ( Belka, C; Ganswindt, U; Haimerl, W; Hölzel, D; Niyazi, M; Schmidt, M; Wolf, M; Zehentmayr, F, 2010) |
| "Squamous cell carcinoma was an adverse factor related to increased postoperative pulmonary complications." | 1.36 | High-dose preoperative chemoradiotherapy in esophageal cancer patients does not increase postoperative pulmonary complications: correlation with dose-volume histogram parameters. ( Hurmuzlu, M; Muren, LP; Smaaland, R; Viste, A; Wentzel-Larsen, T; Øvrebø, K, 2010) |
| "To compare the short-term curative effect of photodynamic therapy (PDT), PDT combined with chemotherapy and chemotherapy alone on the advanced esophageal cancer patients." | 1.36 | Retrospective study of photodynamic therapy vs photodynamic therapy combined with chemotherapy and chemotherapy alone on advanced esophageal cancer. ( Chen, JZ; Li, LB; Luo, RC; Luo, YL; Xie, JM; Zhang, LY; Zhang, XN, 2010) |
| "A 77-year-old male with thoracic esophageal cancer (cT3N3M0, Stage III) received nedaplatin at 80mg/m2 for 1 day and 5-fluorouracil at 800mg/m2 for 5 days as neoadjuvant treatment." | 1.36 | [A case of SIADH developed during neoadjuvant chemotherapy using nedaplatin and 5-fluorouracil in a patient with esophageal cancer]. ( Gyobu, K; Hashiba, R; Isohata, N; Iwasaki, H; Kishida, S; Lee, S; Matsuda, Y; Mori, K; Osugi, H, 2010) |
| "To improve the prognosis of advanced esophageal cancer, neoadjuvant chemotherapy (NACT) followed by surgery is a promising treatment strategy." | 1.36 | Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples. ( Doki, Y; Fujiwara, Y; Komori, T; Matsubara, K; Matsuura, N; Miyata, H; Monden, M; Mori, M; Motoori, M; Takemasa, I; Takeno, A; Takiguchi, S; Yamasaki, M; Yano, M; Yasuda, T, 2010) |
| "These activities compared with those in squamous cell carcinoma." | 1.36 | [Four resected cases with basaloid carcinoma of esophagus--comparison of 5-FU-related enzymes (thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT)) between basaloid carcinoma and squamous cell carcin ( Fujiwara, Y; Morimura, K; Takemura, M; Yoshida, K, 2010) |
| "Frequently advanced or recurrent esophageal cancer was invasive trachea and often causing hemoptysis, stenosis and dyspnea." | 1.36 | [A case of recurrent esophageal cancer with tracheal invasion treated by chemo-radiotherapy (CRT) after placement of tracheal stent that maintained complete response (CR) for two years]. ( Amagasa, H; Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kawasaki, Y; Kurokawa, T; Nagahama, T; Tei, S; Watayou, Y, 2010) |
| "Fifteen patients with esophageal squamous cell carcinoma underwent CDDP/5-FU chemoradiotherapy." | 1.36 | [ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma]. ( Haga, N; Ishibashi, K; Ishida, H; Kumamoto, K; Sobajima, J, 2010) |
| "We report here a case of recurrent esophageal cancer successfully treated by cervical lymph node dissection and chemo-radiation therapy." | 1.36 | [A case of recurrent esophageal cancer successfully treated by combined therapies]. ( Andoh, S; Kitamura, Y; Tokunou, K; Toshimitsu, H; Tsushimi, K; Yamamoto, T, 2010) |
| "This chemotherapy reduced the esophageal cancer mass significantly, and subtotal esophagectomy was performed." | 1.36 | [A case successfully treated with subtotal esophagectomy after preoperative second-line chemotherapy for cT4 esophageal cancer]. ( Hamatsu, T; Hasegawa, H; Honboh, T; Kabashima, A; Kitamura, M; Kudo, K; Ninomiya, M; Ushijima, C, 2010) |
| "Six patients of esophageal cancer with liver metastasis and without extra-hepatic metastasis were enrolled." | 1.36 | [Regional treatment of esophageal liver metastasis by intra-arterial low-dose 5-FU therapy]. ( Akutsu, Y; Kaiho, T; Kono, T; Matsubara, H; Natsume, T; Ohira, G; Okazumi, S; Ota, T; Saito, H; Sato, A; Shuto, K; Tohma, T; Uesato, M, 2010) |
| "A total of 59 patients with esophageal cancer (clinical tumor stage 2-4, N(x), M(0)) received neoadjuvant chemoradiation followed by transthoracic en bloc esophagectomy." | 1.35 | Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer. ( Baldus, SE; Brabender, J; Drebber, U; Hoelscher, AH; Hoffmann, AC; Kuhn, E; Metzger, R; Schneider, PM; Vallböhmer, D; Warnecke-Eberz, U, 2008) |
| "Recurrent lymph node metastasis was detected in 68 patients with thoracic esophageal carcinoma after curative esophagectomy (R0, International Union Against Cancer criteria)." | 1.35 | Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. ( Mitsuhashi, N; Nakamura, T; Narumiya, K; Ohki, T; Ota, M; Sato, T; Yamamoto, M, 2008) |
| "Patients with localized esophageal cancer (LEC) have diverse outcomes (post-therapy pathologic response, disease-free survival [DFS], and overall survival [OS]) after preoperative chemoradiation (P-CTRT), dictated also by inherent molecular heterogeneity." | 1.35 | Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. ( Ajani, JA; Arora, R; Bhutani, MS; Correa, AM; Hofstetter, WL; Izzo, JG; Javeri, H; Lee, JH; Liao, Z; Maru, D; McAleer, MF; Swisher, SG, 2008) |
| " The CDDP dosage was reduced to 40% and HD was started 30 minutes after CDDP administration." | 1.35 | [Successful treatment with 5-fluorouracil and cis-dichlorodiammineplatinum combined with 60Gy of radiation in a case of advanced esophageal cancer complicated with chronic renal failure treated with hemodialysis]. ( Arai, Y; Hotta, K; Miyata, Y; Oyama, T; Tomori, A, 2008) |
| "The basaloid squamous cell carcinoma of the esophagus is highly malignant with poor prognosis." | 1.35 | [Diagnosis and treatment of basaloid squamous cell carcinoma of the esophagus]. ( Chen, JX; Tang, Q; Zheng, YD; Zhu, HN, 2008) |
| "A 63-year-old man who was diagnosed T1b esophageal cancer, for which transthoracic esophagectomy was indicated, received mediastinoscopy-assisted transhiatal esophagectomy because of the previous right thoracotomy for pulmonary tuberculosis." | 1.35 | [A case of esophageal cancer with recurrent lymph-node metastasis successfully treated with chemo-radiotherapy after mediastinoscopy-assisted transhiatal esophagectomy]. ( Nishimura, T; Oka, M; Takeda, S; Tokunou, K; Yoshino, S, 2008) |
| " The toxic grade for leukopenia (grade 0-2/3-4) and pathological effect (grade 3/1-2) were significantly different by univariate analysis (P = 0." | 1.35 | Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer. ( Doki, Y; Eguchi, H; Imaoka, S; Ishikawa, O; Kishi, K; Miyashiro, I; Miyoshi, N; Noura, S; Ohigashi, H; Ohue, M; Sasaki, Y; Takachi, K; Yamada, T; Yano, M, 2009) |
| "Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) chemotherapy and is licensed for the treatment of breast and gastrointestinal cancers." | 1.35 | Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion. ( Kolluri, RB; Raouf, S; Tipples, K, 2009) |
| " Five cardiopulmonary toxic events of Grade 3 or greater were observed in 4 patients, Grade 5 heart failure and Grade 3 pericarditis in 1 patient, and Grade 3 myocardial infarction, Grade 3 radiation pneumonitis, and Grade 3 pleural effusion." | 1.35 | Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. ( Chin, K; Gomi, K; Ito, H; Kozuka, T; Matsuura, M; Morota, M; Oguchi, M; Yamashita, T, 2009) |
| "A total of 61 patients with esophageal cancer were enrolled in this study between June 2002 and January 2004." | 1.35 | Comparison of cisplatin and 5-fluorouracil chemotherapy protocols combined with concurrent radiotherapy for esophageal cancer. ( Hayabuchi, N; Ishioka, C; Itami, J; Kazumoto, T; Makino, M; Nemoto, K; Onimaru, R; Onishi, H; Sakayauchi, T; Sasaki, S; Suzuki, G; Tamamoto, T; Tamamura, H; Yamada, S; Yamamoto, M; Yonekura, R, 2009) |
| "A xenograft model using SCID mice with esophageal cancer cells would monitor gene changes during treatment and regrowth." | 1.35 | Gene expression changes in a chemoresistant model with human esophageal cancer xenografts using cDNA microarray. ( Miyoshi, T; Seike, J; Takechi, H; Tangoku, A; Yamai, H; Yoshida, T; Yuasa, Y, 2009) |
| "Five patients had less than one-third residual tumor cells in resected specimens histopathologically; eight had more than two-thirds residual tumor cells." | 1.35 | Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer. ( Kusunoki, M; Miki, C; Mohri, Y; Ohi, M; Otake, K; Tanaka, K; Toiyama, Y; Tonouchi, H; Yokoe, T, 2009) |
| "A new animal model of esophageal cancer causing tumor colonization of the peritoneal cavity and producing bloody ascites was made by injecting YES-2 cells into the peritoneal cavity of a severe combined immunodeficiency mouse." | 1.35 | Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. ( Bando, Y; Kenzaki, K; Kondo, K; Miyoshi, T; Ohnishi, Y; Sawada, N; Seike, J; Takizawa, H; Tangoku, A; Yamai, H; Yoshida, T, 2009) |
| "Esophageal adenosquamous carcinoma is a rare esophageal disease and prone to be misdiagnosed as esophageal squamous cell carcinoma." | 1.35 | [Clinical analysis of 22 cases of esophageal adenosquamous carcinoma]. ( Fu, JH; Lin, P; Long, H; Ma, GW; Rong, TH; Su, XD; Zhang, DK; Zhang, LJ, 2009) |
| "Of 99 eligible patients with squamous cell carcinoma registered between January 2001 and December 2005, 51 selected CRT and 48 selected surgery." | 1.35 | Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. ( Ariga, H; Ichikawa, H; Ishioka, C; Jingu, K; Kamei, T; Kato, S; Miyata, G; Miyazaki, S; Nemoto, K; Ogawa, Y; Onodera, K; Sakayauchi, T; Satomi, S; Yamada, S; Yoshioka, T, 2009) |
| "Capecitabine regimens were compared with 5-fluorouracil (5-FU) and other chemotherapy regimens, and were stratified by treatment setting." | 1.35 | Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. ( Saif, MW; Shi, N; Zelt, S, 2009) |
| "Five months later, diffuse and multiple brain metastases relapsed, and second-line chemotherapy did not respond well, and finally he was died 3 months after palliative care." | 1.35 | [A case of a 14-month survival patient on advanced esophageal cancer with uncontrolled brain metastasis completely responding to nedaplatin, adriamycin, plus 5-FU (NAF) therapy]. ( Doi, T; Hoshi, M; Iijima, S; Kato, A; Kato, T; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Miyo, M; Ooshima, S; Sakamoto, T, 2009) |
| " Radiation therapy combined with nedaplatin and 5-FU is a safe and effective method for treating cT4 advanced esophageal cancer." | 1.35 | [A case of stage IV advanced esophageal cancer with a long term survival by radiation therapy combined with nedaplatin and 5-FU chemotherapy]. ( Dan, N; Hirakawa, K; Kubo, N; Morimoto, J; Muguruma, K; Nishiguchi, Y; Oohira, M; Sawada, T; Tanaka, H; Yamashita, Y; Yashiro, M, 2009) |
| "The standard chemotherapy regimen for esophageal cancer is cisplatin and 5-fluorouracil (5-FU)." | 1.35 | [A case of esophageal cancer associated with colon cancer successfully treated with combination chemotherapy of FOLFOX and concurrent radiotherapy]. ( Oka, M; Takeda, S; Tsutsui, M; Watanabe, Y; Yoshino, S, 2009) |
| "We have experienced a case of advanced esophageal cancer that has come back eight years after combined modality therapy, and after that, the patient could obtain a long-term survival with a marked effect of chemotherapy." | 1.35 | [A case of advanced esophageal cancer that has come back eight years after combined modality therapy]. ( Aoyama, N; Minamide, J; Ota, Y; Takata, K, 2009) |
| "All tumors were squamous cell carcinomas." | 1.35 | Concurrent chemoradiotherapy for esophageal cancer with malignant fistula. ( Kanamori, S; Koike, R; Nakamatsu, K; Nishimura, Y; Shibata, T, 2008) |
| "A 64-year-old woman with advanced esophageal cancer underwent chemotherapy with docetaxel/5-FU/CDDP (DFP)." | 1.35 | [Complete response in a case of advanced esophageal cancer treated with docetaxel/5-FU/CDDPand S-1/docetaxel as neoadjuvant chemotherapy]. ( Honda, J; Matsuoka, H; Miyoshi, T; Seike, J; Tangoku, A; Yamai, H; Yoshida, T; Yuasa, Y, 2008) |
| "Between 1998 and 2004, 66 esophageal cancer patients with adjuvant chemotherapy and 160 well-matched patients without chemotherapy were included in this study." | 1.35 | Adjuvant chemotherapy of cisplatin, 5-fluorouracil and leucovorin for complete resectable esophageal cancer: a case-matched cohort study in east China. ( Chen, ZW; Hu, H; Lu, S; Luo, QQ; Ma, LF; Miao, LS; Xiang, JQ; Zhang, J; Zhang, YW; Zhou, XY, 2008) |
| "In 71 patients with esophageal cancer who underwent neoadjuvant chemotherapy (cisplatin, adriamycin and 5-fluorouracil) followed by surgery, plasma d-dimer levels were measured before chemotherapy and the clinical and pathological responses to chemotherapy were assessed at 4 weeks after therapy (after surgery)." | 1.35 | Correlation between pretherapeutic d-dimer levels and response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. ( Imaoka, S; Ishikawa, O; Kishi, K; Miyashiro, I; Ohigashi, H; Ohue, M; Sasaki, Y; Takachi, K; Tomimaru, Y; Yano, M, 2008) |
| "Neoadjuvant treatment modalities for esophageal cancer were developed to improve local tumor control as well as to reduce lymph node metastases and distant metastases in patients with locally advanced esophageal cancer." | 1.34 | Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer. ( Baldus, SE; Bollschweiler, E; Dienes, HP; Hölscher, AH; Izbicki, JR; König, A; Mueller, RP; Prenzel, KL; Schneider, PM; Schnickmann, C; Schröder, W, 2007) |
| "The role of surgery for esophageal squamous cell carcinoma (SCC) with clinical evidence of adjacent organ invasion (cT4) is a debated issue." | 1.34 | Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. ( Bernini, M; Cordiano, C; de Manzoni, G; Giacopuzzi, S; Grandinetti, A; Minicozzi, AM; Pasini, F; Pedrazzani, C, 2007) |
| "In cases of esophageal cancer, a different pattern of tumor shrinkage is often observed between primary tumors and metastatic lymph nodes (MLNs)." | 1.34 | Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy. ( Aiko, S; Ishizuka, T; Kumano, I; Maehara, T; Sakano, T; Sugiura, Y; Yoshizumi, Y, 2007) |
| "Thoracic esophageal cancers frequently metastasize to the right recurrent nerve nodes (RRNNs)." | 1.34 | Salvage lymphadenectomy of the right recurrent nerve node with tracheal involvement after definitive chemoradiation therapy for esophageal squamous cell carcinoma: report of two cases. ( Doki, Y; Fujiwara, Y; Makari, Y; Masuoka, T; Matsuyama, J; Miyata, H; Monden, M; Takiguchi, S; Yamasaki, M; Yasuda, T, 2007) |
| "Ninety-nine per cent had squamous cell carcinoma and 56% had the main lesion in the middle thoracic esophagus." | 1.34 | Results of the 1999 2001 Japanese patterns of care study for patients receiving definitive radiation therapy without surgery for esophageal cancer. ( Kenjo, M; Murakami, Y; Oguchi, M; Shimada, M; Teshima, T; Uno, T, 2007) |
| "Basaloid squamous cell carcinoma (BSC) of the esophagus is a rare malignant disease." | 1.34 | Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin. ( Arita, S; Ariyama, H; Baba, E; Kusaba, H; Miki, R; Mitsugi, K; Nakano, S; Noshiro, H; Ogami, N; Qin, B; Shibata, Y; Yao, T, 2007) |
| "Patients with esophageal cancer often develop metastatic disease after esophageal resection and generally receive cisplatin-based chemotherapy or chemoradiotherapy." | 1.34 | Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. ( Fujita, H; Mori, N; Nagano, T; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Tanaka, Y; Yamana, H, 2007) |
| " 60Co gamma-irradiation or 6MVX-ray with conventional fraction were used for radiotherapy with a total volume dosage of 55-70 Gy." | 1.34 | [Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus]. ( Han, JQ; Li, XQ; Liang, RX; Liu, Q; Qu, FS; Sun, YH; Yan, TX, 2007) |
| "Medical records of 108 patients with esophageal cancer who received CRT of 5-FU+CDDP (CDDP group) or 5-FU+CDGP (CDGP group) were analyzed." | 1.34 | [Cost effectiveness of chemoradiotherapy with cisplatin/fluorouracil and nedaplatin/fluorouracil for patients with esophageal cancer]. ( Imawari, M; Inoue, T; Kaneko, K; Kiuchi, Y; Kogo, M; Tomura, K; Yoneyama, K, 2007) |
| " A threshold of tumor response to radiation dose might be present, as suggested by the flattened slope in the high-dose area on the dose-response curve." | 1.33 | Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. ( Ajani, J; Allen, P; Chang, JY; Cox, JD; Guerrero, T; Ho, L; Jeter, M; Jin, J; Komaki, R; Liao, Z; Stevens, CW; Swisher, S; Yao, J; Zhang, Z, 2005) |
| "Treatment of non operable esophageal cancer still remains debatable." | 1.33 | [Role of an exclusive concomitant radio-chemotherapy treatment in non operable esophageal cancer: results of a 10-year experience in Antoine-Lacassagne Center]. ( François, E; Lagrange, JL; Magné, N; Marcy, PY; Touati, L; Van Houtte, P, 2005) |
| "The side effect of anticancer agents such as nausea and vomiting frequently interrupt chemotherapy." | 1.33 | [Effect of steroid on antiemetic for side effect of anticancer chemotherapy]. ( Matsumoto, T; Mikami, T; Momokawa, K; Nakamura, Y; Sakayauchi, T; Sasaki, T; Watanabe, T, 2005) |
| "Ocular metastasis in patients with esophageal cancer is quite rare." | 1.33 | Iris metastasis of esophageal cancer. ( Hirose, N; Ichiki, Y; Morita, M; Sugio, K; Yano, K; Yasumoto, K, 2005) |
| " CM-Na was given 1 h before radiotherapy at Monday, Wednesday, and Friday every week, combined with 2 circles of continuous 5-day chemotherapy of 500 mg x (m(2) x d)(-1) of 5-fluoruracil (5-FU) and 20 mg x (m(2) x d)(-1) of cisplatin (DDP) at the first and the fifth week." | 1.33 | [Phase I study of CM-Na combined with concurrent radiochemotherapy for advanced esophageal carcinoma]. ( Cai, L; Chen, EC; Cui, NJ; Gu, MF; Hu, YH; Huang, Y; Li, QQ; Lin, HX; Liu, H; Liu, MZ; Rong, TH; Wang, HY, 2005) |
| "190 patients suffering from T3 squamous carcinoma of lower thoracic esophagus who underwent radical surgery from January 1990 to January 1999, 158 males and 32 females, aged 62." | 1.33 | [The value of postoperative arterial infusion chemotherapy in patients with T3 esophageal squamous carcinoma after radical surgery]. ( Liu, BD; Xu, QS; Zhi, XY, 2005) |
| "The esophageal cancer was found by endoscopy to have diminished significantly after completion of neoadjuvant therapy, An endoscopic biopsy specimen was found to contain no malignant cells." | 1.33 | [Pathologic complete response of thoracic esophageal cancer developing after gastrectomy to neoadjuvant low-dose nedaplatin (CDGP), 5-fluorouracil and radiotherapy]. ( Fukuhara, K; Iwasaki, H; Lee, S; Nishikawa, T; Osugi, H; Takemura, M, 2005) |
| " The dosage of each drug was based on that for a patient undergoing hemodialysis, and the plasma concentration of each drug was examined." | 1.33 | [Chemotherapy for an esophageal cancer patient undergoing continuous ambulatory peritoneal dialysis for chronic renal failure and measurement of plasma concentration of the drug]. ( Maruyama, K; Motoyama, S; Ogawa, J; Ohta, H; Okuyama, M; Oyake, J; Tsuchiya, N, 2005) |
| "Twenty-two patients with localized esophageal cancer suitable for curative chemoradiation therapy and 24 patients suitable for palliative therapy were enrolled." | 1.33 | Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin. ( Burmeister, BH; Burmeister, EA; Gotley, DC; Harvey, JA; Mark Smithers, B; Thomas, J; Thomson, DB; Walpole, ET, 2005) |
| "Grade 3 dysphagia-esophageal related to radiation was observed in 3 patients (9." | 1.33 | [Hyperfractionated radiotherapy with concurrent chemotherapy for advanced esophageal cancer]. ( Asakura, H; Hosokawa, N; Kiuchi, T; Mitani, M; Ohkawa, M; Seo, H; Takashima, H; Togami, T; Yokoe, K, 2005) |
| "Moderately differentiated squamous cell carcinoma diagnosed by pre-operative endoscopic biopsy." | 1.33 | [A case of complete response after neoadjuvant chemotherapy for advanced esophageal cancer with low-dose FP therapy]. ( Endoh, H; Koyama, K; Miyazawa, M; Muto, A; Ohtani, S; Satoh, M; Tsukada, M, 2005) |
| "HDRBT is safe and beneficial for local control in the radical treatment of patients with esophageal cancer." | 1.33 | The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy. ( Burtin, P; Corns, R; David, M; Devic, S; Evans, M; Faria, S; Mayrand, S; Parent, J; Szego, P; Vuong, T, 2005) |
| "Data from 110 esophageal cancer patients treated between January 1998 and December 2003 were analyzed retrospectively." | 1.33 | Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. ( Ajani, JA; Cox, JD; Komaki, R; Liao, Z; Liu, H; Swisher, S; Tucker, SL; Vaporciyan, AA; Wang, SL; Wei, X, 2006) |
| "Fifty-two patients with resectable esophageal cancers (cT2-4, Nx, and M0) received neoadjuvant radiochemotherapy (cisplatin, 5-5-fluorouracil, 36 Gy) followed by transthoracic en bloc esophagectomy." | 1.33 | High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. ( Baldus, SE; Bollschweiler, E; Brabender, J; Dienes, HP; Hoelscher, AH; Ling, FC; Metzger, R; Moenig, S; Mueller, RP; Neiss, S; Schneider, PM; Warnecke-Eberz, U; Xi, H, 2005) |
| "Treatment of esophageal cancer cells with 5-Fu and cisplatin induced NF-kappaB and AP-1 activation." | 1.33 | Vitamin C enhances chemosensitization of esophageal cancer cells in vitro. ( Abdel-Latif, MM; Kelleher, D; Raouf, AA; Reynolds, JV; Sabra, K, 2005) |
| "SEG1 and BIC1 human esophageal cancer cells were studied." | 1.33 | Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-kappaB. ( Brank, A; Camp, ER; Hochwald, SN; Li, J; Mackay, SL; Minnich, DJ, 2006) |
| "As patients with oesophageal cancer have a high incidence of co-morbidities including cardiac problems, the aim of this paper was to quantify the extent of cardiac radiation and discuss the influence of beam arrangement to reduce this." | 1.33 | Quantification and reduction of cardiac dose in radical radiotherapy for oesophageal cancer. ( Cominos, M; Cornes, P; Henrys, A; Mosleh-Shirazi, MA; Tait, D, 2005) |
| "To evaluate the treatment outcome of radiotherapy combined with cis-diammine-glycolatoplatinum (nedaplatin) plus 5-fluorouracil (5-FU) for esophageal cancer." | 1.33 | Radiation therapy combined with cis-diammine-glycolatoplatinum (nedaplatin) and 5-fluorouracil for Japanese stage II-IV esophageal cancer compared with cisplatin plus 5-fluorouracil regimen: a retrospective study. ( Igaki, H; Nakagawa, K; Nakamura, N; Ohtomo, K; Sasano, N; Shiraishi, K; Tago, M; Yamashita, H, 2006) |
| "This study is the first to evaluate esophageal cancer treatment with a pharmacogenetic paradigm and its application of pharmacogenetic analysis to multiple genes in each drug action pathway as a means of developing a more accurate and consistent risk prediction model." | 1.33 | Pharmacogenetics in esophageal cancer. ( Ajani, JA; Chiang, SS; Lu, C; Wu, X, 2005) |
| " We conclude that tumor ablation by ethanol injection for palliation combined with chemoradiation may be a low-cost alternative for advanced unresectable esophageal cancer." | 1.33 | Palliative ethanol injections of unresectable advanced esophageal carcinoma combined with chemoradiation. ( Abbasi, S; Korman, L; Wadleigh, RG, 2006) |
| "In esophageal squamous cell carcinoma (ESCC), chemoradiotherapy (CRT) has a curative potential even in cases of locally advanced carcinoma." | 1.33 | Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications. ( Aoyagi, K; Ashida, A; Boku, N; Minashi, K; Muto, M; Ochiai, A; Ohtsu, A; Sasaki, H; Sato, H; Tsubosa, Y; Yoshida, S; Yoshida, T, 2006) |
| "DNA was extracted from 26 oesophageal cancer patients undergoing CRX and surgery." | 1.33 | [HPV-infection in esophageal cancer as possible predictive factor after neoadjuvant therapy]. ( Gábor, B; György, L; Imdahl, A; Pál, O, 2006) |
| "Under the diagnosis of multiple lung metastases, the patient was hospitalized and received intensive chemotherapy with docetaxel 40 mg/week (day 1), 5-fluorouracil 500 mg/day (days 1-5), cisplatin 10 mg/day (days 1-5)." | 1.33 | A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy. ( Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T, 2006) |
| "The prognosis of patients with advanced esophageal cancer is still poor." | 1.33 | [Long-term results of chemoradiation therapy for the patients with locally advanced (T4) esophageal cancer]. ( Endo, Y; Fujita, S; Miyamoto, K; Ohki, S; Onogi, H; Sakamoto, W; Sato, Y; Sekikawa, K; Suzuki, S; Takenoshita, S; Yazawa, T, 2006) |
| "The most common sites of distant recurrence are represented by lung, liver and bone while brain and breast metastases are rare." | 1.33 | Successful outcome after combined chemotherapeutic and surgical management in a case of esophageal cancer with breast and brain relapse. ( Cossu Rocca, P; Costantino, S; Fadda, GM; Farris, A; Pinna, MA; Piredda, G; Putzu, C; Sanna, G; Santeufemia, DA; Sarobba, MG, 2006) |
| "The prognosis of esophageal cancer is not only affected by TNM stage but also by the level of serum vascular endothelial growth factor (S-VEGF)." | 1.33 | [Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients--a report of 43 cases]. ( Cai, L; Cui, NJ; Liu, MZ; Wang, XS; Zhang, CQ, 2006) |
| "Docetaxel and nedaplatin are active for esophageal cancer." | 1.33 | Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. ( Chiba, N; Ishioka, C; Kakudo, Y; Kato, S; Miyazaki, S; Nemoto, K; Ohtsuka, K; Sakata, Y; Sakayori, M; Shibata, H; Shimodaira, H; Yoshioka, T, 2006) |
| "From January 1999 to November 2000, a total of 24 esophageal cancer patients (17 untreated and 7 recurrent cases) were treated with radiation therapy (60-70 Gy) combined with cis-diammine-glycolatoplatinum (Nedaplatin) (80-120 mg/body) and 5-fluorouracil (5-FU) (500-1,000 mg/body/24 h, continuous infusion for 5 days)." | 1.32 | Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer. ( Britton, KR; Matsushita, H; Miyata, T; Miyazaki, S; Nemoto, K; Ogawa, Y; Takahashi, C; Takai, Y; Takeda, K; Yamada, S, 2003) |
| "Type 1 undifferentiated carcinoma (non-small cell type) was detected in the middle of the thoracic esophagus in August 1999." | 1.32 | [Complete remission of esophageal undifferentiated carcinoma with nedaplatin and 5-FU chemotherapy and endoesophageal brachytherapy]. ( Iwashige, M; Kikuchi, H; Kumada, K; Midorikawa, T; Nagasaki, H; Nemoto, H; Sanada, Y; Takeuchi, S; Takizawa, K; Tate, G; Yagi, H; Yoshizawa, Y, 2003) |
| "Two hundred and eleven patients with a squamous cell carcinoma in the thoracic esophagus who underwent transthoracic curative (R0) esophagectomy with radical lymphadenectomy, such as 3-field lymphadenectomy or total 2-field lymphadenectomy, between 1988 and 2000, were retrospectively reviewed." | 1.32 | Adjuvant chemotherapy after radical resection of squamous cell carcinoma in the thoracic esophagus: who benefits? A retrospective study. ( Fujita, H; Heroor, A; Matono, S; Mine, T; Sasahara, H; Shirouzu, K; Sudo, T; Sueyoshi, S; Tanaka, T; Toh, U; Yamana, H, 2003) |
| "Basaloid squamous carcinoma (BSC) of the esophagus has been associated with a poor outcome after surgery." | 1.32 | Basaloid-squamous carcinoma of the esophagus treated by preoperative chemotherapy: report of two cases. ( Adachi, W; Amano, J; Hanazaki, K; Igarashi, J; Kishimoto, K; Koide, N; Maezawa, T; Nakamura, T, 2003) |
| " One course of nedaplatin, 5-FU and LV combined with radiation was performed alternatively." | 1.32 | [Effect of nedaplatin, 5-FU, and leucovorin combined with radiation therapy in unresectable esophageal carcinoma]. ( Futami, R; Makino, H; Maruyama, H; Miyashita, M; Miyashita, T; Nomura, T; Sasajima, K; Tajiri, T; Tateno, A, 2003) |
| "Human esophageal cancer cells NEC and human lung adenocarcinoma cells GLC were cultured and then inoculated into the wells." | 1.32 | [The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells]. ( Huang, J; Jiao, SC; Lu, SX; Sun, Y, 2003) |
| "We conducted a pilot study of nedaplatin + 5-fluorouracil (5-FU) combined with radiotherapy for 29 patients with primary advanced (stage IV) esophageal cancer." | 1.32 | [Nedaplatin and 5-fluorouracil combined with radiotherapy for advanced esophageal cancer]. ( Eguchi, R; Hayashi, K; Ide, H; Mitsuhashi, M; Nakamura, T; Narumiya, K; Ota, M; Takasaki, K, 2003) |
| "Esophageal cancer is an aggressive disease, and poor survival is achieved with surgery or chemoradiation therapy alone." | 1.32 | Combined modality therapy in esophageal cancer: the Memorial experience. ( Anderson, SE; Bains, M; Ilson, DH; Kelsen, DP; Minsky, BD, 2003) |
| "We report a case of esophageal cancer infiltrating the left main bronchus in which radical esophagectomy with clear surgical margins could be performed after preoperative radiochemotherapy." | 1.32 | [Resection of esophageal cancer infiltrating the left main bronchus following complete response to preoperative radiochemotherapy--a case report]. ( Fujiwara, Y; Fukuhara, K; Kaneko, M; Kinoshita, H; Lee, S; Nishizawa, S; Osugi, H; Taguchi, S; Takemura, M; Tanaka, Y, 2003) |
| "Ten patients with recurrent esophageal cancer were treated with the combination of docetaxel 60 mg/m2 (day 1), CDDP 10 mg/body (days 1-5) and 5-FU 500 mg/body (days 1-5) at intervals of 2-3 weeks." | 1.32 | [Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study]. ( Fujita, H; Matono, S; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Yamana, H, 2003) |
| "Fifteen patients with advanced squamous cell carcinoma of the thoracic esophagus were treated with neoadjuvant chemoradiotherapy (NAC) combined with concurrent radiation (30 Gy/12 f) and 3 courses of 5-FU and CDDP (CDDP 5 mg/m2/day + 5-FU 250 mg/m2/day: day 1-5: div)." | 1.32 | [Neoadjuvant chemoradiotherapy for advanced squamous cell carcinoma of thoracic esophagus]. ( Honnma, S; Kohashi, S; Kondo, M; Kudo, T; Maeda, Y; Sato, Y; Shimokuni, T; Shinohara, T; Takahashi, S; Todo, S, 2004) |
| "Rare reports of intestinal obstruction have been confined to the stiff plastic and stainless-steel stents." | 1.32 | A rare life-threatening complication of migrated nitinol self-expanding metallic stent (Ultraflex). ( Ho, HS; Ong, HS, 2004) |
| "This is a report of a case with esophageal cancer in which pathological CR was obtained by neoadjvant chemoradiotherapy using a low-dose of nedaplatin (CDGP)/5-FU." | 1.32 | [A resected case of thoracic esophageal cancer in which pCR was obtained using low-dose of nedaplatin (CDGP)/5-FU and radiotherapy]. ( Fujiwara, Y; Higashino, M; Iwasaki, H; Kaneko, M; Lee, S; Nishizawa, S; Osugi, H; Takemura, M; Tanaka, Y, 2004) |
| "We report a patient with esophageal cancer with concomitant liver metastasis in whom complete response was achieved by chemoradiation therapy." | 1.31 | Complete regression of esophageal cancer with concomitant liver metastasis achieved by concurrent chemoradiation therapy. ( Hiramoto, J; Murakami, S; Nagayama, K; Nakada, T; Sakabe, S; Tsuruta, Y, 2002) |
| "Postoperative complications were anastomosis leakage in 1 patient, and anastomosis stenosis in 2 and esophagobronchial fistula in 1." | 1.31 | [Salvage operation for esophageal cancer after radical chemoradiotherapy]. ( Boku, N; Gotohda, N; Nagai, K; Nishimura, M; Ohtsu, A; Yoshida, J, 2002) |
| "Cells derived from human oesophageal squamous cell carcinoma (OSC-1) were grown for 2 days and incubated with cisplatin (CDDP), 5-fluorouracil (5-FU), methotrexate (MTX) or gemcitabine (GEM) for 4 h." | 1.31 | Early changes in [18F]FLT uptake after chemotherapy: an experimental study. ( Bares, R; Bartusek, G; Dittmann, H; Dohmen, BM; Kehlbach, R; Pritzkow, M; Sarbia, M, 2002) |
| "A 77-year-old man with advanced esophageal cancer with tracheal and esophageal obstruction underwent continuous low-dose FP chemotherapy for a total of seven weeks, resulting in a complete response (CR) and disappearance of the esophago-tracheal fistula." | 1.31 | [A trial of continuous and biweekly low-dose cisplatin and 5-FU with UFT chemotherapy for esophageal cancer]. ( Hasebe, K; Sasaki, S; Takamura, H; Urade, M; Yagi, M, 2002) |
| "Advanced esophageal cancer patients with extensive lymph node metastases show extremely poor prognosis and the long-term outcome is poorer with the involvement of more lymph nodes." | 1.31 | A case of advanced esophageal cancer with extensive lymph node metastases successfully treated with multimodal therapy. ( Gunduz, M; Haisa, M; Naomoto, Y; Shigemitsu, K; Shirakawa, Y; Tanaka, N, 2002) |
| " Further study of dosage and schedule is necessary, however, CDGP/5-FU combined with radiation therapy could be used as choices of chemoradiotherapy for esophageal cancer in the future." | 1.31 | [Clinical study of the combination of small amount of nedaplatin (CDGP)/5-FU with radiation for the treatment of esophageal cancer]. ( Endo, T; Hara, T; Hoshikawa, Y; Iino, S; Inaba, H; Kato, N; Kitajima, S; Kobayashi, Y; Koitabashi, Y; Miyazaki, A; Nakagawa, T; Nakaya, S; Ogihara, K; Tsuda, T; Watanabe, Y, 2002) |
| "Sixty-seven patients with progressive esophageal cancer treated with CRT were included in this study." | 1.31 | DNA-PKcs expression in esophageal cancer as a predictor for chemoradiation therapeutic sensitivity. ( Fumoto, S; Mueller, W; Noguchi, T; Shibata, T; Takeno, S; Uchida, Y, 2002) |
| "Thirteen patients with locally advanced esophageal cancer (T4 cases) and 3 with recurrence of esophageal cancer were treated with radiotherapy (40-70 Gy) and 5-FU combined with cisplatin/nedaplatin concurrently." | 1.31 | [Chemoradiotherapy using platinum analogs/5-FU for advanced esophageal cancer]. ( Kawasaki, H; Matsuya, H; Morita, T; Morohashi, H; Nakai, M; Sasaki, M; Shibata, S; Yamada, K, 2002) |
| "Fluorouracil can cause both acute and delayed neurotoxicity." | 1.31 | Fluorouracil-induced neurotoxicity. ( Ali, II; Dafer, RM; Pirzada, NA, 2000) |
| "It is possible to cure oesophageal cancer with chemo-radiotherapy and selective oesophagectomy, and achieve organ preservation in the majority of long term survivors." | 1.31 | Primary chemo-radiotherapy and selective oesophagectomy for oesophageal cancer: goal of cure with organ preservation. ( Lim, JT; Wilson, KS, 2000) |
| "225 patients with squamous cell carcinoma of the oesophagus were prospectively studied." | 1.31 | Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis. ( Busch, R; Roder, RJ; Rosenberg, R; Thorban, S, 2000) |
| "Six nonoperated esophageal cancer patients were treated by daily concurrent CRT, which consisted of continuous 5-fluorouracil administration with leucovorin, combined with a low dose of daily cisplatin administration before each fraction of radiation." | 1.31 | Feasibility of daily concurrent chemoradiation therapy as nonsurgical management for esophageal cancer: our experience and theoretical background. ( Aoki, F; Kaminishi, M; Murakami, T; Shimoyama, S; Toyoda, K, 2000) |
| "The prognosis of upper thoracic esophageal cancer is poor when compared with middle and lower thoracic esophageal cancer because the tumor easily infiltrates the respiratory tract and surgical en-bloc resection is difficult." | 1.31 | Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy. ( Doki, Y; Fujiwara, Y; Inoue, M; Monden, M; Shiozaki, H; Tsujinaka, T; Yano, M, 2000) |
| "Forty-seven patients with squamous cell carcinomas of the esophagus had undergone radiation therapy, followed by surgical resection." | 1.31 | CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. ( Doki, Y; Fujiwara, Y; Inoue, M; Kishi, K; Miyata, H; Monden, M; Nishioka, K; Shiozaki, H; Yamamoto, H; Yano, M, 2000) |
| "Thirty-four patients with advanced squamous cell carcinoma of the thoracic esophagus (T2-4 N0-1 M0), who underwent one cycle of cisplatin and 5-fluorouracil therapy followed by subtotal esophagectomy, were studied." | 1.31 | Assessment of the predictive value of clinical and histopathological factors as well as the immunoexpression of p53 and bcl-2 proteins in response to preoperative chemotherapy for esophageal squamous cell carcinoma. ( Chibowski, D; D browski, A; Szumilo, J, 2000) |
| "Its expression in esophageal cancer, however, has not been reported." | 1.31 | Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. ( Fujii, Y; Kato, J; Kudo, J; Kuwabara, Y; Mitani, M; Mitsui, A; Moriyama, S; Nishiwaki, T; Sato, A; Shinoda, N; Toyama, T, 2001) |
| "Transient hypotension was the most common side effect occurring in association with amifostine." | 1.31 | Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. ( Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E, 2001) |
| " The chemotherapy consisted of protracted infusion of 5-fluorouracil (5-FU), combined with infusion of nedaplatin (NDP)." | 1.31 | [A case of esophageal carcinoma with multiple liver metastases successfully treated with nedaplatin (NDP) and 5-fluorouracil (5-FU) combined with radiotherapy]. ( Eguchi, J; Ito, H; Ito, T; Kaneko, K; Kitahara, T; Konishi, K; Kurahashi, T; Mitamura, K; Yamamoto, T, 2001) |
| "We analyzed expression profiles of 20 esophageal cancer tissues from patients who were treated with the same adjuvant chemotherapy after removal of tumor by operation, and we attempted to find genes associated with the duration of survival after surgery." | 1.31 | Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. ( Furukawa, Y; Hirata, K; Kihara, C; Kitahara, O; Nakamura, Y; Ono, K; Takagi, T; Tanaka, T; Tsunoda, T; Yamana, H; Yanagawa, R; Zembutsu, H, 2001) |
| "We report a case of advanced esophageal cancer, which was treated by chemoradiotherapy combined with surgical treatment." | 1.31 | [Chemoradiotherapy and salvage surgery in a patient with advanced esophageal cancer]. ( Fukao, K; Kawamoto, T; Koike, N; Kondo, T; Moon, Y; Nakagawa, Y; Ohara, K; Shimizu, W; Todoroki, T; Yamamoto, Y; Yoshida, S, 2001) |
| "A 63-year-old male with advanced esophageal cancer was admitted to our hospital." | 1.31 | [Tissue platinum distribution and the effect following intra-arterial injection of cisplatin to metastatic liver cancer--a case report]. ( Kumada, K; Makuuchi, M; Midorikawa, T; Nemoto, H; Sanada, Y; Sasaya, S; Takeuchi, S; Takizawa, K; Uemichi, O; Yamaguchi, M; Yoshizawa, Y, 2001) |
| "Esophageal cancer is associated with the poorest prognosis among the digestive tract cancers, and chemotherapy is the treatment of choice for many patients." | 1.31 | Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene increases the sensitivity of esophageal cancer cells to 5-fluorouracil. ( Akiyama, S; Fujiwara, M; Hamada, H; Ito, K; Kasai, Y; Nakamura, H; Nakao, A; Sekiguchi, H, 2001) |
| " Thirty-one patients with superficial oesophageal or gastric cardiac carcinomas, who refused or were unsuitable for surgery, received endoscopic Nd:YAG laser therapy combined with local injection of chemotherapeutic drugs 5-fluorouracil and mitomycin." | 1.31 | Endoscopic Nd:YAG laser therapy combined with local chemotherapy of superficial carcinomas of the oesophagus and gastric cardia. ( Huang, T; Jia, J; Wang, Y; Zhou, C, 2001) |
| "Therefore, the effect of CRT for esophageal cancer may be predicted by immunohistochemical examination of DPD in biopsied tumor specimens." | 1.31 | [Immunohistochemical study of dihydropyrimidine dehydrogenase (DPD) and p53 in biopsied specimens of esophageal cancer before chemoradiotherapy]. ( Fukuda, K; Hisamitsu, K; Ikeguchi, M; Kaibara, N; Katano, K; Oka, S; Tsujitani, S; Yamaguchi, K, 2001) |
| "A diagnosis of esophageal cancer with subcutaneous abscess was made based on examination and biopsy results." | 1.31 | [A patient with esophageal cancer with subcutaneal abscess and esophago-tracheal fistula who survived more than 2 years following treatment by drainage and chemoradiation therapy]. ( Furukawa, J; Katsumoto, Y; Maruyama, K; Maruyama, N; Morimoto, T; Nakaguchi, K; Nakamura, M; Okajima, S; Shingai, T; Sue, F, 2001) |
| "Telomerase activity was high in esophageal cancer tissue and showed positive correlation with blood vessel invasion." | 1.31 | Telomerase activity in esophageal squamous cell carcinoma: down-regulation by chemotherapeutic agent. ( Fujii, Y; Iwase, H; Kato, J; Kuwabara, Y; Mitani, M; Mitsui, A; Sato, A; Shinoda, N; Sugiura, M; Suzuki, T; Toyama, T, 2002) |
| "These neoadjuvant therapies for esophageal cancer are done widely." | 1.31 | Surgical and oncological advances in the treatment of esophageal cancer. ( Futatsugi, M; Kimura, Y; Miyazaki, M; Nozoe, T; Ohga, T; Saeki, H, 2002) |
| "Ten patients with advanced esophageal cancer were enrolled for this regimen consisting of 5-FU; 500 mg/day x 5/w x 4, CDDP; 10 mg/day x 5/w x 4 and radiation; 2 Gy x 5/w x 4." | 1.30 | [Preoperative synchronized chemoradiation therapy for advanced esophageal cancer]. ( Iihara, K; Kimura, M; Kitada, M; Murotani, M; Niinobu, T; Nose, T; Ogawa, M; Shibata, T; Takada, T; Takami, M; Tsujinaka, T; Tsukahara, Y; Tsukamoto, F, 1997) |
| "Trimodality treatment for esophageal cancer may provide long-term survival in some patients regardless of their pCR status." | 1.30 | Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus. ( Bernard, SA; Detterbeck, FC; Egan, TM; Jones, DR; Parker, LA; Tepper, JE, 1997) |
| "In this case, there were esophageal cancer in the cervical esophagus, with intramural spreading in whole esophagus." | 1.30 | Esophageal intramural pseudodiverticulosis with esophageal cancer improved by target rotation irradiation: case report. ( Katayama, H; Naoi, Y; Tomiyoshi, H, 1997) |
| "Eighty-eight patients with cancer of the esophagus ineligible for surgery were entered in the study between 1986 and 1993." | 1.30 | Accelerated fractionation in esophageal cancers: a multivariate analysis on 88 patients. ( Auperin, A; Dhermain, F; Ducreux, M; Elias, D; Girinsky, T; Kac, J; Marsiglia, H; Randrianarivelo, H; Rougier, P, 1997) |
| "A 57-year-old man suffering from gastric cancer with esophageal invasion and liver and paraaortic lymph nodes metastases was treated with continuous 5-FU injection and intra-hepatic arterial infusion of low-dose cisplatin following non-curative surgery." | 1.30 | [A case of far-advanced gastric cancer treated with continuous 5-fluorouracil injection and intrahepatic arterial infusion of low-dose cisplatin]. ( Oka, M; Ueno, T, 1997) |
| "Chemoradiotherapy combined with hyperthermia was administered to 35 patients with advanced esophageal carcinoma who either required preoperative treatment or had nonresectable disease." | 1.30 | Clinical results of treatment of advanced esophageal carcinoma with hyperthermia in combination with chemoradiotherapy. ( Fujimaki, M; Katoh, H; Sakamoto, T; Shimizu, T; Takemori, S; Tazawa, K; Yamashita, I, 1997) |
| "A series of patients with esophageal cancer was treated with chemotherapeutic regimens of the new antitumor platinum preparation nedaplatin plus 5-FU in combination with radiation therapy, and the therapeutic responses, side effects, and complications were clinically assessed." | 1.30 | Nedaplatin and 5-FU combined with radiation in the treatment for esophageal cancer. ( Asai, A; Hioki, K; Michiura, T; Mori, T; Motohiro, T; Yamanaka, H, 1998) |
| "5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens." | 1.30 | Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. ( Ahmad, M; Aziz, SA; Iqbal, K; Jalal, S; Mohi-ud-Din, K; Tramboo, NA, 1998) |
| "Advanced gastric, colon and esophageal cancers (n = 21) were treated with 5-FU (250 mg) modulated by CDDP (5 mg)." | 1.30 | [Treatment with 5-FU modulated by low-dose CDDP for advanced cancers and recurrent cases of metastasis]. ( Hisano, H; Kida, H; Nomura, M; Shibasaki, S; Shinkai, K; Yano, H, 1999) |
| "The treatment of upper thoracic esophageal cancer remains challenging, and combined treatment is necessary to improve the outcome." | 1.30 | Role of preoperative chemoradiation in the management of upper third thoracic esophageal squamous cell carcinoma. ( Doki, Y; Inoue, M; Monden, M; Shiozaki, H; Tsujinaka, T; Yamamoto, M; Yano, M, 1999) |
| " He was treated with chemotherapy of 5-FU and Cisplatin combined with radiotherapy." | 1.30 | [A case report of esophageal small cell carcinoma responding well to chemotherapy of 5-FU and cisplatin combined with radiotherapy]. ( Kato, H; Nikkuni, K; Sasaki, K; Satoh, T; Tomidokoro, T; Yoshikawa, T, 1999) |
| "Three cases of prominent-type advanced esophageal cancer were treated with chemoradiation therapy using a 5-FU analog and low dose CDDP." | 1.30 | [Chemoradiation therapy for advanced esophageal cancers--report of 3 cases]. ( Fukao, K; Kawai, Y; Kawamoto, T; Koike, N; Maruyama, T; Monoi, H; Ohara, K; Shimizu, W; Todoroki, T; Yamamoto, Y; Yoshida, S, 1999) |
| "A 63-year-old male with an esophageal cancer invading the bronchus was treated with radiation therapy (70 Gy) from November 1995, resulting in the disappearance of the lesion." | 1.30 | [Usefulness of combination therapy with expandable metallic stent replacement and FLEP chemotherapy (consisting of 5-FU, leucovorin, etoposide and cisplatin) for advanced esophageal cancer invading the bronchus: a case report]. ( Hada, T; Kobayashi, I; Kohno, S; Matai, K; Oda, Y; Ohmori, H; Sasaya, K; Yamazaki, Y, 1999) |
| "Fifty-three patients with localized esophageal cancer received concurrent chemoradiotherapy followed by brachytherapy." | 1.30 | High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma. ( Dokiya, T; Oki, Y; Yorozu, A, 1999) |
| "Local control of esophageal cancer is excellent following neoadjuvant chemotherapy and radiation therapy." | 1.30 | Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy. ( Adelstein, DJ; Becker, M; Chidel, MA; Kupelian, PA; Rice, TW; Suh, JH, 1999) |
| " Preoperative chemoradiotherapy consisted of cisplatinum combined chemotherapy and radiotherapy (total dosage of 30-70 Gy)." | 1.30 | Analysis of postoperative complications after esophagectomy for esophageal cancer in patients receiving neoadjuvant therapy. ( Eguchi, R; Hayashi, K; Ide, H; Itoh, H; Nakamura, T; Ohta, M; Okamoto, F; Takasaki, K, 1999) |
| "He was diagnosed as having advanced esophageal cancer (Stage IV) with a massive supraclavicular lymph node metastasis, and the lesion was thought to be unresectable." | 1.30 | [A case of stage IV esophageal cancer successfully treated by chemoradiation]. ( Isogaki, J; Kawabe, A; Kazui, T; Kobayashi, T; Nishimura, T; Nozue, M; Wada, H; Yoshida, M, 1999) |
| "A 64-year-old man with unresectable esophageal cancer (A3, N1, M0) was treated with concurrent chemoradiotherapy." | 1.30 | [A case of stage IV (A3) cervical and upper thoracic esophageal adenocarcinoma successfully treated with concurrent chemoradiotherapy]. ( Inoue, H; Ise, H; Matsumoto, G; Matsuo, S; Suzuki, N, 1999) |
| "We have treated 17 patients with squamous cell carcinoma of the upper esophagus by alternating chemoradiotherapy and by following the patients for 2 to 5 years, or until their death." | 1.29 | Patterns of failure in carcinoma of the upper esophagus after alternating chemoradiotherapy. ( Chadha, M; Malamud, S; Vikram, B; Yu, L, 1994) |
| " In a first step, the 5-FU pharmacokinetic and pharmacodynamic analysis of 25 cycles for 14 patients revealed that both the time-concentration product (ASC) for the entire cycle and the half-cycle were predictive of cycle toxicity and a dose adjustment diagram was established." | 1.29 | [Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion]. ( Klein, T; Levêque, D; Velten, M; Wihlm, J, 1993) |
| "The second patient had advanced gastric cancer with carcinomatosis." | 1.29 | [Nocturnal infusion of 5-fluorouracil in advanced digestive tract cancer--two case reports]. ( Furuya, Y; Hamabe, Y; Ku, Y; Nakamura, T; Saitoh, Y; Yamamoto, K, 1994) |
| "An advanced esophageal cancer patient with multiple liver metastases was treated with a combination of CDDP, 5-FU and THP-ADM." | 1.29 | [A case of nonresectable esophageal cancer treated by the combination of cisplatin, 5-fluorouracil and THP-adriamycin]. ( Anai, H; Ichiyoshi, Y; Matsuzaki, K; Minamisono, Y; Miura, O; Nagasaki, S; Toda, T, 1993) |
| "Seventy patients with local squamous cell carcinoma of the esophagus were treated between 1981 and 1990 with preoperative chemotherapy, surgical resection, and possible postoperative radiation therapy and/or chemotherapy." | 1.29 | Long-term follow-up of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and possible postoperative radiotherapy and/or chemotherapy in squamous cell carcinoma of the esophagus. ( Bromberg, C; Carey, RW; Choi, NC; Grillo, HC; Hilgenberg, AD; Logan, DL; Mathisen, DJ; Wain, JC; Wilkins, EW, 1993) |
| "However, the presence of a tracheoesophageal fistula has historically been considered a relative contraindication to radiation therapy." | 1.29 | Irradiation of carcinoma of the esophagus containing a tracheoesophageal fistula. ( Arlington, A; Bohorquez, J, 1993) |
| "Multiple lymph node metastasis were detected by CT scan." | 1.29 | [A case of advanced esophageal cancer showing good partial response by combination therapy of low dose 5-FU and low dose CDDP]. ( Aisawa, T; Akagi, T; Fukushi, M; Ishiguro, Y; Kimura, S; Kudoh, I; Osanai, S; Sakata, Y; Suzuki, H; Takemori, H; Yoshiike, M, 1996) |
| "The palliative effects on dysphagia of radiotherapy (RT) and chemotherapy (CT) were evaluated retrospectively and compared with the effect of the self-expanding stent, evaluated in the prospective study." | 1.29 | Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment. ( Albertsson, M; Cwikiel, M; Cwikiel, W, 1996) |
| "In patients with esophageal cancer, combined chemotherapy is usually given as a part of multimodality treatment and therefore undesirable toxicity should be diminished." | 1.29 | [Effective combined injection method of fluoropyrimidine and platinum--application for advanced esophageal cancer]. ( Eguchi, R; Hayashi, K; Ide, H; Nakamura, T, 1996) |
| "We conclude that inoperable esophageal cancer can be treated successfully by radiotherapy with a curative intent." | 1.28 | [Radiotherapy of inoperable esophageal cancer. Retrospective analysis apropos of 108 cases]. ( Calais, G; Chauvet, B; Geara, F; Le Floch, O; Reynaud-Bougnoux, A, 1990) |
| "Tolerance was good." | 1.28 | Curative non-surgical combined treatment of squamous cell carcinoma of the oesophagus. ( Gerard, JP; Lambert, R; Romestaing, P; Zenone, T, 1992) |
| "The records of patients with esophageal cancer who were treated with a combined modality therapy were reviewed to determine the effects of simultaneously administered chemotherapy and radiotherapy (RT) at sites of recurrence and the relationship between treatment outcome and clinicopathologic variables." | 1.28 | Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery . ( Denham, JW; Devitt, PG; Gill, PG; Jamieson, GG; Olweny, C; Yeoh, E, 1992) |
| "Twelve patients with unresectable squamous cell carcinoma of the esophagus were treated with a combination chemotherapy regimen consisting of cis-diamminedichloroplatinum (CDDP), bleomycin (BLM) or peplomycin (PEP), and 5-fluorouracil (5-FU)." | 1.28 | [Evaluation of multidisciplinary treatment involving chemotherapy with cis-diamminedichloroplatinum, bleomycin (peplomycin) and 5-fluorouracil for advanced esophageal carcinoma]. ( Inoue, Y; Masamune, O; Nakamura, J; Nasu, H, 1990) |
| "Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2." | 1.28 | Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. ( Coia, LR; Engstrom, PF; Hanks, GE; Paul, AR; Stafford, PM, 1991) |
| "with metastasis) of whom 3 had recurrent disease." | 1.28 | Cisplatin and 5-FU combined with radiotherapy and surgery in the treatment of squamous cell carcinoma of the esophagus. Palliative effects and tumor response. ( Albertsson, M; Hambraeus, G; Lillo-Gil, R; Mercke, C; Ranstam, J; Samuelsson, L; Tennvall, J; Willén, R, 1991) |
| "There are few reports about the methods, amounts, and kinds of dosage about intermittent intra-arterial chemotherapy of liver metastases from primal pathological type's squamous cell carcinoma." | 1.28 | [Study of intermittent intra-arterial infusion chemotherapy in liver metastases from squamous cell carcinoma]. ( Aoki, T; Kasuya, K; Kimura, K; Koyanagi, Y; Ozawa, T; Sato, S; Tsuchida, A; Yasuda, D; Yoshimatsu, A, 1991) |
| "Thirty-five patients with nonmetastatic squamous cell carcinoma of the esophagus were treated with chemotherapy (5-fluorouracil, cisplatin) and concomitant split-course radiation therapy." | 1.28 | Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy. ( Carcassonne, Y; Fuentes, P; Gauthier, AP; Giovannini, M; Giudicelli, R; Padaut-Cesana, J; Seitz, JF, 1990) |
| "Of 25 patients with squamous cell carcinoma, 13 underwent esophagectomy." | 1.28 | Cisplatin, 5-fluorouracil, mitomycin C, and concurrent radiation therapy with and without esophogectomy for esophageal carcinoma. ( Daniel, TM; Hahn, SS; Harkins, BJ; Stewart, FM, 1989) |
| "One patient had lower esophageal cancer (T2N0M0) and the other had metastatic cancer of both lungs." | 1.28 | [5-FU intra-arterial infusion and simultaneous irradiation in the treatment of esophageal cancer and metastatic lung cancer]. ( Bohno, K; Ushijima, T, 1989) |
| "Of 55 patients with esophageal squamous cell carcinoma, 30 with localized disease were treated with a combined modality for curative intent." | 1.27 | Combined modality therapy for esophageal squamous cell carcinoma. ( Asfaw, I; Franklin, R; Hoschner, J; Loh, J; Miller, P; Rosenberg, J; Steiger, Z; Vaishampayan, G, 1983) |
| "Twenty-one patients with squamous cell cancer of the esophagus were entered into a pilot clinical trial using preoperative chemotherapy (5-fluorouracil and cis-platinum) and radiation with the intent of improving cure rate and survival." | 1.27 | Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach. ( Dindogru, A; Kinzie, J; Leichman, L; MacKenzie, G; Seydel, HG; Shell, J; Steiger, Z; Toben, S, 1984) |
| "Forty patients with advanced squamous cell carcinoma of the esophagus were treated with a combination of cisplatin, 5-FU (by continuous 5-day infusion), and allopurinol; 37 are evaluable for response." | 1.27 | Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer. ( Cartei, G; De Besi, P; Fiorentino, M; Fosser, V; Paccagnella, A; Peracchia, A; Salvagno, L; Sileni, VC; Tremolada, C, 1986) |
| "Twenty-one consecutive patients with squamous cell carcinoma of the esophagus (EC) were referred, with advanced Stage III disease in nine patients, severe pulmonary/cardiac disease in five patients, and postsurgical recurrences or metastatic disease in seven patients." | 1.27 | Inoperable esophageal carcinoma: results of aggressive synchronous radiotherapy and chemotherapy. A pilot study. ( Flam, M; John, M; Mowry, PA; Wittlinger, P, 1987) |
| "Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2." | 1.27 | Nonsurgical management of esophageal cancer: report of a study of combined radiotherapy and chemotherapy. ( Coia, LR; Engstrom, PF; Paul, A, 1987) |
| "Of the 77 patients who had squamous cell carcinoma, 62 received definitive treatment for disease confined to the esophagus and regional nodes." | 1.27 | Esophageal carcinoma: modest benefits from combined modality therapy. ( Carlson, RW; Goffinet, DR; Hancock, SL; Mark, JB, 1987) |
| "A synchronous chemoradiotherapy schedule of modest dosage has been used in 36 patients with oesophageal cancer since July 1984 at the Royal Adelaide Hospital." | 1.27 | Preliminary experience with a combined-modality approach to the management of oesophageal cancer. ( Abbott, RL; Britten-Jones, R; Denham, JW; Devitt, P; Fitch, R; Gibson, GE; Gill, PG; Hecker, R; Hetzel, D; Jamieson, GG, 1988) |
| " Compared to a group treated in 1970 bis 1982 with the same dosage of irradiation without the combination of chemotherapy the median survival could be raized from nine to 24 months, the two year survival rate improved from 18% to 42%." | 1.27 | [Simultaneous radio- and chemotherapy of squamous cell carcinoma of the esophagus]. ( Rohloff, R; Tosch, U; Wendt, TG; Willich, N, 1988) |
| "Esophageal cancer was treated with sequential intravenous cisplatin 100 mg/m2 (day 1) and 5-fluorouracil (5-FU) 40 mg/m2/hour X 120 (days 2-7)." | 1.27 | Respiratory tract fistulae in recurrent aerodigestive cancers after chemotherapy. ( Barreras, L; Manten, H; Saldana, MJ; Sridhar, KS, 1988) |
| "We treated 20 patients with squamous cell carcinoma of the esophagus with the following regimen: cisplatin = 100 mg/m2 i." | 1.27 | Cisplatin, high dose folinic acid and 5-fluorouracil in squamous cell carcinoma of the esophagus. A pilot study. ( Farfaglia, R; Lancini, GP; Marini, G; Marpicati, P; Montini, E; Pezzola, D; Simoncini, E; Tonini, G; Zaniboni, A, 1987) |
| "Fifty-seven patients with esophageal cancer were treated with curative intent between January 1979 and June 1985." | 1.27 | Comparison of three treatment strategies for esophageal cancer within a single institution. ( Bae, Y; Burdakin, J; Jacobsen, G; Lewis, J; Richmond, J; Seydel, HG, 1987) |
| "Twenty-four patients with squamous cell cancer of the esophagus were entered into a treatment protocol consisting of preoperative chemotherapy (CT), surgical resection (SR), and possible postoperative CT or radiation therapy (RT) beginning August 1981." | 1.27 | Preoperative chemotherapy followed by surgery with possible postoperative radiotherapy in squamous cell carcinoma of the esophagus: evaluation of the chemotherapy component. ( Carey, RW; Choi, NC; Grillo, H; Hilgenberg, AD; Mathisen, DJ; Wilkins, EW, 1986) |
| "Treatment of the head and neck cancer has surprisingly developed in the last decade." | 1.27 | [Multidisciplinary treatment of the head and neck cancer--FAR therapy and its modification and application]. ( Komiyama, S; Kudo, S; Kuwano, N; Yanagita, T, 1986) |
| "One hundred and eight patients with squamous cell carcinoma of the upper aerodigestive tract (UADT) (T3, T4, NO-N3; 17% stage II, 54% stage III, 27% stage IV) were given three courses of chemotherapy before any local treatment." | 1.27 | Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. ( Caldani, C; Chauvel, P; Demard, F; Santini, J; Schneider, M; Thyss, A; Vallicioni, J, 1986) |
| "The treatment of 192 patients with cancer of the larynx, 60 patients with hypopharyngeal and cervical esophageal cancer, and 23 patients with epipharyngeal cancer with FAR therapy during 6 years from 1972 to 1977 resulted in highly effective synergism, and the improved points of this therapy were considered." | 1.27 | Synergistic combination therapy of 5-fluorouracil, vitamin A, and cobalt-60 radiation for head and neck tumors--antitumor combination therapy with vitamin A. ( Komiyama, S; Kudoh, S; Kuwano, M; Yanagita, T, 1985) |
| "Surgical management of squamous cell carcinoma of the esophagus continues to be a controversial area in thoracic surgery." | 1.27 | Combined treatment approach in surgical management of carcinoma of the esophagus: a preliminary report. ( Hatcher, CR; McIntyre, B; Miller, JI, 1985) |
| "Of the 31 patients with stomach cancer who were evaluable for response and had had no previous chemotherapy, 12 (39%) achieved complete or partial remission." | 1.26 | Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas. ( Bennetts, RW; Heifetz, LJ; Jones, RD; Karlin, DA; Mahal, PS; Stroehlein, JR, 1982) |
| "Less than 20% of advanced colorectal cancers respond to chemotherapy." | 1.26 | Chemotherapy for gastrointestinal malignancy. ( Balint, JA; Van der Veer, LD, 1980) |
| "The treatment of 33 patients with cancer of larynx and 15 patients with hypopharyngeal or cervical esophageal cancer with FAR therapy during three years from 1972 to 1974 resulted in highly effective synergism in vivo, and the improved points of this therapy were presented." | 1.26 | Synergistic combination therapy of 5-fluorouracil, vitamin A and cobalt-60 radiation upon head and neck tumors. ( Endo, H; Hiroto, I; Komiyama, S; Kuwano, M; Nakashima, T; Ryu, S, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 111 (6.01) | 18.7374 |
| 1990's | 286 (15.48) | 18.2507 |
| 2000's | 543 (29.38) | 29.6817 |
| 2010's | 755 (40.85) | 24.3611 |
| 2020's | 153 (8.28) | 2.80 |
| Authors | Studies |
|---|---|
| Kaschula, CH | 1 |
| Hunter, R | 1 |
| Stellenboom, N | 1 |
| Caira, MR | 1 |
| Winks, S | 1 |
| Ogunleye, T | 1 |
| Richards, P | 1 |
| Cotton, J | 1 |
| Zilbeyaz, K | 1 |
| Wang, Y | 13 |
| Siyo, V | 1 |
| Ngarande, E | 1 |
| Parker, MI | 1 |
| Li, LY | 1 |
| Peng, JD | 1 |
| Zhou, W | 2 |
| Qiao, H | 1 |
| Deng, X | 1 |
| Li, ZH | 1 |
| Li, JD | 1 |
| Fu, YD | 1 |
| Li, S | 3 |
| Sun, K | 1 |
| Liu, HM | 1 |
| Zhao, W | 5 |
| Okunaka, M | 1 |
| Kotani, D | 1 |
| Demachi, K | 3 |
| Fujiwara, H | 18 |
| Sakashita, S | 1 |
| Yoshino, T | 5 |
| Fujita, T | 5 |
| Kojima, T | 27 |
| Tanaka, Y | 14 |
| Takeuchi, H | 9 |
| Nakashima, Y | 5 |
| Nagano, H | 3 |
| Ueno, T | 5 |
| Tomizuka, K | 1 |
| Morita, S | 4 |
| Emi, Y | 2 |
| Hamai, Y | 9 |
| Hihara, J | 9 |
| Saeki, H | 10 |
| Oki, E | 7 |
| Kunisaki, C | 2 |
| Otsuji, E | 13 |
| Baba, H | 11 |
| Matsubara, H | 14 |
| Maehara, Y | 7 |
| Kitagawa, Y | 28 |
| Yoshida, K | 16 |
| Roy, PS | 1 |
| Kumar, G | 1 |
| Mallik, S | 1 |
| Sarangi, SS | 1 |
| Saikia, BJ | 1 |
| Hazarika, M | 1 |
| Talukdar, A | 1 |
| Okadome, K | 2 |
| Baba, Y | 9 |
| Yasuda-Yoshihara, N | 1 |
| Nomoto, D | 2 |
| Yagi, T | 1 |
| Toihata, T | 1 |
| Ogawa, K | 10 |
| Sawayama, H | 1 |
| Ishimoto, T | 5 |
| Iwatsuki, M | 4 |
| Iwagami, S | 5 |
| Miyamoto, Y | 6 |
| Yoshida, N | 11 |
| Watanabe, M | 19 |
| Komohara, Y | 1 |
| Nomura, H | 3 |
| Tsuji, D | 2 |
| Ueno, S | 2 |
| Fujii, S | 4 |
| Yano, T | 8 |
| Daiko, H | 16 |
| Itoh, K | 2 |
| Kawasaki, T | 3 |
| Zhang, C | 4 |
| Luo, CL | 1 |
| Shang, GS | 1 |
| Jiang, DX | 1 |
| Song, Q | 1 |
| Rogers, JE | 5 |
| Wang, X | 12 |
| Trail, A | 2 |
| Ajani, JA | 43 |
| Al-Jumayli, M | 1 |
| Choucair, K | 1 |
| Al-Obaidi, A | 1 |
| Park, R | 1 |
| Bansal, A | 1 |
| Baranda, J | 1 |
| Sun, W | 2 |
| Saeed, A | 1 |
| Yoshida, T | 13 |
| Nishino, T | 2 |
| Goto, M | 4 |
| Inoue, S | 1 |
| Fujiwara, S | 1 |
| Takizawa, H | 2 |
| Tangoku, A | 11 |
| Uehara, H | 1 |
| Bando, Y | 4 |
| Sato, Y | 9 |
| Imai, T | 1 |
| Ojio, H | 1 |
| Mase, J | 1 |
| Hatanaka, Y | 1 |
| Suetsugu, T | 1 |
| Fujii, H | 2 |
| Okumura, N | 2 |
| Matsuhashi, N | 2 |
| Takahashi, T | 13 |
| Mori, Y | 1 |
| Kikuchi, O | 2 |
| Horimatsu, T | 4 |
| Hara, H | 11 |
| Hironaka, S | 16 |
| Kato, K | 36 |
| Tsushima, T | 10 |
| Ishihara, R | 3 |
| Mukai, K | 1 |
| Uozumi, R | 1 |
| Tada, H | 1 |
| Kasai, H | 1 |
| Kawaguchi, A | 1 |
| Muto, M | 18 |
| Moore, JL | 1 |
| Kumar, S | 3 |
| Santaolalla, A | 1 |
| Patel, PH | 1 |
| Kapiris, M | 1 |
| Van Hemelrijck, M | 1 |
| Maisey, N | 2 |
| Hill, M | 5 |
| Lagergren, J | 1 |
| Gossage, JA | 4 |
| Kelly, M | 1 |
| Chaudry, A | 2 |
| Allum, WH | 9 |
| Baker, CR | 1 |
| Cunningham, D | 39 |
| Davies, AR | 1 |
| Lohan-Codeço, M | 1 |
| Barambo-Wagner, ML | 1 |
| Nasciutti, LE | 1 |
| Ribeiro Pinto, LF | 1 |
| Meireles Da Costa, N | 1 |
| Palumbo, A | 1 |
| Ishikawa, Y | 2 |
| Suzuki, M | 4 |
| Yamaguchi, H | 3 |
| Seto, I | 1 |
| Machida, M | 1 |
| Takagawa, Y | 1 |
| Jingu, K | 8 |
| Kikuchi, Y | 2 |
| Murakami, M | 12 |
| Futai, R | 1 |
| Yoshie, T | 1 |
| Sanuki, T | 1 |
| Inoue, Y | 5 |
| Abe, T | 10 |
| Sasaki, A | 5 |
| Iemoto, T | 1 |
| Hayashi, H | 7 |
| Ose, T | 1 |
| Morikawa, T | 1 |
| Moussa, O | 1 |
| Bhogal, RH | 1 |
| Malietzis, G | 1 |
| Fribbens, C | 1 |
| Starling, N | 7 |
| Gerlinger, M | 1 |
| Watkins, D | 2 |
| Chau, I | 8 |
| Rao, S | 8 |
| Sugisaki, T | 1 |
| Aoyama, T | 2 |
| Kawakami, K | 4 |
| Yokokawa, T | 1 |
| Kobayashi, K | 11 |
| Suzuki, W | 1 |
| Ogura, M | 4 |
| Ichimura, T | 3 |
| Chin, K | 15 |
| Yamaguchi, K | 9 |
| Hanaoka, S | 1 |
| Yamaguchi, M | 3 |
| Okamoto, H | 3 |
| Taniyama, Y | 3 |
| Sato, C | 3 |
| Fukutomi, T | 1 |
| Ozawa, Y | 3 |
| Ando, R | 1 |
| Takahashi, K | 6 |
| Akaishi, R | 1 |
| Horie, Y | 1 |
| Shinozaki, Y | 1 |
| Unno, M | 1 |
| Kamei, T | 4 |
| Zhu, Y | 5 |
| Liu, K | 3 |
| Ding, D | 1 |
| Zhou, Y | 4 |
| Peng, L | 1 |
| Nagata, Y | 6 |
| Kageyama, S | 1 |
| Ishikawa, T | 6 |
| Kokura, S | 1 |
| Okayama, T | 4 |
| Otsuka, K | 7 |
| Ariyoshi, T | 1 |
| Taniguchi, K | 2 |
| Kobayashi, S | 5 |
| Shimada, H | 10 |
| Yajima, S | 2 |
| Suzuki, T | 13 |
| Hirano, S | 2 |
| Tsuchikawa, T | 2 |
| Shichinohe, T | 2 |
| Ueda, S | 3 |
| Kanetaka, K | 2 |
| Yoneda, A | 2 |
| Wada, H | 5 |
| Doki, Y | 47 |
| Yamaue, H | 5 |
| Katsuda, M | 4 |
| Ohi, M | 4 |
| Yasuda, H | 1 |
| Kondo, K | 4 |
| Kataoka, M | 2 |
| Kodera, Y | 3 |
| Koike, M | 3 |
| Shiraishi, T | 2 |
| Miyahara, Y | 1 |
| Goshima, N | 1 |
| Fukuda, E | 1 |
| Sato, E | 1 |
| Ikeda, H | 1 |
| Yamada, T | 7 |
| Osako, M | 1 |
| Hirai, K | 1 |
| Miyamoto, H | 3 |
| Watanabe, T | 6 |
| Shiku, H | 1 |
| Aktürk Esen, S | 1 |
| Ergun, Y | 1 |
| Erol, C | 1 |
| Arikan, R | 1 |
| Er, MM | 1 |
| Atci, MM | 1 |
| Topçu, A | 1 |
| Uçar, G | 1 |
| Akagündüz, B | 1 |
| Aykan, MB | 1 |
| Özen, M | 1 |
| Baytemur, NK | 1 |
| Özçelik, M | 1 |
| Şahin, E | 1 |
| Güven, D | 1 |
| Menekşe, S | 1 |
| Ak, N | 1 |
| Teker, F | 1 |
| Kut, E | 1 |
| Şakalar, T | 1 |
| Alan, Ö | 1 |
| Kaçan, T | 1 |
| Turhal, NS | 1 |
| Kiliçkap, S | 1 |
| Türker, S | 1 |
| Şendur, MAN | 1 |
| Köstek, O | 1 |
| Karaağaç, M | 1 |
| Sakin, A | 1 |
| Türk, HM | 1 |
| Çağlayan, D | 1 |
| Cihan, Ş | 1 |
| Açikgöz, Y | 1 |
| Uncu, D | 1 |
| Tang, K | 1 |
| Toyozumi, T | 1 |
| Murakami, K | 2 |
| Sakata, H | 1 |
| Kano, M | 2 |
| Endo, S | 4 |
| Matsumoto, Y | 5 |
| Suito, H | 2 |
| Takahashi, M | 5 |
| Sekino, N | 1 |
| Otsuka, R | 1 |
| Kinoshita, K | 2 |
| Hirasawa, S | 1 |
| Hu, J | 1 |
| Uesato, M | 4 |
| Hayano, K | 2 |
| Okamoto, K | 15 |
| Ninomiya, I | 3 |
| Saito, H | 9 |
| Shimada, M | 5 |
| Yamaguchi, T | 5 |
| Terai, S | 2 |
| Moriyama, H | 1 |
| Kinoshita, J | 2 |
| Nakamura, K | 15 |
| Inaki, N | 1 |
| Dos Santos, M | 1 |
| Lequesne, J | 1 |
| Leconte, A | 1 |
| Corbinais, S | 1 |
| Parzy, A | 1 |
| Guilloit, JM | 1 |
| Varatharajah, S | 1 |
| Brachet, PE | 1 |
| Dorbeau, M | 1 |
| Vaur, D | 1 |
| Weiswald, LB | 1 |
| Poulain, L | 1 |
| Le Gallic, C | 1 |
| Castera-Tellier, M | 1 |
| Galais, MP | 6 |
| Clarisse, B | 1 |
| Hoshino, I | 3 |
| Gunji, H | 1 |
| Kuwayama, N | 1 |
| Kurosaki, T | 1 |
| Tonooka, T | 2 |
| Soda, H | 3 |
| Takiguchi, N | 3 |
| Nabeya, Y | 9 |
| Takayama, W | 1 |
| Malthaner, RA | 4 |
| Yu, E | 3 |
| Sanatani, M | 2 |
| Lewis, D | 2 |
| Warner, A | 2 |
| Dar, AR | 3 |
| Yaremko, BP | 3 |
| Bierer, J | 2 |
| Palma, DA | 3 |
| Fortin, D | 2 |
| Inculet, RI | 4 |
| Fréchette, E | 2 |
| Raphael, J | 2 |
| Gaede, S | 1 |
| Kuruvilla, S | 1 |
| Younus, J | 2 |
| Vincent, MD | 2 |
| Rodrigues, GB | 3 |
| Nomura, M | 6 |
| Kii, T | 7 |
| Kawada, J | 1 |
| Hirota, M | 2 |
| Ohta, T | 4 |
| Matsuyama, J | 4 |
| Sakai, D | 2 |
| Shimokawa, T | 1 |
| Kurokawa, Y | 12 |
| Kawakami, H | 7 |
| Tsujinaka, T | 13 |
| Satoh, T | 5 |
| Möhring, C | 2 |
| Timotheou, A | 2 |
| Mańczak, A | 2 |
| Sadeghlar, F | 2 |
| Zhou, T | 3 |
| Mahn, R | 2 |
| Bartels, A | 1 |
| Monin, M | 1 |
| Toma, M | 2 |
| Feldmann, G | 2 |
| Brossart, P | 2 |
| Köksal, M | 2 |
| Sarria, GR | 2 |
| Giordano, FA | 1 |
| Lingohr, P | 2 |
| Jafari, A | 2 |
| Kalff, JC | 2 |
| Strassburg, CP | 2 |
| Gonzalez-Carmona, MA | 2 |
| Nakajima, M | 9 |
| Muroi, H | 5 |
| Kikuchi, M | 4 |
| Kubo, T | 3 |
| Takise, S | 1 |
| Ihara, K | 4 |
| Nakagawa, M | 2 |
| Nakamura, T | 27 |
| Yamaguchi, S | 4 |
| Kojima, K | 3 |
| Nishiwaki, N | 2 |
| Noma, K | 4 |
| Kunitomo, T | 1 |
| Hashimoto, M | 3 |
| Maeda, N | 3 |
| Tanabe, S | 5 |
| Sakurama, K | 3 |
| Shirakawa, Y | 5 |
| Fujiwara, T | 4 |
| Allan, AL | 1 |
| Lowes, LE | 1 |
| Law, J | 1 |
| Matsuda, S | 7 |
| Takemura, R | 4 |
| Okui, J | 4 |
| Okamura, A | 6 |
| Kawakubo, H | 7 |
| Kakeji, Y | 6 |
| Sasaki, K | 13 |
| Tsuruda, Y | 3 |
| Shimonosono, M | 2 |
| Noda, M | 2 |
| Uchikado, Y | 9 |
| Arigami, T | 4 |
| Matsushita, D | 3 |
| Mori, S | 6 |
| Nakajo, A | 1 |
| Kurahara, H | 1 |
| Ohtsuka, T | 1 |
| Ito, R | 1 |
| Nakamura, Y | 5 |
| Sunakawa, H | 1 |
| Hojo, H | 2 |
| Nakamura, N | 5 |
| Akimoto, T | 4 |
| Takamatsu, A | 1 |
| Toshima, F | 1 |
| Kozaka, K | 1 |
| Yamamoto, N | 1 |
| Sai, Y | 1 |
| Gabata, T | 1 |
| Ishibashi, Y | 2 |
| Tsujimoto, H | 3 |
| Sugasawa, H | 2 |
| Wakamatsu, K | 1 |
| Kouzu, K | 1 |
| Itazaki, Y | 1 |
| Sugihara, T | 1 |
| Harada, M | 1 |
| Ito, N | 1 |
| Kishi, Y | 1 |
| Ueno, H | 1 |
| Kadono, T | 1 |
| Yamamoto, S | 9 |
| Hirose, T | 1 |
| Ikeda, G | 1 |
| Ohara, A | 1 |
| Itoyama, M | 1 |
| Yokoyama, K | 1 |
| Honma, Y | 10 |
| Hashimoto, T | 4 |
| Sekine, S | 1 |
| Ishiyama, K | 2 |
| Oguma, J | 4 |
| Zhao, Y | 5 |
| Song, R | 1 |
| Jia, Y | 2 |
| Zhang, X | 7 |
| Zhang, S | 7 |
| Wu, C | 3 |
| Zhang, R | 2 |
| Guo, Z | 1 |
| Sugase, T | 1 |
| Sugimura, K | 7 |
| Kanemura, T | 1 |
| Takeoka, T | 2 |
| Yamamoto, M | 9 |
| Shinno, N | 2 |
| Omori, T | 5 |
| Fujii, Y | 4 |
| Mukai, Y | 1 |
| Mikamori, M | 1 |
| Hasegawa, S | 2 |
| Haraguchi, N | 1 |
| Akita, H | 4 |
| Nishimura, J | 3 |
| Matsuda, C | 1 |
| Yasui, M | 3 |
| Miyata, H | 31 |
| Liu, S | 4 |
| Ren, J | 1 |
| Zhang, H | 3 |
| Chen, S | 2 |
| Chen, Y | 9 |
| Chen, W | 4 |
| Xu, C | 5 |
| Zhong, S | 1 |
| Lin, C | 2 |
| Qu, T | 1 |
| Zhong, Y | 1 |
| Meng, Y | 1 |
| Guo, H | 2 |
| Joo, S | 1 |
| Enzinger, PC | 5 |
| Ramaswamy, A | 1 |
| Bhargava, P | 1 |
| Srinivas, S | 1 |
| Kannan, S | 1 |
| Bhandare, M | 1 |
| Chaudhari, V | 1 |
| Mantri, A | 1 |
| Kapoor, A | 1 |
| Das, S | 1 |
| Booma, N | 1 |
| Chaugule, D | 1 |
| Shrikhande, SV | 1 |
| Ostwal, V | 1 |
| Shimomatsuya, T | 1 |
| Hashimoto, K | 2 |
| Nakamura, S | 5 |
| Nakahara, H | 1 |
| Nagayama, S | 1 |
| Kubota, Y | 3 |
| Chan, WL | 1 |
| Choi, CW | 1 |
| Wong, IY | 1 |
| Tsang, TH | 1 |
| Lam, AT | 1 |
| Tse, RP | 1 |
| Chan, KK | 1 |
| Wong, C | 1 |
| Law, BT | 1 |
| Cheung, EE | 1 |
| Chan, SY | 1 |
| Lam, KO | 3 |
| Kwong, D | 2 |
| Law, S | 9 |
| Lin, CH | 1 |
| Chuang, HN | 1 |
| Hsiao, TH | 1 |
| Kumar, VB | 1 |
| Hsu, CH | 9 |
| Huang, CY | 2 |
| Lee, LW | 1 |
| Mao, CL | 1 |
| Ko, JL | 1 |
| Hsu, CP | 2 |
| Tang, JL | 1 |
| Zhang, B | 4 |
| Xu, JP | 1 |
| Qi, L | 1 |
| Xin, D | 1 |
| Wang, L | 8 |
| Wang, BZ | 1 |
| Tian, YT | 1 |
| Li, Y | 12 |
| Huang, J | 3 |
| Marcisz-Grzanka, K | 1 |
| Winiarek, M | 1 |
| Pałucki, J | 1 |
| Wieszczy, P | 1 |
| Olesiński, T | 1 |
| Jóźwiak, M | 2 |
| Samsel, R | 1 |
| Sułkowska, U | 1 |
| Kolasińska-Ćwikła, A | 1 |
| Wyrwicz, LS | 1 |
| Zeng, H | 1 |
| Wang, C | 5 |
| Song, LY | 1 |
| Jia, SJ | 1 |
| Zeng, X | 1 |
| Liu, Q | 8 |
| Linde, P | 3 |
| Mallmann, M | 3 |
| Adams, A | 3 |
| Wegen, S | 3 |
| Rosenbrock, J | 3 |
| Trommer, M | 3 |
| Marnitz, S | 3 |
| Baues, C | 3 |
| Celik, E | 3 |
| Ura, T | 12 |
| Tsubosa, Y | 17 |
| Mizusawa, J | 11 |
| Fushiki, K | 3 |
| Tomori, A | 5 |
| Okuno, T | 18 |
| Matsushita, H | 12 |
| Kusaba, H | 5 |
| Fujitani, K | 14 |
| Seki, S | 7 |
| Inagaki, T | 3 |
| Sato, M | 4 |
| Kin, M | 3 |
| Kogo, M | 7 |
| Mitani, S | 2 |
| Shiraishi, O | 13 |
| Kanemura, H | 2 |
| Suzuki, S | 16 |
| Haratani, K | 2 |
| Yonesaka, K | 2 |
| Chiba, Y | 2 |
| Yasuda, T | 29 |
| Nakagawa, K | 18 |
| Aoyama, S | 2 |
| Motoori, M | 13 |
| Yamasaki, M | 27 |
| Hirao, M | 8 |
| Takeno, A | 5 |
| Makino, T | 14 |
| Tanaka, K | 14 |
| Hamakawa, T | 2 |
| Yamashita, K | 12 |
| Kimura, Y | 19 |
| Yano, M | 26 |
| Kurita, D | 1 |
| Kanematsu, K | 1 |
| Kubo, K | 1 |
| Utsunomiya, D | 1 |
| Kato, H | 20 |
| Momose, K | 1 |
| Hiraki, Y | 8 |
| Yasuda, A | 4 |
| Shinkai, M | 5 |
| Imano, M | 6 |
| Miyoshi, S | 2 |
| Nishibuchi, I | 3 |
| Murakami, Y | 10 |
| Katsuta, T | 1 |
| Imano, N | 2 |
| Hirokawa, J | 1 |
| Emi, M | 7 |
| Okada, M | 8 |
| Umeki, Y | 1 |
| Matsuoka, H | 2 |
| Fujita, M | 5 |
| Goto, A | 2 |
| Serizawa, A | 1 |
| Akimoto, S | 1 |
| Nakauchi, M | 1 |
| Tanaka, T | 16 |
| Shibasaki, S | 2 |
| Inaba, K | 2 |
| Uyama, I | 1 |
| Suda, K | 1 |
| Oiki, H | 1 |
| Kawabata, R | 2 |
| Izutani, Y | 1 |
| Kitagawa, A | 1 |
| Ushimaru, Y | 1 |
| Ohhara, N | 1 |
| Miyake, Y | 2 |
| Maeda, S | 1 |
| Nakata, K | 2 |
| Nishikawa, K | 4 |
| Miyamoto, A | 1 |
| Kamio, Y | 1 |
| Nakano, R | 1 |
| Musha, H | 1 |
| Ashino, K | 1 |
| Kanno, H | 1 |
| Kono, M | 1 |
| Nozu, S | 1 |
| Motoi, F | 1 |
| Nara, K | 1 |
| Yamamoto, T | 8 |
| Yagi, K | 1 |
| Kawasaki, K | 1 |
| Toriumi, T | 1 |
| Takada, T | 2 |
| Seto, Y | 3 |
| Suzuki, H | 2 |
| Sisic, L | 2 |
| Crnovrsanin, N | 1 |
| Nienhueser, H | 1 |
| Jung, JO | 1 |
| Schiefer, S | 1 |
| Haag, GM | 3 |
| Bruckner, T | 2 |
| Schneider, M | 2 |
| Müller-Stich, BP | 1 |
| Büchler, MW | 2 |
| Schmidt, T | 2 |
| Shimizu, D | 2 |
| Miyata, K | 1 |
| Fukaya, M | 1 |
| Sugita, S | 1 |
| Ebata, T | 1 |
| Goetze, TO | 1 |
| Hofheinz, RD | 7 |
| Gaiser, T | 1 |
| Schmalenberg, H | 3 |
| Strumberg, D | 2 |
| Goekkurt, E | 3 |
| Angermeier, S | 1 |
| Zander, T | 1 |
| Kopp, HG | 1 |
| Pink, D | 2 |
| Siegler, G | 1 |
| Schenk, M | 1 |
| de Vita, F | 4 |
| Galizia, G | 4 |
| Maiello, E | 1 |
| Bechstein, WO | 1 |
| Elshafei, M | 1 |
| Loose, M | 1 |
| Sookthai, D | 1 |
| Brulin, T | 1 |
| Pauligk, C | 7 |
| Homann, N | 7 |
| Al-Batran, SE | 10 |
| Monin, MB | 1 |
| Sommer, N | 1 |
| Tan, R | 1 |
| Liu, J | 8 |
| Wang, J | 19 |
| Zhang, W | 6 |
| He, M | 1 |
| Zhang, Y | 17 |
| Hingorani, M | 1 |
| Goody, R | 1 |
| Bozas, G | 1 |
| Zahid, K | 1 |
| Mitton, DJ | 1 |
| Jain, P | 1 |
| Wong, V | 1 |
| Roy, R | 3 |
| Inoue, N | 1 |
| Yamasaki, Y | 2 |
| Ryotokuji, T | 4 |
| Matsui, T | 1 |
| Miura, T | 1 |
| Chiba, T | 6 |
| Hayashi, M | 5 |
| Yokosuka, T | 1 |
| Noguchi, N | 1 |
| Tsunemi, A | 1 |
| Iseki, H | 1 |
| Kurogochi, T | 2 |
| Matsumoto, A | 5 |
| Nyumura, Y | 1 |
| Tanishima, Y | 3 |
| Nakayoshi, T | 1 |
| Okamoto, T | 3 |
| Yano, F | 1 |
| Eto, K | 1 |
| Gao, X | 1 |
| Yang, ZH | 1 |
| Cheng, YH | 1 |
| Chi, CL | 1 |
| Yang, TY | 1 |
| Chuang, KH | 1 |
| Wu, CE | 1 |
| van Lanschot, JJ | 1 |
| Wen, YW | 4 |
| Chao, YK | 6 |
| Tsuji, T | 1 |
| Takeuchi, M | 2 |
| Shariff, B | 1 |
| Mehta, R | 1 |
| Takahari, D | 6 |
| Nakayama, I | 2 |
| Jiang, H | 3 |
| Makelike, K | 1 |
| Chen, B | 1 |
| Xi, M | 8 |
| Li, Q | 7 |
| Hu, Y | 8 |
| Tsukamoto, Y | 2 |
| Kurogi, S | 1 |
| Fujishima, H | 2 |
| Shibata, T | 9 |
| Fumoto, S | 5 |
| Nishiki, K | 2 |
| Suzuki, K | 2 |
| Etoh, T | 2 |
| Shiraishi, N | 3 |
| Fuchino, T | 1 |
| Hirashita, Y | 1 |
| Nakada, C | 1 |
| Uchida, T | 1 |
| Inomata, M | 3 |
| Moriyama, M | 3 |
| Hijiya, N | 1 |
| Shimomura, A | 1 |
| Hagiwara, T | 1 |
| Yamada, K | 4 |
| Yokoi, C | 1 |
| Terayama, M | 1 |
| Nohara, K | 1 |
| Igari, T | 1 |
| Kawamura, YI | 1 |
| Ogo, T | 1 |
| Ishihara, K | 1 |
| Nishino, M | 3 |
| Inokuch, M | 1 |
| Sakurai, U | 1 |
| Tasnim, S | 1 |
| Sudarshan, M | 2 |
| Terada, M | 1 |
| Kadota, T | 2 |
| Hori, K | 1 |
| Ogawa, H | 5 |
| Ogata, T | 3 |
| Sakanaka, K | 3 |
| Sakamoto, T | 5 |
| Sunde, B | 2 |
| Klevebro, F | 4 |
| Johar, A | 1 |
| Johnsen, G | 4 |
| Jacobsen, AB | 4 |
| Glenjen, NI | 3 |
| Friesland, S | 5 |
| Lindblad, M | 4 |
| Ajengui, A | 1 |
| Lundell, L | 6 |
| Lagergren, P | 1 |
| Nilsson, M | 7 |
| Hagi, T | 1 |
| Nishida, N | 1 |
| Mori, M | 23 |
| Ushigome, H | 1 |
| Asukai, K | 1 |
| Yanagimoto, Y | 3 |
| Takahashi, Y | 4 |
| Yamada, D | 1 |
| Yamamoto, K | 5 |
| Takahashi, H | 6 |
| Ohue, M | 6 |
| Murata, K | 4 |
| Kuroda, D | 1 |
| Okamoto, S | 2 |
| Fujinaka, R | 1 |
| Arai, K | 3 |
| Otowa, Y | 2 |
| Mii, Y | 1 |
| Kakinoki, K | 1 |
| Mani, M | 1 |
| Oka, S | 2 |
| Eba, S | 1 |
| Notsuda, H | 1 |
| Hoshi, F | 1 |
| Oishi, H | 1 |
| Matsuda, Y | 4 |
| Sado, T | 1 |
| Sakurada, A | 1 |
| Saijo, K | 1 |
| Okoshi, A | 1 |
| Tanaka, N | 7 |
| Okada, Y | 1 |
| Chen, D | 1 |
| Menon, H | 1 |
| Verma, V | 1 |
| Seyedin, SN | 1 |
| Hofstetter, WL | 8 |
| Nguyen, QN | 1 |
| Chang, JY | 3 |
| Gomez, DR | 2 |
| Amini, A | 2 |
| Swisher, SG | 14 |
| Blum, MA | 4 |
| Younes, AI | 1 |
| Barsoumian, HB | 1 |
| Erasmus, JJ | 2 |
| Lee, JH | 7 |
| Bhutani, MS | 6 |
| Hess, KR | 1 |
| Minsky, BD | 10 |
| Welsh, JW | 1 |
| Chen, J | 7 |
| Yin, W | 1 |
| Yao, H | 1 |
| Gu, W | 1 |
| Borg, D | 1 |
| Sundberg, J | 1 |
| Brun, E | 1 |
| Kjellén, E | 1 |
| Petersson, K | 1 |
| Hermansson, M | 1 |
| Johansson, J | 1 |
| Eberhard, J | 1 |
| Johnsson, A | 1 |
| Wang, WT | 1 |
| Guo, CQ | 1 |
| Cui, GH | 1 |
| Zhao, S | 1 |
| Xiang, X | 1 |
| Xiong, R | 1 |
| Yu, C | 1 |
| Deng, L | 2 |
| Bie, J | 1 |
| Xiao, D | 1 |
| Chen, Z | 4 |
| Li, X | 8 |
| Feng, G | 2 |
| Han, L | 2 |
| Cui, D | 1 |
| Li, B | 8 |
| Xu, WW | 5 |
| Lam, AKY | 1 |
| Chan, KT | 5 |
| Lee, NPY | 2 |
| Law, SYK | 2 |
| Guan, XY | 7 |
| Qin, YR | 5 |
| Chan, KW | 5 |
| Ma, S | 3 |
| Tsao, SW | 6 |
| Cheung, ALM | 1 |
| Dohi, O | 3 |
| Kamada, K | 3 |
| Uchiyama, K | 3 |
| Takagi, T | 5 |
| Konishi, H | 12 |
| Shiozaki, A | 13 |
| Naito, Y | 3 |
| Teramukai, S | 1 |
| Itoh, Y | 11 |
| Sundar, R | 1 |
| Ng, A | 1 |
| Zouridis, H | 1 |
| Padmanabhan, N | 1 |
| Sheng, T | 1 |
| Lee, MH | 1 |
| Ooi, WF | 1 |
| Qamra, A | 1 |
| Inam, I | 1 |
| Hewitt, LC | 1 |
| So, JB | 1 |
| Koh, V | 1 |
| Nankivell, MG | 1 |
| Langley, RE | 5 |
| Rozen, SG | 1 |
| Yong, WP | 1 |
| Grabsch, HI | 3 |
| Tan, P | 1 |
| Nagashima, K | 6 |
| Hirano, H | 2 |
| Shoji, H | 4 |
| Iwasa, S | 7 |
| Takashima, A | 6 |
| Okita, N | 4 |
| Boku, N | 20 |
| Murakami, N | 1 |
| Ito, Y | 16 |
| Itami, J | 5 |
| Kanamori, J | 2 |
| Zhang, K | 3 |
| Bai, Y | 1 |
| Xu, R | 2 |
| Li, J | 14 |
| Guan, F | 3 |
| Iqbal, S | 2 |
| McDonough, S | 1 |
| Lenz, HJ | 3 |
| Ilson, D | 1 |
| Burtness, B | 3 |
| Nangia, CS | 1 |
| Barzi, A | 1 |
| Schneider, CJ | 1 |
| Liu, JJ | 1 |
| Dotan, E | 1 |
| Guthrie, KA | 1 |
| Hochster, HS | 2 |
| Mine, S | 3 |
| Imamura, Y | 6 |
| Asari, T | 1 |
| Osumi, H | 2 |
| Ooki, A | 1 |
| Dai, H | 1 |
| Shao, YW | 1 |
| Tong, X | 1 |
| Wu, X | 7 |
| Pang, J | 1 |
| Feng, A | 1 |
| Yang, Z | 2 |
| Li, L | 6 |
| Yue, GGL | 1 |
| Fung, KP | 2 |
| Yu, J | 5 |
| Lau, CBS | 1 |
| Chiu, PWY | 1 |
| Lee, MC | 1 |
| Chen, YK | 1 |
| Hsu, YJ | 1 |
| Lin, BR | 1 |
| Katsui, K | 1 |
| Nishizaki, M | 1 |
| Randrian, V | 1 |
| Adenis, A | 16 |
| Desrame, J | 2 |
| Barbier, E | 1 |
| Di Fiore, F | 4 |
| Lièvre, A | 3 |
| Dahan, L | 6 |
| Laurent-Puig, P | 2 |
| Mineur, L | 3 |
| Breysacher, G | 1 |
| Roquin, G | 1 |
| Louafi, S | 1 |
| Lopez, A | 1 |
| Louvet, C | 5 |
| Borg, C | 3 |
| Metges, JP | 5 |
| Faroux, R | 1 |
| Gaba, L | 1 |
| Manfredi, S | 1 |
| Tougeron, D | 4 |
| Fujii, K | 1 |
| Mizowaki, T | 2 |
| Connell, C | 1 |
| Smyth, EC | 2 |
| Lordick, F | 21 |
| Herrmann, K | 2 |
| Barbour, AP | 2 |
| Walpole, ET | 6 |
| Mai, GT | 1 |
| Barnes, EH | 1 |
| Watson, DI | 7 |
| Ackland, SP | 4 |
| Martin, JM | 1 |
| Burge, M | 1 |
| Finch, R | 1 |
| Karapetis, CS | 3 |
| Shannon, J | 1 |
| Nott, LM | 1 |
| Varma, S | 1 |
| Marx, G | 1 |
| Falk, GL | 2 |
| Gebski, V | 4 |
| Oostendorp, M | 1 |
| Wilson, K | 2 |
| Thomas, J | 5 |
| Lampe, G | 1 |
| Zalcberg, JR | 2 |
| Simes, J | 1 |
| Smithers, BM | 8 |
| Wei, B | 1 |
| Xu, L | 2 |
| Hui, H | 1 |
| Sun, Y | 2 |
| Wu, J | 4 |
| Ganschow, P | 1 |
| Hofmann, L | 1 |
| Stintzing, S | 1 |
| Heinemann, V | 2 |
| Angele, M | 2 |
| Werner, J | 1 |
| Schulz, C | 1 |
| Catenacci, DVT | 1 |
| Chase, L | 1 |
| Lomnicki, S | 1 |
| Karrison, T | 1 |
| de Wilton Marsh, R | 1 |
| Rampurwala, MM | 1 |
| Narula, S | 1 |
| Alpert, L | 1 |
| Setia, N | 1 |
| Xiao, SY | 1 |
| Hart, J | 1 |
| Siddiqui, UD | 1 |
| Peterson, B | 1 |
| Moore, K | 1 |
| Kipping-Johnson, K | 1 |
| Markevicius, U | 1 |
| Gordon, B | 1 |
| Allen, K | 1 |
| Racette, C | 1 |
| Maron, SB | 1 |
| Liao, CY | 1 |
| Polite, BN | 1 |
| Kindler, HL | 1 |
| Turaga, K | 1 |
| Prachand, VN | 1 |
| Roggin, KK | 1 |
| Ferguson, MK | 3 |
| Posner, MC | 2 |
| Xiao, L | 2 |
| Blum Murphy, M | 1 |
| Palmer, M | 1 |
| Ueki, S | 1 |
| Fujishima, F | 1 |
| Kumagai, T | 1 |
| Ishida, H | 3 |
| Takaya, K | 1 |
| Taniyma, Y | 1 |
| Sasano, H | 1 |
| Modesto, A | 1 |
| Dalmasso, C | 1 |
| Lusque, A | 1 |
| Vieillevigne, L | 1 |
| Izar, F | 1 |
| Moyal, E | 1 |
| Carrère, N | 1 |
| Guimbaud, R | 3 |
| Rives, M | 2 |
| Iwama, M | 3 |
| Motegi, D | 1 |
| Ichikawa, H | 3 |
| Kano, Y | 1 |
| Hanyu, T | 2 |
| Usui, K | 1 |
| Sakai, T | 2 |
| Hirose, Y | 1 |
| Miura, K | 2 |
| Nagahashi, M | 1 |
| Shimada, Y | 5 |
| Sakata, J | 1 |
| Kobayashi, T | 6 |
| Kameyama, H | 2 |
| Wakai, T | 2 |
| Hayashi, Y | 3 |
| Nakatsuka, R | 1 |
| Nishizawa, Y | 1 |
| Komatsu, H | 2 |
| Miyazaki, S | 5 |
| Tomokuni, A | 2 |
| Komori, T | 3 |
| Iwase, K | 1 |
| Iwamoto, R | 1 |
| Kubota, H | 2 |
| Kinoshita, S | 1 |
| Kitagawa, S | 1 |
| Ueno, M | 4 |
| Mineta, S | 1 |
| Okamoto, Y | 5 |
| Watanabe, Y | 6 |
| Higashida, M | 2 |
| Okada, T | 5 |
| Tsuruta, A | 1 |
| Fujiwara, Y | 29 |
| Nakatani, Y | 1 |
| Ushijima, T | 3 |
| Chen, L | 3 |
| Bi, S | 1 |
| Wei, Q | 2 |
| Zhao, Z | 5 |
| Xie, S | 1 |
| Ishikura, S | 13 |
| Kondo, T | 2 |
| Murai, T | 1 |
| Yanagi, T | 1 |
| Sugie, C | 1 |
| Miyakawa, A | 1 |
| Shibamoto, Y | 2 |
| Cui, Y | 2 |
| Yang, D | 1 |
| Wang, W | 4 |
| Zhang, L | 12 |
| Liu, H | 14 |
| Guo, W | 1 |
| Yao, M | 1 |
| Li, W | 2 |
| Ekheden, I | 1 |
| Ebrahim, F | 1 |
| Ólafsdóttir, H | 1 |
| Raaschou, P | 1 |
| Wettermark, B | 1 |
| Henriksson, R | 1 |
| Ye, W | 1 |
| Zhang, J | 9 |
| Yao, N | 1 |
| Tian, S | 1 |
| Sato, S | 2 |
| Ota, Y | 3 |
| Tachibana, S | 4 |
| Suda, T | 2 |
| Makuuchi, Y | 2 |
| Iwasaki, K | 4 |
| Nagakawa, Y | 1 |
| Osaka, Y | 3 |
| Seshimo, A | 1 |
| Katsumata, K | 1 |
| Tsuchida, A | 6 |
| Aoki, K | 4 |
| Mizoguchi, Y | 1 |
| Kitano, S | 2 |
| Yachida, S | 1 |
| Shiba, S | 1 |
| Park, H | 2 |
| Jin, RU | 1 |
| Wang-Gillam, A | 2 |
| Suresh, R | 1 |
| Rigden, C | 1 |
| Amin, M | 1 |
| Tan, BR | 2 |
| Pedersen, KS | 1 |
| Lim, KH | 1 |
| Trikalinos, NA | 1 |
| Acharya, A | 1 |
| Copsey, ML | 1 |
| Navo, KA | 1 |
| Morton, AE | 1 |
| Gao, F | 1 |
| Lockhart, AC | 2 |
| Jogo, T | 2 |
| Kawazoe, T | 1 |
| Kamori, T | 1 |
| Nakaji, Y | 1 |
| Zaitsu, Y | 2 |
| Fujiwara, M | 6 |
| Iwata, N | 3 |
| Egashira, A | 1 |
| Nakanoko, T | 2 |
| Morita, M | 7 |
| Makiyama, A | 1 |
| Tokunaga, S | 1 |
| Shimokawa, M | 1 |
| Tintelnot, J | 1 |
| Binder, M | 1 |
| Thuss-Patience, P | 5 |
| Lorenzen, S | 10 |
| Knorrenschild, JR | 1 |
| Kretzschmar, A | 2 |
| Ettrich, T | 1 |
| Lindig, U | 1 |
| Jacobasch, L | 1 |
| Hinke, A | 1 |
| Hegewisch-Becker, S | 4 |
| Nilsson, S | 1 |
| Bokemeyer, C | 2 |
| Stein, A | 2 |
| Hough, NE | 1 |
| Chapman, SJ | 1 |
| Flight, WG | 1 |
| Zhao, K | 6 |
| Hu, S | 1 |
| Huang, Y | 7 |
| Ma, L | 2 |
| Song, Y | 2 |
| Li, M | 5 |
| Maruya, Y | 1 |
| Isagawa, Y | 1 |
| Yoshimoto, T | 2 |
| Migita, K | 2 |
| Kawaguchi, Y | 3 |
| Kuba, S | 1 |
| Okada, S | 1 |
| Kosaka, T | 2 |
| Adachi, T | 1 |
| Hidaka, M | 1 |
| Torashima, Y | 1 |
| Ito, S | 3 |
| Takatsuki, M | 1 |
| Eguchi, S | 1 |
| Kanda, M | 2 |
| Tanaka, C | 2 |
| Hattori, N | 1 |
| Yamada, S | 9 |
| Omae, K | 2 |
| Nakayama, G | 3 |
| Geng, X | 1 |
| Zhu, L | 1 |
| Zheng, F | 1 |
| Huang, Z | 1 |
| Huang, X | 1 |
| Pan, Z | 1 |
| Jiang, Y | 6 |
| Gu, S | 1 |
| Zhao, C | 1 |
| Zhang, Q | 3 |
| Shi, G | 2 |
| Pucher, PH | 1 |
| Rahman, SA | 1 |
| Walker, RC | 1 |
| Grace, BL | 1 |
| Bateman, A | 1 |
| Iveson, T | 9 |
| Jackson, A | 1 |
| Rees, C | 1 |
| Byrne, JP | 3 |
| Kelly, JJ | 3 |
| Noble, F | 4 |
| Underwood, TJ | 4 |
| Mochizuki, N | 2 |
| Matsuzawa, H | 1 |
| Higaki, E | 1 |
| Hosoi, T | 1 |
| Nagao, T | 1 |
| Bando, H | 2 |
| Kadowaki, S | 4 |
| Muro, K | 13 |
| Tajika, M | 4 |
| Niwa, Y | 5 |
| Shimizu, Y | 3 |
| Wong, IYH | 2 |
| Zhang, RQ | 1 |
| Chan, WWL | 1 |
| Wong, CLY | 1 |
| Chan, FSY | 2 |
| Kwong, DLW | 1 |
| Wen, Y | 1 |
| Liao, D | 1 |
| Miao, J | 1 |
| Gui, Y | 1 |
| Cai, H | 1 |
| Wei, M | 1 |
| Jia, Q | 1 |
| Tian, H | 1 |
| Sun, M | 1 |
| Du, X | 2 |
| Arakawa, Y | 2 |
| Yuda, M | 2 |
| Mitsumori, N | 2 |
| Yanaga, K | 2 |
| Jiang, DM | 1 |
| Sim, HW | 1 |
| Espin-Garcia, O | 1 |
| Chan, BA | 1 |
| Natori, A | 1 |
| Lim, CH | 1 |
| Moignard, S | 1 |
| Chen, EX | 1 |
| Liu, G | 2 |
| Darling, G | 1 |
| Swallow, CJ | 1 |
| Brar, S | 1 |
| Brierley, J | 3 |
| Ringash, J | 3 |
| Wong, R | 2 |
| Kim, J | 2 |
| Rogalla, P | 1 |
| Hafezi-Bakhtiari, S | 1 |
| Knox, JJ | 1 |
| Jang, RW | 1 |
| Elimova, E | 3 |
| Fouladian, P | 1 |
| Kohlhagen, J | 1 |
| Arafat, M | 1 |
| Afinjuomo, F | 1 |
| Workman, N | 1 |
| Abuhelwa, AY | 1 |
| Garg, S | 1 |
| Blencowe, A | 1 |
| Katada, C | 6 |
| Sugawara, M | 2 |
| Nakajima, TE | 5 |
| Ando, T | 4 |
| Watanabe, A | 1 |
| Sakamoto, Y | 4 |
| Ishikawa, H | 2 |
| Hosokawa, A | 2 |
| Hamamoto, Y | 10 |
| Tahara, M | 6 |
| Koizumi, W | 5 |
| Li, N | 3 |
| Miao, F | 1 |
| Cai, S | 1 |
| Liu, P | 2 |
| Yu, Y | 1 |
| Wang, B | 3 |
| Hino, K | 1 |
| Kajiwara, T | 2 |
| Nishina, T | 3 |
| Inoue, T | 7 |
| Yoshimatsu, M | 1 |
| Sakaguchi, C | 1 |
| Nakasya, A | 1 |
| Nishide, N | 1 |
| Asagi, A | 1 |
| Hasebe, A | 1 |
| Terao, T | 1 |
| Hori, S | 2 |
| Nadano, S | 1 |
| Tanimizu, M | 1 |
| Kudou, M | 1 |
| Shimizu, H | 3 |
| Arita, T | 4 |
| Kosuga, T | 3 |
| Yamamoto, Y | 10 |
| Morimura, R | 4 |
| Ikoma, H | 8 |
| Kuriu, Y | 6 |
| Kubota, T | 6 |
| Evrard, C | 1 |
| Hajbi, FE | 1 |
| Fiore, FD | 1 |
| Malicot, KL | 1 |
| Aparicio, T | 3 |
| Bouché, O | 6 |
| Bibeau, F | 1 |
| Lecomte, T | 2 |
| Kim, S | 3 |
| Zaanan, A | 3 |
| Sokol, H | 1 |
| Chibaudel, B | 3 |
| Pierre, S | 1 |
| Gonzalez, D | 2 |
| Lepage, C | 1 |
| Runkel, M | 1 |
| Verst, R | 1 |
| Spiegelberg, J | 1 |
| Fichtner-Feigl, S | 1 |
| Hoeppner, J | 2 |
| Glatz, T | 2 |
| Katsube, R | 2 |
| Ohara, T | 2 |
| Komoto, S | 1 |
| Sato, H | 5 |
| Kashima, H | 1 |
| Kato, T | 9 |
| Kikuchi, S | 3 |
| Tazawa, H | 1 |
| Kagawa, S | 1 |
| Kobayashi, H | 2 |
| Hirakawa, T | 1 |
| Morimoto, J | 3 |
| Tanaka, H | 4 |
| Tsujio, G | 1 |
| Kurihara, S | 1 |
| Matsutani, S | 1 |
| Nagashima, D | 1 |
| Hirata, K | 5 |
| Iwauchi, T | 1 |
| Yamagata, S | 1 |
| Uchima, Y | 1 |
| Takeuchi, K | 2 |
| Dreyfuss, AD | 1 |
| Barsky, AR | 1 |
| Wileyto, EP | 1 |
| Eads, JR | 2 |
| Kucharczuk, JC | 1 |
| Williams, NN | 1 |
| Karasic, TB | 1 |
| Metz, JM | 1 |
| Ben-Josef, E | 2 |
| Plastaras, JP | 1 |
| Wojcieszynski, AP | 1 |
| Stocker, G | 2 |
| Thieme, R | 1 |
| Zhang, M | 2 |
| Li, R | 2 |
| Zhu, H | 3 |
| Rivin Del Campo, E | 2 |
| Ye, J | 3 |
| Simone, CB | 1 |
| Zhu, Z | 3 |
| Zhou, J | 3 |
| Tang, H | 2 |
| Fan, M | 3 |
| Lin, Q | 6 |
| Xia, Y | 2 |
| Mo, M | 1 |
| Jia, H | 2 |
| Lu, S | 3 |
| Nie, Y | 1 |
| Wu, S | 2 |
| Hamaji, M | 1 |
| Haque, W | 1 |
| Jeong, BK | 1 |
| Shridhar, R | 4 |
| Zhang, Z | 9 |
| Zhu, J | 3 |
| Wen, B | 1 |
| Lu, Y | 2 |
| Xu, W | 2 |
| Karadag, I | 1 |
| Karakaya, S | 1 |
| Ates, O | 1 |
| Cakmak Oksuzoglu, OB | 1 |
| Onitilo, AA | 1 |
| Stankowski-Drengler, TJ | 1 |
| Shiyanbola, O | 1 |
| Engel, J | 1 |
| Tanimu, S | 1 |
| Fagbemi, SO | 1 |
| Li, YH | 1 |
| Yarrarapu, SNS | 1 |
| Govero, AB | 1 |
| Kukhon, FR | 1 |
| Sanghavi, DK | 1 |
| Marguet, S | 1 |
| Delaine-Clisant, S | 1 |
| Penel, N | 2 |
| Bonastre, J | 1 |
| Tabernero, J | 1 |
| Bang, YJ | 1 |
| Van Cutsem, E | 6 |
| Fuchs, CS | 2 |
| Janjigian, YY | 3 |
| Bhagia, P | 2 |
| Li, K | 1 |
| Adelberg, D | 1 |
| Qin, SK | 2 |
| Matsuura, N | 4 |
| Saito, T | 4 |
| Nakajima, K | 13 |
| Eguchi, H | 2 |
| Nakagawa, H | 2 |
| Goodman, KA | 2 |
| Ou, FS | 1 |
| Hall, NC | 1 |
| Bekaii-Saab, T | 1 |
| Fruth, B | 1 |
| Twohy, E | 1 |
| Meyers, MO | 1 |
| Boffa, DJ | 1 |
| Mitchell, K | 1 |
| Frankel, WL | 1 |
| Niedzwiecki, D | 3 |
| Noonan, A | 1 |
| Thurmes, PJ | 1 |
| Venook, AP | 2 |
| Meyerhardt, JA | 2 |
| O'Reilly, EM | 2 |
| Ilson, DH | 13 |
| Shim, YM | 5 |
| Yun, J | 2 |
| Im, YH | 4 |
| Lee, G | 1 |
| Kang, D | 1 |
| Cho, J | 1 |
| Kim, K | 5 |
| Park, SI | 8 |
| Na, KJ | 2 |
| Kim, SB | 10 |
| Zo, JI | 2 |
| Nakaya, S | 2 |
| Ogawa, R | 2 |
| Hayakawa, S | 1 |
| Fujihata, S | 1 |
| Okubo, T | 1 |
| Sagawa, H | 1 |
| Matsuo, Y | 2 |
| Takiguchi, S | 21 |
| Wang, Z | 7 |
| Hu, M | 1 |
| Fong, WP | 1 |
| Ren, C | 1 |
| Wang, D | 4 |
| Tan, Q | 1 |
| Yang, H | 9 |
| Sun, JM | 3 |
| Shen, L | 4 |
| Shah, MA | 5 |
| Enzinger, P | 2 |
| Doi, T | 8 |
| Li, Z | 1 |
| Cho, BC | 2 |
| Mansoor, W | 2 |
| Li, SH | 3 |
| Sunpaweravong, P | 2 |
| Maqueda, MA | 1 |
| Antunes, L | 1 |
| Fountzilas, C | 1 |
| Tsuji, A | 4 |
| Oliden, VC | 1 |
| Shah, S | 2 |
| Koide, Y | 2 |
| Kodaira, T | 4 |
| Tachibana, H | 2 |
| Tomita, N | 1 |
| Makita, C | 1 |
| Itoh, M | 1 |
| Naganawa, S | 1 |
| Ikemura, K | 1 |
| Oshima, K | 1 |
| Enokiya, T | 1 |
| Okamoto, A | 1 |
| Oda, H | 1 |
| Mizuno, T | 1 |
| Ishinaga, H | 1 |
| Muraki, Y | 1 |
| Iwamoto, T | 1 |
| Katayama, N | 1 |
| Okuda, M | 1 |
| Li, D | 4 |
| Zheng, X | 4 |
| Lian, J | 1 |
| Cui, H | 2 |
| Sang, L | 1 |
| Yu, JJ | 1 |
| Lu, T | 1 |
| Lee, S | 9 |
| Kishida, S | 4 |
| Hashiba, R | 3 |
| Gyobu, K | 3 |
| Takemura, M | 6 |
| Osugi, H | 9 |
| Ma, Q | 1 |
| Shi, Y | 1 |
| Wang, M | 1 |
| Ge, J | 1 |
| Yue, GG | 1 |
| Lee, JK | 1 |
| Wong, EC | 1 |
| Lau, CB | 1 |
| Chiu, PW | 2 |
| Anvari, K | 1 |
| Sima, HR | 1 |
| Seilanian Toussi, M | 1 |
| Anvari, A | 1 |
| Shahidsales, S | 1 |
| Memar, B | 1 |
| Aledavoud, SA | 1 |
| Forghani, MN | 1 |
| Abdollahi, A | 1 |
| Ghaffarzadegan, K | 1 |
| Fang, M | 1 |
| Song, T | 1 |
| Liang, X | 1 |
| Lv, S | 1 |
| Xu, H | 1 |
| Luo, L | 1 |
| Naito, M | 1 |
| Shimamoto, C | 1 |
| Miwa, Y | 1 |
| Yamashita, H | 11 |
| Abe, O | 2 |
| Deng, W | 1 |
| Yue, J | 1 |
| Zhang, P | 8 |
| Yang, YD | 2 |
| Liu, SL | 5 |
| Fu, JH | 5 |
| Liu, MZ | 11 |
| Pernot, S | 1 |
| Badoual, C | 1 |
| Terme, M | 1 |
| Castan, F | 2 |
| Cazes, A | 1 |
| Bennouna, J | 3 |
| Francois, E | 5 |
| Ghiringhelli, F | 1 |
| De La Fouchardiere, C | 1 |
| Samalin, E | 6 |
| Bachet, JB | 3 |
| Ducreux, M | 3 |
| Marcheteau, E | 1 |
| Stanbury, T | 1 |
| Gourgou, S | 2 |
| Malka, D | 1 |
| Taieb, J | 2 |
| Haisley, KR | 1 |
| Hart, KD | 1 |
| Nabavizadeh, N | 1 |
| Bensch, KG | 1 |
| Vaccaro, GM | 1 |
| Thomas, CR | 3 |
| Schipper, PH | 1 |
| Hunter, JG | 1 |
| Dolan, JP | 1 |
| Hao, D | 1 |
| Xing, W | 1 |
| Yang, Y | 2 |
| He, C | 1 |
| Sanford, NN | 1 |
| Catalano, PJ | 1 |
| King, BL | 1 |
| Bueno, R | 1 |
| Martin, NE | 1 |
| Hong, TS | 1 |
| Wo, JY | 1 |
| Mamon, HJ | 1 |
| Schröder, W | 3 |
| Bruns, CJ | 3 |
| Takenaka, R | 4 |
| Okuma, K | 7 |
| Kiritooshi, T | 1 |
| Mori, K | 6 |
| Fukuda, T | 2 |
| Kaminishi, M | 4 |
| Miyoshi, N | 3 |
| Nakajima, Y | 4 |
| Kawada, K | 3 |
| Tokairin, Y | 4 |
| Hoshino, A | 3 |
| Kawano, T | 7 |
| Pant, S | 1 |
| Patel, M | 1 |
| Kurkjian, C | 1 |
| Hemphill, B | 1 |
| Flores, M | 1 |
| Thompson, D | 1 |
| Bendell, J | 1 |
| Akiyama, Y | 3 |
| Iwaya, T | 6 |
| Endo, F | 3 |
| Takahara, T | 3 |
| Nitta, H | 4 |
| Koeda, K | 7 |
| Mizuno, M | 3 |
| Baggio, R | 1 |
| Chavel, P | 1 |
| Tisseau, L | 1 |
| Darrieux, L | 1 |
| Safa, G | 1 |
| Hokamura, N | 3 |
| Sudo, K | 3 |
| Hamaguchi, T | 2 |
| Umezawa, R | 4 |
| Koyanagi, K | 2 |
| Igaki, H | 14 |
| Tachimori, Y | 4 |
| Wakatsuki, K | 1 |
| Matsumoto, S | 1 |
| Ito, M | 2 |
| Kunishige, T | 1 |
| Nakade, H | 1 |
| Nakatani, M | 1 |
| Kitano, M | 1 |
| Takano, M | 1 |
| Obayashi, C | 1 |
| Sho, M | 1 |
| Wakabayashi, M | 1 |
| Shinoda, M | 11 |
| Katayama, H | 6 |
| Okabe, H | 2 |
| Kosugi, S | 5 |
| Toh, Y | 4 |
| Fukuda, H | 14 |
| Ando, N | 18 |
| Mynhardt, C | 1 |
| Damelin, LH | 1 |
| Jivan, R | 1 |
| Peres, J | 1 |
| Prince, S | 1 |
| Veale, RB | 1 |
| Mavri-Damelin, D | 1 |
| Yokota, T | 9 |
| Nozaki, I | 2 |
| Miyata, Y | 9 |
| Kuroki, Y | 1 |
| Voncken, FEM | 1 |
| van der Kaaij, RT | 2 |
| Sikorska, K | 2 |
| van Werkhoven, E | 1 |
| van Dieren, JM | 2 |
| Grootscholten, C | 1 |
| Snaebjornsson, P | 2 |
| van Sandick, JW | 3 |
| Aleman, BMP | 1 |
| Ter Veer, E | 3 |
| Ngai, LL | 2 |
| Valkenhoef, GV | 1 |
| Mohammad, NH | 1 |
| Anderegg, MCJ | 1 |
| van Oijen, MGH | 3 |
| van Laarhoven, HWM | 4 |
| Tamtai, A | 1 |
| Jiarpinitnun, C | 1 |
| Hiranyatheb, P | 1 |
| Unwanatham, N | 1 |
| Sirachainun, E | 1 |
| Supsamutchai, C | 1 |
| Pattaranutaporn, P | 1 |
| Ngamphaiboon, N | 1 |
| Davuluri, R | 1 |
| Jiang, W | 1 |
| Fang, P | 1 |
| Komaki, R | 18 |
| Welsh, J | 1 |
| Cox, JD | 9 |
| Crane, CH | 1 |
| Hsu, CC | 1 |
| Lin, SH | 2 |
| Vellayappan, BA | 1 |
| Soon, YY | 1 |
| Ku, GY | 2 |
| Leong, CN | 1 |
| Lu, JJ | 1 |
| Tey, JC | 1 |
| Bascoul-Mollevi, C | 1 |
| Raoul, JL | 9 |
| Douillard, JY | 4 |
| Etienne, PL | 7 |
| Juzyna, B | 2 |
| Bedenne, L | 9 |
| Conroy, T | 11 |
| Tsang, JS | 1 |
| Tong, DKH | 1 |
| Law, BTT | 1 |
| Chan, DKK | 1 |
| Hayami, M | 1 |
| Francis, SR | 1 |
| Orton, A | 1 |
| Thorpe, C | 1 |
| Stoddard, G | 1 |
| Lloyd, S | 1 |
| Anker, CJ | 1 |
| Kumabe, A | 2 |
| Zenda, S | 2 |
| Motegi, A | 2 |
| Onozawa, M | 5 |
| Shigematsu, N | 2 |
| Kanaji, S | 2 |
| Matsuda, T | 1 |
| Oshikiri, T | 1 |
| Sumi, Y | 2 |
| Pang, Y | 1 |
| Du, N | 1 |
| Liang, R | 1 |
| Ren, H | 1 |
| Tang, SC | 1 |
| Sun, X | 2 |
| Mazzone, M | 1 |
| Finisguerra, V | 1 |
| Prenen, H | 1 |
| Lloyd, MA | 1 |
| Turkington, R | 1 |
| Griffiths, E | 1 |
| O'Donovan, M | 1 |
| O'Neill, JR | 1 |
| Mercer, S | 1 |
| Parsons, SL | 6 |
| Fitzgerald, RC | 1 |
| Song, DJ | 1 |
| Xu, ZL | 1 |
| Xie, SP | 1 |
| Hu, JH | 1 |
| Fujimoto, Y | 2 |
| Sasaki, S | 3 |
| Hirose, K | 3 |
| Edahiro, K | 1 |
| Korehisa, S | 1 |
| Taniguchi, D | 1 |
| Kudou, K | 1 |
| Nakaji, YU | 1 |
| Nakanishi, R | 1 |
| Ando, K | 5 |
| Oda, Y | 4 |
| Guo, L | 2 |
| Cheng, X | 2 |
| Ke, S | 1 |
| Shi, W | 1 |
| Cartwright, E | 1 |
| de Castro Junior, G | 1 |
| Segalla, JG | 1 |
| de Azevedo, SJ | 1 |
| Andrade, CJ | 1 |
| Grabarz, D | 1 |
| de Araújo Lima França, B | 1 |
| Del Giglio, A | 2 |
| Lazaretti, NS | 1 |
| Álvares, MN | 1 |
| Pedrini, JL | 1 |
| Kussumoto, C | 1 |
| de Matos Neto, JN | 1 |
| Forones, NM | 1 |
| Fernandes Júnior, HJ | 1 |
| Borges, G | 1 |
| Girotto, G | 1 |
| da Silva, IDCG | 1 |
| Maluf-Filho, F | 1 |
| Skare, NG | 1 |
| Miyazaki, Y | 5 |
| Wada, N | 2 |
| Fukada, J | 1 |
| Kota, R | 1 |
| Koike, N | 4 |
| Shiraishi, Y | 1 |
| Shimodaira, Y | 2 |
| Slack, RS | 1 |
| Harada, K | 3 |
| Chen, HC | 1 |
| Sagebiel, T | 2 |
| Weston, B | 2 |
| Amlashi, FG | 1 |
| Mizrak Kaya, D | 1 |
| Roth, JA | 15 |
| Skinner, HD | 4 |
| Mares, J | 1 |
| Thomas, I | 1 |
| Maru, DM | 4 |
| Walsh, G | 7 |
| Sun, Q | 2 |
| Zang, W | 1 |
| Zhao, G | 1 |
| Shida, Y | 1 |
| Kurayama, E | 1 |
| Ogata, H | 1 |
| Sakai, M | 6 |
| Sohda, M | 6 |
| Miyazaki, T | 7 |
| Kuwano, H | 7 |
| Shoda, K | 2 |
| Okumura, H | 12 |
| Setoyama, T | 5 |
| Hiwatashi, K | 1 |
| Minami, K | 2 |
| Maenohara, S | 2 |
| Omoto, I | 5 |
| Natsugoe, S | 14 |
| Okada, K | 2 |
| Miki, H | 2 |
| Masuzawa, T | 2 |
| Tamura, S | 5 |
| Kawai, K | 1 |
| Inatome, J | 1 |
| Naito, A | 1 |
| Katsura, Y | 2 |
| Ohmura, Y | 2 |
| Kagawa, Y | 2 |
| Egawa, C | 1 |
| Takeda, Y | 5 |
| Hikami, S | 1 |
| Murayama, Y | 5 |
| Komatsu, S | 8 |
| Nakanishi, M | 7 |
| Ichikawa, D | 9 |
| Imamoto, H | 3 |
| Odagiri, K | 1 |
| Yamazaki, M | 2 |
| Creemers, A | 1 |
| de Waal, L | 1 |
| Muroya, T | 3 |
| Wajima, N | 8 |
| Yachi, T | 2 |
| Akaishi, T | 2 |
| Umetsu, S | 2 |
| Wakasa, Y | 2 |
| Sato, K | 3 |
| Mitsuhashi, Y | 3 |
| Umemura, K | 1 |
| Tsuruta, S | 1 |
| Hakamada, K | 8 |
| Zhou, Q | 1 |
| Kamimura, K | 1 |
| Saijo, Y | 1 |
| Zhang, JZ | 1 |
| Liu, JF | 2 |
| Li, HY | 1 |
| Goense, L | 1 |
| van Rossum, PSN | 1 |
| Carter, BW | 1 |
| Meijer, GJ | 1 |
| Ho, L | 5 |
| van Hillegersberg, R | 3 |
| Odawara, S | 1 |
| Kitajima, K | 1 |
| Katsuura, T | 1 |
| Kurahashi, Y | 1 |
| Shinohara, H | 1 |
| Yamakado, K | 1 |
| Bozkurt, M | 1 |
| Antonoff, M | 1 |
| Jaramillo, S | 1 |
| Murphy, MB | 1 |
| Hsieh, HY | 1 |
| Yeh, HL | 1 |
| Chuang, CY | 1 |
| Lin, JF | 1 |
| Chang, CF | 1 |
| MacGregor, TP | 1 |
| Carter, R | 1 |
| Gillies, RS | 1 |
| Findlay, JM | 1 |
| Kartsonaki, C | 1 |
| Castro-Giner, F | 1 |
| Sahgal, N | 1 |
| Wang, LM | 1 |
| Chetty, R | 1 |
| Maynard, ND | 1 |
| Cazier, JB | 1 |
| Buffa, F | 1 |
| McHugh, PJ | 1 |
| Tomlinson, I | 1 |
| Middleton, MR | 1 |
| Sharma, RA | 1 |
| Naka, R | 1 |
| Nishiyama, M | 7 |
| Ihara, T | 1 |
| Kawakami, T | 1 |
| Shirasu, H | 1 |
| Kito, Y | 1 |
| Yoshida, Y | 3 |
| Hamauchi, S | 2 |
| Todaka, A | 1 |
| Machida, N | 1 |
| Yamazaki, K | 2 |
| Fukutomi, A | 2 |
| Onozawa, Y | 3 |
| Yasui, H | 4 |
| Tin, AW | 1 |
| Smith, E | 1 |
| Hepworth, R | 1 |
| Walker, J | 1 |
| Wilson, D | 1 |
| Wadd, N | 1 |
| Doosti-Irani, A | 1 |
| Holakouie-Naieni, K | 1 |
| Rahimi-Foroushani, A | 1 |
| Mansournia, MA | 1 |
| Haddad, P | 1 |
| Cortellini, A | 1 |
| Cannita, K | 1 |
| Parisi, A | 1 |
| Venditti, O | 1 |
| Lanfiuti Baldi, P | 1 |
| De Berardis, B | 1 |
| Vicentini, R | 1 |
| Vicentini, V | 1 |
| Verna, L | 1 |
| Porzio, G | 1 |
| Ficorella, C | 1 |
| Takeuchi, Y | 2 |
| Takahashi, I | 2 |
| Kimura, T | 4 |
| Sakurai, T | 3 |
| Heishi, T | 1 |
| Teshima, J | 1 |
| Maruyama, S | 2 |
| Ito, K | 5 |
| Onodera, Y | 1 |
| Konno-Kumagai, T | 1 |
| Nikai, H | 2 |
| Amano, S | 1 |
| Umemura, A | 1 |
| Baba, S | 3 |
| Venkat, PS | 1 |
| Naghavi, AO | 1 |
| Hoffe, SE | 3 |
| Almhanna, K | 3 |
| Pimiento, JM | 1 |
| Fontaine, JP | 1 |
| Abuodeh, Y | 1 |
| Meredith, KL | 2 |
| Frakes, JM | 1 |
| Hu, X | 6 |
| Akutsu, Y | 9 |
| Suganami, A | 1 |
| Qin, W | 2 |
| Hanari, N | 3 |
| Murakam, K | 1 |
| Usui, A | 1 |
| Otsuta, R | 1 |
| Tamura, Y | 1 |
| Lavin, VJ | 1 |
| Mehta, S | 1 |
| Sumra, P | 1 |
| Bhatt, L | 1 |
| Jackson, AS | 1 |
| Sheikh, HY | 1 |
| Boilève, A | 1 |
| Osman, D | 1 |
| Marthey, L | 1 |
| Carbonnel, F | 1 |
| Kawamoto, T | 4 |
| Nihei, K | 7 |
| Sasai, K | 2 |
| Karasawa, K | 3 |
| Gombodorj, N | 1 |
| Yokobori, T | 5 |
| Kuriyama, K | 1 |
| Kumakura, Y | 1 |
| Baatar, S | 1 |
| Shirabe, K | 1 |
| Hashimoto, J | 1 |
| Katano, S | 1 |
| Saito, Y | 1 |
| Chen, YH | 1 |
| Lu, HI | 2 |
| Lo, CM | 1 |
| Wang, YM | 2 |
| Chou, SY | 1 |
| Hsiao, CC | 1 |
| Huang, CC | 2 |
| Shih, LH | 1 |
| Chen, SW | 1 |
| von Döbeln, GA | 1 |
| Johannessen, HO | 1 |
| Nielsen, NH | 1 |
| Hatlevoll, I | 2 |
| Komori, K | 1 |
| Aoki, M | 2 |
| Sandou, M | 1 |
| Takagi, M | 1 |
| Uejima, E | 1 |
| Lin, K | 2 |
| Zhuang, SS | 1 |
| Qin, YS | 1 |
| Qiu, GD | 1 |
| She, YQ | 1 |
| Zheng, JT | 1 |
| Chen, C | 3 |
| Fang, L | 1 |
| Zhang, SY | 1 |
| Doki, N | 1 |
| Najima, Y | 1 |
| Kaito, S | 1 |
| Athauda, A | 1 |
| Mohammed, K | 1 |
| Tait, D | 5 |
| Aitken, K | 1 |
| Ai, D | 1 |
| Deng, J | 1 |
| Ren, W | 1 |
| Wei, S | 2 |
| Luo, H | 1 |
| Cao, J | 1 |
| Huang, G | 1 |
| Wu, K | 2 |
| Fan, J | 1 |
| Badakhshi, H | 1 |
| Lyu, J | 1 |
| Li, T | 4 |
| Wang, Q | 2 |
| Li, F | 2 |
| Diao, P | 1 |
| Liu, L | 4 |
| Li, C | 2 |
| Lang, J | 2 |
| Huang, TC | 3 |
| Lin, CC | 7 |
| Wu, YC | 2 |
| Chia-Hsien Cheng, J | 2 |
| Lee, JM | 8 |
| Wang, HP | 2 |
| Huang, PM | 5 |
| Hsu, FM | 4 |
| Yeh, KH | 4 |
| Cheng, AL | 4 |
| Tzen, KY | 1 |
| Kijima, T | 1 |
| Chandramouleeswaran, PM | 1 |
| Hara, T | 2 |
| Sahu, V | 1 |
| Kasagi, Y | 4 |
| Giroux, V | 1 |
| Muir, AB | 1 |
| Whelan, KA | 1 |
| Ohashi, S | 1 |
| Naganuma, S | 1 |
| Klein-Szanto, AJ | 1 |
| Shinden, Y | 1 |
| Kita, Y | 6 |
| Bass, AJ | 1 |
| Diehl, JA | 1 |
| Ginsberg, GG | 1 |
| Avadhani, NG | 1 |
| Basu, D | 1 |
| Rustgi, AK | 1 |
| Kim, TH | 2 |
| Lee, IJ | 3 |
| Kim, JH | 9 |
| Lee, CG | 3 |
| Lee, YC | 6 |
| Kim, JW | 2 |
| Gabrielson, S | 1 |
| Tsai, JA | 5 |
| Celebioglu, F | 1 |
| Rouvelas, I | 2 |
| Bjäreback, A | 1 |
| Tomson, A | 1 |
| Axelsson, R | 1 |
| Yoshida, J | 4 |
| Handa, O | 1 |
| Nakanuma, S | 1 |
| Makino, I | 1 |
| Miyashita, T | 2 |
| Tajima, H | 1 |
| Takamura, H | 2 |
| Fushida, S | 2 |
| Huang, C | 1 |
| Yuan, Y | 1 |
| Liu, M | 4 |
| Dohmae, T | 1 |
| Hotta, K | 2 |
| Kageyama, SI | 1 |
| Kohno, R | 1 |
| Tsuchihara, K | 1 |
| Pendleton, EG | 1 |
| Jamasbi, RJ | 1 |
| Geusz, ME | 1 |
| Roviello, G | 3 |
| Petrioli, R | 3 |
| Rosellini, P | 1 |
| Multari, AG | 1 |
| Conca, R | 1 |
| Paganini, G | 1 |
| Chiriacò, G | 1 |
| Aieta, M | 1 |
| Ueda, H | 1 |
| Chikugo, T | 1 |
| Özgüroğlu, M | 1 |
| Kostorov, V | 1 |
| Hierro, C | 1 |
| McLean, LA | 1 |
| Gunjigake, K | 1 |
| Gabata, R | 1 |
| Iijima, H | 2 |
| Isohashi, F | 4 |
| Tsujii, Y | 1 |
| Fujinaga, T | 1 |
| Nagai, K | 9 |
| Yoshii, S | 1 |
| Sakatani, A | 1 |
| Hiyama, S | 1 |
| Shinzaki, S | 2 |
| Takehara, T | 2 |
| Ma, J | 1 |
| Liao, C | 2 |
| Xiao, H | 1 |
| Zhu, Q | 2 |
| Liu, Z | 3 |
| Tao, A | 1 |
| He, Z | 2 |
| Zheng, K | 3 |
| Cleary, JM | 1 |
| Horick, NK | 1 |
| McCleary, NJ | 1 |
| Abrams, TA | 1 |
| Yurgelun, MB | 1 |
| Azzoli, CG | 1 |
| Rubinson, DA | 1 |
| Brooks, GA | 1 |
| Chan, JA | 1 |
| Blaszkowsky, LS | 1 |
| Clark, JW | 1 |
| Goyal, L | 1 |
| Ng, K | 1 |
| Schrag, D | 2 |
| Savarese, DMF | 1 |
| Graham, C | 1 |
| Fitzpatrick, B | 1 |
| Gibb, KA | 1 |
| Boucher, Y | 1 |
| Duda, DG | 1 |
| Jain, RK | 1 |
| Mayanagi, S | 1 |
| Irino, T | 1 |
| Fukuda, K | 2 |
| Nakamura, R | 2 |
| Lu, B | 1 |
| Lu, C | 2 |
| Sun, Z | 1 |
| Qu, C | 1 |
| Hua, Z | 1 |
| Tong, R | 1 |
| Han, C | 1 |
| Wang, P | 2 |
| Pang, Q | 1 |
| Lin, Y | 3 |
| Ge, X | 1 |
| Zhou, Z | 1 |
| Ni, W | 1 |
| Chang, X | 1 |
| Liang, J | 2 |
| Xiao, Z | 1 |
| Hong, P | 1 |
| Zheng, CC | 1 |
| Dai, W | 2 |
| Chen, WY | 1 |
| Yang, QS | 1 |
| Xu, LY | 1 |
| Li, EM | 1 |
| Lung, ML | 2 |
| He, QY | 3 |
| Cheung, AL | 5 |
| Zhou, S | 1 |
| Zhao, L | 6 |
| Chen, Q | 4 |
| Hou, J | 1 |
| Wu, Z | 1 |
| Zhao, J | 1 |
| Catenacci, DV | 1 |
| Tesfaye, A | 1 |
| Tejani, M | 1 |
| Cheung, E | 1 |
| Eisenberg, P | 1 |
| Scott, AJ | 1 |
| Eng, C | 1 |
| Hnatyszyn, J | 1 |
| Marina, N | 1 |
| Powers, J | 1 |
| Wainberg, Z | 1 |
| Nagai, Y | 4 |
| Imai, K | 3 |
| Karashima, R | 3 |
| Koga, Y | 1 |
| Wagner, AD | 1 |
| Mauer, M | 1 |
| Marreaud, S | 1 |
| Caballero, C | 1 |
| Mueller, L | 1 |
| Elme, A | 1 |
| Moehler, MH | 1 |
| Martens, U | 1 |
| Kang, YK | 4 |
| Rha, SY | 1 |
| Cats, A | 3 |
| Tokunaga, M | 4 |
| Ota, T | 3 |
| Sakamoto, N | 3 |
| Inoue, K | 1 |
| Izumi, N | 1 |
| Tsukioka, T | 1 |
| Inoue, H | 4 |
| Nishiyama, N | 1 |
| Ozawa, S | 6 |
| Kazuno, A | 2 |
| Ninomiya, Y | 1 |
| Yatabe, K | 1 |
| Monma, S | 1 |
| Shouji, H | 1 |
| Yamada, Y | 5 |
| Ito, T | 7 |
| Boustani, J | 1 |
| Blanc, J | 1 |
| Peiffert, D | 3 |
| Benezery, K | 1 |
| Pereira, R | 1 |
| Rio, E | 2 |
| Le Prisé, E | 7 |
| Créhange, G | 6 |
| Huguet, F | 3 |
| Ohkura, Y | 1 |
| Udagawa, H | 5 |
| Hatogai, K | 2 |
| Maki, Y | 1 |
| Tanaka, M | 3 |
| Saito, S | 3 |
| Hayakawa, Y | 1 |
| Matsuoka, M | 1 |
| Nozaka, T | 1 |
| Misumi, Y | 1 |
| Matsumoto, T | 3 |
| Miura, N | 1 |
| Furumoto, Y | 1 |
| Asano, T | 1 |
| Horiuchi, T | 1 |
| Fujiki, K | 1 |
| Takahashi, N | 1 |
| Ishikawa, K | 2 |
| Itasaka, S | 5 |
| Sakayauchi, T | 5 |
| Ohsawa, M | 1 |
| Ibuki, Y | 1 |
| Kojima, Y | 2 |
| Makiuchi, T | 1 |
| Nagumo, R | 1 |
| Fan, H | 1 |
| Ma, Y | 1 |
| Liang, D | 1 |
| Huang, R | 2 |
| Zhou, F | 2 |
| Kan, Q | 1 |
| Ming, L | 1 |
| Li, H | 4 |
| Giercksky, KE | 1 |
| Nesland, JM | 1 |
| Suo, Z | 1 |
| Cabau, M | 1 |
| Luc, G | 2 |
| Terrebonne, E | 1 |
| Belleanne, G | 1 |
| Vendrely, V | 2 |
| Sa Cunha, A | 1 |
| Collet, D | 2 |
| Kripp, M | 2 |
| Rosowski, J | 1 |
| Hartmann, JT | 3 |
| Moehler, M | 5 |
| Piessen, G | 5 |
| Petyt, G | 1 |
| Duhamel, A | 1 |
| Mirabel, X | 6 |
| Huglo, D | 1 |
| Mariette, C | 11 |
| Uronis, HE | 2 |
| Bendell, JC | 4 |
| Altomare, I | 1 |
| Blobe, GC | 2 |
| Hsu, SD | 1 |
| Morse, MA | 3 |
| Pang, H | 1 |
| Zafar, SY | 1 |
| Conkling, P | 1 |
| Favaro, J | 1 |
| Arrowood, CC | 1 |
| Cushman, SM | 1 |
| Meadows, KL | 1 |
| Brady, JC | 1 |
| Nixon, AB | 1 |
| Hurwitz, HI | 4 |
| Mukaida, H | 2 |
| Kobayashi, Y | 3 |
| Hato, S | 1 |
| Kobatake, T | 1 |
| Ohta, K | 1 |
| Kubo, Y | 1 |
| Tanada, M | 1 |
| Kurita, A | 2 |
| Yoshizawa, J | 1 |
| Koide, N | 2 |
| Takeuchi, D | 1 |
| Suzuki, A | 3 |
| Shinoda, A | 1 |
| Miyagawa, S | 1 |
| Gordon, MA | 1 |
| Gundacker, HM | 1 |
| Benedetti, J | 1 |
| Macdonald, JS | 2 |
| Baranda, JC | 1 |
| Levin, WJ | 1 |
| Blanke, CD | 3 |
| Elatre, W | 1 |
| Weng, P | 1 |
| Zhou, JY | 1 |
| Press, MF | 1 |
| Heinzow, HS | 1 |
| Seifert, H | 1 |
| Tsepetonidis, S | 1 |
| Wolters, H | 1 |
| Kucharzik, T | 1 |
| Domschke, W | 1 |
| Domagk, D | 1 |
| Meister, T | 1 |
| Mayahara, H | 1 |
| Kobayashi, R | 4 |
| Shiraishi, K | 4 |
| Ohtomo, K | 8 |
| Scheithauer, W | 1 |
| Tseng, CK | 5 |
| Liu, YH | 6 |
| Wan, YL | 1 |
| Chiu, CT | 1 |
| Chang, WC | 1 |
| Chang, HK | 5 |
| Ishiyama, H | 3 |
| Tokunaga, SY | 1 |
| Yoshimura, K | 1 |
| Aoki, Y | 4 |
| Sakogawa, K | 2 |
| Kono, K | 4 |
| Shi, L | 2 |
| Sun, J | 2 |
| Kitao, H | 1 |
| Ikura, T | 2 |
| Niida, H | 1 |
| Tashiro, S | 2 |
| Aichler, M | 2 |
| Elsner, M | 1 |
| Ludyga, N | 1 |
| Feuchtinger, A | 1 |
| Zangen, V | 1 |
| Maier, SK | 1 |
| Balluff, B | 1 |
| Schöne, C | 1 |
| Hierber, L | 1 |
| Braselmann, H | 1 |
| Meding, S | 1 |
| Rauser, S | 2 |
| Zischka, H | 1 |
| Aubele, M | 1 |
| Schmitt, M | 2 |
| Feith, M | 5 |
| Hauck, SM | 1 |
| Ueffing, M | 1 |
| Langer, R | 10 |
| Kuster, B | 1 |
| Zitzelsberger, H | 1 |
| Höfler, H | 7 |
| Walch, AK | 1 |
| Haller, B | 2 |
| Schuster, T | 4 |
| Luley, K | 2 |
| Bichev, D | 3 |
| Schumacher, G | 2 |
| Waddell, T | 1 |
| Okines, AF | 6 |
| Frances, A | 1 |
| Okines, C | 1 |
| Wotherspoon, A | 5 |
| Saffery, C | 2 |
| Middleton, G | 3 |
| Wadsley, J | 1 |
| Ferry, D | 3 |
| Crosby, T | 5 |
| Coxon, F | 4 |
| Smith, D | 3 |
| Waters, J | 2 |
| Falk, S | 3 |
| Slater, S | 2 |
| Peckitt, C | 2 |
| Barbachano, Y | 1 |
| Wong, S | 1 |
| Hennequin, C | 4 |
| Quero, L | 1 |
| Zhang, SS | 1 |
| Xie, X | 1 |
| Luo, KJ | 1 |
| Wen, J | 1 |
| Bella, AE | 1 |
| Yang, F | 1 |
| Hurt, CN | 1 |
| Gollins, S | 1 |
| Mukherjee, S | 3 |
| Staffurth, J | 2 |
| Ray, R | 1 |
| Bashir, N | 1 |
| Bridgewater, JA | 1 |
| Geh, JI | 3 |
| Blazeby, J | 1 |
| Maughan, T | 1 |
| Griffiths, G | 2 |
| Weber, JM | 2 |
| Chuong, MD | 1 |
| Karl, RC | 2 |
| Meredith, K | 2 |
| Motoyama, S | 7 |
| Nanjo, H | 1 |
| Yoshino, K | 1 |
| Sasaki, T | 6 |
| Kuribayashi, K | 1 |
| Nagaki, Y | 1 |
| Minamiya, Y | 3 |
| Ogawa, J | 4 |
| Khanna, A | 1 |
| Reece-Smith, AM | 2 |
| Cunnell, M | 1 |
| Madhusudan, S | 4 |
| Thomas, A | 1 |
| Bowrey, DJ | 1 |
| Mirinezhad, SK | 2 |
| Somi, MH | 2 |
| Seyednezhad, F | 1 |
| Jangjoo, AG | 2 |
| Ghojazadeh, M | 2 |
| Mohammadzadeh, M | 2 |
| Naseri, AR | 2 |
| Nasiri, B | 2 |
| Hou, W | 1 |
| Qin, X | 1 |
| Zhu, X | 2 |
| Fei, M | 1 |
| Moon, H | 1 |
| Greshock, J | 1 |
| Bachman, KE | 1 |
| Ye, BC | 1 |
| Wang, H | 5 |
| Zang, CY | 1 |
| Gerber, N | 1 |
| Wu, AJ | 1 |
| Kelsen, DP | 13 |
| Zheng, J | 1 |
| Bains, MS | 1 |
| Rizk, N | 1 |
| Rusch, VW | 1 |
| Castoro, C | 4 |
| Scarpa, M | 2 |
| Cagol, M | 3 |
| Alfieri, R | 3 |
| Ruol, A | 8 |
| Cavallin, F | 3 |
| Michieletto, S | 1 |
| Zanchettin, G | 2 |
| Chiarion-Sileni, V | 5 |
| Corti, L | 3 |
| Ancona, E | 8 |
| Ochiai, T | 12 |
| Inoue, J | 1 |
| Inazawa, J | 1 |
| Ikeda, M | 2 |
| Morimoto, M | 1 |
| Furukawa, T | 1 |
| Furukita, Y | 4 |
| Takechi, H | 6 |
| Seike, J | 9 |
| Imanishi, S | 1 |
| Shuto, K | 6 |
| Aoyagi, T | 1 |
| Kono, T | 4 |
| Shirmohamadi, M | 1 |
| Seyednejad, F | 1 |
| Buyse, M | 1 |
| Lichinitser, M | 2 |
| Gorbunova, V | 3 |
| Bodoky, G | 4 |
| Cascinu, S | 4 |
| Zaucha, R | 1 |
| Carrato, A | 2 |
| Moiseyenko, V | 3 |
| Tsuda, Y | 2 |
| Hidaka, G | 1 |
| Kawano, H | 1 |
| Otsu, H | 1 |
| Kusumoto, T | 1 |
| Murphy, CC | 1 |
| Incalcaterra, JR | 1 |
| Albright, HW | 1 |
| Correa, AM | 7 |
| Chiu, CH | 2 |
| Chan, SC | 2 |
| Chen, WH | 2 |
| Rumiato, E | 1 |
| Boldrin, E | 1 |
| Basso, D | 1 |
| Amadori, A | 1 |
| Saggioro, D | 1 |
| Shimoji, H | 3 |
| Kinjo, T | 1 |
| Karimata, H | 2 |
| Nagahama, M | 1 |
| Nishimaki, T | 6 |
| Liao, Z | 12 |
| Rice, DC | 2 |
| Vaporciyan, AA | 5 |
| Eid, A | 1 |
| Yao, JC | 4 |
| Phan, AP | 1 |
| Halpin, A | 1 |
| Taketa, T | 2 |
| Thall, PF | 1 |
| Xu, JM | 1 |
| Feng, FY | 2 |
| Jiao, SC | 2 |
| Wang, LW | 1 |
| Guan, ZZ | 3 |
| Wang, JJ | 1 |
| Yu, SY | 1 |
| Wang, YJ | 1 |
| Jin, YN | 1 |
| Tao, M | 1 |
| Zheng, LZ | 1 |
| Pan, LX | 2 |
| Nagase, M | 1 |
| Hosoya, Y | 3 |
| Bao, Q | 1 |
| Schwarz, B | 1 |
| Mysliwietz, J | 1 |
| Ellwart, J | 1 |
| Renner, A | 1 |
| Hirner, H | 1 |
| Niess, H | 1 |
| Camaj, P | 2 |
| Gros, S | 1 |
| Izbicki, J | 1 |
| Jauch, KW | 2 |
| Nelson, PJ | 2 |
| Chen, WW | 1 |
| Arnold, D | 4 |
| Thuss-Patience, PC | 4 |
| Grothe, W | 1 |
| Seufferlein, T | 2 |
| Reinacher-Schick, A | 1 |
| Geissler, M | 1 |
| Schmoll, HJ | 3 |
| Misumi, K | 1 |
| Horikoshi, Y | 1 |
| Kubo, H | 2 |
| Nakasuga, C | 1 |
| Tada, K | 1 |
| Miyahara, M | 1 |
| Hasegawa, H | 4 |
| Kondo, S | 2 |
| Yamashita, Y | 7 |
| Wadhwa, R | 2 |
| Campagna, MC | 1 |
| Skinner, H | 1 |
| Swisher, S | 9 |
| Popa, EC | 1 |
| Hinai, Y | 1 |
| Niioka, T | 1 |
| Miura, M | 1 |
| Lin, W | 2 |
| Lin, S | 1 |
| Han, S | 1 |
| Lee, CW | 1 |
| Trevino, JG | 1 |
| Hughes, SJ | 1 |
| Sarosi, GA | 2 |
| Omatsu, H | 4 |
| Kuwahara, A | 9 |
| Yamamori, M | 10 |
| Miki, I | 10 |
| Tamura, T | 13 |
| Nishiguchi, K | 7 |
| Okamura, N | 4 |
| Azuma, T | 4 |
| Hirano, T | 1 |
| Ozawa, K | 1 |
| Hirai, M | 3 |
| Mirza, A | 1 |
| Pritchard, S | 1 |
| Welch, I | 1 |
| Omori, M | 3 |
| Nagata, M | 3 |
| Cho, A | 1 |
| Kainuma, O | 2 |
| Ikeda, A | 2 |
| Yamamoto, H | 4 |
| Sugiyama, T | 4 |
| Itami, M | 1 |
| Curtis, NJ | 1 |
| Bailey, IS | 2 |
| Touchefeu, Y | 1 |
| Archambeaud, I | 1 |
| Landi, B | 1 |
| Lepère, C | 1 |
| Rougier, P | 4 |
| Mitry, E | 2 |
| Sunpaweravong, S | 1 |
| Puttawibul, P | 1 |
| Ruangsin, S | 1 |
| Laohawiriyakamol, S | 1 |
| Sangthawan, D | 1 |
| Pradutkanchana, J | 1 |
| Raungkhajorn, P | 1 |
| Geater, A | 1 |
| Di Lauro, L | 1 |
| Vici, P | 1 |
| Belli, F | 1 |
| Tomao, S | 1 |
| Fattoruso, SI | 1 |
| Arena, MG | 1 |
| Pizzuti, L | 1 |
| Giannarelli, D | 1 |
| Paoletti, G | 1 |
| Barba, M | 1 |
| Sergi, D | 1 |
| Maugeri-Saccà, M | 1 |
| Kajiura, S | 1 |
| Yoshita, H | 1 |
| Ueda, Y | 2 |
| Ueda, A | 1 |
| Mihara, H | 1 |
| Fujinami, H | 1 |
| Nishikawa, J | 1 |
| Minemura, M | 1 |
| Ubink, I | 1 |
| van der Sluis, P | 1 |
| Schipper, M | 1 |
| Reerink, O | 1 |
| Voest, E | 1 |
| Borel-Rinkes, I | 1 |
| Wijrdeman, H | 1 |
| Vleggaar, F | 1 |
| Agterof, M | 1 |
| Overkleeft, E | 1 |
| Siersema, P | 1 |
| Lolkema, MP | 2 |
| Yang, ZR | 2 |
| Dong, WG | 2 |
| Zhang, JX | 2 |
| Guo, XF | 3 |
| Song, J | 3 |
| Qiu, S | 1 |
| Qiu, H | 1 |
| Mao, Y | 2 |
| Gu, Y | 1 |
| Zeng, J | 1 |
| Huang, N | 1 |
| Nako, Y | 1 |
| Sakakura, C | 5 |
| Asaka, S | 2 |
| Naitou, E | 1 |
| Shimakawa, T | 4 |
| Endo, M | 2 |
| Usuda, A | 1 |
| Shimazaki, A | 1 |
| Miyaki, A | 1 |
| Murayama, M | 2 |
| Yokomizo, H | 1 |
| Yoshimatsu, K | 1 |
| Shiozawa, S | 1 |
| Katsube, T | 3 |
| Naritaka, Y | 4 |
| Takemoto, K | 1 |
| Kubo, N | 8 |
| Lee, T | 1 |
| Shinto, O | 1 |
| Sakurai, K | 2 |
| Toyokawa, T | 1 |
| Muguruma, K | 3 |
| Shibutani, M | 1 |
| Yamazoe, S | 1 |
| Nagahara, H | 1 |
| Kimura, K | 3 |
| Amano, R | 2 |
| Ohtani, H | 1 |
| Yashiro, M | 3 |
| Maeda, K | 2 |
| Ohira, M | 3 |
| Hirakawa, K | 4 |
| Kitahara, M | 2 |
| Kanekiyo, S | 2 |
| Takeda, S | 4 |
| Yoshino, S | 4 |
| Hazama, S | 4 |
| Oka, M | 6 |
| Endo, C | 2 |
| Takagawa, R | 3 |
| Kawamoto, M | 3 |
| Konishi, T | 5 |
| Minami, Y | 2 |
| Watanabe, J | 2 |
| Morita, T | 3 |
| Mogaki, M | 2 |
| Masui, H | 2 |
| Fujikawa, H | 1 |
| Shirai, J | 1 |
| Cho, H | 1 |
| Yoshikawa, T | 2 |
| Ohta, Y | 1 |
| Oosaka, Y | 2 |
| Homma, Y | 1 |
| Nolan, L | 1 |
| Bateman, AC | 1 |
| Sharland, DM | 1 |
| Rees, CN | 1 |
| Iveson, TJ | 3 |
| Bateman, AR | 1 |
| Shen, ZT | 1 |
| Wu, XH | 1 |
| Shen, JS | 1 |
| Zhu, XX | 1 |
| Nandy, N | 1 |
| Dasanu, CA | 1 |
| Seetharamu, N | 1 |
| Melamed, J | 1 |
| Miller, G | 1 |
| Rotterdam, H | 1 |
| Gonda, T | 1 |
| Villanueva, G | 1 |
| Halmos, B | 1 |
| Kim, GJ | 1 |
| Koshy, M | 1 |
| Hanlon, AL | 1 |
| Horiba, MN | 1 |
| Edelman, MJ | 2 |
| Burrows, WM | 1 |
| Battafarano, RJ | 1 |
| Suntharalingam, M | 4 |
| Honing, J | 1 |
| Smit, JK | 2 |
| Muijs, CT | 2 |
| Burgerhof, JGM | 1 |
| de Groot, JW | 1 |
| Paardekooper, G | 2 |
| Muller, K | 2 |
| Woutersen, D | 2 |
| Legdeur, MJC | 1 |
| Fiets, WE | 1 |
| Slot, A | 1 |
| Beukema, JC | 3 |
| Plukker, JTM | 2 |
| Hospers, GAP | 2 |
| Cosson, VF | 1 |
| Ng, VW | 1 |
| Lehle, M | 1 |
| Lum, BL | 1 |
| Yusup, G | 2 |
| Mutallip, M | 1 |
| Komatsu-Akimoto, A | 2 |
| Akanuma, N | 2 |
| Isozaki, Y | 2 |
| Gourgou-Bourgade, S | 1 |
| Boige, V | 5 |
| Martel-Lafay, I | 1 |
| Michel, P | 7 |
| Llacer-Moscardo, C | 1 |
| Abdelghani, MB | 1 |
| Xu, J | 4 |
| Pan, H | 1 |
| Dai, G | 2 |
| Qin, S | 1 |
| Shu, Y | 1 |
| Liu, Y | 7 |
| Yu, S | 1 |
| Bu, L | 2 |
| Piao, Y | 1 |
| Yin, SY | 1 |
| Chen, TP | 1 |
| Yeh, CH | 1 |
| Xing, L | 1 |
| Liang, Y | 1 |
| Wu, P | 1 |
| Xu, D | 1 |
| Liu, F | 2 |
| Yu, X | 2 |
| Jiang, Z | 2 |
| Song, X | 2 |
| Zang, Q | 1 |
| Minegaki, T | 1 |
| Sakaeda, T | 10 |
| Kawasaki, Y | 2 |
| Owaki, T | 6 |
| Ishigami, S | 9 |
| Ludwig, DL | 1 |
| Novosyadlyy, R | 1 |
| Li, YY | 2 |
| Cheng, JC | 4 |
| Graber, MS | 1 |
| Tsai, CL | 2 |
| Castaneda, L | 1 |
| Chang, DT | 2 |
| Koong, AC | 2 |
| Hiyoshi, Y | 3 |
| Sugimachi, K | 1 |
| Uchiyama, H | 2 |
| Kawanaka, H | 1 |
| Ikeda, T | 3 |
| Iinuma, H | 1 |
| Fukushima, R | 1 |
| Inaba, T | 1 |
| Tamura, J | 1 |
| Ogawa, E | 1 |
| Horikawa, M | 1 |
| Ikeda, Y | 2 |
| Matsutani, N | 1 |
| Takeda, K | 5 |
| Tsunoda, T | 2 |
| Okinaga, K | 1 |
| Dorth, JA | 1 |
| Pura, JA | 1 |
| Palta, M | 1 |
| Willett, CG | 7 |
| D'Amico, TA | 4 |
| Czito, BG | 3 |
| Maheen Anwar, SS | 1 |
| Mubarak, F | 1 |
| Sajjad, Z | 1 |
| Azeemuddin, M | 1 |
| Uenosono, Y | 2 |
| Suh, YG | 1 |
| Koom, WS | 1 |
| Cha, J | 1 |
| Lee, JY | 1 |
| Kim, SK | 1 |
| Jia, X | 1 |
| Liu, B | 2 |
| Wan, X | 1 |
| Ida, S | 2 |
| Furutani, A | 2 |
| Sowa, Y | 1 |
| Freilich, J | 1 |
| Fulp, WJ | 1 |
| Yue, B | 1 |
| Honjo, S | 2 |
| Scott, AW | 1 |
| Stroehlein, J | 1 |
| Johnson, RL | 2 |
| Song, S | 2 |
| Hategan, M | 1 |
| Cook, N | 1 |
| Prewett, S | 1 |
| Hindmarsh, A | 1 |
| Qian, W | 1 |
| Gilligan, D | 2 |
| Boggs, DH | 1 |
| Tarabolous, C | 1 |
| Morris, CG | 1 |
| Hanna, A | 1 |
| Burrows, W | 1 |
| Horiba, N | 1 |
| Higuchi, K | 3 |
| Komori, S | 2 |
| Azuma, M | 1 |
| Ishido, K | 1 |
| Katada, N | 3 |
| Hayakawa, K | 2 |
| Sio, TT | 1 |
| Wilson, ZC | 1 |
| Stauder, MC | 1 |
| Bhatia, S | 1 |
| Martenson, JA | 2 |
| Quevedo, JF | 1 |
| Schomas, DA | 1 |
| Miller, RC | 1 |
| Huang, RW | 1 |
| Novotny, AR | 1 |
| Reim, D | 1 |
| Friess, HM | 1 |
| Schuhmacher, C | 3 |
| Blazeby, JM | 3 |
| Strong, S | 1 |
| Donovan, JL | 1 |
| Wilson, C | 1 |
| Hollingworth, W | 1 |
| Nicklin, J | 1 |
| Falk, SJ | 2 |
| Barham, CP | 2 |
| Hollowood, AD | 2 |
| Streets, CG | 2 |
| Titcomb, D | 1 |
| Krysztopik, R | 2 |
| Griffin, SM | 2 |
| Brookes, ST | 1 |
| Kubota, A | 2 |
| Furukawa, M | 2 |
| Kitani, Y | 1 |
| Nakayama, Y | 1 |
| Nonaka, T | 1 |
| Mizoguchi, N | 1 |
| Shiomi, M | 1 |
| Lyu, X | 1 |
| Feng, Q | 1 |
| Shao, K | 1 |
| Gao, S | 1 |
| He, J | 1 |
| Mornex, F | 2 |
| Maillard, E | 1 |
| Thomas, PA | 1 |
| Meunier, B | 6 |
| Pezet, D | 1 |
| Robb, WB | 3 |
| Le Brun-Ly, V | 1 |
| Bosset, JF | 4 |
| Mabrut, JY | 2 |
| Triboulet, JP | 7 |
| Seitz, JF | 7 |
| Fakhrian, K | 3 |
| Ordu, AD | 3 |
| Theisen, J | 3 |
| Omrčen, T | 1 |
| Molls, M | 4 |
| Nieder, C | 3 |
| Geinitz, H | 4 |
| Alcindor, T | 5 |
| Ades, S | 3 |
| Aloraini, A | 1 |
| van Huyse, M | 1 |
| Asselah, J | 2 |
| David, M | 2 |
| Frechette, D | 1 |
| Brisson, S | 1 |
| Thirlwell, M | 1 |
| Ferri, L | 2 |
| Taniki, T | 1 |
| Taira, K | 1 |
| Nakamatsu, K | 6 |
| Nishimura, Y | 9 |
| O'Callaghan, C | 1 |
| Fanning, LJ | 1 |
| Barry, OP | 1 |
| Nemoto, H | 3 |
| Tate, G | 2 |
| Umemoto, T | 1 |
| Matsubara, T | 2 |
| Mizukami, H | 1 |
| Saito, M | 4 |
| Kigawa, G | 1 |
| Matsumiya, A | 1 |
| Tanaka, J | 2 |
| Sawano, T | 1 |
| Kawasaki, H | 5 |
| Miyamoto, K | 5 |
| Ishizawa, Y | 1 |
| Nakai, M | 2 |
| Shen, JX | 1 |
| Li, QQ | 6 |
| He, LR | 3 |
| Kandioler, D | 1 |
| Schoppmann, SF | 1 |
| Zwrtek, R | 1 |
| Kappel, S | 1 |
| Wolf, B | 1 |
| Mittlböck, M | 1 |
| Kührer, I | 1 |
| Hejna, M | 2 |
| Pluschnig, U | 1 |
| Ba-Ssalamah, A | 1 |
| Wrba, F | 1 |
| Zacherl, J | 1 |
| Yao, X | 1 |
| Kortmansky, JS | 1 |
| Fischbach, NA | 1 |
| Stein, S | 1 |
| Deng, Y | 1 |
| Doddamane, I | 1 |
| Karimeddini, D | 1 |
| Lacy, J | 1 |
| Noronha, V | 1 |
| Joshi, A | 1 |
| Jandyal, S | 1 |
| Jambhekar, N | 1 |
| Prabhash, K | 1 |
| McNamara, MJ | 1 |
| Adelstein, DJ | 10 |
| Bodmann, JW | 1 |
| Greskovich, JF | 1 |
| Ives, DI | 4 |
| Mason, DP | 3 |
| Murthy, SC | 4 |
| Rice, TW | 11 |
| Saxton, JP | 5 |
| Sohal, D | 1 |
| Stephans, K | 1 |
| Rodriguez, CP | 4 |
| Videtic, GM | 5 |
| Rybicki, LA | 7 |
| Ma, W | 1 |
| Zhang, T | 3 |
| Pan, J | 2 |
| Shi, N | 2 |
| Fan, Q | 2 |
| Lu, SH | 1 |
| Lindner, K | 1 |
| Borchardt, C | 1 |
| Schöpp, M | 1 |
| Bürgers, A | 1 |
| Stock, C | 1 |
| Hussey, DJ | 6 |
| Haier, J | 4 |
| Hummel, R | 4 |
| Motschmann, M | 1 |
| Jütting, U | 1 |
| Luber, B | 2 |
| Becker, K | 8 |
| Ott, K | 7 |
| Siewert, JR | 10 |
| Walch, A | 2 |
| Ahlgren, J | 1 |
| Patel, N | 1 |
| Simmens, S | 1 |
| Akin, E | 1 |
| Bishop, C | 1 |
| Kirkel, D | 1 |
| Siegel, P | 1 |
| Schuck, S | 1 |
| Guebre-Xabiher, H | 1 |
| Siegel, R | 1 |
| Goff, LW | 1 |
| Thakkar, N | 1 |
| Du, L | 1 |
| Chan, E | 1 |
| Cardin, DB | 1 |
| McLeod, HL | 2 |
| Berlin, JD | 2 |
| Zehnbauer, B | 1 |
| Fournier, C | 1 |
| Picus, J | 1 |
| Lee, W | 1 |
| Ozdemir, N | 1 |
| Abali, H | 1 |
| Vural, M | 1 |
| Yalcin, S | 2 |
| Oksuzoglu, B | 1 |
| Civelek, B | 1 |
| Oguz, D | 1 |
| Bostanci, B | 1 |
| Yalcin, B | 1 |
| Zengin, N | 1 |
| Nishida, T | 6 |
| Tsujii, M | 1 |
| Tsutsui, S | 1 |
| Kato, M | 3 |
| Yamahsita, S | 1 |
| Kishino, T | 1 |
| Nakajima, T | 5 |
| Kushima, R | 2 |
| Nagino, M | 1 |
| Yan, H | 1 |
| Wang, S | 3 |
| Zhang, LY | 2 |
| Larsen, AC | 1 |
| Holländer, C | 1 |
| Duval, L | 1 |
| Schønnemann, K | 1 |
| Achiam, M | 1 |
| Pfeiffer, P | 3 |
| Yilmaz, MK | 1 |
| Thorlacius-Ussing, O | 1 |
| Bæksgaard, L | 1 |
| Ladekarl, M | 1 |
| Yue, D | 1 |
| Chen, X | 2 |
| Ping, Y | 1 |
| Gao, Q | 1 |
| Yang, L | 1 |
| Huang, L | 1 |
| Sie, C | 1 |
| Wang, T | 4 |
| Ansar, A | 1 |
| Michael, MZ | 3 |
| Van der Hoek, M | 2 |
| Kup, PG | 2 |
| Deymann, LF | 1 |
| Scherer, V | 2 |
| Combs, SE | 2 |
| Hagiwara, K | 2 |
| Kochi, M | 3 |
| Fujii, M | 3 |
| Song, K | 2 |
| Tamegai, H | 3 |
| Takayama, Y | 2 |
| Suda, H | 2 |
| Teshima, Y | 1 |
| Takayama, T | 6 |
| Cools-Lartigue, J | 1 |
| Jones, D | 1 |
| Spicer, J | 1 |
| Zourikian, T | 1 |
| Rousseau, M | 1 |
| Eckert, E | 1 |
| Vanhuyse, M | 1 |
| Ferri, LE | 3 |
| Tan, BH | 1 |
| Brammer, K | 1 |
| Randhawa, N | 1 |
| Welch, NT | 1 |
| James, EJ | 1 |
| Catton, JA | 1 |
| Cinar, P | 1 |
| Calkins, SM | 1 |
| Kelley, RK | 1 |
| Cha, RR | 1 |
| Jung, WT | 1 |
| Oh, HW | 1 |
| Kim, HJ | 2 |
| Ha, CY | 1 |
| Ko, GH | 1 |
| Kim, HW | 1 |
| Park, JJ | 1 |
| Youn, YH | 1 |
| Ieta, K | 3 |
| Sano, A | 3 |
| Inose, T | 3 |
| Fukuchi, M | 3 |
| Ojima, H | 4 |
| Derouet, MF | 1 |
| Darling, GE | 1 |
| Lund, M | 1 |
| Alexandersson von Döbeln, G | 2 |
| Winter, R | 1 |
| Kalman, S | 1 |
| Yu, W | 1 |
| Cai, XW | 1 |
| Zhu, ZF | 1 |
| Feng, W | 1 |
| Zhang, YJ | 1 |
| Yao, ZF | 1 |
| Fu, XL | 1 |
| Satomura, H | 2 |
| Domeki, Y | 2 |
| Takada, A | 1 |
| Zhang, WW | 1 |
| Zhu, YJ | 1 |
| Wang, QX | 1 |
| Wang, XH | 2 |
| Xiao, WW | 1 |
| Hu, YH | 5 |
| Minashi, K | 9 |
| Kataoka, K | 4 |
| Shibuya, Y | 1 |
| Li, MH | 1 |
| Shang, DP | 1 |
| Kong, L | 1 |
| Yu, JM | 3 |
| Saito, K | 5 |
| Riera Knorrenschild, J | 1 |
| Pohl, M | 1 |
| Bassermann, F | 2 |
| Helbig, U | 1 |
| Weißinger, F | 2 |
| Schnoy, E | 1 |
| Rüschoff, J | 1 |
| Eisenmenger, A | 1 |
| Karapanagiotou-Schenkel, I | 1 |
| Scheulen, ME | 1 |
| Rivera, F | 1 |
| Jassem, J | 2 |
| Vynnychenko, I | 2 |
| Prausová, J | 1 |
| Van Laethem, JL | 3 |
| Yamashita, M | 2 |
| Takenaka, HY | 1 |
| Kitagawa, M | 1 |
| Akasaka, H | 3 |
| Kimura, A | 1 |
| Sakuraba, S | 1 |
| Yamana, D | 1 |
| Okano, K | 1 |
| Ichinohe, D | 2 |
| Shimada, T | 1 |
| Katayanagi, S | 2 |
| Sumi, T | 2 |
| Shimazu, M | 1 |
| Kawachi, S | 2 |
| Zhao, LJ | 1 |
| Liu, NB | 1 |
| Zhang, WC | 1 |
| Pang, QS | 1 |
| Yuan, ZY | 1 |
| Francini, E | 2 |
| Roviello, F | 2 |
| Marrelli, D | 2 |
| Fiaschi, AI | 2 |
| Laera, L | 2 |
| Rossi, G | 1 |
| Bianco, V | 1 |
| Brozzetti, S | 1 |
| Soularue, É | 1 |
| Cohen, R | 1 |
| Tournigand, C | 3 |
| Hentic, O | 1 |
| de Gramont, A | 4 |
| André, T | 2 |
| Ji, YH | 1 |
| Yang, XY | 1 |
| Wu, JQ | 1 |
| Huo, XQ | 1 |
| Li, WW | 1 |
| Li, GJ | 1 |
| Mu, YL | 1 |
| Lu, P | 1 |
| Doi, Y | 1 |
| Okabe, T | 2 |
| Kenjo, M | 4 |
| Ericson, J | 1 |
| Kumagai, K | 2 |
| Wang, N | 2 |
| Bowen, JM | 1 |
| White, I | 1 |
| Smith, L | 1 |
| Tsykin, A | 1 |
| Kristaly, K | 1 |
| Thompson, SK | 2 |
| Tan, H | 1 |
| Game, PA | 1 |
| Irvine, T | 1 |
| Keefe, DM | 1 |
| Thoen, H | 1 |
| Ceelen, W | 1 |
| Boterberg, T | 2 |
| Van Daele, E | 1 |
| Pattyn, P | 2 |
| Treese, C | 1 |
| von Winterfeld, M | 1 |
| Breithaupt, K | 2 |
| Dogan, Y | 1 |
| Schmidt, SC | 1 |
| Daum, S | 2 |
| Yuda, S | 1 |
| Yang, JS | 1 |
| Qiu, MQ | 1 |
| Li, QL | 1 |
| Nishimura, S | 2 |
| Imamura, YU | 1 |
| Ohgaki, K | 2 |
| Ohga, S | 2 |
| Shen, Y | 1 |
| Guo, S | 2 |
| Johnson, E | 1 |
| Viste, A | 5 |
| Myrnäs, T | 1 |
| Szabo, E | 1 |
| Persson, S | 1 |
| Oyanagi, H | 1 |
| Banba, T | 1 |
| Hirashima, K | 2 |
| Minagawa, M | 1 |
| Koyama, Y | 1 |
| Taniguchi, H | 4 |
| Sakisaka, H | 1 |
| Kidane, B | 1 |
| Coughlin, S | 1 |
| Vogt, K | 1 |
| Malthaner, R | 1 |
| Zhao, Q | 1 |
| Qiao, X | 1 |
| Tan, B | 1 |
| Tian, Y | 1 |
| Xu, Q | 1 |
| Yang, P | 1 |
| Hou, PY | 1 |
| Teng, CJ | 1 |
| Chung, CS | 1 |
| Liu, CY | 1 |
| Chang, MH | 1 |
| Shueng, PW | 1 |
| Hsieh, CH | 1 |
| Mingol, F | 1 |
| Gallego, J | 1 |
| Orduña, A | 1 |
| Martinez-Blasco, A | 1 |
| Sola-Vera, J | 1 |
| Moya, P | 1 |
| Morcillo, MA | 1 |
| Ruiz, JA | 1 |
| Calpena, R | 1 |
| Lacueva, FJ | 1 |
| Springfeld, C | 1 |
| Wiecha, C | 1 |
| Kunzmann, R | 1 |
| Heger, U | 1 |
| Weichert, W | 2 |
| Stange, A | 2 |
| Blank, S | 1 |
| Jäger, D | 2 |
| Grenacher, L | 1 |
| Gronnier, C | 1 |
| Lebreton, G | 2 |
| Brigand, C | 1 |
| Bail, JP | 1 |
| Stiles, B | 1 |
| Altorki, N | 1 |
| Nishina, S | 1 |
| Sakiyama, T | 1 |
| Nonagase, Y | 1 |
| Van De Voorde, L | 1 |
| Janssen, L | 1 |
| Larue, R | 1 |
| Houben, R | 1 |
| Buijsen, J | 1 |
| Sosef, M | 1 |
| Vanneste, B | 1 |
| Schraepen, MC | 1 |
| Berbée, M | 1 |
| Lambin, P | 1 |
| Oze, I | 2 |
| Komori, A | 2 |
| Narita, Y | 2 |
| Masuishi, T | 2 |
| Andoh, M | 2 |
| Kawai, R | 1 |
| Uemura, N | 2 |
| Ishihara, M | 1 |
| Hayashi, K | 9 |
| Messager, M | 3 |
| Neofytou, K | 1 |
| Chaudry, MA | 1 |
| Yeh, CJ | 1 |
| Negoro, Y | 4 |
| Kawaguchi, G | 1 |
| Kobayashi, M | 3 |
| Ariga, T | 2 |
| Yamada, M | 1 |
| Nakai, K | 1 |
| Yamamichi, K | 1 |
| Komai, H | 1 |
| Yoshioka, K | 1 |
| Kon, M | 1 |
| Wu, YJ | 1 |
| Luo, LL | 3 |
| Ruffier-Loubière, A | 1 |
| Janoray, G | 1 |
| Chapet, S | 2 |
| de Calan, L | 2 |
| Dumont, P | 1 |
| Dorval, É | 3 |
| Orain, I | 1 |
| Calais, G | 3 |
| Miano, ST | 1 |
| Bellini, MA | 1 |
| Ohnuma, H | 1 |
| Hirakawa, M | 1 |
| Okagawa, Y | 1 |
| Osuga, T | 1 |
| Hayashi, T | 2 |
| Sato, T | 3 |
| Miyanishi, K | 2 |
| Kobune, M | 1 |
| Takimoto, R | 2 |
| Sagawa, T | 2 |
| Hori, M | 1 |
| Someya, M | 1 |
| Sakata, K | 1 |
| Kato, J | 4 |
| Tu, YK | 1 |
| O'Donovan, TR | 5 |
| Rajendran, S | 1 |
| O'Reilly, S | 2 |
| O'Sullivan, GC | 4 |
| McKenna, SL | 5 |
| Bronsert, P | 1 |
| Schäfer, M | 1 |
| Kulemann, B | 1 |
| Marjanovic, G | 1 |
| Sick, O | 1 |
| Hopt, UT | 1 |
| Zirlik, K | 1 |
| Makowiec, F | 1 |
| Shapiro, J | 1 |
| van Lanschot, JJB | 1 |
| Hulshof, MCCM | 1 |
| van Hagen, P | 1 |
| van Berge Henegouwen, MI | 1 |
| Wijnhoven, BPL | 1 |
| Nieuwenhuijzen, GAP | 1 |
| Bonenkamp, JJ | 1 |
| Cuesta, MA | 1 |
| Blaisse, RJB | 1 |
| Busch, ORC | 1 |
| Ten Kate, FJW | 1 |
| Creemers, GM | 1 |
| Punt, CJA | 1 |
| Verheul, HMW | 1 |
| Bilgen, EJS | 1 |
| van Dekken, H | 1 |
| van der Sangen, MJC | 1 |
| Rozema, T | 1 |
| Biermann, K | 1 |
| Piet, AHM | 1 |
| van Rij, CM | 1 |
| Reinders, JG | 1 |
| Tilanus, HW | 2 |
| Steyerberg, EW | 1 |
| van der Gaast, A | 4 |
| Yoshio, T | 1 |
| Kumekawa, Y | 3 |
| Suenaga, M | 1 |
| Matsusaka, S | 1 |
| Shinozaki, E | 1 |
| Morishige, K | 1 |
| Ishiyama, A | 1 |
| Hirasawa, T | 1 |
| Tsuchida, T | 1 |
| Fujisaki, J | 1 |
| Igarashi, M | 1 |
| Mizunuma, N | 2 |
| Imae, T | 1 |
| Piro, G | 1 |
| Giacopuzzi, S | 5 |
| Bencivenga, M | 1 |
| Carbone, C | 1 |
| Verlato, G | 3 |
| Frizziero, M | 1 |
| Zanotto, M | 1 |
| Mina, MM | 1 |
| Merz, V | 1 |
| Santoro, R | 1 |
| Zanoni, A | 4 |
| De Manzoni, G | 8 |
| Tortora, G | 1 |
| Melisi, D | 1 |
| Scott, A | 1 |
| Jin, J | 4 |
| Li, XD | 1 |
| Ban, X | 1 |
| Zeng, TT | 1 |
| Zhang, BZ | 1 |
| Xie, D | 4 |
| Etchebehere, E | 1 |
| Shiozaki, H | 9 |
| Planjery, V | 1 |
| Charalampakis, N | 1 |
| Hofstetter, W | 1 |
| Weston, BR | 1 |
| Maru, D | 2 |
| Macapinlac, HA | 1 |
| Tian, J | 2 |
| Shang, M | 1 |
| Shi, SB | 1 |
| Han, Y | 2 |
| Oya, H | 1 |
| Nishio, N | 1 |
| Hiramatsu, M | 2 |
| Kobayashi, D | 1 |
| Fujii, T | 7 |
| Sugimoto, H | 1 |
| Nomoto, S | 1 |
| Najafzadeh, N | 1 |
| Mazani, M | 1 |
| Abbasi, A | 1 |
| Farassati, F | 1 |
| Amani, M | 1 |
| Ochenduszko, S | 1 |
| Puskulluoglu, M | 1 |
| Konopka, K | 1 |
| Fijorek, K | 1 |
| Urbanczyk, K | 1 |
| Budzynski, A | 1 |
| Matlok, M | 1 |
| Lazar, A | 1 |
| Sinczak-Kuta, A | 1 |
| Pedziwiatr, M | 1 |
| Krzemieniecki, K | 1 |
| Kumaki, N | 1 |
| Makuuchi, H | 3 |
| Chino, O | 1 |
| Yasuda, S | 2 |
| Tamayama, T | 1 |
| Sakai, I | 1 |
| Okada, N | 1 |
| Hayashi, R | 2 |
| Otomo, H | 1 |
| Jia, XJ | 1 |
| Huang, JZ | 1 |
| Arimitsu, H | 1 |
| Yanagibashi, H | 1 |
| Chibana, T | 1 |
| Ishige, F | 1 |
| Kaburagi, T | 1 |
| Harada, H | 1 |
| Aga, K | 1 |
| Watanabe, H | 5 |
| Seki, H | 1 |
| Yasui, N | 1 |
| Sakata, M | 1 |
| Matsumoto, H | 2 |
| Shimada, A | 1 |
| Lu, SL | 1 |
| Wu, JK | 1 |
| Lee, NP | 3 |
| Tam, PY | 1 |
| Yuen, HF | 1 |
| Song, B | 2 |
| Cheng, C | 2 |
| Yang, B | 2 |
| Wang, F | 2 |
| Kong, P | 1 |
| Jia, Z | 1 |
| Bi, Y | 1 |
| Shi, R | 1 |
| Yang, J | 2 |
| Yan, T | 1 |
| Xu, E | 1 |
| Qian, Y | 1 |
| Xi, Y | 1 |
| Li, G | 1 |
| Jia, J | 2 |
| Guo, J | 2 |
| Zhan, Q | 1 |
| Vargas, A | 1 |
| Pagés, M | 1 |
| Buxó, E | 1 |
| Choi, MY | 1 |
| Lam, HY | 1 |
| Tung, LN | 1 |
| Tzang, FC | 1 |
| Han, H | 1 |
| Lam, IP | 1 |
| Kwok, SY | 1 |
| Lau, SH | 1 |
| Man, C | 1 |
| Tong, DK | 1 |
| Wong, BL | 1 |
| Kawamori, H | 1 |
| Ohno, M | 1 |
| Kusunoki, N | 1 |
| Yamazaki, Y | 2 |
| Takase, S | 1 |
| Gotoh, K | 1 |
| Noura, S | 3 |
| Asahara, T | 1 |
| Nomoto, K | 1 |
| Ishikawa, O | 6 |
| Sakon, M | 2 |
| Izumi, D | 1 |
| Shiraishi, S | 1 |
| Kosumi, K | 1 |
| Tokunaga, R | 1 |
| Taki, K | 1 |
| Higashi, T | 1 |
| Miyata, T | 2 |
| Beumer, JH | 1 |
| Negrea, L | 1 |
| Holleran, JL | 1 |
| Strychor, S | 1 |
| Meropol, NJ | 2 |
| Ojima, T | 3 |
| Nakamori, M | 4 |
| Nakamura, M | 7 |
| Hayata, K | 3 |
| Matsumura, S | 1 |
| Iwahashi, M | 3 |
| Chang, S | 1 |
| Koo, PJ | 1 |
| Kwak, JJ | 1 |
| Kim, SJ | 1 |
| Haga, A | 1 |
| Kiritoshi, T | 1 |
| Lind, P | 1 |
| Kotecki, N | 1 |
| Hiret, S | 1 |
| Tresch, E | 2 |
| Ben Abdelghani, M | 2 |
| Ghiringelli, F | 1 |
| Peugniez, C | 2 |
| El Hajbi, F | 2 |
| Clisant, S | 2 |
| Kramar, A | 3 |
| Imanishi, T | 1 |
| Kanemitsu, K | 1 |
| Megumi, K | 1 |
| Urata, M | 1 |
| Kawagoe, K | 1 |
| Satake, S | 1 |
| Baba, K | 1 |
| Yoshikawa, M | 1 |
| Kameda, C | 1 |
| Koga, C | 1 |
| Hitora, T | 1 |
| Ikenaga, M | 1 |
| Shimizu, J | 1 |
| Miwa, H | 1 |
| Hasegawa, J | 1 |
| Lledo, G | 1 |
| Artru, P | 4 |
| Blondin, V | 1 |
| Dupuis, O | 1 |
| Abdiche, MS | 1 |
| Jovenin, N | 1 |
| Pozet, A | 1 |
| Bonnetain, F | 3 |
| Attia, M | 1 |
| Kitadani, J | 1 |
| Tabata, H | 1 |
| Takeuchi, A | 1 |
| Ng, HY | 1 |
| Ko, JM | 1 |
| Yu, VZ | 1 |
| Ip, JC | 1 |
| Cal, S | 1 |
| Tebbutt, NC | 6 |
| Price, TJ | 1 |
| Ferraro, DA | 1 |
| Wong, N | 1 |
| Veillard, AS | 1 |
| Hall, M | 2 |
| Sjoquist, KM | 1 |
| Pavlakis, N | 1 |
| Strickland, A | 2 |
| Varma, SC | 1 |
| Cooray, P | 1 |
| Young, R | 1 |
| Underhill, C | 2 |
| Shannon, JA | 1 |
| Ganju, V | 2 |
| Moriya, H | 2 |
| Hosoda, K | 2 |
| Mieno, H | 2 |
| Hoshi, K | 1 |
| Nyhan, MJ | 3 |
| Boersma, AW | 1 |
| Wiemer, EA | 2 |
| Yamada, A | 2 |
| Tanahashi, T | 1 |
| Honjo, H | 1 |
| Hara, K | 1 |
| Ozawa, D | 1 |
| Koca, D | 1 |
| Ozdemir, O | 1 |
| Demir, D | 1 |
| Akdeniz, H | 1 |
| Kurt, M | 1 |
| Takebayashi, K | 3 |
| Kawamorita, K | 1 |
| Niihara, M | 1 |
| Ishida, Y | 1 |
| Ezoe, Y | 2 |
| Aoyama, I | 1 |
| Miyamoto, S | 3 |
| Hiraoka, M | 4 |
| Hoshino, S | 3 |
| Boland, PM | 1 |
| Meyer, JE | 1 |
| Berger, AC | 1 |
| Cohen, SJ | 2 |
| Neuman, T | 1 |
| Cooper, HS | 1 |
| Olszanski, AJ | 1 |
| Davey, M | 1 |
| Cheng, JD | 2 |
| Lebenthal, A | 1 |
| Burtness, BA | 3 |
| Scott, WJ | 1 |
| Astsaturov, IA | 1 |
| Kiyozaki, H | 1 |
| Obitsu, T | 1 |
| Imoto, H | 1 |
| Takata, O | 1 |
| Rikiyama, T | 1 |
| Zhai, T | 1 |
| Chang, D | 1 |
| Zhou, M | 1 |
| Miyawaki, Y | 2 |
| Tryakin, A | 1 |
| Pokataev, I | 1 |
| Kononets, P | 1 |
| Fedyanin, M | 1 |
| Bokhyan, V | 1 |
| Malikhova, O | 1 |
| Minin, K | 1 |
| Shogenov, M | 1 |
| Stilidi, I | 1 |
| Vybarava, A | 1 |
| Davydov, M | 1 |
| Tjulandin, S | 3 |
| Liang, P | 1 |
| Cheng, Z | 1 |
| Han, Z | 1 |
| Tan, S | 2 |
| Bai, L | 2 |
| Sakuyama, T | 1 |
| Omura, N | 1 |
| Aiba, K | 3 |
| Chung, V | 1 |
| Frankel, P | 1 |
| Lim, D | 1 |
| Yeon, C | 1 |
| Leong, L | 1 |
| Chao, J | 1 |
| Ruel, N | 1 |
| Luevanos, E | 1 |
| Koehler, S | 1 |
| Chung, S | 1 |
| Lau, SC | 1 |
| Fakih, MG | 1 |
| Takiguchi, Y | 1 |
| Ohtsu, A | 23 |
| Kathiravetpillai, N | 1 |
| Koëter, M | 1 |
| van der Sangen, MJ | 2 |
| Creemers, GJ | 2 |
| Luyer, MD | 1 |
| Rutten, HJ | 2 |
| Nieuwenhuijzen, GA | 2 |
| Sinclair, R | 1 |
| Navidi, M | 1 |
| Sumpter, K | 3 |
| Guo, X | 2 |
| Satake, H | 2 |
| Mochizuki, S | 1 |
| Kiyota, N | 1 |
| Yamazaki, T | 1 |
| Paumier, A | 2 |
| Glehen, O | 1 |
| Vasseur, F | 1 |
| Lacornerie, T | 1 |
| Saboor-Maleki, S | 1 |
| Rassouli, FB | 1 |
| Matin, MM | 1 |
| Iranshahi, M | 1 |
| Al-Fakeeh, A | 1 |
| Mulla, N | 1 |
| Doerksen, T | 1 |
| Al-Ruzug, I | 1 |
| Santos, F | 1 |
| Fassan, M | 1 |
| Lampis, A | 1 |
| Hahne, JC | 1 |
| Rugge, M | 2 |
| Nankivell, M | 1 |
| Langley, R | 1 |
| Ghidini, M | 1 |
| Braconi, C | 1 |
| Valeri, N | 1 |
| Fan, L | 1 |
| Kang, Q | 1 |
| Zeng, Y | 1 |
| Wu, H | 3 |
| Ye, X | 1 |
| Douglas, K | 1 |
| Villaflor, VM | 1 |
| Mayer, RJ | 1 |
| Venook, A | 1 |
| Benson, AB | 2 |
| Goldberg, RM | 1 |
| Cho, JY | 1 |
| Tan, IB | 1 |
| Yen, CJ | 1 |
| Kang, A | 1 |
| Shames, DS | 1 |
| Paget-Bailly, S | 1 |
| Nguyen, T | 1 |
| Mathieu, P | 1 |
| Lamfichekh, N | 1 |
| Fein, F | 1 |
| Fratté, S | 1 |
| Cléau, D | 1 |
| Lakkis, Z | 1 |
| Jary, M | 1 |
| Sakek, N | 1 |
| Jacquin, M | 1 |
| Foubert, A | 1 |
| Fiteni, F | 1 |
| Hu, G | 1 |
| Tang, N | 1 |
| Han, X | 2 |
| Motton, M | 1 |
| Casella, F | 2 |
| Weindelmayer, J | 2 |
| Ambrosi, E | 1 |
| Di Leo, A | 1 |
| Vassiliadis, A | 1 |
| Ricci, F | 1 |
| Herbst, A | 1 |
| Kalinski, T | 1 |
| Qin, J | 1 |
| Benedix, F | 1 |
| Franke, S | 1 |
| Wartman, T | 1 |
| Halangk, W | 1 |
| Kolligs, FT | 1 |
| Lee, J | 3 |
| Lin, JB | 1 |
| Sun, FJ | 1 |
| Lu, KW | 1 |
| Lee, CH | 1 |
| Chen, YJ | 2 |
| Huang, WC | 1 |
| Liu, HC | 2 |
| Wu, MH | 1 |
| Due, SL | 1 |
| Bastian, I | 1 |
| Ding, GQ | 1 |
| Sukocheva, OA | 1 |
| Astill, DS | 1 |
| Vat, L | 1 |
| Kawaguchi, T | 1 |
| Takeshita, H | 1 |
| Miyamae, M | 1 |
| Ohashi, T | 1 |
| Okajima, W | 1 |
| Imamura, T | 1 |
| Kiuchi, J | 1 |
| Haj Mohammad, N | 1 |
| van Valkenhoef, G | 1 |
| Mali, RMA | 1 |
| Anderegg, MC | 1 |
| Gepfner-Tuma, I | 1 |
| Maderer, A | 1 |
| Ruessel, J | 1 |
| Wilke, H | 8 |
| Rafiyan, MR | 1 |
| Kullmann, F | 1 |
| von Weikersthal, LF | 1 |
| Siveke, JT | 1 |
| Weusmann, J | 1 |
| Kanzler, S | 2 |
| Schimanski, CC | 1 |
| Otte, M | 1 |
| Schollenberger, L | 1 |
| Koenig, J | 1 |
| Galle, PR | 2 |
| Huang, T | 2 |
| Mary, F | 1 |
| Coriat, R | 1 |
| Boubaya, M | 1 |
| Benallaoua, M | 1 |
| Afchain, P | 2 |
| Locher, C | 1 |
| Baumgaertner, I | 1 |
| Lecaille, C | 1 |
| des Guetz, G | 1 |
| Kurashige, J | 2 |
| Jin, YY | 1 |
| Chen, QJ | 1 |
| Xu, K | 1 |
| Ren, HT | 1 |
| Bao, X | 1 |
| Ma, YN | 1 |
| Wei, Y | 1 |
| Ma, HB | 1 |
| Häussler, U | 1 |
| Bitzer, M | 1 |
| Bösmüller, H | 1 |
| Clasen, S | 1 |
| Götz, M | 1 |
| Malek, NP | 1 |
| Plentz, RR | 1 |
| Gemici, C | 1 |
| Yaprak, G | 1 |
| Batirel, HF | 1 |
| Ilhan, M | 1 |
| Mayadagli, A | 1 |
| Borro, M | 1 |
| Botticelli, A | 1 |
| Mazzuca, F | 1 |
| Onesti, EC | 1 |
| Gentile, G | 1 |
| Romiti, A | 1 |
| Cerbelli, B | 1 |
| Mazzotti, E | 1 |
| Marchetti, L | 1 |
| Lionetto, L | 1 |
| Simmaco, M | 1 |
| Marchetti, P | 1 |
| Yoon, HH | 2 |
| Braiteh, FS | 1 |
| Firdaus, I | 2 |
| Philip, PA | 2 |
| Cohn, AL | 1 |
| Lewis, N | 1 |
| Anderson, DM | 1 |
| Arrowsmith, E | 1 |
| Schwartz, JD | 1 |
| Gao, L | 1 |
| Hsu, Y | 1 |
| Xu, Y | 2 |
| Alberts, SR | 4 |
| Wainberg, ZA | 2 |
| Van Der Kraak, L | 1 |
| Goel, G | 2 |
| Ramanan, K | 1 |
| Kaltenmeier, C | 1 |
| Normolle, DP | 1 |
| Freeman, GJ | 1 |
| Tang, D | 1 |
| Nason, KS | 1 |
| Davison, JM | 1 |
| Luketich, JD | 3 |
| Dhupar, R | 1 |
| Lotze, MT | 1 |
| Li, CY | 1 |
| Chu, PY | 1 |
| Chen, PM | 1 |
| Lin, MW | 1 |
| Kuo, SW | 2 |
| Lu, YX | 1 |
| Chen, DL | 1 |
| Wang, DS | 1 |
| Chen, LZ | 1 |
| Mo, HY | 1 |
| Sheng, H | 1 |
| Wu, QN | 1 |
| Yu, HE | 1 |
| Yun, JP | 1 |
| Zeng, ZL | 1 |
| Ju, HQ | 1 |
| Xu, RH | 2 |
| Asami, C | 1 |
| Lim, SH | 1 |
| Park, SH | 1 |
| Kim, HK | 1 |
| Choi, YS | 1 |
| Ahn, MJ | 1 |
| Park, K | 4 |
| Shigaki, H | 1 |
| DeWitt, JM | 1 |
| Murthy, SK | 1 |
| Ardhanari, R | 1 |
| DuVall, GA | 1 |
| Wallner, G | 1 |
| Litka, P | 1 |
| Daugherty, C | 1 |
| Fowers, K | 1 |
| Nagy, T | 1 |
| Rubovszky, G | 1 |
| Su, J | 1 |
| Zhu, S | 1 |
| Song, C | 1 |
| Nishikage, T | 1 |
| Hall, PS | 1 |
| Lord, SR | 1 |
| Collinson, M | 1 |
| Marshall, H | 1 |
| Jones, M | 1 |
| Lowe, C | 1 |
| Howard, H | 1 |
| Swinson, D | 1 |
| Velikova, G | 1 |
| Anthoney, A | 1 |
| Dent, J | 1 |
| Cheeseman, S | 1 |
| Last, K | 1 |
| Seymour, MT | 2 |
| Lu, N | 1 |
| Pan, Y | 1 |
| Kawai, T | 1 |
| Matsuno, Y | 1 |
| Osakabe, H | 1 |
| Shigoka, M | 1 |
| Fujisaki, S | 1 |
| Takashina, M | 1 |
| Tomita, R | 1 |
| Iida, M | 1 |
| Tokumitsu, Y | 1 |
| Tomochika, S | 1 |
| Tokuhisa, Y | 1 |
| Sakamoto, K | 2 |
| Suzuki, N | 3 |
| Kaida, S | 1 |
| Murata, S | 1 |
| Ohtake, R | 1 |
| Ueki, T | 1 |
| Miyake, T | 1 |
| Iida, H | 1 |
| Akabori, H | 1 |
| Sonoda, H | 1 |
| Mori, T | 3 |
| Shimizu, T | 3 |
| Naka, S | 1 |
| Tani, M | 1 |
| Noro, H | 1 |
| Hirao, T | 2 |
| Takaichi, S | 1 |
| Son, C | 1 |
| Iwamoto, K | 1 |
| Kono, E | 1 |
| Yasumasa, K | 1 |
| Mizuno, H | 1 |
| Morimoto, Y | 2 |
| Hatanaka, N | 2 |
| Hasebe, T | 3 |
| Yakoshi, Y | 1 |
| Katsumi, C | 1 |
| Bamba, T | 1 |
| Nakagawa, S | 3 |
| Aizawa, M | 1 |
| Matsuki, A | 2 |
| Yabusaki, H | 3 |
| Homma, K | 1 |
| Fernandez, E | 1 |
| Cacheux, W | 1 |
| Frossard, JL | 1 |
| Koessler, T | 1 |
| Abou, M | 1 |
| Moniez, M | 1 |
| Huber, O | 1 |
| Puppa, G | 1 |
| Roth, A | 2 |
| Falvey, CM | 1 |
| El-Mashed, S | 1 |
| Zhu, ZQ | 1 |
| Zhu, ZA | 1 |
| Cai, HX | 1 |
| Saunders, JH | 1 |
| Bowman, CR | 1 |
| Pang, V | 1 |
| Dorrington, MS | 1 |
| Mumtaz, E | 1 |
| Soomro, I | 1 |
| Kaye, P | 2 |
| McDowell, LJ | 1 |
| Huang, SH | 1 |
| Che, J | 1 |
| Wong, RKS | 1 |
| Cummings, B | 2 |
| Waldron, J | 1 |
| Bayley, A | 1 |
| Hansen, A | 1 |
| Witterick, I | 1 |
| Voncken, FE | 1 |
| Jansen, EP | 2 |
| Sasako, M | 1 |
| Kuga, Y | 1 |
| Kitamura, S | 1 |
| Mouri, T | 1 |
| Miwata, T | 1 |
| Sakimoto, H | 1 |
| Vallböhmer, D | 7 |
| Kuhn, E | 1 |
| Warnecke-Eberz, U | 6 |
| Brabender, J | 8 |
| Hoffmann, AC | 1 |
| Metzger, R | 10 |
| Baldus, SE | 8 |
| Drebber, U | 4 |
| Hoelscher, AH | 6 |
| Schneider, PM | 9 |
| Dank, M | 1 |
| Zaluski, J | 2 |
| Barone, C | 2 |
| Valvere, V | 2 |
| Peschel, C | 9 |
| Wenczl, M | 1 |
| Goker, E | 1 |
| Cisar, L | 1 |
| Wang, K | 1 |
| Bugat, R | 2 |
| Tian, F | 5 |
| Song, M | 1 |
| Xu, PR | 1 |
| Liu, HT | 1 |
| Xue, LX | 1 |
| Winter, K | 2 |
| Bradley, J | 1 |
| Fromm, M | 1 |
| Hornback, D | 1 |
| Ota, M | 2 |
| Narumiya, K | 2 |
| Ohki, T | 1 |
| Mitsuhashi, N | 3 |
| Maruyama, K | 7 |
| Usami, S | 1 |
| Kitamura, M | 3 |
| Saito, R | 2 |
| Higuchi, I | 2 |
| Tatsumi, M | 1 |
| Fukunaga, H | 1 |
| Hatazawa, J | 1 |
| Monden, M | 13 |
| Javeri, H | 1 |
| Arora, R | 1 |
| McAleer, MF | 1 |
| Izzo, JG | 3 |
| Hiroe, S | 1 |
| Okumura, K | 3 |
| Chayahara, N | 4 |
| Hofheinz, R | 5 |
| Rethwisch, V | 2 |
| Probst, S | 2 |
| Stoehlmacher, J | 2 |
| Clemens, MR | 1 |
| Mahlberg, R | 1 |
| Fritz, M | 1 |
| Seipelt, G | 2 |
| Sievert, M | 1 |
| Atmaca, A | 3 |
| Jäger, E | 4 |
| Liu, C | 1 |
| Hang, X | 1 |
| Zhong, B | 1 |
| Mohri, Y | 3 |
| Yokoe, T | 2 |
| Koike, Y | 1 |
| Miki, C | 2 |
| Tonouchi, H | 2 |
| Kusunoki, M | 3 |
| Bazarbashi, S | 2 |
| Abdelsalam, M | 1 |
| Amin, T | 1 |
| El-Bassiouni, M | 1 |
| Soudy, H | 1 |
| Elweshi, A | 1 |
| Alhusseiny, H | 1 |
| Rehman, K | 1 |
| Memon, M | 2 |
| Ajarim, D | 2 |
| Ehara, K | 2 |
| Tsutsumi, K | 1 |
| Kinoshita, Y | 2 |
| Button, MR | 1 |
| Morgan, CA | 1 |
| Croydon, ES | 1 |
| Roberts, SA | 4 |
| Crosby, TD | 5 |
| Hattori, S | 1 |
| Yoshida, S | 15 |
| Brücher, B | 1 |
| Zimmermann, F | 2 |
| Riera, J | 1 |
| Roethling, N | 2 |
| Innocente, R | 2 |
| Cavina, R | 1 |
| Pigozzo, J | 2 |
| Del Bianco, P | 2 |
| Fumagalli, U | 1 |
| Santoro, A | 1 |
| Bollschweiler, E | 10 |
| Baldus, S | 1 |
| Kocher, M | 2 |
| Hölscher, AH | 7 |
| Fujita, Y | 1 |
| Kawai, M | 1 |
| Sumiyoshi, K | 1 |
| Nishimura, H | 1 |
| Tanigawa, N | 1 |
| Arai, Y | 1 |
| Oyama, T | 3 |
| Viret, F | 1 |
| Ychou, M | 5 |
| Giovannini, M | 3 |
| Yataghene, Y | 2 |
| Burmeister, BH | 9 |
| D'Arcy, N | 1 |
| Burmeister, EA | 3 |
| Cox, S | 1 |
| Thomson, DB | 4 |
| Harvey, JA | 4 |
| Gao, XS | 2 |
| Qiao, XY | 2 |
| Chen, K | 2 |
| Wang, YD | 1 |
| Zhou, ZG | 2 |
| Chen, JX | 1 |
| Tang, Q | 1 |
| Zhu, HN | 1 |
| Zheng, YD | 1 |
| Koyota, S | 1 |
| Koizumi, Y | 1 |
| Takasawa, S | 1 |
| Itaya-Hironaka, A | 1 |
| Sakuramoto-Tsuchida, S | 1 |
| Idelevich, E | 2 |
| Buyevich, V | 1 |
| Machlenkin, S | 1 |
| Ziv-Sokolovsky, N | 1 |
| Dinerman, M | 2 |
| Brenner, B | 2 |
| Kashtan, H | 2 |
| Fareed, KR | 2 |
| Soomro, IN | 2 |
| Ilyas, M | 2 |
| Martin, S | 1 |
| Kagami, Y | 2 |
| Nishimura, T | 2 |
| Tokunou, K | 2 |
| Wolff, K | 2 |
| Wein, A | 3 |
| Reulbach, U | 2 |
| Männlein, G | 3 |
| Brückl, V | 1 |
| Meier, C | 1 |
| Ostermeier, N | 2 |
| Schwab, SA | 1 |
| Horbach, T | 1 |
| Hohenberger, W | 2 |
| Hahn, EG | 3 |
| Boxberger, F | 3 |
| Gennatas, C | 1 |
| Michalaki, V | 1 |
| Gennatas, S | 1 |
| Norman, AR | 11 |
| Oates, J | 14 |
| Hawkins, R | 2 |
| Nicolson, M | 11 |
| Harper, P | 5 |
| Seymour, M | 4 |
| Hickish, T | 7 |
| Mitsumori, M | 2 |
| Koike, R | 5 |
| Kawamura, M | 2 |
| Fujiwara, K | 1 |
| Sakurai, H | 1 |
| Takachi, K | 4 |
| Kishi, K | 6 |
| Miyashiro, I | 4 |
| Ohigashi, H | 5 |
| Sasaki, Y | 5 |
| Imaoka, S | 3 |
| Zhang, GQ | 2 |
| Han, F | 1 |
| Pang, ZL | 1 |
| SiKanDaer, AB | 1 |
| Wang, HJ | 3 |
| Makino, H | 4 |
| Ono, HA | 1 |
| Akiyama, H | 1 |
| Saltz, LB | 1 |
| Maki, RG | 1 |
| Osawa, S | 2 |
| Iwaizumi, M | 2 |
| Hamaya, Y | 2 |
| Takagaki, K | 2 |
| Kodaira, C | 2 |
| Muramatsu, A | 1 |
| Sugimoto, K | 2 |
| Futami, H | 1 |
| Furuta, T | 2 |
| Ikuma, M | 2 |
| Arbab, D | 1 |
| Huan, X | 1 |
| Grimminger, P | 2 |
| Ling, F | 1 |
| Neiss, S | 2 |
| Qin, TJ | 1 |
| An, GL | 1 |
| Zhao, XH | 1 |
| Li, XH | 1 |
| Lian, JW | 1 |
| Pan, BR | 1 |
| Gu, SZ | 1 |
| Javle, MM | 2 |
| Yang, G | 1 |
| Nwogu, CE | 1 |
| Wilding, GE | 1 |
| O'Malley, L | 1 |
| Vinjamaram, S | 1 |
| Schiff, MD | 1 |
| Nava, HR | 1 |
| LeVea, C | 1 |
| Clark, KR | 1 |
| Prey, JD | 1 |
| Smith, PF | 1 |
| Pendyala, L | 4 |
| Benson, M | 2 |
| Lüpfert, C | 2 |
| Kurek, R | 2 |
| Baselga, J | 1 |
| Hill, A | 4 |
| Jamieson, GG | 8 |
| Wu, TC | 1 |
| Zhu, GJ | 1 |
| Drew, PA | 1 |
| Kim, MK | 1 |
| Cho, KJ | 4 |
| Kim, YH | 3 |
| Song, HY | 7 |
| Shin, JH | 3 |
| Jung, HY | 6 |
| Lee, GH | 4 |
| Choi, KD | 3 |
| Song, HJ | 2 |
| Ryu, JS | 2 |
| Saha, AK | 1 |
| Sutton, C | 1 |
| Rotimi, O | 1 |
| Dexter, S | 1 |
| Sue-Ling, H | 1 |
| Sarela, AI | 1 |
| Lee, SJ | 1 |
| Ahn, BM | 1 |
| Kim, JG | 1 |
| Sohn, SK | 1 |
| Chae, YS | 1 |
| Moon, JH | 1 |
| Lee, EB | 1 |
| Kim, JC | 1 |
| Park, IK | 1 |
| Jeon, SW | 1 |
| Tipples, K | 1 |
| Kolluri, RB | 1 |
| Raouf, S | 1 |
| Hyodo, I | 1 |
| Moriwaki, T | 1 |
| Nasu, J | 1 |
| Matsuura, B | 1 |
| Hiasa, Y | 1 |
| Onji, M | 1 |
| Morota, M | 1 |
| Gomi, K | 1 |
| Kozuka, T | 1 |
| Matsuura, M | 1 |
| Oguchi, M | 2 |
| Ito, H | 6 |
| Yamashita, T | 1 |
| Kasuya, G | 1 |
| Tamaki, W | 2 |
| Toita, T | 1 |
| Kakinohana, Y | 1 |
| Murayama, S | 2 |
| Ströbel, P | 1 |
| Dinter, D | 1 |
| Lukan, N | 1 |
| Hochhaus, A | 3 |
| Fujisawa, J | 1 |
| Matsukawa, H | 1 |
| Rino, Y | 1 |
| Masuda, M | 2 |
| Iishi, H | 1 |
| Sugimoto, N | 1 |
| Higashino, K | 1 |
| Uedo, N | 1 |
| Tatsuta, M | 1 |
| Imai, A | 1 |
| Nishiyama, K | 2 |
| Sasamoto, R | 3 |
| Kanda, T | 3 |
| Hatakeyama, K | 2 |
| Daniel, F | 2 |
| Nemoto, K | 8 |
| Ishioka, C | 4 |
| Onishi, H | 1 |
| Kazumoto, T | 1 |
| Makino, M | 1 |
| Yonekura, R | 1 |
| Suzuki, G | 3 |
| Hayabuchi, N | 3 |
| Tamamura, H | 1 |
| Onimaru, R | 1 |
| Tamamoto, T | 2 |
| Miyoshi, T | 5 |
| Yamai, H | 5 |
| Yuasa, Y | 3 |
| Otake, K | 1 |
| Toiyama, Y | 2 |
| Okines, A | 1 |
| Allum, W | 1 |
| Thompson, J | 1 |
| Brown, G | 2 |
| Riddell, A | 1 |
| Stavridi, F | 1 |
| Ashley, S | 4 |
| Yoshioka, A | 1 |
| Nushijima, Y | 1 |
| Mano, M | 3 |
| Matsutani, T | 6 |
| Sasajima, K | 10 |
| Maruyama, H | 8 |
| Miyamoto, M | 3 |
| Yokoyama, T | 5 |
| Sugiura, A | 1 |
| Matsushita, A | 5 |
| Yanagi, K | 2 |
| Matsuda, A | 2 |
| Arai, H | 3 |
| Nishi, Y | 1 |
| Wakabayashi, H | 3 |
| Tajiri, T | 4 |
| Kaji, S | 1 |
| Harada, N | 1 |
| Tanaka, S | 1 |
| Hanyu, F | 3 |
| Sawada, N | 1 |
| Kenzaki, K | 1 |
| Ohnishi, Y | 1 |
| Xie, L | 1 |
| Wei, L | 2 |
| Lv, L | 1 |
| Okines, AFC | 1 |
| McCloud, P | 1 |
| Zemanova, M | 1 |
| Petruzelka, L | 1 |
| Pazdro, A | 1 |
| Kralova, D | 1 |
| Smejkal, M | 1 |
| Pazdrova, G | 1 |
| Honova, H | 1 |
| Valentini, V | 1 |
| Massaccesi, M | 1 |
| Balducci, M | 1 |
| Mantini, G | 1 |
| Micciché, F | 1 |
| Mattiucci, GC | 1 |
| Dinapoli, N | 1 |
| Meduri, B | 1 |
| D'Agostino, GR | 1 |
| Salvi, G | 1 |
| Nardone, L | 1 |
| Porschen, R | 1 |
| Grabowski, P | 1 |
| Greten, T | 1 |
| Müller, L | 1 |
| Röthling, N | 1 |
| Sato, A | 4 |
| Togo, A | 1 |
| Tanaka, O | 4 |
| Yamana, H | 12 |
| Li, BK | 1 |
| Rao, HL | 1 |
| Deng, HX | 1 |
| Zeng, YX | 2 |
| Zhang, DK | 1 |
| Su, XD | 1 |
| Lin, P | 1 |
| Long, H | 1 |
| Zhang, LJ | 1 |
| Ma, GW | 1 |
| Rong, TH | 3 |
| Takeda, M | 2 |
| Wakui, R | 1 |
| Hoffmann, A | 1 |
| Schulte, C | 1 |
| Kersting, S | 1 |
| Konopke, R | 1 |
| Dittert, D | 1 |
| Distler, M | 1 |
| Rückert, F | 1 |
| Gastmeier, J | 1 |
| Baretton, GB | 1 |
| Saeger, HD | 1 |
| Hurmuzlu, M | 4 |
| Monge, OR | 2 |
| Smaaland, R | 3 |
| Dähn, D | 1 |
| Martell, J | 1 |
| Vorwerk, H | 1 |
| Hess, CF | 1 |
| Becker, H | 1 |
| Jung, K | 1 |
| Hilgers, R | 1 |
| Wolff, HA | 1 |
| Hermann, RM | 1 |
| Christiansen, H | 1 |
| Fukuhara, K | 3 |
| Omura, T | 1 |
| Katsuragi, K | 1 |
| Li, BS | 1 |
| Wang, ZT | 1 |
| Li, HS | 1 |
| Sun, HF | 1 |
| Zhang, ZC | 1 |
| Lin, HQ | 1 |
| Wei, YM | 1 |
| Gong, HY | 1 |
| Huang, W | 2 |
| Yi, Y | 2 |
| Wang, LY | 1 |
| Ariga, H | 3 |
| Yoshioka, T | 5 |
| Ogawa, Y | 3 |
| Miyata, G | 3 |
| Onodera, K | 3 |
| Kato, S | 5 |
| Satomi, S | 1 |
| Raab, R | 1 |
| Sparano, JA | 1 |
| Ocean, AJ | 1 |
| Christos, P | 1 |
| Ramirez, M | 1 |
| Vinciguerra, V | 1 |
| Kaubisch, A | 1 |
| Saif, MW | 1 |
| Zelt, S | 1 |
| Stenning, SP | 3 |
| Bancewicz, J | 1 |
| Clark, PI | 1 |
| Kaye, PV | 1 |
| Lobo, DN | 1 |
| Inokuma, T | 2 |
| Takemoto, Y | 2 |
| Kitagawa, H | 1 |
| Akimori, T | 1 |
| Namikawa, T | 1 |
| Okino, T | 1 |
| Nishioka, A | 1 |
| Hanazaki, K | 2 |
| Tran Vuong, TN | 1 |
| Vauléon, E | 1 |
| Boucher, E | 2 |
| Audrain, O | 1 |
| Yoshioka, S | 2 |
| Arimura, Y | 1 |
| Okahara, S | 1 |
| Tanuma, T | 1 |
| Kodaira, J | 1 |
| Hokari, K | 1 |
| Tsukagoshi, H | 2 |
| Shinomura, Y | 1 |
| Hosokawa, M | 2 |
| Kosugi, T | 1 |
| Terai, T | 1 |
| Yamade, M | 1 |
| Takayanagi, Y | 1 |
| Kanaoka, S | 1 |
| Zhu, WG | 2 |
| Yu, CH | 2 |
| Han, JH | 2 |
| Zhou, XL | 1 |
| Tao, GZ | 1 |
| Hong, L | 1 |
| Gong, T | 1 |
| Sun, L | 1 |
| Mueller, RP | 5 |
| Dienes, HP | 5 |
| Kaneko, K | 9 |
| Makino, R | 1 |
| Nozawa, H | 1 |
| Hirayama, Y | 1 |
| Konishi, K | 3 |
| Katagiri, A | 2 |
| Muramoto, T | 2 |
| Kushima, M | 1 |
| Ohmori, T | 2 |
| Kagawa, N | 1 |
| Imawari, M | 5 |
| Umehara, S | 2 |
| Suchi, K | 1 |
| Okamura, S | 3 |
| Okamura, H | 2 |
| Todo, M | 2 |
| Kokuba, Y | 2 |
| Sonoyama, T | 3 |
| Noda, E | 1 |
| Yamada, N | 1 |
| Sawada, T | 2 |
| Iijima, S | 3 |
| Makari, Y | 3 |
| Ooshima, S | 1 |
| Hoshi, M | 1 |
| Kato, A | 1 |
| Miyo, M | 1 |
| Kurokawa, E | 1 |
| Kikkawa, N | 2 |
| Satoh, E | 1 |
| Maruyama, M | 5 |
| Uehira, D | 1 |
| Koike, T | 1 |
| Ebana, K | 1 |
| Ohinata, R | 1 |
| Koide, A | 1 |
| Sanada, T | 1 |
| Sakoma, T | 1 |
| Oohira, M | 1 |
| Dan, N | 1 |
| Nishiguchi, Y | 1 |
| Tsutsui, M | 1 |
| Minamide, J | 6 |
| Takata, K | 1 |
| Aoyama, N | 11 |
| Cummins, MM | 1 |
| Sourjina, T | 1 |
| Van Hazel, G | 1 |
| Gibbs, D | 1 |
| Stockler, M | 1 |
| Zalcberg, J | 1 |
| Miura, A | 4 |
| Izumi, Y | 4 |
| Monma, K | 4 |
| Tomita, I | 1 |
| Murayama, A | 1 |
| Sawa, M | 1 |
| Noguchi, Y | 2 |
| Hoshikawa, Y | 2 |
| Shimizu, A | 1 |
| Overman, MJ | 1 |
| Kazmi, SM | 1 |
| Jhamb, J | 1 |
| Lin, E | 1 |
| Abbruzzese, JL | 2 |
| Ajani, J | 7 |
| Phan, A | 2 |
| Turaga, KK | 1 |
| Siegel, EM | 1 |
| McLoughlin, J | 1 |
| Hoffe, S | 1 |
| Marcovalerio, M | 1 |
| Shah, N | 1 |
| Kelley, S | 1 |
| Karl, R | 1 |
| Shim, HJ | 1 |
| Cho, SH | 2 |
| Hwang, JE | 1 |
| Bae, WK | 1 |
| Song, SY | 2 |
| Cho, SB | 1 |
| Lee, WS | 1 |
| Joo, YE | 1 |
| Chung, IJ | 2 |
| Isohata, N | 2 |
| Konno, S | 3 |
| Ide, H | 11 |
| Kadoyama, K | 3 |
| Verstovsek, S | 1 |
| Jin, Y | 1 |
| Cao, Q | 1 |
| Rodriguez, W | 1 |
| Garin, A | 1 |
| Lang, I | 1 |
| Falcon, S | 1 |
| Lu, JC | 1 |
| Kong, C | 1 |
| Tao, H | 1 |
| Jørgensen, JT | 1 |
| Guo, JF | 1 |
| Wu, F | 1 |
| Xing, H | 1 |
| Zhu, GY | 1 |
| Nie, XY | 1 |
| Peng, J | 1 |
| Loupakis, F | 1 |
| Masi, G | 1 |
| Fornaro, L | 1 |
| Vasile, E | 1 |
| Allegrini, G | 1 |
| Fontana, E | 1 |
| Granetto, C | 1 |
| Salvatore, L | 1 |
| Mentuccia, L | 1 |
| Andreuccetti, M | 1 |
| Cortesi, E | 1 |
| Merlano, M | 1 |
| Falcone, A | 1 |
| Spigel, DR | 1 |
| Greco, FA | 2 |
| Meluch, AA | 2 |
| Lane, CM | 1 |
| Farley, C | 1 |
| Gray, JR | 1 |
| Clark, BL | 1 |
| Burris, HA | 1 |
| Hainsworth, JD | 2 |
| Lo, SS | 1 |
| Khorana, AA | 1 |
| Javle, M | 2 |
| Simon, S | 1 |
| Kiefer, G | 1 |
| Rajasenan, K | 1 |
| Hantel, A | 1 |
| Shayne, M | 1 |
| Hwang, J | 1 |
| Schmotzer, A | 1 |
| Ramanathan, RK | 2 |
| Lefor, A | 1 |
| Hirashima, Y | 2 |
| Nokubi, M | 1 |
| Yamaguti, T | 1 |
| Jinbu, Y | 1 |
| Muroi, K | 1 |
| Nakazawa, M | 1 |
| Yasuda, Y | 1 |
| Andersen, M | 2 |
| Schønnemann, KR | 2 |
| Yilmaz, M | 2 |
| Jensen, HA | 1 |
| Vestermark, LW | 1 |
| Sun, H | 1 |
| Gong, H | 1 |
| Ruhstaller, T | 1 |
| Valladares-Ayerbes, M | 2 |
| Archer, C | 1 |
| Beadman, C | 1 |
| Øvrebø, K | 2 |
| Wentzel-Larsen, T | 2 |
| Jauhri, M | 1 |
| Negi, A | 1 |
| Aggarwal, S | 1 |
| Honda, M | 2 |
| Fujiwara, J | 1 |
| Egashira, H | 1 |
| Nemoto, T | 2 |
| Mimura, N | 1 |
| Tsujimura, H | 1 |
| Ise, M | 1 |
| Sakai, C | 1 |
| Kelly, P | 1 |
| Appleyard, V | 1 |
| Murray, K | 1 |
| Paulin, F | 1 |
| Lamont, D | 1 |
| Baker, L | 1 |
| Suttie, S | 1 |
| Exon, D | 1 |
| Thompson, A | 1 |
| Schultheis, B | 1 |
| Riebeling, J | 1 |
| Allali, M | 1 |
| Bergmann, U | 1 |
| Kummer, G | 1 |
| Sendler, U | 1 |
| Tannapfel, A | 1 |
| Sendler, A | 2 |
| Courrech Staal, EF | 1 |
| Aleman, BM | 1 |
| van Velthuysen, ML | 1 |
| Boot, H | 2 |
| van Coevorden, F | 1 |
| Wolf, M | 1 |
| Zehentmayr, F | 1 |
| Niyazi, M | 1 |
| Ganswindt, U | 1 |
| Haimerl, W | 1 |
| Schmidt, M | 1 |
| Hölzel, D | 1 |
| Belka, C | 2 |
| Besch, S | 1 |
| Mönig, SP | 2 |
| Specht, K | 4 |
| Davies, L | 1 |
| Lewis, WG | 2 |
| Arnold, DT | 1 |
| Escofet, X | 2 |
| Blackshaw, G | 1 |
| Gwynne, S | 2 |
| Evans, M | 3 |
| Appadurai, I | 1 |
| Konings, IR | 1 |
| Sleijfer, S | 1 |
| Mathijssen, RH | 1 |
| de Bruijn, P | 1 |
| Ghobadi Moghaddam-Helmantel, IM | 1 |
| van Dam, LM | 1 |
| Verweij, J | 1 |
| Loos, WJ | 1 |
| Ashley, SE | 1 |
| Turner, A | 1 |
| Webb, J | 1 |
| Chua, YJ | 3 |
| Shinoto, M | 1 |
| Shioyama, Y | 2 |
| Ohura, H | 1 |
| Higaki, Y | 1 |
| Ohnishi, K | 1 |
| Atsumi, K | 1 |
| Hirata, H | 1 |
| Honda, H | 2 |
| Ma, G | 1 |
| Kawamura, K | 1 |
| Liang, M | 1 |
| Tada, Y | 1 |
| Tatsumi, K | 1 |
| Hiroshima, K | 1 |
| Tagawa, M | 1 |
| Park, YH | 1 |
| Kim, KH | 1 |
| Cho, EY | 2 |
| Ahn, YC | 1 |
| Ahn, JS | 1 |
| Muren, LP | 1 |
| Bartholomeusz, D | 1 |
| Devitt, PG | 4 |
| Lamb, PJ | 1 |
| Ruszkiewicz, AR | 1 |
| Li, LB | 1 |
| Xie, JM | 1 |
| Zhang, XN | 1 |
| Chen, JZ | 1 |
| Luo, YL | 1 |
| Luo, RC | 1 |
| Aarstad, HJ | 1 |
| Aarstad, AK | 1 |
| Hjermstad, MJ | 1 |
| Malik, I | 1 |
| Bernal, P | 1 |
| Byrd, J | 1 |
| Iwasaki, H | 3 |
| Monjazeb, AM | 1 |
| Riedlinger, G | 1 |
| Aklilu, M | 1 |
| Geisinger, KR | 1 |
| Mishra, G | 1 |
| Isom, S | 1 |
| Clark, P | 1 |
| Levine, EA | 1 |
| Blackstock, AW | 1 |
| Takemasa, I | 1 |
| Matsubara, K | 1 |
| Sanada, Y | 3 |
| Osada, S | 1 |
| Schauer, MC | 1 |
| Holzmann, B | 1 |
| Peiper, M | 2 |
| Friess, H | 2 |
| Knoefel, WT | 2 |
| Park, JW | 1 |
| Choi, EK | 3 |
| Lee, SW | 1 |
| Yoon, SM | 1 |
| Lee, YS | 1 |
| Ahn, SD | 1 |
| Akitake, R | 1 |
| Nakamura, F | 2 |
| Takiuchi, H | 4 |
| Komatsu, Y | 1 |
| Senellart, H | 1 |
| Lamezec, B | 2 |
| Uchida, E | 3 |
| Hirakata, A | 3 |
| Umakoshi, M | 3 |
| Horio, T | 1 |
| Akase, T | 1 |
| Yaguchi, Y | 1 |
| Hiraki, S | 1 |
| Aiko, S | 2 |
| Hase, K | 1 |
| Maehara, T | 2 |
| Pantling, AZ | 1 |
| Mamidanna, R | 1 |
| Newman, G | 1 |
| Robinson, A | 1 |
| Manifold, DK | 1 |
| Hale, PC | 1 |
| Juan, HC | 1 |
| Tsai, HT | 1 |
| Chang, PH | 1 |
| Hu, CP | 1 |
| Wong, FH | 1 |
| Thomas, JM | 1 |
| Gotley, DC | 5 |
| Morimura, K | 1 |
| Tu, CH | 1 |
| Taku, K | 1 |
| Mueller, A | 1 |
| Trarbach, T | 2 |
| Kubicka, S | 1 |
| Geißler, M | 1 |
| Schwarz, S | 1 |
| Lu, TY | 2 |
| Li, WB | 2 |
| Wang, LX | 3 |
| Gao, DL | 2 |
| Wang, RL | 2 |
| Lu, SX | 3 |
| Fan, QX | 3 |
| Thukral, A | 1 |
| Metz, J | 1 |
| Hwang, WT | 1 |
| O'Dwyer, P | 1 |
| Plastaras, J | 1 |
| Both, S | 1 |
| Bar-Ad, V | 1 |
| Ad, VB | 1 |
| Zhang, TR | 1 |
| Zhao, T | 2 |
| Xu, X | 1 |
| Gu, XW | 1 |
| Pan, YK | 1 |
| Stauffer, JA | 1 |
| Mathew, J | 1 |
| Odell, JA | 1 |
| Balukrishna, S | 1 |
| Jennifer, P | 1 |
| Viswanathan, PN | 1 |
| Jhawer, M | 1 |
| Lefkowitz, RA | 1 |
| Robinson, E | 1 |
| Capanu, M | 1 |
| Nagai, M | 1 |
| Hirst, J | 1 |
| Barbour, A | 1 |
| Wu, XA | 1 |
| Ami, K | 2 |
| Nagahama, T | 3 |
| Ando, M | 2 |
| Watayou, Y | 1 |
| Amagasa, H | 2 |
| Ganno, H | 2 |
| Hataji, K | 1 |
| Kurokawa, T | 2 |
| Fukuda, A | 2 |
| Tei, S | 1 |
| Okumura, Y | 1 |
| Tomemori, T | 1 |
| Mitsuhashi, T | 1 |
| Sobajima, J | 1 |
| Haga, N | 1 |
| Kumamoto, K | 1 |
| Ishibashi, K | 1 |
| Toshimitsu, H | 1 |
| Kitamura, Y | 1 |
| Andoh, S | 1 |
| Tsushimi, K | 1 |
| Honboh, T | 1 |
| Kudo, K | 1 |
| Ninomiya, M | 1 |
| Hamatsu, T | 1 |
| Kabashima, A | 1 |
| Ushijima, C | 1 |
| Toma, T | 1 |
| Ohira, G | 2 |
| Natsume, T | 2 |
| Tohma, T | 1 |
| Okazumi, S | 6 |
| Kaiho, T | 1 |
| Orditura, M | 3 |
| Martinelli, E | 2 |
| Vecchione, L | 1 |
| Innocenti, R | 1 |
| Sileni, VC | 3 |
| Pinto, C | 2 |
| Di Maio, M | 1 |
| Farella, A | 1 |
| Troiani, T | 1 |
| Morgillo, F | 2 |
| Napolitano, V | 1 |
| Di Martino, N | 3 |
| Del Genio, A | 2 |
| Ciardiello, F | 2 |
| Smith, C | 1 |
| Kist, J | 1 |
| Sato, N | 5 |
| Hayashi, N | 2 |
| Chun, CL | 1 |
| Eisenstat, S | 1 |
| Dormady, S | 1 |
| Lombard, C | 1 |
| Triadafilopoulos, G | 1 |
| He, Y | 1 |
| Hu, B | 1 |
| Ji, C | 1 |
| Yang, SY | 1 |
| Yang, PW | 2 |
| Shun, CT | 1 |
| Wu, MT | 1 |
| Wang, YH | 1 |
| Chuang, TH | 1 |
| Chen, JS | 1 |
| Hsu, HH | 1 |
| Tixier, F | 1 |
| Le Rest, CC | 1 |
| Hatt, M | 1 |
| Albarghach, N | 1 |
| Pradier, O | 1 |
| Corcos, L | 1 |
| Visvikis, D | 1 |
| Rachakonda, PS | 1 |
| Panzram, B | 1 |
| Keller, G | 2 |
| Buechler, M | 1 |
| Hemminki, K | 1 |
| Kumar, R | 1 |
| Shitara, K | 3 |
| Hatooka, S | 2 |
| Mizota, A | 2 |
| Kondoh, C | 1 |
| Kusano, T | 1 |
| Noguchi, T | 4 |
| Ogawa, T | 2 |
| Shinohara, M | 1 |
| Takagi, Y | 2 |
| Aoki, T | 6 |
| Minowa, M | 1 |
| Hasebe, S | 1 |
| Ogawa, M | 2 |
| Yoshida, H | 3 |
| Ikeda, N | 1 |
| Yoneyama, Y | 1 |
| Miyazawa, Y | 2 |
| Shien, K | 1 |
| Okazaki, M | 1 |
| Suehisa, H | 1 |
| Sawada, S | 1 |
| Pignon, JP | 1 |
| Ducourtieux, M | 1 |
| Fabre, JM | 1 |
| Saint-Aubert, B | 1 |
| Genève, J | 1 |
| Lasser, P | 2 |
| Yoon, MS | 1 |
| Nam, TK | 1 |
| Lee, JS | 6 |
| Song, JY | 1 |
| Ahn, SJ | 1 |
| Jeong, JU | 1 |
| Chung, WK | 1 |
| Nah, BS | 1 |
| Ben-David, K | 1 |
| Rossidis, G | 1 |
| Zlotecki, RA | 1 |
| Grobmyer, SR | 1 |
| Cendan, JC | 1 |
| Hochwald, SN | 3 |
| Winter, KA | 2 |
| Komaki, RU | 1 |
| Wu, TT | 8 |
| Konski, AA | 1 |
| Koucky, K | 1 |
| Konturek, PC | 1 |
| Albrecht, H | 1 |
| Busse, D | 1 |
| Golcher, H | 1 |
| Schildberg, C | 1 |
| Janka, R | 1 |
| Siebler, J | 1 |
| Neurath, MF | 1 |
| Lone, GN | 1 |
| Sheikh, AA | 1 |
| Sheikh, ZA | 1 |
| Baba, KM | 1 |
| Qurieshi, MA | 1 |
| Mufti, GN | 1 |
| Naikoo, ZA | 1 |
| Syed, AA | 1 |
| Ahangar, AG | 1 |
| Lone, RA | 1 |
| Sharma, ML | 1 |
| Singh, S | 1 |
| Bhat, MA | 1 |
| Dar, AM | 1 |
| Fukui, T | 2 |
| Takeda, H | 5 |
| Kawada, S | 2 |
| Veeramootoo, D | 1 |
| Taylor, C | 1 |
| Wajed, SA | 2 |
| Pellen, MG | 1 |
| Sabri, S | 1 |
| Razack, A | 1 |
| Gilani, SQ | 1 |
| Jain, PK | 1 |
| Chen, PC | 1 |
| Chen, YC | 1 |
| Lai, LC | 1 |
| Tsai, MH | 1 |
| Chen, SK | 1 |
| Hsiao, CK | 1 |
| Chuang, EY | 1 |
| Norman, G | 1 |
| Rice, S | 1 |
| Spackman, E | 1 |
| Stirk, L | 1 |
| Danso-Appiah, A | 1 |
| Suh, D | 1 |
| Palmer, S | 1 |
| Eastwood, A | 1 |
| Farkas, R | 2 |
| Pozsgai, E | 1 |
| Bellyei, S | 2 |
| Cseke, L | 4 |
| Szigeti, A | 1 |
| Vereczkei, A | 1 |
| Marton, S | 2 |
| Mangel, L | 1 |
| Horvath, OP | 3 |
| Papp, A | 3 |
| Hatata, T | 1 |
| Higaki, K | 1 |
| Nanba, E | 1 |
| Tatebe, S | 1 |
| Ikeguchi, M | 2 |
| Werner Kraus, T | 1 |
| Bruch, HP | 1 |
| Noack, F | 1 |
| Altmannsberger, HM | 1 |
| Lu, L | 1 |
| Hao, Y | 2 |
| Mo, Y | 1 |
| Cui, N | 1 |
| Rong, T | 1 |
| Thézenas, S | 1 |
| Abbas, F | 1 |
| Romano, O | 2 |
| Bécouarn, Y | 1 |
| Desseigne, F | 2 |
| Edeline, J | 1 |
| Pera, M | 2 |
| Gallego, R | 2 |
| Montagut, C | 1 |
| Martín-Richard, M | 2 |
| Iglesias, M | 1 |
| Conill, C | 2 |
| Reig, A | 1 |
| Balagué, C | 1 |
| Pétriz, L | 1 |
| Momblan, D | 1 |
| Bellmunt, J | 1 |
| Maurel, J | 2 |
| Tsai, YC | 2 |
| Miyagi, K | 1 |
| Suzuki, O | 1 |
| Matsumoto, M | 7 |
| Uchicado, Y | 1 |
| Sakamoto, F | 1 |
| Yoshinaka, H | 1 |
| von Gall, C | 1 |
| Weitz, J | 1 |
| Haberkorn, U | 1 |
| Abel, U | 1 |
| Debus, J | 1 |
| Münter, MW | 1 |
| Ma, JB | 1 |
| Song, YP | 1 |
| Cheng, EC | 1 |
| Zhang, XQ | 1 |
| Wahba, HA | 1 |
| El-Hadaad, HA | 1 |
| Abd-Ellatif, EA | 1 |
| Ucar, DA | 1 |
| Cox, A | 1 |
| He, DH | 1 |
| Ostrov, DA | 1 |
| Kurenova, E | 1 |
| Kanamori, N | 1 |
| Kaiga, T | 1 |
| Mihara, Y | 1 |
| Funada, T | 1 |
| Chiba, I | 1 |
| Morioka, T | 1 |
| Takamatsu, R | 1 |
| Yoshimi, N | 1 |
| Ikeda, E | 1 |
| Fuse, N | 1 |
| Lieto, E | 1 |
| Vitiello, F | 1 |
| Pacelli, R | 1 |
| Renda, A | 1 |
| Izumiya, M | 1 |
| Yamagishi, Y | 1 |
| Sakai, G | 1 |
| Funakoshi, S | 1 |
| Adachi, M | 1 |
| Higuchi, H | 1 |
| Takaishi, H | 1 |
| Sugiura, J | 1 |
| Irie, E | 1 |
| Hibi, T | 1 |
| Peng, YF | 2 |
| Lin, LS | 1 |
| DiCarlo, B | 1 |
| Dao, KM | 1 |
| Patel, R | 1 |
| Park, DJ | 1 |
| Elashoff, R | 1 |
| Ryba, N | 1 |
| Hecht, JR | 2 |
| Saigusa, S | 1 |
| Ishino, Y | 1 |
| Okugawa, Y | 1 |
| Schauer, M | 1 |
| Yamamura, Y | 1 |
| Takashima, M | 1 |
| Minato, T | 3 |
| Verhage, RJ | 1 |
| van der Horst, S | 1 |
| van der Sluis, PC | 1 |
| Piacentini, P | 1 |
| Durante, E | 2 |
| Trolese, A | 1 |
| Mercanti, A | 1 |
| Bonetti, A | 1 |
| Gujral, DM | 1 |
| Hawkins, MA | 2 |
| Leonulli, BG | 1 |
| Chen, EL | 1 |
| Weng, XR | 1 |
| Ikeda, K | 6 |
| Yun, T | 1 |
| Han, JY | 1 |
| Choi, HL | 1 |
| Kim, HY | 1 |
| Nam, BH | 1 |
| Kim, HT | 1 |
| Rollins, KE | 1 |
| Peters, CJ | 1 |
| Safranek, PM | 1 |
| Ford, H | 2 |
| Baglin, TP | 1 |
| Hardwick, RH | 2 |
| Kajiura, K | 1 |
| Alakus, H | 1 |
| Kütting, F | 1 |
| Grimminger, PP | 1 |
| Kondo, C | 1 |
| Yatabe, Y | 1 |
| Koo, DH | 1 |
| Yoon, DH | 1 |
| Kokubu, A | 1 |
| Narisawa-Saito, M | 1 |
| Sasaki, H | 2 |
| Aoyagi, K | 2 |
| Yoshimatsu, Y | 1 |
| Kiyono, T | 1 |
| Vande Walle, C | 1 |
| Ceelen, WP | 1 |
| Vande Putte, D | 1 |
| Van Nieuwenhove, Y | 1 |
| Varin, O | 1 |
| Leichman, LP | 1 |
| Goldman, BH | 1 |
| Bohanes, PO | 1 |
| Billingsley, KG | 1 |
| Corless, CL | 1 |
| Gold, PJ | 1 |
| Benedetti, JK | 1 |
| Danenberg, KD | 3 |
| Bayraktar, UD | 1 |
| Bayraktar, S | 1 |
| Hosein, P | 1 |
| Chen, E | 1 |
| Koniaris, LG | 1 |
| Rocha-Lima, CM | 1 |
| Montero, AJ | 1 |
| Chasen, M | 2 |
| Marcus, V | 2 |
| Hickeson, M | 2 |
| Artho, G | 2 |
| Thirlwell, MP | 2 |
| Okamoto, N | 1 |
| Shimoda, T | 1 |
| Masutomi, K | 1 |
| Narazaki, K | 2 |
| Koto, M | 1 |
| Sugawara, T | 4 |
| Kubozono, M | 2 |
| Scotté, M | 1 |
| Hamidou, H | 1 |
| Paillot, B | 4 |
| Michot, F | 1 |
| Semrau, R | 1 |
| Herzog, SL | 1 |
| Müller, RP | 1 |
| Damodaran, S | 1 |
| Bellavia, T | 1 |
| Sait, SN | 1 |
| Wang, ES | 1 |
| Wetzler, M | 1 |
| Khushalani, NI | 3 |
| Deplazes, J | 1 |
| Eichmann, M | 1 |
| Folprecht, G | 1 |
| Wöll, E | 2 |
| Decker, T | 1 |
| Endlicher, E | 1 |
| Fend, F | 1 |
| Hamano, R | 1 |
| Hou, E | 1 |
| Sawaki, A | 1 |
| Ohashi, Y | 1 |
| Omuro, Y | 1 |
| Satoh, A | 1 |
| Baba, E | 2 |
| Hatake, K | 1 |
| Fan, T | 2 |
| Orihara, M | 1 |
| Yoshizawa, K | 1 |
| Nakazuru, S | 1 |
| Mita, E | 1 |
| Eisterer, W | 1 |
| DE Vries, A | 1 |
| Kendler, D | 1 |
| Spechtenhauser, B | 1 |
| Königsrainer, A | 1 |
| Nehoda, H | 1 |
| Virgolini, I | 1 |
| Lukas, P | 1 |
| Bechter, O | 1 |
| Ofner, D | 1 |
| Maruyama, A | 1 |
| Tanizaki, K | 1 |
| Nishioka, K | 2 |
| Hyuga, S | 1 |
| Igarashi, Y | 1 |
| Yamanaka, C | 1 |
| Uemura, Y | 1 |
| Ogasawara, H | 1 |
| Kauppi, JT | 1 |
| Oksala, N | 1 |
| Salo, JA | 1 |
| Helin, H | 1 |
| Karhumäki, L | 1 |
| Kemppainen, J | 1 |
| Sihvo, EI | 1 |
| Räsänen, JV | 1 |
| Pan, JY | 1 |
| Gu, J | 2 |
| Gong, Y | 2 |
| Qin, A | 1 |
| Quin, A | 1 |
| Hung, M | 1 |
| Ferte, C | 1 |
| Bourgeois, V | 1 |
| Lindet, C | 1 |
| Ladrat, L | 1 |
| Hebbar, M | 1 |
| Elzinga, B | 1 |
| Crowley, LC | 1 |
| Zhang, JQ | 1 |
| Hooker, CM | 1 |
| Brock, MV | 1 |
| Shin, J | 1 |
| How, R | 1 |
| Franco, N | 1 |
| Prevas, H | 1 |
| Hulbert, A | 1 |
| Yang, SC | 2 |
| Berger, B | 1 |
| Stahlberg, K | 1 |
| Lemminger, A | 1 |
| Bleif, M | 1 |
| Bamberg, M | 1 |
| Zhu, XF | 1 |
| Zhong, GS | 1 |
| Deng, BG | 1 |
| Gao, ZT | 1 |
| Wang, XC | 1 |
| Tian, LL | 1 |
| Zheng, H | 1 |
| Meng, AM | 1 |
| Shingai, T | 3 |
| Shiratori, T | 3 |
| Sheng, W | 1 |
| Feng, XZ | 1 |
| Han, JQ | 2 |
| Nabeki, B | 1 |
| Nakajo, M | 3 |
| Hatakenaka, M | 1 |
| Yonezawa, M | 1 |
| Nonoshita, T | 1 |
| Yabuuchi, H | 1 |
| Nagao, M | 1 |
| Kamitani, T | 1 |
| Higo, T | 1 |
| Setoguchi, T | 1 |
| Bagheri, R | 1 |
| RajabiMashhadi, MT | 1 |
| Ghazvini, K | 1 |
| Asnaashari, A | 1 |
| Zahediyan, A | 1 |
| Sahebi, MA | 1 |
| Rau, KM | 1 |
| Tien, WY | 1 |
| Liang, JL | 1 |
| Lin, WC | 1 |
| Chen, H | 1 |
| Goto, Y | 1 |
| Furukawa, H | 2 |
| Zhang, HQ | 1 |
| Wang, RB | 1 |
| Yan, HJ | 1 |
| Zhu, KL | 1 |
| Jiang, SM | 1 |
| Hu, XG | 1 |
| Takao, Y | 1 |
| Hayakawa, T | 1 |
| Hosone, M | 1 |
| Chang, KJ | 1 |
| Reid, T | 1 |
| Senzer, N | 1 |
| Pinto, H | 1 |
| Hanna, N | 2 |
| Chak, A | 1 |
| Soetikno, R | 1 |
| Tian, W | 1 |
| Peer, CJ | 1 |
| McManus, TJ | 1 |
| Petros, WP | 1 |
| Zhou, K | 1 |
| Chen, XF | 1 |
| Phillips, BE | 1 |
| Tubbs, RR | 1 |
| Plesec, T | 1 |
| Yoshii, T | 1 |
| Ohkawa, S | 1 |
| Tamai, S | 3 |
| Kameda, Y | 4 |
| Kofoed, SC | 1 |
| Lundsgaard, M | 1 |
| Ellemann, AC | 1 |
| Svendsen, LB | 1 |
| Peng, F | 1 |
| Zhou, L | 1 |
| Huang, M | 2 |
| Florschütz, A | 1 |
| Mantovani-Löffler, L | 1 |
| Kneba, M | 1 |
| Glanemann, M | 1 |
| Schlattmann, P | 1 |
| Reichardt, P | 1 |
| Gahn, B | 1 |
| Sung, EZ | 1 |
| Arasaradnam, RP | 1 |
| Jarvie, EM | 1 |
| James, S | 1 |
| Goodyear, SJ | 1 |
| Borman, RA | 1 |
| Snead, D | 1 |
| Sanger, GJ | 1 |
| Nwokolo, CU | 1 |
| Iitaka, D | 1 |
| Przyborek, M | 1 |
| Schleucher, N | 1 |
| Heeger, S | 1 |
| Vanhoefer, U | 2 |
| Roy, A | 1 |
| Sörbye, H | 1 |
| Barcelo, JR | 1 |
| Lopez-Vivanco, G | 1 |
| Adler, G | 1 |
| Canon, JL | 1 |
| Lofts, F | 2 |
| Castanon, C | 1 |
| Fonseca, E | 1 |
| Rixe, O | 1 |
| Aparicio, J | 1 |
| Cassinello, J | 1 |
| Mousseau, M | 1 |
| Schalhorn, A | 1 |
| D'Hondt, L | 1 |
| Kerger, J | 1 |
| Hossfeld, DK | 1 |
| Garcia Giron, C | 2 |
| Rodriguez, R | 1 |
| Schoffski, P | 1 |
| Misset, JL | 2 |
| Matsumori, T | 1 |
| Murakami, S | 2 |
| Araki, O | 1 |
| Tsuda, T | 2 |
| Goto, N | 1 |
| Adachi, K | 1 |
| Itani, T | 1 |
| Mimura, J | 1 |
| Araki, N | 2 |
| Sugiyama, M | 1 |
| Maehara, S | 1 |
| Sakaguchi, Y | 1 |
| Okamura, T | 1 |
| Uehara, S | 1 |
| Klein, Y | 1 |
| Buevich, V | 1 |
| Baruch, NB | 1 |
| Tokar, M | 1 |
| Kundel, Y | 1 |
| Schneider, BJ | 1 |
| Hayman, JA | 1 |
| Chang, AC | 1 |
| Orringer, MB | 5 |
| Pickens, A | 1 |
| Pan, CC | 1 |
| Merajver, SD | 1 |
| Urba, SG | 5 |
| Spezi, E | 1 |
| Wills, L | 1 |
| Nixon, L | 1 |
| Hurt, C | 1 |
| Joseph, G | 1 |
| Zhong, Z | 1 |
| Gu, X | 1 |
| Qing, Y | 1 |
| Dai, N | 1 |
| Shi, X | 1 |
| Yao, W | 1 |
| Jiang, GL | 1 |
| Zhao, R | 1 |
| Quaroni, L | 1 |
| Casson, AG | 2 |
| Yoshikawa, R | 2 |
| Tsujimura, T | 1 |
| Tao, L | 1 |
| Kamikonya, N | 2 |
| Nakashima, S | 2 |
| Yoshikawa, Y | 1 |
| Tominaga, H | 1 |
| Sunada, S | 1 |
| Nishitani, A | 1 |
| Hiraoka, K | 1 |
| Irei, T | 1 |
| Boku, M | 1 |
| Wakahara, M | 1 |
| Kamiike, W | 1 |
| Taniyama, K | 1 |
| Ikebe, M | 1 |
| Saitoh, G | 1 |
| Pijaume, CP | 1 |
| Saigí, E | 1 |
| Varga, G | 2 |
| Pavlovics, G | 1 |
| Potó, L | 1 |
| Rostom, Y | 1 |
| Zaghloul, H | 1 |
| Khedr, G | 1 |
| El-Shazly, W | 1 |
| Abd-Allah, D | 1 |
| Clavier, JB | 1 |
| Antoni, D | 1 |
| Atlani, D | 1 |
| Schumacher, C | 1 |
| Dufour, P | 1 |
| Kurtz, JE | 1 |
| Noel, G | 1 |
| Thompson, LC | 2 |
| Stevenson, L | 1 |
| Middleton, GW | 1 |
| Evans, L | 1 |
| Ford, D | 1 |
| Petty, RD | 1 |
| Plummer, C | 1 |
| Griffin, M | 4 |
| Eatock, MM | 2 |
| Bampton, CL | 1 |
| Strickland, AH | 2 |
| Swieboda-Sadlej, A | 1 |
| Nanayakkara, N | 1 |
| Sun, YN | 1 |
| Zhong, ZD | 1 |
| Bass, MB | 1 |
| Adewoye, AH | 1 |
| Yajima, Y | 1 |
| Yoda, Y | 1 |
| Ikematsu, H | 1 |
| Oono, Y | 1 |
| Mizuno, S | 1 |
| Kishi, M | 1 |
| Taniguchi, F | 1 |
| Kuwata, K | 1 |
| Watanabe, N | 1 |
| Kokudo, Y | 1 |
| Muraoka, A | 1 |
| Tatemoto, A | 1 |
| Tsumura, M | 1 |
| Manabe, Y | 1 |
| Bi, LW | 1 |
| Zhang, LZ | 1 |
| Zhao, HF | 1 |
| Pasini, F | 6 |
| Grandinetti, A | 5 |
| Capirci, C | 1 |
| Pavarana, M | 1 |
| Tomezzoli, A | 3 |
| Rubello, D | 1 |
| Cordiano, C | 5 |
| Takahashi, C | 3 |
| Abe, K | 1 |
| Tanabe, T | 1 |
| Shirata, Y | 1 |
| Kligerman, S | 1 |
| Lu, M | 1 |
| Kim, G | 1 |
| Feigenberg, S | 1 |
| D'Souza, WD | 1 |
| Lu, W | 1 |
| Murakami, H | 1 |
| Kawabe, Y | 1 |
| Nakashima, H | 1 |
| Oka, Y | 1 |
| Hirai, T | 2 |
| Mayr, M | 1 |
| Schulte, N | 1 |
| Belle, S | 1 |
| Krause, A | 1 |
| Schmid, RM | 1 |
| Röcken, C | 1 |
| Ebert, MP | 1 |
| Reis-Filho, JS | 1 |
| Waddell, TS | 1 |
| Noor, D | 1 |
| Eltahir, Z | 1 |
| Stenning, S | 1 |
| Steger, F | 1 |
| Hautmann, MG | 1 |
| Kölbl, O | 1 |
| Seki, R | 1 |
| Takasaki, J | 1 |
| Kamikozuru, H | 1 |
| Kodaka, F | 1 |
| Nishigaki, T | 1 |
| Ebisui, C | 1 |
| Wada, Y | 1 |
| Kato, R | 1 |
| Makino, S | 1 |
| Owada, Y | 1 |
| Yanagisawa, T | 1 |
| Yokouchi, H | 3 |
| Kinuta, M | 3 |
| Suto, Y | 1 |
| Tomizawa, N | 1 |
| Andoh, T | 1 |
| Arakawa, K | 1 |
| Itoh, H | 2 |
| Sunose, Y | 1 |
| Takeyoshi, I | 2 |
| Rousseau, D | 1 |
| Capitain, O | 1 |
| Denis, F | 1 |
| Girault, S | 1 |
| Poirier, AL | 1 |
| Cellier, P | 1 |
| Hamy, A | 1 |
| Mahé, MA | 1 |
| Mesgouez-Nebout, N | 1 |
| Burgerhof, JG | 1 |
| Timmer, PR | 1 |
| Mul, VE | 1 |
| Hospers, GA | 1 |
| van Dijk, BA | 1 |
| Langendijk, JA | 1 |
| Plukker, JT | 1 |
| Zhao, E | 1 |
| Andalib, A | 1 |
| Chen, MY | 1 |
| Luo, JC | 1 |
| Parameswaran, R | 1 |
| Titcomb, DR | 1 |
| Blencowe, NS | 1 |
| Berrisford, RG | 1 |
| Anter, AH | 1 |
| Abdel-Latif, RM | 1 |
| Gu, M | 1 |
| Li, SY | 1 |
| Huang, XE | 1 |
| Cheng, HY | 1 |
| Ge, L | 1 |
| Yin, D | 1 |
| Lei, C | 1 |
| Zhu, JF | 1 |
| Cai, XH | 1 |
| Qian, D | 1 |
| Cai, MY | 1 |
| Mai, SJ | 1 |
| Liao, YJ | 1 |
| Lin, MC | 1 |
| Bian, XW | 1 |
| Huang, JJ | 2 |
| Kung, HF | 1 |
| Wood, MD | 1 |
| Zaki, BI | 1 |
| Gordon, SR | 1 |
| Sutton, JE | 1 |
| Lisovsky, M | 1 |
| Gui, J | 1 |
| Bubis, JA | 2 |
| Dragnev, KH | 2 |
| Rigas, JR | 2 |
| Chang, J | 1 |
| Yu, H | 1 |
| Ji, D | 1 |
| Peng, W | 1 |
| Anbai, A | 1 |
| Koga, M | 1 |
| Jin, M | 1 |
| Shibata, H | 3 |
| Yoneda, M | 1 |
| Erickson, AL | 1 |
| Pierce, G | 1 |
| Nakada, T | 1 |
| Nagayama, K | 1 |
| Hiramoto, J | 1 |
| Tsuruta, Y | 1 |
| Sakabe, S | 1 |
| Nguyen, NP | 1 |
| Leonardo, JM | 1 |
| Karlsson, U | 1 |
| Salehpour, M | 1 |
| Vos, P | 1 |
| Robiou, C | 1 |
| Moran, JF | 1 |
| Thomas, P | 1 |
| Bullock, L | 1 |
| Ludin, A | 1 |
| Jendrasiak, G | 1 |
| Sallah, S | 1 |
| Chan, AC | 3 |
| Lee, DW | 1 |
| Griffith, JF | 2 |
| Leung, SF | 3 |
| Lam, YH | 1 |
| Lam, CC | 1 |
| Lau, JY | 1 |
| Ng, EK | 4 |
| Chung, SC | 2 |
| Gotohda, N | 1 |
| Nishimura, M | 3 |
| Evans, TR | 1 |
| Pentheroudakis, G | 2 |
| Paul, J | 1 |
| McInnes, A | 1 |
| Blackie, R | 1 |
| Raby, N | 1 |
| Morrison, R | 1 |
| Fullarton, GM | 1 |
| Soukop, M | 2 |
| McDonald, AC | 1 |
| Toba, T | 1 |
| Kimura, M | 3 |
| Urashima, Y | 1 |
| Terashima, H | 1 |
| Masuda, K | 1 |
| Rahal, M | 1 |
| Raja, MA | 1 |
| El Weshi, A | 1 |
| Pai, C | 1 |
| Ezzat, A | 1 |
| Al Fadda, M | 1 |
| Magois, K | 1 |
| Robert, V | 1 |
| Chiron, A | 1 |
| Lepessot, F | 1 |
| Bodenant, C | 1 |
| Roque, I | 1 |
| Seng, SK | 1 |
| Frebourg, T | 1 |
| Leonard, GD | 2 |
| Zhuang, SH | 1 |
| Grem, JL | 1 |
| Isogai, K | 2 |
| Suzuki, C | 1 |
| Nakahara, S | 2 |
| Yabana, T | 2 |
| Murakami, R | 2 |
| Senoda, A | 1 |
| Ban, T | 2 |
| Endo, T | 3 |
| Norman, A | 7 |
| Mochlinski, K | 1 |
| Prior, Y | 1 |
| Cosenza, A | 1 |
| Catalano, G | 1 |
| Mercier, M | 1 |
| Chander, S | 1 |
| Rath, GK | 1 |
| Sharma, DN | 1 |
| Shukla, NK | 1 |
| Maraveyas, A | 1 |
| O'Boyle, C | 1 |
| Cowen, M | 1 |
| Oettle, H | 1 |
| Kern, M | 1 |
| Hoepffner, N | 1 |
| Settmacher, U | 1 |
| Neuhaus, P | 1 |
| Riess, H | 1 |
| Dittmann, H | 1 |
| Dohmen, BM | 1 |
| Kehlbach, R | 1 |
| Bartusek, G | 1 |
| Pritzkow, M | 1 |
| Sarbia, M | 8 |
| Bares, R | 1 |
| Hasebe, K | 1 |
| Urade, M | 1 |
| Yagi, M | 1 |
| Shigemitsu, K | 1 |
| Naomoto, Y | 1 |
| Haisa, M | 1 |
| Gunduz, M | 1 |
| Inaba, H | 1 |
| Miyazaki, A | 1 |
| Koitabashi, Y | 1 |
| Ogihara, K | 1 |
| Kato, N | 1 |
| Nakagawa, T | 1 |
| Kitajima, S | 1 |
| Iino, S | 1 |
| Tsuchiya, Y | 3 |
| Onda, M | 3 |
| Nomura, T | 4 |
| Hagiwara, N | 3 |
| Takubo, K | 2 |
| Miyashita, M | 5 |
| Uchida, Y | 1 |
| Mueller, W | 1 |
| Takeno, S | 2 |
| Shibata, S | 1 |
| Morohashi, H | 1 |
| Matsuya, H | 1 |
| Sasaki, M | 1 |
| Maruyama, N | 2 |
| Katsumoto, Y | 4 |
| Nakaguchi, K | 3 |
| Furukawa, J | 3 |
| Sue, F | 3 |
| Terashima, M | 4 |
| Kogure, M | 1 |
| Gotoh, M | 2 |
| Taussky, D | 1 |
| Rousson, V | 1 |
| Pescia, R | 1 |
| Yamada, R | 1 |
| Morinaga, S | 2 |
| Britton, KR | 1 |
| Takai, Y | 2 |
| Higashimoto, M | 1 |
| Kanzaki, A | 1 |
| Nitta, Y | 1 |
| Shirata, S | 1 |
| Yoshida, A | 1 |
| Terada, K | 1 |
| Takebayashi, Y | 1 |
| Terrosu, G | 1 |
| Cedolini, C | 1 |
| Bresadola, V | 1 |
| Baccarani, U | 1 |
| Uzzau, A | 1 |
| Signor, M | 1 |
| Fongione, S | 1 |
| Buffoli, A | 1 |
| Iop, A | 1 |
| Vigevani, E | 1 |
| Sacco, C | 1 |
| Cartei, G | 2 |
| Bresadola, F | 1 |
| Kirkup, ME | 1 |
| Narayan, S | 1 |
| Kennedy, CT | 1 |
| Takeuchi, S | 3 |
| Nagasaki, H | 1 |
| Yoshizawa, Y | 2 |
| Kikuchi, H | 2 |
| Yagi, H | 1 |
| Midorikawa, T | 2 |
| Kumada, K | 2 |
| Iwashige, M | 1 |
| Takizawa, K | 2 |
| Tsujie, M | 1 |
| Shibata, N | 1 |
| Morimoto, T | 3 |
| Fujita, S | 2 |
| Kitani, K | 1 |
| Nakahira, S | 1 |
| Okuda, H | 1 |
| Beech, DJ | 1 |
| Madan, AK | 1 |
| Aliabadi-Wahle, S | 1 |
| Hays, AN | 1 |
| Long, WP | 1 |
| Kleinberg, L | 2 |
| Knisely, JP | 2 |
| Heitmiller, R | 1 |
| Zahurak, M | 2 |
| Salem, R | 2 |
| Heath, EI | 2 |
| Forastiere, AA | 4 |
| Fritz, P | 2 |
| Stoll, P | 1 |
| Wannenmacher, M | 2 |
| Zierhut, D | 1 |
| Heroor, A | 1 |
| Fujita, H | 8 |
| Sueyoshi, S | 6 |
| Toh, U | 1 |
| Mine, T | 1 |
| Sasahara, H | 5 |
| Sudo, T | 1 |
| Matono, S | 4 |
| Shirouzu, K | 8 |
| Kishimoto, K | 1 |
| Igarashi, J | 1 |
| Maezawa, T | 1 |
| Adachi, W | 1 |
| Amano, J | 1 |
| Weisser, A | 1 |
| Willer, A | 1 |
| Hehlmann, R | 2 |
| Futami, R | 2 |
| Tateno, A | 1 |
| Kelleher, M | 1 |
| Andreyev, J | 1 |
| Allen, M | 1 |
| Denham, JW | 8 |
| Steigler, A | 1 |
| Kilmurray, J | 1 |
| Wratten, C | 1 |
| Burmeister, B | 2 |
| Lamb, DS | 5 |
| Joseph, D | 2 |
| Delaney, G | 1 |
| Christie, D | 1 |
| Jamieson, G | 1 |
| Ackland, S | 2 |
| Walpole, E | 2 |
| Harney, J | 1 |
| Goodchild, K | 1 |
| Phillips, H | 1 |
| Glynne-Jones, R | 3 |
| Hoskin, PJ | 1 |
| Saunders, MI | 1 |
| Aston, D | 1 |
| Minett, M | 1 |
| Brewster, AE | 3 |
| Jessner, W | 1 |
| Vogelsang, H | 1 |
| Püspök, A | 1 |
| Ferenci, P | 1 |
| Gangl, A | 1 |
| Novacek, G | 1 |
| Bodisch, A | 1 |
| Wenzl, E | 1 |
| Nahon, P | 1 |
| Krulik, M | 2 |
| Eguchi, R | 5 |
| Takasaki, K | 2 |
| Mitsuhashi, M | 1 |
| Lee, JL | 2 |
| Kim, DK | 2 |
| Kim, WK | 2 |
| Min, YI | 3 |
| Rich, TA | 5 |
| Shepard, R | 1 |
| Nesbitt, JC | 1 |
| Lahoti, S | 2 |
| Martin, F | 1 |
| Putnam, JB | 7 |
| Smythe, WR | 2 |
| Walsh, GL | 3 |
| An, FS | 1 |
| Huang, JQ | 1 |
| Xie, YT | 1 |
| Chen, SH | 1 |
| Tachibana, M | 2 |
| Yoshimura, H | 2 |
| Kinugasa, S | 2 |
| Shibakita, M | 1 |
| Dhar, DK | 1 |
| Nagasue, N | 2 |
| Kanamori, S | 3 |
| Shigeoka, H | 2 |
| Nagashima, F | 2 |
| Haruno, M | 1 |
| Ogino, T | 5 |
| Ochiai, A | 3 |
| MYHRE, K | 1 |
| FJAERLI, J | 1 |
| Leichman, L | 11 |
| Leichman, CG | 5 |
| Moriuchi, R | 1 |
| Tarasawa, I | 1 |
| Senota, A | 1 |
| Goldberg, M | 3 |
| Farma, J | 1 |
| Lampert, C | 1 |
| Colarusso, P | 2 |
| Coia, L | 1 |
| Frucht, H | 1 |
| Goosenberg, E | 1 |
| Beard, M | 2 |
| Weiner, LM | 4 |
| Faust, J | 2 |
| Yao, J | 3 |
| Stevens, C | 1 |
| Vaporciyan, A | 4 |
| Smythe, R | 5 |
| Rice, D | 2 |
| Roth, J | 2 |
| Balart, J | 1 |
| Balmaña, J | 1 |
| Rius, X | 1 |
| Salazar, R | 2 |
| Gallen, M | 1 |
| Navarro, S | 1 |
| Arcusa, A | 1 |
| Gallardo, E | 1 |
| Brunet, J | 1 |
| Lim, JT | 2 |
| Truong, PT | 1 |
| Berthelet, E | 1 |
| Pai, H | 1 |
| Joe, H | 1 |
| Wai, E | 1 |
| Larsson, S | 1 |
| Kader, HA | 1 |
| Weinerman, B | 1 |
| Olivotto, IA | 1 |
| Anderson, SE | 2 |
| Bains, M | 3 |
| Taguchi, S | 1 |
| Kaneko, M | 2 |
| Nishizawa, S | 2 |
| Kinoshita, H | 1 |
| Iizuka, T | 5 |
| Ishida, K | 9 |
| Takiyama, W | 3 |
| Isono, K | 4 |
| Ikeuchi, S | 2 |
| Kabuto, T | 4 |
| Kinjo, Y | 1 |
| Assersohn, L | 1 |
| Ward, C | 2 |
| Waters, JS | 2 |
| Hill, ME | 3 |
| Giglio, P | 1 |
| Tremont-Lukats, IW | 1 |
| Groves, MD | 1 |
| Gibson, MK | 3 |
| Abraham, SC | 1 |
| Heitmiller, RF | 2 |
| Heath, E | 1 |
| Forastiere, A | 4 |
| Samuel, J | 1 |
| Flood, TP | 1 |
| Agbemadzo, B | 1 |
| Renta, V | 1 |
| Mullai, N | 1 |
| Osafo, DC | 1 |
| Holloway, N | 1 |
| Cohen, JA | 1 |
| Borley, A | 1 |
| Perschky, L | 1 |
| Kehagioglou, P | 1 |
| Court, J | 2 |
| Maughan, TS | 2 |
| Yamamoto, J | 1 |
| Asaka, M | 1 |
| Takahashi, S | 2 |
| Kondo, M | 1 |
| Kudo, T | 1 |
| Shimokuni, T | 2 |
| Maeda, Y | 1 |
| Honnma, S | 1 |
| Shinohara, T | 1 |
| Kohashi, S | 1 |
| Todo, S | 1 |
| Mulligan, ED | 1 |
| Dunne, B | 2 |
| Keeling, N | 2 |
| Reynolds, JV | 6 |
| Berkey, BA | 1 |
| Gaspar, LE | 5 |
| Herskovic, A | 9 |
| Gunderson, LL | 2 |
| Ho, HS | 1 |
| Ong, HS | 1 |
| Victorzon, M | 1 |
| Tolonen, P | 1 |
| Kohonen, M | 1 |
| Salmo, M | 1 |
| Kim, SH | 2 |
| Morris, J | 1 |
| Lynch, PM | 3 |
| Cohen, DS | 1 |
| Nivers, R | 1 |
| Saletti, P | 1 |
| Ghielmini, M | 1 |
| Martinoli, S | 1 |
| Goldhirsch, A | 1 |
| Miyazono, F | 2 |
| Doerfler, W | 1 |
| Aikou, T | 8 |
| Sai, H | 1 |
| Yamauchi, C | 1 |
| Okumura, S | 1 |
| Gupta, D | 1 |
| Ross, K | 1 |
| Piacentino, V | 1 |
| Stepnowski, D | 1 |
| McClurken, JB | 1 |
| Furukawa, S | 1 |
| Dempsey, DT | 1 |
| Reilly, EM | 1 |
| Delaunoit, T | 1 |
| Maréchal, R | 1 |
| Hendlisz, A | 2 |
| Eisendrath, P | 1 |
| Legendre, H | 1 |
| Pector, JC | 1 |
| De Becker, D | 1 |
| Bleiberg, H | 3 |
| Krauss, N | 1 |
| Baum, U | 1 |
| Sezer, O | 1 |
| Benninger, J | 1 |
| Voelter, V | 2 |
| Busch, R | 6 |
| Choi, N | 1 |
| Park, SD | 1 |
| Lynch, T | 1 |
| Wright, C | 2 |
| Ancukiewicz, M | 1 |
| Wain, J | 1 |
| Donahue, D | 1 |
| Mathisen, D | 1 |
| Patonay, P | 3 |
| Naszály, A | 3 |
| Mayer, A | 3 |
| Bessell, JR | 3 |
| Beller, E | 1 |
| Martin, I | 1 |
| Doyle, L | 1 |
| Burmeister, E | 1 |
| Morimatsu, M | 1 |
| Jeter, M | 2 |
| Guerrero, T | 2 |
| Stevens, CW | 3 |
| Putnam, J | 2 |
| Allen, P | 2 |
| Higashino, M | 1 |
| Maish, M | 1 |
| Bresalier, R | 1 |
| Macapinlac, H | 1 |
| Munden, RF | 1 |
| Taillier, G | 1 |
| Van Seuningen, I | 1 |
| Imdahl, A | 2 |
| Schöffel, U | 1 |
| Ruf, G | 1 |
| Hopf, UT | 1 |
| Naughton, P | 1 |
| Walsh, TN | 3 |
| Brücher, BL | 2 |
| Stein, HJ | 3 |
| Werner, M | 1 |
| Dittler, HJ | 1 |
| Fink, U | 5 |
| Pozzo, C | 1 |
| Szanto, J | 1 |
| Padi, E | 1 |
| Bükki, J | 1 |
| Biakhov, M | 1 |
| Zuber, E | 1 |
| Jacques, C | 1 |
| Raab, B | 1 |
| Mai, S | 1 |
| Wenz, F | 2 |
| Willeke, F | 1 |
| Emig, M | 1 |
| Buchheidt, D | 1 |
| Allen, PK | 1 |
| Xia, ZJ | 1 |
| Chang, JH | 1 |
| Jiang, WQ | 2 |
| Liu, JW | 2 |
| Hu, XH | 2 |
| Wu, GH | 1 |
| Wang, HQ | 1 |
| Chen, ZC | 1 |
| Chen, JC | 1 |
| Zhou, QH | 1 |
| Lu, JW | 1 |
| Lukaschek, J | 1 |
| Nufer, M | 1 |
| Maurer, D | 1 |
| Asanger, M | 1 |
| Honegger, H | 1 |
| Widmer, L | 1 |
| Malet-Martino, M | 1 |
| Legay, R | 1 |
| Martino, R | 1 |
| Pócza, K | 1 |
| Kovács, L | 1 |
| Král, V | 1 |
| Neoral, C | 1 |
| Aujeský, R | 1 |
| Havlík, R | 1 |
| Klein, J | 1 |
| Hajdúch, M | 1 |
| Benes, P | 1 |
| Vrba, R | 1 |
| Alter, P | 1 |
| Herzum, M | 1 |
| Schaefer, JR | 1 |
| Maisch, B | 1 |
| Govindan, R | 1 |
| McLeod, H | 1 |
| Mantravadi, P | 1 |
| Fineberg, N | 1 |
| Helft, P | 1 |
| Kesler, K | 1 |
| Stoner, C | 1 |
| Ansari, R | 1 |
| Fox, E | 1 |
| Seung, SK | 2 |
| Smith, JW | 2 |
| Molendyk, J | 1 |
| Bader, SB | 1 |
| Phillips, M | 1 |
| Regan, J | 1 |
| Louie, J | 1 |
| Soo, E | 1 |
| Seligman, M | 1 |
| Ruzich, J | 1 |
| Skokan, L | 1 |
| Ross, HJ | 2 |
| Schneider, S | 1 |
| Uchida, K | 1 |
| Yochim, J | 1 |
| Salonga, D | 1 |
| Chen, P | 1 |
| Tsao-Wei, D | 1 |
| Groshen, S | 1 |
| Danenberg, PV | 2 |
| Magné, N | 1 |
| Touati, L | 1 |
| Marcy, PY | 1 |
| Van Houtte, P | 2 |
| Lagrange, JL | 1 |
| Morita, N | 1 |
| Kashihara, K | 1 |
| Tagashira, H | 1 |
| Otsuka, H | 1 |
| Yoneda, K | 2 |
| Murase, T | 1 |
| Tsujikawa, T | 1 |
| Furutani, S | 1 |
| Furutani, K | 1 |
| Minato, M | 1 |
| Nishitani, H | 2 |
| Yamagishi, H | 1 |
| Itoi, H | 1 |
| Fuji, N | 1 |
| Takatori, H | 2 |
| Chan, L | 1 |
| Yeo, W | 1 |
| Griffith, J | 1 |
| Chan, AT | 1 |
| Joshi, MB | 1 |
| Shirota, Y | 1 |
| Conlon, DH | 1 |
| Salonga, DS | 1 |
| Herndon, JE | 2 |
| Harpole, DH | 3 |
| Momokawa, K | 1 |
| Mikami, T | 1 |
| Stahl, M | 8 |
| Stuschke, M | 4 |
| Lehmann, N | 1 |
| Meyer, HJ | 3 |
| Walz, MK | 3 |
| Seeber, S | 4 |
| Klump, B | 1 |
| Budach, W | 2 |
| Teichmann, R | 1 |
| Schmitt, G | 1 |
| Franke, C | 1 |
| Chen, EC | 3 |
| Cai, L | 4 |
| Lin, HX | 3 |
| Wang, HY | 3 |
| Cui, NJ | 4 |
| Chong, G | 1 |
| Cervantes, A | 1 |
| Manzano, H | 1 |
| Chirivella, I | 1 |
| Marfa, X | 1 |
| Ichiki, Y | 1 |
| Yano, K | 1 |
| Sugio, K | 1 |
| Yasumoto, K | 2 |
| Hirose, N | 1 |
| Hokita, S | 2 |
| Xi, H | 2 |
| Higashi, H | 1 |
| Gu, MF | 1 |
| Pedrazzani, C | 4 |
| Laterza, E | 3 |
| Bernini, M | 3 |
| Zerman, G | 2 |
| Tasselli, S | 1 |
| Ruzzenente, A | 2 |
| Makimoto, H | 1 |
| Hamana, N | 1 |
| Shirasaka, D | 2 |
| Morita, Y | 1 |
| Yamada, H | 1 |
| Kasuga, M | 2 |
| Inutsuka, H | 1 |
| Naoi, Y | 2 |
| Yokoyama, S | 1 |
| Mauer, AM | 1 |
| Kraut, EH | 1 |
| Krauss, SA | 1 |
| Ansari, RH | 1 |
| Kasza, K | 1 |
| Szeto, L | 1 |
| Vokes, EE | 3 |
| Harper-Wynne, C | 1 |
| Tebbutt, N | 1 |
| Duyster, J | 1 |
| Lersch, C | 1 |
| von Delius, S | 1 |
| Hennig, M | 2 |
| Bredenkamp, R | 2 |
| Gabbani, M | 1 |
| Griso, C | 1 |
| Guglielmi, A | 1 |
| Pelosi, G | 1 |
| Maluta, S | 1 |
| Cetto, GL | 1 |
| Liu, BD | 1 |
| Zhi, XY | 1 |
| Xu, QS | 1 |
| Serkies, K | 1 |
| Badzio, A | 1 |
| Yokomakura, N | 1 |
| Takao, S | 2 |
| Abou-Jawde, RM | 1 |
| Mekhail, T | 1 |
| Mazzone, PJ | 1 |
| Caroll, MA | 1 |
| Nishikawa, T | 1 |
| Okuyama, M | 2 |
| Ohta, H | 1 |
| Tsuchiya, N | 1 |
| Oyake, J | 1 |
| Okur, A | 1 |
| Kantarci, M | 1 |
| Akgun, M | 1 |
| Alper, F | 1 |
| Cayir, K | 1 |
| Koc, M | 1 |
| Onbas, O | 1 |
| Tsai, JY | 1 |
| Iannitti, D | 2 |
| Berkenblit, A | 2 |
| Akerman, P | 3 |
| Nadeem, A | 1 |
| Rathore, R | 1 |
| Harrington, D | 2 |
| Roye, D | 1 |
| Miner, T | 3 |
| Barnett, JM | 1 |
| Maia, C | 1 |
| Stuart, K | 2 |
| Safran, H | 3 |
| Dimri, K | 1 |
| Balachandran, P | 1 |
| Kumar, A | 1 |
| Lal, P | 1 |
| Sikora, SS | 1 |
| Rastogi, N | 1 |
| Saxena, R | 1 |
| Datta, NR | 1 |
| Ayyagari, S | 1 |
| Kapoor, VK | 1 |
| Fodor, MB | 1 |
| Tjulandin, SA | 1 |
| Moiseyenko, VM | 3 |
| Chao, Y | 3 |
| Cabral Filho, S | 1 |
| Majlis, A | 3 |
| Assadourian, S | 1 |
| Morgan-Meadows, S | 1 |
| Mulkerin, D | 1 |
| Bailey, H | 1 |
| Saphner, T | 1 |
| Jumonville, A | 1 |
| Hansen, R | 1 |
| Ahuja, H | 1 |
| McFarland, T | 1 |
| Thomas, JP | 1 |
| Abdel-Latif, MM | 2 |
| O'Riordan, JM | 1 |
| Ravi, N | 1 |
| Kelleher, D | 2 |
| Fitzgerald, L | 1 |
| Simes, RJ | 1 |
| Devitt, P | 3 |
| Millar, J | 1 |
| North, J | 1 |
| Mark Smithers, B | 1 |
| Hung, SK | 1 |
| Huang, CJ | 1 |
| Chen, CC | 1 |
| Chen, MJ | 1 |
| Chang, CC | 1 |
| Tai, CJ | 1 |
| Tzen, CY | 1 |
| Lu, LH | 1 |
| Ohashi, M | 1 |
| Shimizu, K | 1 |
| Toge, T | 5 |
| Lee, KE | 1 |
| Kang, WK | 2 |
| Piehler, JM | 1 |
| Asakura, H | 1 |
| Takashima, H | 1 |
| Yokoe, K | 1 |
| Togami, T | 1 |
| Mitani, M | 3 |
| Kiuchi, T | 1 |
| Hosokawa, N | 1 |
| Seo, H | 1 |
| Ohkawa, M | 1 |
| Muto, A | 1 |
| Miyazawa, M | 1 |
| Tsukada, M | 1 |
| Ohtani, S | 1 |
| Endoh, H | 1 |
| Koyama, K | 1 |
| Satoh, M | 1 |
| Vuong, T | 1 |
| Szego, P | 1 |
| Parent, J | 1 |
| Mayrand, S | 1 |
| Corns, R | 1 |
| Burtin, P | 2 |
| Faria, S | 1 |
| Devic, S | 1 |
| Koishi, K | 1 |
| Nakao, K | 2 |
| Yagyu, R | 1 |
| Nishiwaki, M | 1 |
| Kojima, S | 1 |
| Yamamura, T | 1 |
| Raderer, M | 1 |
| Wang, SL | 2 |
| Tucker, SL | 2 |
| Wei, X | 2 |
| Ewald, P | 3 |
| Bekesch, M | 1 |
| Lorchel, F | 1 |
| Mantion, G | 1 |
| Buffet, J | 1 |
| Bosset, M | 2 |
| Chaigneau, L | 1 |
| Servagi, S | 1 |
| Jatoi, A | 3 |
| Murphy, BR | 1 |
| Foster, NR | 2 |
| Nikcevich, DA | 2 |
| Knost, JA | 1 |
| Fitch, TR | 2 |
| Rowland, KM | 1 |
| Tago, M | 3 |
| Sasano, N | 2 |
| Cavanna, L | 1 |
| Lazzaro, A | 1 |
| Trabacchi, E | 1 |
| Anselmi, E | 1 |
| Vallisa, D | 1 |
| Foroni, RP | 1 |
| Dobelbower, MC | 1 |
| Russo, SM | 1 |
| Raisch, KP | 1 |
| Seay, LL | 1 |
| Clemons, LK | 1 |
| Suter, S | 1 |
| Posey, J | 1 |
| Bonner, JA | 1 |
| Ling, FC | 1 |
| Moenig, S | 1 |
| Raouf, AA | 1 |
| Sabra, K | 1 |
| von Weyhern, C | 1 |
| Weirich, G | 1 |
| Pühringer-Oppermann, F | 2 |
| Gunji, Y | 2 |
| Uno, T | 3 |
| Tripp, P | 1 |
| Malhotra, HK | 1 |
| Shaukat, A | 1 |
| Russo, R | 1 |
| De Boer, S | 1 |
| Podgorsak, M | 1 |
| Nava, H | 3 |
| Yang, GY | 1 |
| Minnich, DJ | 1 |
| Camp, ER | 1 |
| Brank, A | 1 |
| Mackay, SL | 1 |
| Cominos, M | 1 |
| Mosleh-Shirazi, MA | 1 |
| Henrys, A | 1 |
| Cornes, P | 1 |
| Chiang, SS | 2 |
| Malhotra, U | 1 |
| Ensor, J | 1 |
| Luthra, R | 1 |
| Chao, KS | 1 |
| Hittelman, WN | 2 |
| Aggarwal, BB | 1 |
| Takigawa, J | 1 |
| Haraguchi, Y | 1 |
| Henry, LR | 1 |
| Scott, W | 1 |
| Konski, A | 1 |
| Freedman, G | 1 |
| Watts, P | 1 |
| McLaughlin, S | 1 |
| Araki, H | 2 |
| Iyama, S | 1 |
| Abe, S | 1 |
| Murase, K | 1 |
| Nagakura, H | 1 |
| Hareyama, M | 1 |
| Niitsu, Y | 1 |
| Wadleigh, RG | 3 |
| Abbasi, S | 1 |
| Korman, L | 1 |
| Giordano, KF | 1 |
| Stella, PJ | 1 |
| Foster, N | 1 |
| Tschetter, LK | 2 |
| Dakhil, SR | 1 |
| Mailliard, JA | 1 |
| Flynn, PJ | 1 |
| Okuno, Y | 1 |
| Kusumi, F | 4 |
| Takakuwa, H | 1 |
| Matsusue, S | 3 |
| Nakata, E | 1 |
| Kitabayashi, H | 1 |
| Kamata, T | 1 |
| Tsujii, H | 1 |
| Shakuto, S | 1 |
| Fujita, F | 1 |
| Baker, J | 1 |
| Oortgiesen, M | 1 |
| Eduljee, A | 1 |
| Michaeli, D | 1 |
| Kaur, T | 2 |
| Khanduja, KL | 2 |
| Kaushik, T | 1 |
| Kaushik, G | 1 |
| Gupta, R | 2 |
| Gupta, NM | 2 |
| Vaiphei, K | 2 |
| Rades, D | 1 |
| Tribius, S | 1 |
| Yekebas, EF | 1 |
| Bahrehmand, R | 1 |
| Wildfang, I | 1 |
| Kilic, E | 1 |
| Muellerleile, U | 1 |
| Gross, E | 1 |
| Schild, SE | 1 |
| Alberti, W | 1 |
| Masuda, A | 1 |
| Tongu, M | 1 |
| Hiraku, O | 1 |
| Etou, T | 1 |
| Atsuda, K | 1 |
| Suzuki, Y | 1 |
| Osaku, M | 1 |
| Miyagawa, T | 1 |
| Asanuma, F | 1 |
| Forshaw, MJ | 2 |
| Chrystal, K | 2 |
| Cheong, K | 2 |
| Atkinson, S | 1 |
| Botha, A | 1 |
| Harper, PG | 5 |
| Mason, RC | 4 |
| Burge, ME | 1 |
| Topham, C | 1 |
| Jackson, DP | 1 |
| Anthoney, DA | 1 |
| Halstead, F | 1 |
| Valencia Julve, J | 1 |
| Alonso Orduña, V | 1 |
| Escó Barón, R | 1 |
| López-Mata, M | 1 |
| Méndez Villamón, A | 1 |
| Ashida, A | 1 |
| Corporaal, S | 1 |
| Smit, WM | 1 |
| Russel, MG | 1 |
| van der Palen, J | 1 |
| Legdeur, MC | 1 |
| Abraham, J | 1 |
| Brewster, A | 1 |
| Hardwick, R | 1 |
| Havard, T | 1 |
| Lewis, W | 1 |
| Askill, C | 1 |
| Manson, J | 1 |
| Williamst, GT | 1 |
| Mafune, K | 1 |
| Roof, KS | 1 |
| Coen, J | 1 |
| Lynch, TJ | 2 |
| Fidias, P | 1 |
| Choi, NC | 7 |
| Lamblin, A | 1 |
| Gábor, B | 1 |
| György, L | 1 |
| Pál, O | 1 |
| Etzel, CJ | 1 |
| Amos, CI | 1 |
| Milas, L | 1 |
| Abbrederis, K | 1 |
| Kurahashi, T | 2 |
| Kuwahara, M | 2 |
| Mizutani, Y | 1 |
| Thompson, JN | 1 |
| Van de Velde, CJ | 1 |
| Scarffe, JH | 3 |
| Lofts, FJ | 1 |
| Smith, DB | 1 |
| Verma, M | 1 |
| Weeden, S | 1 |
| Lecleire, S | 1 |
| Rigal, O | 1 |
| Ben Soussan, E | 1 |
| David, I | 1 |
| Jacob, JH | 3 |
| Wen, HT | 1 |
| Zhang, YH | 1 |
| Wu, LY | 1 |
| Gao, YJ | 1 |
| Guan, XQ | 1 |
| Nan, KJ | 1 |
| Suo, AL | 1 |
| Wang, XW | 1 |
| Zhang, MH | 1 |
| Zhang, WD | 1 |
| Li, CW | 1 |
| Zhao, JB | 1 |
| Marini, A | 1 |
| Hengge, UR | 1 |
| Munakata, M | 1 |
| Ishiguro, A | 1 |
| Hoshi, Y | 1 |
| Okada, R | 1 |
| Tomioka, R | 1 |
| Mitobe, S | 1 |
| Sakata, Y | 3 |
| Ebina, A | 1 |
| Honda, J | 3 |
| Umemoto, A | 2 |
| Qiu, XH | 1 |
| Yang, YX | 1 |
| Zhang, SQ | 1 |
| Chen, ZM | 1 |
| Sekikawa, K | 1 |
| Onogi, H | 1 |
| Yazawa, T | 1 |
| Sakamoto, W | 1 |
| Endo, Y | 1 |
| Ohki, S | 1 |
| Takenoshita, S | 1 |
| Santeufemia, DA | 1 |
| Piredda, G | 1 |
| Fadda, GM | 1 |
| Cossu Rocca, P | 1 |
| Costantino, S | 1 |
| Sanna, G | 1 |
| Sarobba, MG | 1 |
| Pinna, MA | 1 |
| Putzu, C | 1 |
| Farris, A | 1 |
| Ono, S | 1 |
| Chochi, K | 1 |
| Ichikura, T | 1 |
| Mochizuki, H | 1 |
| Yang, CH | 2 |
| Lin, JT | 1 |
| Dawson, SJ | 1 |
| Michael, M | 1 |
| Biagi, J | 1 |
| Foo, KF | 1 |
| Jefford, M | 2 |
| Ngan, SY | 2 |
| Leong, T | 1 |
| Hui, A | 1 |
| Milner, AD | 1 |
| Thomas, RJ | 1 |
| Huang, WZ | 1 |
| Wang, XS | 1 |
| Zhang, CQ | 1 |
| Kim, DW | 1 |
| Shyr, Y | 1 |
| Berlin, J | 1 |
| Beauchamp, RD | 1 |
| Chakravarthy, B | 1 |
| Prenzel, KL | 1 |
| König, A | 1 |
| Schnickmann, C | 1 |
| Izbicki, JR | 1 |
| Lawrence, D | 1 |
| Nava, E | 2 |
| Proulx, G | 2 |
| Clark, K | 1 |
| Berdzik, J | 2 |
| Greco, W | 2 |
| Smith, P | 2 |
| Creaven, PJ | 1 |
| Kepner, JL | 1 |
| Lowy, AM | 1 |
| Roychowdhury, D | 1 |
| Redmond, K | 1 |
| Howington, JA | 1 |
| Sussman, JJ | 1 |
| Safa, M | 1 |
| Ahmad, SA | 1 |
| Reed, MF | 1 |
| Rose, P | 1 |
| James, L | 1 |
| Jazieh, AR | 1 |
| Di Fabio, F | 1 |
| Siena, S | 1 |
| Rojas Llimpe, FL | 1 |
| Ceccarelli, C | 1 |
| Mutri, V | 1 |
| Giannetta, L | 1 |
| Giaquinta, S | 1 |
| Funaioli, C | 1 |
| Berardi, R | 1 |
| Longobardi, C | 1 |
| Piana, E | 1 |
| Martoni, AA | 1 |
| Shi, YX | 1 |
| Huang, H | 1 |
| Ma, ZY | 1 |
| Wang, JH | 1 |
| Xie, WM | 1 |
| Li, XG | 1 |
| Liu, YL | 1 |
| Dai, AD | 1 |
| Zhuang, W | 1 |
| Sakayori, M | 1 |
| Chiba, N | 1 |
| Shimodaira, H | 2 |
| Ohtsuka, K | 2 |
| Kakudo, Y | 1 |
| González-González, JJ | 1 |
| Sanz-Alvarez, L | 1 |
| Marqués-Alvarez, L | 1 |
| Navarrete-Guijosa, F | 1 |
| Martínez-Rodríguez, E | 1 |
| Kelsey, CR | 2 |
| Fernando, NH | 1 |
| Honeycutt, W | 1 |
| Yu, D | 1 |
| Horváth Ors, P | 1 |
| Kalmár, K | 2 |
| Yousuf, AF | 1 |
| Esik, O | 1 |
| Takada, K | 1 |
| Oota, Y | 1 |
| Isobe, K | 1 |
| Ueno, N | 1 |
| Kawata, T | 1 |
| Boso, C | 1 |
| Mazzarotto, R | 1 |
| Tomassi, O | 1 |
| Poligone, B | 1 |
| Christensen, SR | 1 |
| Lazova, R | 1 |
| Heald, PW | 1 |
| Minicozzi, AM | 1 |
| Ozyiğit, T | 1 |
| Buğra, Z | 1 |
| Dhillon, S | 1 |
| Scott, LJ | 2 |
| Ou, SH | 1 |
| Holcombe, RF | 1 |
| Sakai, K | 4 |
| Inakoshi, H | 2 |
| Sueyama, H | 7 |
| Sugita, T | 4 |
| Tsuchida, E | 3 |
| Yamanoi, T | 1 |
| Abe, E | 1 |
| Yamana, N | 1 |
| Kawano, S | 1 |
| Kusunoki, R | 1 |
| Aimi, M | 1 |
| Higashi, R | 1 |
| Ishii, Y | 1 |
| Fujishiro, H | 1 |
| Okada, H | 1 |
| Shiratori, Y | 1 |
| Zuccaro, G | 4 |
| Vargo, JJ | 2 |
| Dumot, JA | 2 |
| Carroll, MA | 1 |
| van Meerten, E | 1 |
| Eskens, FA | 1 |
| van Gameren, EC | 1 |
| Doorn, L | 1 |
| Yoshizumi, Y | 1 |
| Ishizuka, T | 1 |
| Sakano, T | 1 |
| Kumano, I | 1 |
| Sugiura, Y | 1 |
| Zou, K | 1 |
| Ju, JH | 1 |
| Xie, H | 1 |
| Briez, N | 1 |
| Hummer, A | 1 |
| Kelsen, D | 4 |
| Kadowaki, Y | 1 |
| Peignaux, K | 2 |
| Servagi-Vernat, S | 1 |
| Maingon, P | 2 |
| Masuoka, T | 1 |
| Ding, F | 1 |
| Luo, A | 1 |
| Chen, A | 1 |
| Yu, Z | 1 |
| Ren, S | 1 |
| Watanabe, S | 1 |
| Kawahara, K | 1 |
| Teshima, T | 1 |
| Briasoulis, E | 1 |
| Fatouros, M | 1 |
| Roukos, DH | 1 |
| Carstens, H | 1 |
| Albertsson, M | 6 |
| Gardner-Thorpe, J | 1 |
| Dwerryhouse, SJ | 1 |
| Shibata, Y | 1 |
| Ariyama, H | 1 |
| Miki, R | 1 |
| Ogami, N | 1 |
| Arita, S | 1 |
| Qin, B | 1 |
| Mitsugi, K | 1 |
| Noshiro, H | 1 |
| Yao, T | 1 |
| Nakano, S | 3 |
| Constenla, M | 2 |
| Boni, C | 2 |
| Rodrigues, A | 2 |
| Fodor, M | 3 |
| Voznyi, E | 2 |
| Marabotti, C | 1 |
| Awad, L | 1 |
| Hanazono, K | 1 |
| Oowaki, T | 1 |
| Arimura, K | 1 |
| Mortimer, J | 2 |
| Estes, NC | 1 |
| Haller, DG | 3 |
| Kocha, W | 2 |
| Kawabe, S | 1 |
| Ohta, S | 1 |
| Kuwakado, S | 1 |
| Katsu, K | 1 |
| Deeks, ED | 1 |
| Hsu, C | 1 |
| Hsu, WL | 1 |
| Evans, D | 2 |
| Millis, R | 1 |
| Jean, M | 1 |
| Kennedy, T | 2 |
| Hong, YS | 1 |
| Lee, HR | 1 |
| Kim, HS | 1 |
| Kim, MJ | 1 |
| Lee, WB | 1 |
| Sy, HM | 1 |
| Filip, DJ | 1 |
| Grossniklaus, HE | 1 |
| Kazama, T | 1 |
| Yanagawa, N | 1 |
| Kikuta, S | 1 |
| Asakage, T | 1 |
| Sugasawa, M | 1 |
| Blanchard, P | 1 |
| Cruff, D | 1 |
| Maia-Acuna, C | 1 |
| Habr, F | 1 |
| Chauhan, B | 1 |
| Sears, D | 1 |
| Chino, JP | 1 |
| Clough, RW | 1 |
| van de Schoot, L | 1 |
| Romme, EA | 1 |
| van Lijnschoten, G | 1 |
| van Driel, OJ | 1 |
| Morgan, MA | 1 |
| Harvard, TJ | 1 |
| Clark, GW | 1 |
| Cen, P | 1 |
| Lair, BS | 1 |
| Nichols, F | 1 |
| Moore, DF | 1 |
| Ott, N | 1 |
| Sujendran, V | 1 |
| Wheeler, J | 1 |
| Baron, R | 1 |
| Warren, BF | 1 |
| Maynard, N | 1 |
| Lee, SS | 1 |
| Mori, N | 1 |
| Nagano, T | 1 |
| Meric, JB | 1 |
| N'guyen, TD | 1 |
| Marchal, C | 1 |
| Verrelle, P | 1 |
| Roullet, B | 1 |
| Liang, RX | 1 |
| Qu, FS | 1 |
| Yan, TX | 1 |
| Sun, YH | 1 |
| Li, XQ | 1 |
| Sarrazin, T | 1 |
| Lartigau, E | 1 |
| Tomura, K | 1 |
| Yoneyama, K | 3 |
| Kiuchi, Y | 2 |
| Wong, SK | 1 |
| Cheung, KY | 1 |
| Au-Yeung, AC | 1 |
| Chung, SS | 1 |
| Hosono, Y | 1 |
| Weber, WA | 1 |
| Wieder, H | 1 |
| Schwaiger, M | 1 |
| Mera, K | 1 |
| Brunner, TB | 1 |
| Rupp, A | 1 |
| Melzner, W | 1 |
| Grabenbauer, GG | 1 |
| Sauer, R | 1 |
| Ishiguro, H | 1 |
| Kuwabara, Y | 3 |
| Mitsui, A | 3 |
| Sugito, N | 1 |
| Mori, R | 1 |
| Katada, T | 1 |
| Tanimoto, K | 1 |
| Hiyama, K | 1 |
| Otani, K | 1 |
| Ohtaki, M | 1 |
| Hiyama, E | 1 |
| Koutras, AK | 1 |
| Gerolymos, MK | 1 |
| Kontogeorgou, E | 1 |
| Iconomou, G | 1 |
| Vourli, G | 1 |
| Tsiata, E | 1 |
| Makatsoris, T | 1 |
| Chrysanthopoulos, C | 1 |
| Kalofonos, HP | 1 |
| Borghesi, S | 1 |
| Tepper, J | 1 |
| Krasna, MJ | 2 |
| Hollis, D | 1 |
| Reed, CE | 1 |
| Goldberg, R | 1 |
| Kiel, K | 1 |
| Willett, C | 1 |
| Sugarbaker, D | 1 |
| Mayer, R | 1 |
| Liu, HH | 1 |
| Hu, C | 1 |
| Mohan, R | 1 |
| Zhao, YN | 1 |
| Asaumi, J | 1 |
| Hollerbach, S | 1 |
| Wilhelm, G | 1 |
| Schuch, G | 1 |
| Derigs, HG | 1 |
| Grossmann, J | 1 |
| Knuth, A | 1 |
| Yan, D | 1 |
| Wei, WQ | 1 |
| Liu, DZ | 1 |
| Zeng, HY | 1 |
| Yang, LX | 1 |
| Funada, N | 1 |
| Fabrício, Vde C | 1 |
| Amado, F | 1 |
| Zhang, YW | 1 |
| Chen, ZW | 1 |
| Zhou, XY | 1 |
| Luo, QQ | 1 |
| Hu, H | 1 |
| Miao, LS | 1 |
| Ma, LF | 1 |
| Xiang, JQ | 1 |
| Shirao, K | 2 |
| Akatsuka, S | 1 |
| Matsubara, J | 1 |
| Asakawa, T | 1 |
| Hamguchi, T | 1 |
| Bölke, E | 1 |
| Hasuike, N | 1 |
| Inui, T | 1 |
| Yamaguchi, Y | 1 |
| Ono, H | 1 |
| Tomimaru, Y | 1 |
| Pennathur, A | 1 |
| Landreneau, RJ | 1 |
| Ward, J | 1 |
| Christie, NA | 1 |
| Schuchert, M | 1 |
| Cooper, K | 1 |
| Land, SR | 1 |
| Belani, CP | 2 |
| Coia, LR | 10 |
| Engstrom, PF | 5 |
| Paul, A | 2 |
| Gallagher, MJ | 1 |
| Stoll, D | 1 |
| Catalano, R | 1 |
| Richter, MP | 1 |
| Gainza, V | 1 |
| Csendes, A | 1 |
| Byfield, JE | 1 |
| Barone, R | 1 |
| Mendelsohn, J | 1 |
| Frankel, S | 1 |
| Quinol, L | 1 |
| Sharp, T | 1 |
| Seagren, S | 1 |
| Bottoni, P | 1 |
| Bobba, L | 1 |
| Ranieri, MG | 1 |
| Croce, M | 1 |
| Zaietta, P | 1 |
| Provera, F | 1 |
| Kolarić, K | 2 |
| Dujmović, I | 1 |
| Hilaris, B | 1 |
| Martini, N | 1 |
| Franklin, R | 2 |
| Steiger, Z | 7 |
| Vaishampayan, G | 1 |
| Asfaw, I | 3 |
| Rosenberg, J | 2 |
| Loh, J | 1 |
| Hoschner, J | 1 |
| Miller, P | 2 |
| Seydel, HG | 4 |
| Vaitkevicius, VK | 4 |
| Ibayashi, J | 1 |
| Dindogru, A | 2 |
| Kinzie, J | 2 |
| Toben, S | 1 |
| MacKenzie, G | 1 |
| Shell, J | 1 |
| Shields, TW | 2 |
| Rosen, ST | 2 |
| Hellerstein, SM | 1 |
| Tsang, T | 1 |
| Ujiki, GT | 1 |
| Kies, MS | 2 |
| Gisselbrecht, C | 3 |
| Calvo, F | 2 |
| Mignot, L | 3 |
| Pujade, E | 2 |
| Bouvry, M | 2 |
| Danne, O | 2 |
| Belpomme, D | 3 |
| Marty, M | 3 |
| Matsuoka, S | 1 |
| Maezawa, S | 1 |
| Sakuma, M | 1 |
| Ohira, S | 1 |
| Wakui, A | 2 |
| Iwanaga, T | 1 |
| Terasawa, T | 1 |
| Mathé, G | 1 |
| Boiron, M | 1 |
| Morvan, F | 2 |
| Tattersall, MH | 1 |
| Bedikian, AY | 1 |
| Valdivieso, M | 2 |
| Bodey, GP | 1 |
| Trux, F | 1 |
| Karlin, DA | 1 |
| Stroehlein, JR | 1 |
| Bennetts, RW | 1 |
| Jones, RD | 1 |
| Heifetz, LJ | 1 |
| Mahal, PS | 1 |
| Wilson, RF | 1 |
| Seydel, H | 1 |
| Loh, JJ | 1 |
| Vaishamapayan, G | 1 |
| Knechtges, T | 1 |
| Rosenberg, JC | 2 |
| Buroker, T | 1 |
| Torres, A | 1 |
| Hoschner, D | 1 |
| Pietruk, T | 1 |
| Vaitkevicius, V | 2 |
| Lin, PZ | 2 |
| Cai, HY | 2 |
| Shu, YJ | 1 |
| Wang, GQ | 1 |
| Wu, AR | 1 |
| Liu, SF | 1 |
| Li, MX | 1 |
| Van der Veer, LD | 1 |
| Balint, JA | 1 |
| Ezdinli, EZ | 1 |
| Gelber, R | 1 |
| Desai, DV | 1 |
| Falkson, G | 4 |
| Moertel, CG | 2 |
| Hahn, RG | 1 |
| Wagatsuma, Y | 1 |
| Ishikawa, S | 1 |
| Wakasugi, S | 1 |
| Yagawa, H | 1 |
| Mah, K | 1 |
| Keane, TJ | 2 |
| Van Dyk, J | 1 |
| Braban, LE | 1 |
| Poon, PY | 1 |
| Turrisi, AT | 1 |
| Highley, MS | 2 |
| Parnis, FX | 1 |
| Trotter, GA | 1 |
| Houston, SJ | 1 |
| Penson, RT | 1 |
| Kitajima, M | 2 |
| Liew, CT | 1 |
| Li, AK | 1 |
| Julienne, V | 1 |
| Gosselin, M | 1 |
| Launois, B | 5 |
| Lozac'h, P | 4 |
| Reddy, SP | 1 |
| Lad, T | 1 |
| Mullane, M | 1 |
| Rosen, F | 1 |
| Carroll, R | 1 |
| Marks, JE | 1 |
| Ishiguro, S | 1 |
| Nakano, H | 1 |
| Nakamori, S | 2 |
| Hiratsuka, M | 1 |
| Kameyama, M | 1 |
| Akiyama, S | 3 |
| Nonami, T | 1 |
| Kasai, Y | 3 |
| Hibi, K | 1 |
| Takagi, H | 2 |
| Tenawa, A | 1 |
| Muramoto, H | 1 |
| Katoh, E | 1 |
| Fuwa, N | 2 |
| Lee, KH | 1 |
| Lee, JW | 1 |
| Kim, SW | 1 |
| Suh, CW | 1 |
| Chang, HS | 1 |
| Yu, L | 2 |
| Vikram, B | 2 |
| Malamud, S | 2 |
| Yudelman, I | 1 |
| Nussbaum, M | 1 |
| Beattie, E | 1 |
| Ohwada, S | 1 |
| Izumi, M | 1 |
| Kawashima, Y | 1 |
| Kobayashi, I | 2 |
| Hosomura, Y | 1 |
| Joshita, T | 1 |
| Lino, Y | 1 |
| Morishita, Y | 2 |
| O'Brien, M | 3 |
| Gill, PG | 5 |
| Yeoh, E | 3 |
| Hamilton, CS | 2 |
| Theodossiou, C | 2 |
| Temeck, B | 1 |
| Vargas, H | 1 |
| Vargas, M | 1 |
| Hahn, S | 1 |
| Pass, H | 1 |
| Benulic, T | 1 |
| Jancar, B | 1 |
| Roubein, LD | 1 |
| Ryan, MB | 1 |
| Natrajan, G | 1 |
| Gould, P | 1 |
| Nishino, N | 1 |
| Konno, H | 1 |
| Maruo, Y | 1 |
| Matsuda, I | 1 |
| Kanai, T | 1 |
| Loganzo, F | 1 |
| Maslak, P | 1 |
| Lai, L | 1 |
| de Oliveira, AR | 1 |
| Schwartz, GK | 1 |
| Blundell, ML | 1 |
| Altorki, NK | 1 |
| Albino, AP | 1 |
| Okamoto, M | 1 |
| Yamashita, I | 2 |
| Takemori, S | 2 |
| Karaki, Y | 1 |
| Tazawa, K | 2 |
| Fujimaki, M | 2 |
| Sirott, M | 1 |
| Saltz, L | 2 |
| Heelan, R | 2 |
| Keresztes, R | 1 |
| Reeder, LB | 1 |
| Hoffman, PC | 2 |
| Haraf, DJ | 2 |
| Drinkard, LC | 2 |
| Naunheim, KS | 2 |
| Petruska, PJ | 1 |
| Roy, TS | 2 |
| Schlueter, JM | 2 |
| Kim, H | 1 |
| Baue, AE | 2 |
| Girvin, GW | 1 |
| Matsumoto, GH | 1 |
| Bates, DM | 1 |
| Garcia, JM | 1 |
| Clyde, JC | 1 |
| Lin, PH | 1 |
| Algan, O | 1 |
| Keller, SM | 2 |
| Schultheiss, TE | 1 |
| Hanks, GE | 2 |
| Le Prise, EA | 1 |
| Meunier, BC | 1 |
| Julienne, VC | 1 |
| Gedouin, DM | 1 |
| Ben Hassel, M | 2 |
| Campion, JP | 3 |
| Kido, Y | 1 |
| Murata, A | 1 |
| Nishijima, J | 1 |
| Inoue, M | 5 |
| Sauter, ER | 1 |
| Oda, J | 1 |
| Saito, A | 2 |
| Fukura, K | 1 |
| Imamura, H | 1 |
| Kimura, S | 2 |
| Toyoyama, H | 1 |
| Hamahata, H | 1 |
| Nakai, H | 1 |
| Imakiire, K | 1 |
| Okubo, K | 1 |
| Miyaji, K | 1 |
| Bamias, A | 2 |
| Nicolson, V | 3 |
| Webb, A | 7 |
| Hickey, K | 1 |
| Grehan, D | 1 |
| Reid, IM | 1 |
| O'Briain, S | 1 |
| Hennessy, TP | 2 |
| Khansur, T | 1 |
| Allred, C | 1 |
| Tavassoli, M | 1 |
| Chadha, M | 1 |
| Wright, CD | 2 |
| Mathisen, DJ | 6 |
| Wain, JC | 4 |
| Grillo, HC | 5 |
| Hilgenberg, AD | 5 |
| Moncure, AC | 2 |
| Carey, RW | 6 |
| Daly, M | 1 |
| Logan, DL | 3 |
| Hasegawa, M | 1 |
| Higuchi, S | 1 |
| Fujita, K | 1 |
| Findlay, M | 2 |
| Mansi, J | 3 |
| Nash, A | 1 |
| Sacks, N | 1 |
| Urso, SU | 1 |
| Castaldini, G | 1 |
| Ravasi, G | 1 |
| Valente, M | 1 |
| Buswell, L | 1 |
| Recht, A | 1 |
| Clark, J | 1 |
| Ravikumar, T | 1 |
| Busse, PM | 1 |
| Coleman, CN | 1 |
| Poplin, EA | 2 |
| Khanuja, PS | 1 |
| Kraut, MJ | 1 |
| Herskovic, AM | 1 |
| Lattin, PB | 2 |
| Cummings, G | 1 |
| Kinzie, JL | 1 |
| Sewell, GJ | 1 |
| Allsopp, M | 1 |
| Collinson, MP | 1 |
| Tyrrell, C | 1 |
| Prentice, AJ | 1 |
| Copplestone, JA | 1 |
| Koizumi, H | 5 |
| Moriwaki, R | 2 |
| Hasamada, S | 1 |
| Tang, SG | 1 |
| Lin, FJ | 1 |
| Leung, WM | 1 |
| Sun, JF | 1 |
| Maddern, G | 1 |
| Gedouin, D | 1 |
| Boutin, D | 1 |
| Wihlm, J | 1 |
| Levêque, D | 1 |
| Velten, M | 1 |
| Klein, T | 1 |
| Furuya, Y | 1 |
| Ku, Y | 1 |
| Hamabe, Y | 1 |
| Saitoh, Y | 1 |
| Preusser, P | 2 |
| Berns, T | 1 |
| Achterrath, W | 2 |
| Knipp, H | 2 |
| Harstrick, A | 2 |
| Berger, M | 1 |
| Nürnberger, HR | 1 |
| Löffler, T | 1 |
| Hausamen, TU | 1 |
| Theophil, B | 1 |
| Löhlein, D | 1 |
| Koba, I | 2 |
| Ohnaka, O | 1 |
| Shimizu, W | 4 |
| Nishihira, T | 2 |
| Hirayama, K | 1 |
| Shineha, R | 2 |
| Endoh, M | 1 |
| Kakegawa, T | 2 |
| Shinozaki, K | 1 |
| Anai, H | 1 |
| Toda, T | 1 |
| Ichiyoshi, Y | 1 |
| Miura, O | 1 |
| Matsuzaki, K | 1 |
| Minamisono, Y | 1 |
| Nagasaki, S | 1 |
| Omura, K | 2 |
| Ishida, F | 2 |
| Hoff, SJ | 1 |
| Stewart, JR | 1 |
| Sawyers, JL | 1 |
| Murray, MJ | 1 |
| Merrill, WH | 1 |
| Adkins, RB | 1 |
| Johnson, DH | 1 |
| Terz, JJ | 1 |
| Leong, LA | 1 |
| Lipsett, JA | 1 |
| Wagman, LD | 1 |
| Fukano, F | 1 |
| Ziras, N | 1 |
| Samandas, N | 1 |
| Owen, W | 1 |
| Dussek, J | 1 |
| Barker, S | 1 |
| Darnton, SJ | 4 |
| Allen, SM | 2 |
| Edwards, CW | 1 |
| Matthews, HR | 3 |
| Peddada, AV | 1 |
| Harvey, JC | 1 |
| Anderson, PJ | 1 |
| Davidson, W | 1 |
| Smith, DE | 1 |
| Kagan, AR | 1 |
| Wadler, S | 4 |
| Fell, S | 3 |
| Haynes, H | 4 |
| Katz, HJ | 1 |
| Rozenblit, A | 2 |
| Kaleya, R | 1 |
| Wiernik, PH | 2 |
| Wilkins, EW | 3 |
| Bromberg, C | 2 |
| Scholz, J | 1 |
| Steinhöfel, U | 1 |
| Dürig, M | 1 |
| Prause, A | 1 |
| Bause, HW | 1 |
| Hamper, K | 1 |
| Schulte am Esch, J | 1 |
| Perez-Tamayo, C | 3 |
| Arlington, A | 1 |
| Bohorquez, J | 1 |
| Hosokawa, K | 3 |
| Cappelaere, P | 1 |
| Hecquet, B | 1 |
| Rolland, F | 1 |
| Meeus, L | 1 |
| Domenge, C | 1 |
| Krakowski, I | 1 |
| De Gislain, C | 1 |
| Chauvergne, J | 1 |
| Dufour-Esquerré, F | 1 |
| Carde, P | 1 |
| Beitler, JJ | 3 |
| Wolf, E | 2 |
| Levine, BA | 1 |
| Akagi, T | 1 |
| Takemori, H | 1 |
| Kudoh, I | 1 |
| Fukushi, M | 1 |
| Aisawa, T | 1 |
| Ishiguro, Y | 1 |
| Yoshiike, M | 1 |
| Osanai, S | 1 |
| Neuberg, D | 2 |
| Pisansky, TM | 2 |
| Ginsberg, R | 2 |
| Benson, A | 1 |
| Bates, BA | 1 |
| Detterbeck, FC | 2 |
| Bernard, SA | 2 |
| Qaqish, BF | 1 |
| Tepper, JE | 2 |
| Malhaire, JP | 2 |
| Labat, JP | 2 |
| Simon, H | 2 |
| Lucas, B | 2 |
| Topart, P | 3 |
| Volant, A | 2 |
| Pouliquen, X | 2 |
| Levard, H | 2 |
| Hay, JM | 2 |
| McGee, K | 1 |
| Fingerhut, A | 2 |
| Langlois-Zantin, O | 1 |
| Goyal, S | 1 |
| Wang, LS | 1 |
| Chi, KH | 1 |
| Hu, MH | 1 |
| Fahn, HJ | 1 |
| Huang, MH | 1 |
| Cwikiel, M | 2 |
| Cwikiel, W | 1 |
| Fett, W | 1 |
| Makoski, HB | 1 |
| Breuer, N | 1 |
| Schmidt, U | 1 |
| Niebel, W | 1 |
| Sack, H | 2 |
| Eigler, FW | 1 |
| Ahmed, FY | 1 |
| Watson, M | 2 |
| Hill, AS | 2 |
| Nicolson, MC | 1 |
| O'Brien, ME | 1 |
| Evans, TC | 1 |
| Temeck, BK | 1 |
| Liebmann, JE | 1 |
| Steinberg, SM | 1 |
| Cook, JA | 1 |
| Metz, DC | 1 |
| Shawker, TH | 1 |
| Allegra, CJ | 1 |
| Russo, A | 1 |
| Pass, HI | 1 |
| Camacho, M | 2 |
| Levine, B | 1 |
| Andreyev, HJ | 2 |
| Padhani, AR | 1 |
| Ross, PJ | 3 |
| Noonan, N | 1 |
| Hollywood, D | 1 |
| Kelly, A | 2 |
| Kumegawa, H | 1 |
| Kanazawa, M | 1 |
| Morinaga, K | 1 |
| Wang, R | 2 |
| Geara, F | 1 |
| Chauvet, B | 1 |
| Reynaud-Bougnoux, A | 2 |
| Le Floch, O | 2 |
| Roca, E | 1 |
| Pennella, E | 1 |
| Sardi, M | 1 |
| Carraro, S | 1 |
| Barugel, M | 1 |
| Milano, C | 1 |
| Fiorini, A | 1 |
| Giglio, R | 1 |
| Gonzalez, G | 1 |
| Kneitschel, R | 1 |
| Aman, E | 1 |
| Jarentchuk, A | 1 |
| Blajman, C | 1 |
| Nadal, J | 1 |
| Santarelli, MT | 1 |
| Navigante, A | 1 |
| Kok, TC | 2 |
| Splinter, TA | 2 |
| Spry, NA | 2 |
| Joseph, DJ | 1 |
| O'Brien, P | 1 |
| Walker, QJ | 1 |
| Windsor, AC | 1 |
| Somers, SS | 1 |
| Crellin, A | 1 |
| Hassan, S | 1 |
| Macadam, R | 1 |
| Sadek, SA | 1 |
| Guillou, PJ | 1 |
| Jacobson, J | 1 |
| Panella, TJ | 1 |
| Hutchins, LF | 1 |
| Hazamada, S | 1 |
| Watabe, N | 1 |
| Kashihara, S | 1 |
| Kiyonari, N | 1 |
| Hayashi, S | 1 |
| Sasada, A | 1 |
| Feliu, J | 1 |
| González Barón, M | 1 |
| Espinosa, E | 1 |
| Vicent, JM | 1 |
| Gómez Navarro, J | 1 |
| Berrocal, A | 1 |
| Ordóñez, A | 1 |
| Vilches, Y | 1 |
| de Castro, J | 1 |
| Díaz, J | 1 |
| Melcher, AA | 1 |
| Mort, D | 1 |
| Chauveinc, L | 1 |
| Giralt, EG | 1 |
| Joffe, JK | 2 |
| Hughes, M | 1 |
| Wardley, A | 1 |
| Meehan, M | 1 |
| al-Sarraf, M | 2 |
| Martz, K | 2 |
| Brindle, JS | 1 |
| Cooper, J | 3 |
| Byhardt, R | 3 |
| Davis, L | 2 |
| Emami, B | 2 |
| MacKean, J | 1 |
| Ebie, N | 1 |
| Kang, HJ | 1 |
| Millikan, K | 1 |
| Murthy, AK | 1 |
| Griem, K | 1 |
| Hartsell, W | 1 |
| Recine, DC | 1 |
| Doolas, A | 1 |
| Taylor, S | 1 |
| Ganem, G | 1 |
| Dubray, B | 1 |
| Raoul, Y | 1 |
| Colin, P | 1 |
| Bardet, E | 1 |
| Goudier, MJ | 1 |
| Walter, S | 1 |
| Michel-Langlet, P | 1 |
| Martin, P | 1 |
| Maron, D | 1 |
| Andolenko, P | 1 |
| Extra, JM | 1 |
| Garg, MB | 1 |
| Dunstan, RH | 1 |
| Takami, M | 1 |
| Kitada, M | 1 |
| Tsukahara, Y | 1 |
| Niinobu, T | 1 |
| Murotani, M | 1 |
| Iihara, K | 1 |
| Tsukamoto, F | 1 |
| Nose, T | 1 |
| Miyaji, N | 1 |
| Miki, T | 1 |
| Takeshita, T | 1 |
| Churei, H | 1 |
| Fukumoto, T | 3 |
| Aiko, T | 1 |
| Minamimagari, H | 1 |
| Prendiville, J | 2 |
| Shanahan, F | 1 |
| Qian, C | 1 |
| Kocha, WI | 2 |
| Graham, M | 2 |
| Sharma, D | 1 |
| Krasnow, SH | 1 |
| Davis, EB | 1 |
| Lunzer, S | 1 |
| Hussain, MA | 2 |
| MacLeod, C | 1 |
| Moylan, E | 1 |
| Morishima, Y | 1 |
| Tashiro, T | 1 |
| Yamamori, H | 1 |
| Takagi, K | 1 |
| Ohtsubo, Y | 1 |
| Sugiura, T | 1 |
| Furukawa, K | 1 |
| Itabashi, T | 1 |
| Sano, W | 1 |
| Toyoda, Y | 1 |
| Nakajima, N | 1 |
| Jones, DR | 1 |
| Egan, TM | 1 |
| Parker, LA | 1 |
| Louisot, P | 1 |
| Bourlier, P | 1 |
| Klein, V | 1 |
| Huten, N | 1 |
| Aget, H | 1 |
| Tomiyoshi, H | 1 |
| Fok, M | 1 |
| Chow, S | 1 |
| Chu, KM | 1 |
| Wong, J | 3 |
| Girinsky, T | 2 |
| Auperin, A | 1 |
| Marsiglia, H | 1 |
| Dhermain, F | 1 |
| Randrianarivelo, H | 1 |
| Kac, J | 3 |
| Elias, D | 2 |
| Lacave, AJ | 1 |
| Blijham, G | 1 |
| Namer, M | 1 |
| De Besi, P | 3 |
| Gay, F | 3 |
| Collette, L | 1 |
| Sahmoud, T | 1 |
| Becker, M | 3 |
| Larto, MA | 2 |
| Kirby, TJ | 1 |
| Koka, A | 1 |
| Tefft, M | 1 |
| Irwin, JF | 1 |
| Waterfield, W | 1 |
| Poussin-Rosillo, H | 1 |
| Sardi, A | 1 |
| Saji, S | 1 |
| Shirasaka, T | 3 |
| Sowa, M | 1 |
| Chung, Y | 1 |
| Yamamitsu, S | 3 |
| Kuroda, Y | 3 |
| Yoden, E | 2 |
| Takakita, S | 1 |
| Kato, Y | 1 |
| Ayabe, H | 2 |
| Grossbard, ML | 1 |
| Shimoyama, S | 4 |
| Ito, A | 3 |
| Kawahara, M | 3 |
| Nouchi, T | 1 |
| Sekiguchi, K | 1 |
| Shimizu, S | 2 |
| Hojo, K | 3 |
| Uemastu, T | 1 |
| Kaizu, M | 1 |
| Katoh, H | 1 |
| Merigliano, S | 2 |
| Santi, S | 2 |
| Bonavina, L | 3 |
| Peracchia, A | 5 |
| Rowinsky, EK | 1 |
| Landreaneau, RJ | 1 |
| Kim, R | 2 |
| Day, R | 1 |
| Ferson, PF | 1 |
| Keenan, RJ | 1 |
| Posner, M | 1 |
| Seeger, J | 1 |
| Lembersky, B | 1 |
| Dresler, C | 1 |
| Ueda, M | 1 |
| Nagao, N | 1 |
| Nishi, M | 1 |
| Ogasawara, S | 2 |
| Hajiro, K | 2 |
| Jeremic, B | 2 |
| Acimovic, L | 1 |
| Matovic, Z | 1 |
| Milicic, B | 1 |
| Milisavljevic, S | 1 |
| Nikolic, N | 1 |
| Matsui, M | 1 |
| Shirouzu, Y | 1 |
| Bhalla, K | 1 |
| Patel, P | 1 |
| Martin, L | 1 |
| Donegan, J | 1 |
| Pazdur, R | 2 |
| Reed, C | 1 |
| Delouche, D | 1 |
| Haefliger, JM | 1 |
| Kawamura, H | 2 |
| Takiyama, I | 2 |
| Takagane, A | 1 |
| Maesawa, C | 3 |
| Yoshinari, H | 2 |
| Bando, K | 2 |
| Takita, M | 1 |
| Okawa, K | 1 |
| Ujihara, Y | 1 |
| Etienne, MC | 1 |
| Chatelut, E | 1 |
| Pivot, X | 1 |
| Lavit, M | 1 |
| Pujol, A | 1 |
| Canal, P | 1 |
| Milano, G | 1 |
| Hara, S | 1 |
| Itoyanagi, N | 1 |
| Ryu, C | 1 |
| Fukuoka, H | 1 |
| Nakao, H | 1 |
| Nogawa, T | 1 |
| Steyn, RS | 1 |
| Vijeyasingam, R | 1 |
| Cullen, MH | 3 |
| Müller, C | 1 |
| Heresbach, D | 1 |
| Milan, C | 1 |
| Renard, P | 1 |
| Fraisse, J | 1 |
| Lacourt, J | 1 |
| Janoray, P | 1 |
| Faivre, J | 1 |
| Caroli-Bosc, FX | 2 |
| Caujolle, C | 1 |
| Gastaud, P | 1 |
| Montoya, ML | 1 |
| Demarquay, JF | 1 |
| Delmont, JP | 1 |
| Slabber, CF | 1 |
| Nel, JS | 1 |
| Schoeman, L | 3 |
| Burger, W | 3 |
| Falkson, CI | 1 |
| Smith, TJ | 1 |
| Ryan, LM | 1 |
| Douglass, HO | 1 |
| Dayal, Y | 1 |
| Kirkwood, J | 1 |
| Tormey, DC | 1 |
| Schutt, AJ | 1 |
| Hinson, J | 1 |
| Sischy, B | 1 |
| Tsuchiyama, T | 1 |
| Maeda, H | 1 |
| Iida, A | 1 |
| Katayama, SK | 1 |
| Yamaguch, A | 1 |
| Nakagawara, G | 1 |
| Langlois-Zantain, O | 1 |
| Huguier, M | 2 |
| Lozach, P | 1 |
| Testart, J | 1 |
| Yamanaka, H | 1 |
| Motohiro, T | 1 |
| Michiura, T | 1 |
| Asai, A | 1 |
| Hioki, K | 1 |
| Bygrave, HA | 1 |
| Jani, Y | 1 |
| Nagayama, T | 1 |
| Pajak, TF | 1 |
| Sheahan, DG | 1 |
| Gunderson, L | 1 |
| Estes, N | 1 |
| Ferry, DR | 2 |
| Aziz, SA | 1 |
| Tramboo, NA | 1 |
| Mohi-ud-Din, K | 1 |
| Iqbal, K | 1 |
| Jalal, S | 1 |
| Ahmad, M | 1 |
| Heep, H | 2 |
| Dutkowski, P | 1 |
| Willers, R | 1 |
| Gabbert, HE | 1 |
| Tanaka, E | 1 |
| Sekiguchi, H | 2 |
| Nakamura, H | 4 |
| Sakamoto, J | 1 |
| Shinkai, K | 1 |
| Kida, H | 1 |
| Hisano, H | 1 |
| Yano, H | 2 |
| Ginsberg, RJ | 2 |
| Pajak, T | 1 |
| Salter, M | 1 |
| Mukaiya, M | 1 |
| Oikawa, I | 1 |
| Kimura, H | 1 |
| Denno, R | 1 |
| Goldblum, J | 1 |
| Medendorp, SV | 1 |
| Pimentel, R | 1 |
| Gitlin, L | 1 |
| Guzel, Z | 1 |
| Bedford, JL | 1 |
| Childs, PJ | 1 |
| Nahum, AE | 1 |
| Webb, S | 1 |
| Oldham, M | 1 |
| Oba, H | 1 |
| Warner, E | 1 |
| Jensen, JL | 1 |
| Cripps, C | 1 |
| Khoo, KE | 1 |
| Goel, R | 1 |
| Kerr, IA | 1 |
| Bjarnason, GA | 1 |
| Fields, AL | 1 |
| Hrincu, A | 1 |
| Wang, HZ | 1 |
| Lin, ZT | 1 |
| Fietkau, R | 1 |
| Tominaga, K | 1 |
| Arakawa, T | 1 |
| Hamaguchi, Y | 1 |
| Takaishi, O | 1 |
| Chono, S | 1 |
| Kuroki, T | 1 |
| Mackean, M | 1 |
| Leahy, M | 1 |
| Baba, M | 3 |
| Kusano, C | 3 |
| Streeter, OE | 1 |
| Martz, KL | 1 |
| Delrowe, JD | 1 |
| Asbell, SO | 1 |
| Salter, MM | 1 |
| Roach, M | 1 |
| Nikkuni, K | 1 |
| Tomidokoro, T | 1 |
| Hafez, N | 1 |
| Ayache, S | 1 |
| Jones, BD | 1 |
| Damle, S | 1 |
| Asano, A | 1 |
| Sasaoka, M | 1 |
| Jonker, D | 1 |
| Mehran, R | 1 |
| Maroun, J | 1 |
| Crepeau, A | 1 |
| Todoroki, T | 2 |
| Maruyama, T | 1 |
| Fukao, K | 2 |
| Ohara, K | 2 |
| Monoi, H | 1 |
| Kawai, Y | 1 |
| Kohno, S | 1 |
| Hada, T | 1 |
| Ohmori, H | 1 |
| Sasaya, K | 1 |
| Matai, K | 1 |
| Shibusawa, H | 1 |
| Nagai, H | 1 |
| Ueno, I | 1 |
| Sakuma, K | 1 |
| Nagashima, T | 1 |
| Kobayashi, N | 1 |
| Kanazawa, K | 1 |
| Yorozu, A | 1 |
| Dokiya, T | 1 |
| Oki, Y | 1 |
| Iizuka, N | 1 |
| Noma, T | 1 |
| Burch, PA | 1 |
| Keppen, MD | 1 |
| Schroeder, G | 1 |
| Rubin, J | 1 |
| Krook, JE | 1 |
| Dalton, RJ | 1 |
| Gerstner, JB | 1 |
| Jancewicz, MT | 1 |
| Ebbert, LP | 1 |
| Dady, P | 1 |
| Chidel, MA | 1 |
| Kupelian, PA | 1 |
| Suh, JH | 1 |
| Yoshiyuki, T | 1 |
| Kiyama, T | 1 |
| Takekuni, K | 1 |
| Azama, T | 1 |
| Okajima, S | 2 |
| Satake, M | 2 |
| Nakamura, A | 1 |
| Gamoh, M | 1 |
| Ishibashi, S | 1 |
| Murakawa, Y | 1 |
| Kanamaru, R | 3 |
| Taieb, S | 1 |
| Vaillant, E | 1 |
| Pommier, P | 1 |
| Bonvoisin, S | 1 |
| Morignat, E | 1 |
| Gerard, JP | 2 |
| Azria, D | 1 |
| Senesse, P | 1 |
| Dubois, JB | 1 |
| Via, A | 1 |
| Incarbone, R | 1 |
| Kamiya, J | 1 |
| Ohta, M | 1 |
| Okamoto, F | 1 |
| Ohsawa, H | 1 |
| Sugiyama, K | 1 |
| Horikoshi, N | 1 |
| Yoshida, M | 1 |
| Kawabe, A | 1 |
| Isogaki, J | 1 |
| Kazui, T | 1 |
| Nozue, M | 1 |
| Matsumoto, G | 1 |
| Ise, H | 1 |
| Matsuo, S | 1 |
| Pirzada, NA | 1 |
| Ali, II | 1 |
| Dafer, RM | 1 |
| Talamini, MA | 1 |
| Kaufman, HS | 1 |
| Canto, MI | 1 |
| Topazian, M | 1 |
| Olukayode, K | 1 |
| Dickie, G | 1 |
| Hodge, R | 1 |
| Morton, K | 1 |
| Wilson, KS | 1 |
| Alexander, EP | 1 |
| Lipman, T | 1 |
| Harmon, J | 1 |
| Wadleigh, R | 1 |
| Gentile, M | 1 |
| Cecere, C | 1 |
| Elia, S | 1 |
| De Palma, G | 1 |
| Fraioli, G | 1 |
| Griffo, S | 1 |
| Ferrante, G | 1 |
| Ciezki, J | 1 |
| Saxton, J | 1 |
| DeCamp, M | 1 |
| Walz, M | 1 |
| Oldenburg, A | 1 |
| Stüben, G | 1 |
| Thorban, S | 1 |
| Rosenberg, R | 1 |
| Roder, RJ | 1 |
| Oyama, K | 1 |
| Hirosawa, H | 1 |
| Fukushima, W | 1 |
| Masutani, H | 1 |
| Kadoya, N | 1 |
| Izumi, R | 1 |
| Hirono, T | 1 |
| Aoki, F | 1 |
| Murakami, T | 3 |
| Toyoda, K | 1 |
| Kwok, QS | 1 |
| Banerji, U | 1 |
| Livingstone, JI | 1 |
| Townsend, ER | 1 |
| Harrison, RA | 1 |
| Mitchell, IC | 1 |
| Inokuchi, K | 1 |
| Hanawa, H | 1 |
| Tamura, H | 1 |
| Tajika, K | 1 |
| Dan, K | 1 |
| Hayter, CR | 1 |
| Huff-Winters, C | 1 |
| Paszat, L | 1 |
| Youssef, YM | 1 |
| Shelley, WE | 1 |
| Schulze, K | 1 |
| Kijima, F | 1 |
| Aridome, K | 1 |
| Nakanishi, Y | 1 |
| Tajima, M | 1 |
| Ichikawa, W | 1 |
| Uetake, Y | 1 |
| Osanai, T | 1 |
| Takenaka, S | 1 |
| Nihei, Z | 1 |
| Sugihara, K | 1 |
| Kumagai, Y | 1 |
| Nara, S | 1 |
| Arii, S | 1 |
| Iwai, T | 1 |
| Sumi, H | 1 |
| Goldwasser, F | 1 |
| Gross-Goupil, M | 1 |
| Tigaud, JM | 1 |
| Di Palma, M | 1 |
| Marceau-Suissa, J | 1 |
| Wasserman, E | 1 |
| Yovine, A | 1 |
| Cvitkovic, E | 2 |
| Gayet, B | 2 |
| Sauvanet, A | 1 |
| Blazy, A | 1 |
| Perniceni, T | 2 |
| Panis, Y | 1 |
| Mal, F | 2 |
| Sarfati, E | 1 |
| Valleur, P | 1 |
| Belghiti, J | 1 |
| Fekete, F | 1 |
| Maylin, C | 2 |
| Szumilo, J | 1 |
| Chibowski, D | 1 |
| D browski, A | 1 |
| Sharma, V | 2 |
| Agarwal, J | 1 |
| Dinshaw, K | 1 |
| Nehru, RM | 1 |
| Mohandas, M | 1 |
| Deshpande, R | 2 |
| Rayabhattnavar, S | 1 |
| Turrisi, A | 1 |
| Iannettoni, M | 1 |
| Strawderman, M | 1 |
| Schnirer, II | 1 |
| Pisters, PW | 2 |
| Shinoda, N | 2 |
| Toyama, T | 2 |
| Nishiwaki, T | 1 |
| Moriyama, S | 1 |
| Kudo, J | 1 |
| Salemkour, A | 1 |
| Boudet, MJ | 1 |
| Raymond, E | 1 |
| Yip, D | 1 |
| Moore, MB | 1 |
| Aloia, T | 1 |
| Sporn, T | 1 |
| Parr, A | 1 |
| Linoila, I | 1 |
| Allegra, C | 1 |
| Delcambre, C | 1 |
| Pottier, D | 1 |
| Gignoux, M | 1 |
| Ollivier, JM | 1 |
| Vie, B | 1 |
| Roussel, A | 1 |
| Segol, P | 1 |
| Genvresse, I | 1 |
| Lange, C | 1 |
| Schanz, J | 1 |
| Schweigert, M | 1 |
| Harder, H | 1 |
| Possinger, K | 1 |
| Späth-Schwalbe, E | 1 |
| Koussis, H | 1 |
| Zaninotto, G | 1 |
| Kovàcs, G | 1 |
| Jiao, X | 1 |
| Sonett, J | 1 |
| Gamliel, Z | 1 |
| Doyle, A | 1 |
| Greenwald, B | 1 |
| Bédard, EL | 1 |
| Brecevic, E | 1 |
| Vincent, M | 1 |
| Dar, R | 1 |
| Eguchi, J | 1 |
| Kitahara, T | 1 |
| Mitamura, K | 1 |
| Lew, JI | 1 |
| Gooding, WE | 1 |
| Ribeiro, U | 1 |
| Safatle-Ribeiro, AV | 1 |
| Slater, MS | 1 |
| Holland, J | 1 |
| Faigel, DO | 1 |
| Sheppard, BC | 1 |
| Deveney, CW | 1 |
| Samel, S | 1 |
| Hundt, A | 1 |
| Sturm, J | 1 |
| Knoll, MR | 1 |
| Queisser, W | 1 |
| Post, S | 1 |
| Polee, MB | 1 |
| Siersema, PD | 1 |
| Stoter, G | 1 |
| Nesbitt, J | 1 |
| Raijman, I | 1 |
| Martin, FD | 1 |
| Leprise, E | 1 |
| Takeda, A | 1 |
| Funami, Y | 1 |
| Yukiiri, K | 1 |
| Mizushige, K | 1 |
| Ueda, T | 1 |
| Kohno, M | 1 |
| Kihara, C | 1 |
| Furukawa, Y | 1 |
| Ono, K | 1 |
| Kitahara, O | 1 |
| Zembutsu, H | 1 |
| Yanagawa, R | 1 |
| Nakagawa, Y | 1 |
| Moon, Y | 1 |
| Uemichi, O | 1 |
| Sasaya, S | 1 |
| Makuuchi, M | 1 |
| Wong, CS | 1 |
| Catton, P | 1 |
| Catton, C | 1 |
| McLean, M | 1 |
| Keane, T | 1 |
| Panzarella, T | 1 |
| Archer, VR | 1 |
| Mulholland, PJ | 1 |
| Stocken, DD | 1 |
| Tas, F | 1 |
| Basaran, M | 1 |
| Aydiner, A | 1 |
| Eralp, Y | 1 |
| Topuz, E | 1 |
| Forget, F | 1 |
| Vermund, H | 1 |
| Pories, WJ | 1 |
| Hillard, J | 1 |
| Wiley, AL | 1 |
| Youngblood, R | 1 |
| Stockeld, D | 1 |
| Tennvall, J | 2 |
| Wagenius, G | 1 |
| Backman, L | 1 |
| Brodin, O | 1 |
| Granström, L | 1 |
| Gustafsson, G | 1 |
| Gustavsson, S | 1 |
| Hambraeus, G | 2 |
| Lewensohn, R | 1 |
| Sjöstedt, S | 1 |
| Strander, H | 1 |
| Aberg, B | 1 |
| Fagerberg, J | 1 |
| Watanabe, O | 1 |
| Kuwahara, Y | 1 |
| Ishigaki, T | 1 |
| Mulligan, E | 2 |
| Hamada, H | 1 |
| Nakao, A | 1 |
| Imamura, M | 1 |
| Zhou, C | 1 |
| Hisamitsu, K | 1 |
| Katano, K | 1 |
| Tsujitani, S | 1 |
| Kaibara, N | 1 |
| Matsui, S | 1 |
| Iwazawa, T | 1 |
| Tono, T | 1 |
| Nakano, Y | 1 |
| Kanoh, T | 1 |
| Monden, T | 1 |
| Dono, K | 1 |
| Umeshita, K | 1 |
| Okada, A | 1 |
| Kure, N | 1 |
| Ebuchi, M | 1 |
| Heise, JW | 1 |
| Frieling, T | 1 |
| Hartmann, KA | 1 |
| Röher, HD | 1 |
| Egreteau, J | 1 |
| Lesimple, T | 1 |
| Raouf, A | 1 |
| Evoy, D | 1 |
| Carton, E | 1 |
| Sweeney, E | 1 |
| Iwase, H | 1 |
| Sugiura, M | 1 |
| Liu, X | 1 |
| Fu, X | 1 |
| Horváth, G | 1 |
| Duffaud, F | 1 |
| Ries, P | 1 |
| Ville, E | 1 |
| Laugier, R | 1 |
| Kamijo, T | 1 |
| Saitoh, H | 1 |
| Nashimoto, A | 1 |
| Ohga, T | 1 |
| Futatsugi, M | 1 |
| Miyazaki, M | 1 |
| Nozoe, T | 1 |
| Lim, KC | 1 |
| Dunlop, DJ | 1 |
| Itoh, S | 1 |
| Ohnishi, T | 1 |
| Takamatsu, M | 1 |
| Horimi, T | 1 |
| Uesugi, N | 1 |
| Chan, R | 1 |
| Morrill, S | 1 |
| Freeman, D | 1 |
| Colman, M | 1 |
| Zwischenberger, J | 1 |
| El Nakadi, I | 1 |
| Houben, JJ | 1 |
| Closset, J | 1 |
| Danhier, S | 1 |
| Limbosch, JM | 1 |
| Lambilliotte, JP | 1 |
| Gelin, M | 1 |
| Baujat, B | 1 |
| Mabro, M | 1 |
| Carola, E | 1 |
| Maindrault, F | 1 |
| Morihiro, M | 1 |
| Ross, P | 1 |
| Valle, J | 1 |
| Price, T | 1 |
| Anderson, H | 1 |
| Hanawa, T | 1 |
| Fujii, E | 1 |
| Shih, CH | 1 |
| Yagyu, Y | 1 |
| Toner, GC | 1 |
| Smith, JG | 1 |
| Rischin, D | 1 |
| Guiney, MJ | 1 |
| Matsumura, Y | 1 |
| Vaishampayan, UN | 1 |
| Du, W | 1 |
| Levin, KJ | 1 |
| Shields, AF | 1 |
| Bodnar, L | 1 |
| Klippenstein, D | 1 |
| Litwin, A | 1 |
| Smith, J | 1 |
| Douglass, H | 1 |
| Just-Viera, JO | 1 |
| Silva, JE | 1 |
| Prostman, TJ | 1 |
| Hattori, T | 3 |
| Nagusa, Y | 1 |
| Nakano, A | 1 |
| Chevrel, JP | 1 |
| Damsin, JP | 1 |
| Lebhar, E | 1 |
| Oberfield, RA | 1 |
| Kuriya, Y | 1 |
| Kasai, M | 1 |
| Dietz, R | 2 |
| Wilhelm, HJ | 1 |
| Ganzer, U | 1 |
| Ryzmann, G | 1 |
| Vosteen, KH | 1 |
| Mootz, W | 1 |
| Komiyama, S | 3 |
| Hiroto, I | 1 |
| Ryu, S | 1 |
| Nakashima, T | 1 |
| Kuwano, M | 2 |
| Endo, H | 1 |
| Takino, T | 1 |
| Misawa, S | 1 |
| Kadono, A | 1 |
| Yamaguchi, N | 1 |
| Yokomori, T | 1 |
| Taniguchi, T | 1 |
| Iesato, H | 1 |
| Kobayashi, J | 1 |
| Owada, S | 1 |
| Schlag, PM | 1 |
| Guillot, T | 1 |
| Spielmann, M | 2 |
| Luboinski, B | 1 |
| Tellez-Bernal, E | 1 |
| Munck, JN | 1 |
| Bachouchi, M | 1 |
| Armand, JP | 1 |
| Schraube, P | 1 |
| Oberle, J | 1 |
| Friedl, P | 1 |
| Segawa, Y | 1 |
| Ohnoshi, T | 1 |
| Ueoka, H | 1 |
| Kiura, K | 1 |
| Horiguchi, T | 1 |
| Kodani, T | 1 |
| Kamei, H | 1 |
| Tabata, M | 1 |
| Shibayama, T | 1 |
| Maeda, T | 1 |
| Donnelly, RJ | 1 |
| Girling, DJ | 1 |
| Schlag, P | 1 |
| Zenone, T | 1 |
| Romestaing, P | 1 |
| Lambert, R | 1 |
| Takagi, I | 1 |
| Arimori, M | 1 |
| Alberts, AS | 2 |
| Greeff, F | 1 |
| Friediger, D | 1 |
| Nel, J | 1 |
| Steyn, E | 1 |
| Schmid, EU | 1 |
| Ryan, B | 2 |
| McMurtrey, M | 2 |
| DeCaro, L | 2 |
| Levin, B | 2 |
| Mountain, C | 2 |
| Wils, JA | 1 |
| Pene, F | 1 |
| Balosso, J | 1 |
| Benmiloud, M | 1 |
| Laugier, A | 1 |
| Greef, F | 1 |
| Köhne-Wömpner, CH | 1 |
| Charlois, T | 1 |
| Ben Bouali, AK | 2 |
| Person, B | 1 |
| Ferrero, P | 1 |
| Delaby, J | 2 |
| Boyer, J | 2 |
| Charneau, J | 1 |
| Chassevent, A | 1 |
| Larra, F | 1 |
| Petruska, P | 1 |
| Andrus, CH | 1 |
| Johnson, FE | 1 |
| Doden, K | 1 |
| Munemoto, Y | 1 |
| Miyanaga, T | 1 |
| Brindle, J | 1 |
| Olweny, C | 1 |
| Aliev, BM | 1 |
| Khydyrov, KhB | 2 |
| Kondrat'eva, NF | 1 |
| Nakamura, J | 2 |
| Nasu, H | 2 |
| Masamune, O | 2 |
| Tohma, H | 1 |
| Shikama, T | 1 |
| Sunagawa, M | 1 |
| Paul, AR | 2 |
| Stafford, PM | 1 |
| Araújo, CM | 1 |
| Souhami, L | 1 |
| Gil, RA | 1 |
| Carvalho, R | 1 |
| Garcia, JA | 1 |
| Froimtchuk, MJ | 1 |
| Pinto, LH | 1 |
| Canary, PC | 1 |
| Köhler, AH | 2 |
| Mercke, C | 2 |
| Lillo-Gil, R | 1 |
| Samuelsson, L | 1 |
| Willén, R | 1 |
| Ranstam, J | 1 |
| Nogami, A | 1 |
| Hanashi, T | 1 |
| Kubota, N | 1 |
| Zhou, JC | 1 |
| Bromberg, J | 2 |
| Lovett, D | 1 |
| Buckley, M | 1 |
| Murray, P | 1 |
| Lightdale, C | 1 |
| Walker, SJ | 1 |
| Steel, A | 1 |
| Szawłowski, AW | 1 |
| Falkowski, S | 1 |
| Morysiński, T | 1 |
| Nasierowska-Guttmejer, A | 1 |
| Karwowski, A | 1 |
| Krawczyk, M | 1 |
| Kułakowski, A | 1 |
| Koyanagi, Y | 1 |
| Yoshimatsu, A | 1 |
| Ozawa, T | 1 |
| Yasuda, D | 1 |
| Kasuya, K | 1 |
| Port, RE | 1 |
| Daniel, B | 1 |
| Ding, RW | 1 |
| Herrmann, R | 1 |
| Gabrail, NY | 1 |
| Harrison, BR | 1 |
| Sunwoo, YC | 1 |
| Dinshaw, KA | 1 |
| Pendse, AM | 1 |
| Telang, CS | 1 |
| Vege, SS | 1 |
| Malliat, MK | 1 |
| Desai, PB | 1 |
| Nio, Y | 1 |
| Imai, S | 1 |
| Tsubono, M | 1 |
| Morimoto, H | 1 |
| Tseng, CC | 1 |
| Tobe, T | 1 |
| Urba, S | 1 |
| Takasugi, BJ | 1 |
| Jinushi, K | 2 |
| Hirabayashi, N | 2 |
| Kirihara, Y | 2 |
| Takagami, S | 2 |
| Ryuji, K | 1 |
| Yorishima, T | 1 |
| Noso, Y | 2 |
| Jevremovic, S | 1 |
| Djuric, L | 1 |
| Mijatovic, L | 1 |
| Höring, E | 1 |
| Neef, B | 1 |
| von Gaisberg, U | 1 |
| Jackson, DE | 1 |
| Kuvshinov, IuP | 1 |
| Poddubnyĭ, BK | 1 |
| Aliev, VM | 1 |
| Vasygova, NF | 1 |
| Efimov, ON | 1 |
| Saliuk, VA | 1 |
| Padaut-Cesana, J | 2 |
| Fuentes, P | 2 |
| Giudicelli, R | 2 |
| Gauthier, AP | 1 |
| Carcassonne, Y | 1 |
| Britsis, FA | 1 |
| Kalninia, IIa | 1 |
| Berzinia, VIu | 1 |
| Purkalne, TS | 1 |
| Salvagno, L | 2 |
| Tremolada, C | 2 |
| Fosser, V | 2 |
| Paccagnella, A | 2 |
| Fiorentino, M | 1 |
| Wang, ZY | 1 |
| Matsumoto, N | 1 |
| Tapazoglou, E | 1 |
| Arbulu, A | 1 |
| John, M | 2 |
| Flam, M | 2 |
| Wittlinger, P | 2 |
| Mowry, PA | 2 |
| Hukku, S | 1 |
| Fernandes, P | 1 |
| Vasishta, S | 1 |
| Sharma, VK | 1 |
| Chan, A | 1 |
| Wong, A | 1 |
| Arthur, K | 1 |
| Stewart, FM | 1 |
| Harkins, BJ | 1 |
| Hahn, SS | 1 |
| Daniel, TM | 1 |
| Zhang, ZH | 1 |
| Lackey, VL | 1 |
| Reagan, MT | 1 |
| Smith, RA | 1 |
| Anderson, WJ | 1 |
| Bohno, K | 1 |
| Zilling, TL | 1 |
| Ahrén, B | 1 |
| Yang, CJ | 1 |
| Jin, SW | 1 |
| Watson, KJ | 1 |
| Shulkes, A | 1 |
| Smallwood, RA | 1 |
| Douglas, MC | 1 |
| Hurley, R | 1 |
| Kalnins, R | 1 |
| Moran, L | 1 |
| Petursson, SR | 1 |
| Gauthier, A | 1 |
| Reboud, E | 1 |
| Podolsky, W | 1 |
| Padmanabhan, A | 1 |
| Niimoto, M | 2 |
| Hancock, SL | 1 |
| Goffinet, DR | 1 |
| Carlson, RW | 1 |
| Mark, JB | 1 |
| Hetzel, D | 1 |
| Fitch, R | 1 |
| Britten-Jones, R | 1 |
| Gibson, GE | 1 |
| Abbott, RL | 1 |
| Hecker, R | 1 |
| Tosch, U | 1 |
| Wendt, TG | 1 |
| Rohloff, R | 1 |
| Willich, N | 1 |
| Lattin, P | 1 |
| Han, I | 1 |
| Ahmad, K | 1 |
| Leichman, G | 1 |
| Bendal, C | 1 |
| White, B | 1 |
| Eskilsson, J | 1 |
| Saeki, T | 1 |
| Sridhar, KS | 1 |
| Barreras, L | 1 |
| Saldana, MJ | 1 |
| Manten, H | 1 |
| Libnock, J | 1 |
| Speyer, J | 1 |
| Tschan, J | 1 |
| Eschwege, F | 1 |
| Bertin, F | 1 |
| Leclercq, B | 1 |
| Nitenberg, G | 1 |
| Toso, S | 1 |
| Fiorentino, MV | 1 |
| Tsang, TK | 1 |
| Shetty, R | 1 |
| Schneider, PA | 1 |
| Wallemark, CB | 1 |
| Mendoza, EA | 1 |
| Thomas, LC | 1 |
| Sutherland, CM | 1 |
| Zaniboni, A | 1 |
| Simoncini, E | 1 |
| Tonini, G | 1 |
| Pezzola, D | 1 |
| Farfaglia, R | 1 |
| Lancini, GP | 1 |
| Marpicati, P | 1 |
| Montini, E | 1 |
| Marini, G | 1 |
| Lokich, JJ | 1 |
| Shea, M | 1 |
| Chaffey, J | 1 |
| Richmond, J | 1 |
| Bae, Y | 1 |
| Lewis, J | 1 |
| Burdakin, J | 1 |
| Jacobsen, G | 1 |
| Arakawa, H | 1 |
| Dobberstein, N | 1 |
| Stoltmann, R | 1 |
| Hinkel, M | 1 |
| Grillo, H | 1 |
| Yanagita, T | 2 |
| Kudo, S | 1 |
| Kuwano, N | 1 |
| Li, XT | 1 |
| Li, PY | 1 |
| Thyss, A | 1 |
| Santini, J | 1 |
| Caldani, C | 1 |
| Vallicioni, J | 1 |
| Chauvel, P | 1 |
| Demard, F | 1 |
| Ryan, RF | 1 |
| Robertson, D | 1 |
| Godfrey, R | 1 |
| Kudoh, S | 1 |
| Parker, EF | 1 |
| Marks, RD | 1 |
| Kratz, JM | 1 |
| Chaikhouni, A | 1 |
| Warren, ET | 1 |
| Bartles, DM | 1 |
| Miller, JI | 1 |
| McIntyre, B | 1 |
| Hatcher, CR | 1 |
| Harwood, AR | 1 |
| Elhakim, T | 1 |
| Rider, WD | 1 |
| Cummings, BJ | 1 |
| Cooper, JC | 1 |
| Burdette, WJ | 1 |
| Hellriegel, W | 1 |
| Shaw, HJ | 1 |
| Missale, G | 1 |
| Cocconi, G | 1 |
| Pettenati, V | 1 |
| Sandeman, TF | 1 |
| Muller, CJ | 1 |
| Krakoff, IH | 1 |
| Lychev, VA | 1 |
| Mil'man, MSh | 2 |
| Chirkina, IuM | 1 |
| Shek, BA | 2 |
| Li, MI | 1 |
| Chernyshev, VK | 1 |
| Lapsa, RKh | 1 |
| Valieva, RK | 2 |
| Turganbaev, AT | 1 |
| Balmukhanov, SB | 2 |
| Litvin, AI | 1 |
| Karimova, SB | 1 |
| Tsuya, A | 1 |
| Kaneda, K | 1 |
| Okano, S | 1 |
| Goto, H | 1 |
| Schwartz, GF | 1 |
| Green, HL | 1 |
| Bendon, ML | 1 |
| Graham, WP | 1 |
| Blakemore, WS | 1 |
| Nelson, CS | 1 |
| Tsoĭ, AI | 2 |
| Dement'eva, NI | 2 |
| Sulaeva, LS | 1 |
| Letiagin, VP | 1 |
| Holyoke, ED | 1 |
| Dao, TL | 1 |
| Abdrakhmanov, ZhN | 1 |
| Taborakhamov, ZN | 1 |
| Jesse, RH | 1 |
| Goepfert, H | 1 |
| Lindberg, RD | 1 |
| Johnson, RH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Ad[NCT03189719] | Phase 3 | 749 participants (Actual) | Interventional | 2017-07-25 | Completed | ||
| Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT): A Phase II Study (GASPAR)[NCT04736485] | Phase 2 | 67 participants (Anticipated) | Interventional | 2021-06-28 | Active, not recruiting | ||
| Prospective Randomized Phase III Trial Comparing Preoperative Chemoradiation Therapy (Cisplatin, 5-FU and Radiotherapy Followed by Surgery) to Surgery Followed by Postoperative Chemoradiation (Cisplatin, Epirubicin, 5-FU, Radiotherapy) for Esophageal Canc[NCT00907543] | 96 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomac[NCT01216644] | Phase 2/Phase 3 | 716 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Adjuvant Treatment of Cancer of the Esophagus or Cardia Before Resection With Curative Intent. Comparative Study Between Chemotherapy and Radiochemotherapy[NCT01362127] | Phase 2 | 181 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Phase I/II Study of Evaluating the Safety and Efficacy of Using a Simultaneous Integrated Boost for Dose Escalation in Patients With Esophageal Cancer[NCT01102088] | Phase 1 | 61 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Nal-IRI/LV5-FU VERSUS PACLITAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA A Multi-centre, Randomized, Non-comparative Phase II Study[NCT03719924] | Phase 2 | 106 participants (Actual) | Interventional | 2019-03-07 | Active, not recruiting | ||
| PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma[NCT02366819] | Phase 4 | 36 participants (Anticipated) | Interventional | 2014-12-11 | Recruiting | ||
| A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma[NCT05213312] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma FRONTiER Trial[NCT03914443] | Phase 1 | 36 participants (Anticipated) | Interventional | 2019-05-07 | Active, not recruiting | ||
| Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors[NCT01928290] | Phase 2 | 67 participants (Actual) | Interventional | 2013-11-08 | Completed | ||
| Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in Previously Untreated HER2 Positive Locally Advanced or Metastatic EsophagoGastric Adenocarcinoma[NCT03409848] | Phase 2 | 97 participants (Actual) | Interventional | 2018-03-01 | Completed | ||
| Prospective, Randomized, Multicenter, Phase II Noninferiority Study of S-1 Concurrent Intensity-modulated Radiation Therapy (IMRT) Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma[NCT02913066] | Phase 2 | 88 participants (Anticipated) | Interventional | 2016-09-30 | Recruiting | ||
| A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric Orgastroe[NCT03675737] | Phase 3 | 1,579 participants (Actual) | Interventional | 2018-11-08 | Active, not recruiting | ||
| Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer[NCT01333033] | Phase 2 | 257 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Paclitaxel In Combination With Cisplatin and 5-fluorouracil(TPF) Induction Chemotherapy for Locally Advanced Borderline-resectable Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial[NCT02976909] | Phase 2 | 46 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| First-line Anti-PD-1 Therapy Plus Chemotherapy With or Without Radiotherapy in Metastatic Esophageal Squamous Cell Carcinoma: A Phase II Multi-center, Randomized Trial (SCR-ESCC-01)[NCT05978193] | Phase 2 | 160 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer: A Randomized Multicenter Phase III Trial[NCT06086457] | Phase 3 | 436 participants (Anticipated) | Interventional | 2023-11-28 | Not yet recruiting | ||
| Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy: a Patient Preference Multicenter Randomized Phase II Trial[NCT06084897] | Phase 2 | 120 participants (Anticipated) | Interventional | 2023-10-16 | Recruiting | ||
| Tislelizumab Plus Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma: a Phase II, Randomized Trial (EC-CRT-002)[NCT05520619] | Phase 2 | 114 participants (Anticipated) | Interventional | 2022-09-15 | Recruiting | ||
| A Phase I/II Multicenter Study Evaluating the Efficacy and Safety of Induction Immunochemotherapy Followed by Concurrent Immuno-Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Cancer(SCR-ESCC-02)[NCT06173986] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2023-01-10 | Recruiting | ||
| CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1[NCT04455282] | 100 participants (Anticipated) | Observational | 2021-02-01 | Recruiting | |||
| Prospective Randomized Controlled Trial of Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy[NCT03734952] | 537 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | |||
| A Phase II, Randomized, Controlled, Open-Label Study Comparing Standard Chemoradiation Versus Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer[NCT01249352] | Phase 2/Phase 3 | 104 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| An Oxaliplatin-Based Phase II Randomized Study of Induction Chemotherapy Followed by Preoperative Chemoradiotherapy or Preoperative Chemoradiotherapy in Patients With Resectable Esophageal or Gastroesophageal Carcinoma[NCT00525915] | Phase 2 | 126 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Comparison of Paclitaxel in Combination With Cisplatin(TP), Carboplatin(TC) or Fluorouracil(TF) Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Squamous Cell Carcinoma: A Three-Arm Randomized Phase III Trial[NCT02459457] | Phase 3 | 321 participants (Actual) | Interventional | 2015-07-01 | Completed | ||
| The Third Phase of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence Was Compared With the Clinical Comparison[NCT04404491] | Phase 3 | 240 participants (Anticipated) | Interventional | 2020-06-01 | Not yet recruiting | ||
| A Prospective Single-arm Phase Ⅱ Study of Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma[NCT04844385] | Phase 2 | 83 participants (Anticipated) | Interventional | 2021-02-20 | Recruiting | ||
| Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer[NCT01191697] | Phase 2 | 37 participants (Actual) | Interventional | 2011-02-28 | Active, not recruiting | ||
| A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| A Phase III Randomized Clinical Trial of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma[NCT01591135] | Phase 3 | 436 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| A Phase II/III Study Comparing Simultaneous Integrated Boost (SIB) Intensity Modulated Radiation Therapy (IMRT) With S1 Based SIB-IMRT Followed by Adjuvant Chemotherapy With S1 in Elderly Patients With Esophageal or Esophagogastric Cancer (3JECROG-P01)[NCT02979691] | Phase 2/Phase 3 | 350 participants (Anticipated) | Interventional | 2016-10-31 | Completed | ||
| A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors[NCT02318329] | Phase 1 | 79 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL[NCT02205047] | Phase 2 | 171 participants (Anticipated) | Interventional | 2015-07-15 | Active, not recruiting | ||
| CT-PET for Prediction of Histopathologic Response, Nodal Status and Oncologic Outcome Following Neoadjuvant Chemoradiation for Esophageal Cancer[NCT02385604] | 250 participants (Actual) | Observational | 2014-01-31 | Completed | |||
| Concurrent Radiotherapy and Weekly Chemotherapy of 5-fluorouracil and Cisplatin for Postoperative Locoregional Recurrence of Oesophageal Squamous Cell Carcinoma[NCT02325986] | Phase 2 | 46 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| A Randomized, Open-label, Multicenter Trial of the Chemoradiation Versus Standard Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Cancer in Chinese Patients[NCT02972372] | 196 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | |||
| Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer[NCT02607540] | Phase 3 | 210 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer[NCT02025036] | Phase 3 | 249 participants (Actual) | Interventional | 2014-10-31 | Active, not recruiting | ||
| REAL 3 : A Randomised Open-labelled Multicentre Trial of the Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-gastric Cancer[NCT00824785] | Phase 3 | 574 participants (Actual) | Interventional | 2008-05-31 | Terminated (stopped due to Lack of efficacy) | ||
| Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903)[NCT04138212] | Phase 3 | 456 participants (Anticipated) | Interventional | 2019-10-22 | Recruiting | ||
| An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease[NCT00400179] | Phase 3 | 1,053 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| A Phase II Randomized Trial of Induction Chemotherapy Versus no Induction Chemotherapy Followed by Definitive Chemoradiotherapy in Patients With Inoperable Thoracic Esophageal Cancer[NCT02403531] | Phase 2 | 110 participants (Actual) | Interventional | 2015-05-01 | Completed | ||
| A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer[NCT03234842] | Phase 2 | 0 participants (Actual) | Interventional | 2017-10-30 | Withdrawn (stopped due to non-accrual) | ||
| Multi-Modality Treatment of Resectable Oesophageal Adenocarcinoma Using Peri-operative Chemotherapy With Additional Pre-operative Combined Radiotherapy and Cetuximab[NCT00827671] | Phase 2 | 12 participants (Actual) | Interventional | 2009-03-31 | Terminated (stopped due to Experimental treatment not feasible due to high rate of drop out) | ||
| Phase II-III Study Comparing Radiochemotherapy With the FOLFOX Regimen Versus Radiochemotherapy With 5FU-cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Oesophageal Cancer.[NCT00861094] | Phase 2/Phase 3 | 266 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial[NCT02604615] | Phase 3 | 60 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer[NCT00632333] | Phase 1 | 9 participants (Anticipated) | Interventional | 2008-02-29 | Recruiting | ||
| The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma, an Open, Prospective, Single-arm Phase II Study[NCT04212598] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-08-03 | Recruiting | ||
| Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With Intensity-modulated Radiotherapy in High Risk Locregionally Advanced Nasopharyngeal Carcinoma: a Phase 2 Randomized Controlled Trial[NCT02610556] | Phase 2 | 130 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Randomized Study of Pre-Operative Radio-Chemotherapy Versus Surgery Alone in Thoracic Esophageal Cancer Deemed to be Resectable[NCT00047112] | Phase 3 | 195 participants (Actual) | Interventional | 2002-05-31 | Completed | ||
| Trial Evaluating the Efficacy and Tolerance of Perioperative Chemotherapy With 5FU-Cisplatin-Cetuximab in Adenocarcinomas of the Stomach and Gastroesophageal Junction. Phase II Single Arm, Multicenter.[NCT01360086] | Phase 2 | 65 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| A Phase III Clinical Trial of Docetaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma[NCT02465736] | Phase 3 | 610 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Neoadjuvant Chemoradiotherapy VS. Neoadjuvant Chemotherapy Followed by Minimally Invasive Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma（cT3-4aN0-1M0):A Multi-center Prospective Randomized Clinical Trial[NCT03001596] | 264 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal (GEJ) Tumors: A Phase II Study[NCT00515216] | Phase 2 | 26 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers[NCT02296671] | Phase 2 | 0 participants (Actual) | Interventional | 2015-02-28 | Withdrawn (stopped due to Was unable to accrue any patients) | ||
| Docetaxel, Cisplatin and Fluorouracil Combination in the Neoadjuvant Treatment of Locally Advanced Gastric Adenocarcinoma : Phase II Clinical Study[NCT00343239] | Phase 2 | 59 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)[NCT05660083] | Phase 2 | 36 participants (Anticipated) | Interventional | 2023-01-12 | Recruiting | ||
| PET/MR-imaging and Circulating Tumour Cells to Evaluate the Response of Chemotherapy in Patients With Gastroesophageal Junction Cancer[NCT02433301] | 23 participants (Actual) | Observational | 2015-04-30 | Completed | |||
| The Utility of Circulating Tumour Cells and Plasma microRNA Detection to Predict the Response to Treatment in Patients With Esophageal Adenocarcinoma[NCT02812680] | 200 participants (Anticipated) | Observational | 2016-06-30 | Active, not recruiting | |||
| Identification of Chemo and Radiation Induced Systolic and Diastolic Myocardial Dysfunction in Patients With Cancer in Oesophagus and Gastroesophagael Junction - a Prospective Study[NCT03619317] | 56 participants (Anticipated) | Observational | 2018-06-25 | Recruiting | |||
| Dose Escalation Using a Simultaneous Integrated Boost Technique Based on 18FDG-PET/CT for Unresectable Thoracic Esophageal Cancer: a Phase I/II Trial[NCT01843049] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| Lapatinib Versus Lapatinib With Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial[NCT01145404] | Phase 2 | 76 participants (Anticipated) | Interventional | 2010-06-30 | Terminated (stopped due to Changes of SoC for third line therapy resulting in poor recruitment) | ||
| Maintenance Treatment With S-1 Versus Observation After First-line Chemotherapy in Patients With Advanced Gastric Cancer: a Randomized Phase II Study[NCT03701373] | Phase 2 | 200 participants (Anticipated) | Interventional | 2016-01-01 | Recruiting | ||
| Phase II Study of Optimum Design of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer[NCT02938195] | Phase 2 | 50 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| The Safety and Feasibility of Neoadjuvant Camrelizumab With Dalpiciclib for the Treatment of Resectable Esophageal or Head and Neck Squamous Cell Carcinoma：A Phase 1 Trial[NCT06109207] | Phase 1 | 12 participants (Anticipated) | Interventional | 2023-10-31 | Recruiting | ||
| The Efficacy of Neoadjuvant PD-1 Plus Concurrent Chemotherapy for Stage II-IVA Operable Esophageal Squamous Cell Carcinoma：A Single Armed, Open-label, Multicentre, Clinical Trial[NCT04225364] | Phase 2 | 56 participants (Actual) | Interventional | 2020-01-17 | Completed | ||
| Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by Surgery for Thoracic Esophageal Squamous Cell Cancer: A Prospective, Single Arm, Pilot Study[NCT04776590] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-01-28 | Recruiting | ||
| Sichuan Cancer Hospital & Institute[NCT05604950] | 2 participants (Actual) | Observational [Patient Registry] | 2009-01-01 | Completed | |||
| Induction Chemotherapy for Locally Advanced Esophageal Cancer: A Phase II Study[NCT03110926] | Phase 2 | 40 participants (Anticipated) | Interventional | 2017-06-19 | Active, not recruiting | ||
| Mechanisms and Treatment of Unintentional Weight Loss After Oesophagectomy With Curative Intent[NCT05074914] | 64 participants (Anticipated) | Interventional | 2021-06-30 | Recruiting | |||
| Different Radiation Dose of Neoadjuvant Chemoradiation Followed By Surgery in Treating Patients With Locally Advanced, Resectable Thoracic Esophageal Cancer[NCT03381651] | 144 participants (Anticipated) | Interventional | 2018-02-22 | Recruiting | |||
| Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study[NCT05028231] | 46 participants (Anticipated) | Observational | 2021-06-05 | Recruiting | |||
| A Prospective Cohort Study on Active Surveillance After Neoadjuvant Chemoradiation for Oesophageal Cancer: SANO-2 Study[NCT04886635] | 360 participants (Anticipated) | Observational | 2021-03-09 | Recruiting | |||
| FDG-PET-CT and Biomarkers to Assess Pathologic Response in Surgical Specimens of Patients With Localized Esophageal Cancer After Chemoradiation[NCT00833625] | 31 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| [NCT02445209] | Phase 3 | 56 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Measurement of the Distance Between the Corresponding Anatomical Landmarks in the Thoracic Cavity and the Incisors[NCT03720405] | 520 participants (Anticipated) | Observational [Patient Registry] | 2018-07-31 | Recruiting | |||
| A Multicenter Randomized Phase II Study to Evaluate the Benefit of Chemotherapy Plus Best Supportive Care (BSC) Versus BSC in Patients With Metastatic Oesophageal Cancer of Squamous Cell-type Who Have Not Experienced a Disease Progression or Unacceptable [NCT01248299] | Phase 2 | 105 participants (Actual) | Interventional | 2011-01-31 | Terminated | ||
| Assessment of Cardiorespiratory Fitness and Lung Function in Lung Cancer Patients Undergoing Neoadjuvant Cancer Therapy and Role of Prehabilitation in Preventing Associated Decline[NCT05636969] | 25 participants (Anticipated) | Observational | 2023-02-01 | Not yet recruiting | |||
| PReoperative Chemoradiation With Paclitaxel-carboplatin or With Fluorouracil-oxaliplatine-acide Folinique (FOLFOX) for Resectable Esophageal and Junctional Cancer - A Randomized Phase II Trial[NCT02359968] | Phase 2 | 106 participants (Actual) | Interventional | 2015-02-26 | Active, not recruiting | ||
| A Pilot Study in Gastric Cancer of Assignment to Postoperative Chemoradiation or Chemotherapy Based Upon Surgical Lymph Node Assessment After Preoperative Chemotherapy, With Gene Assay as Correlate of Biologic Response[NCT03515941] | Early Phase 1 | 6 participants (Actual) | Interventional | 2018-06-22 | Terminated (stopped due to The PI has decided to close the study due to the outdated study design.) | ||
| Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer[NCT00381706] | Phase 2 | 245 participants (Actual) | Interventional | 2006-09-15 | Completed | ||
| A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic HER2-Negative G[NCT01590719] | Phase 2 | 123 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Toripalimab Combined With Docetaxel or Nab-paclitaxel in the Treatment of Advanced Gastric Cancer : a Single-arm, Open Label, Prospective Phase II Clinical Trial[NCT04563975] | Phase 2 | 54 participants (Anticipated) | Interventional | 2020-07-02 | Recruiting | ||
| Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach[NCT01246960] | Phase 2 | 168 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Randomized Study of the Efficacy and Safety of OncoGel™ Treatment as an Adjunctive Therapy to Systemic Chemotherapy and Concurrent External Beam Radiation Prior to Surgery in Subjects With Localized or Loco-regional Esophageal Cancer[NCT00573131] | Phase 2 | 137 participants (Actual) | Interventional | 2008-01-31 | Terminated (stopped due to OncoGel did not show any impact on overall tumor response) | ||
| Non-Operative Therapy Of Local-Regional Carcinoma Of The Esophagus: A Randomizd Phase II Study Of Two Paclitaxel-Based Chemoradiotherapy Regimens[NCT00009880] | Phase 2 | 0 participants | Interventional | 2001-04-30 | Completed | ||
| Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma: a Phase II Randomized Controlled Trial[NCT02969473] | Phase 2 | 120 participants (Anticipated) | Interventional | 2010-10-31 | Active, not recruiting | ||
| A Multicenter, Randomised Phase II Trial on the Therapy of Advanced Gastric Cancer or Adenocarcinoma of the Esophagogastric Junction in Patients Older Than 65 Years With Specific Regard of Quality of Life and Pharmacogenetic Risk Profile[NCT00737373] | Phase 2 | 143 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction[NCT00849615] | Phase 2 | 252 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Prospective Study to Analyze the Predictive Role of Factors Implicated in the Signaling Pathway of ERCC1 in Response to Treatment With Neoadjuvant Radiochemotherapy in Patients With Esophageal Cancer[NCT00953511] | 80 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| Phase I Trial of Irinotecan, Cisplatin, and Fluorouracil in Patients With Advanced Solid Tumor Malignancies[NCT00005791] | Phase 1 | 0 participants | Interventional | 1999-10-31 | Completed | ||
| Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative[NCT02797405] | 97 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to Withdrawal of analysis study Partner.) | |||
| Venous Thromboembolism and Bleeding Risk in Patients With Esophageal Cancer[NCT03646409] | 542 participants (Actual) | Observational | 2018-06-11 | Completed | |||
| Prospective Observational Study of Patients With Locally Advanced Gastric Cancer Treated With Perioperative Chemotherapy and Surgery[NCT01633203] | 61 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| Low-dose Radiotherapy as a Chemo-potentiator of a Induction Chemotherapy Regimen With Gem-based Doublets and Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer[NCT02416609] | 44 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | |||
| An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer[NCT01627379] | Phase 3 | 300 participants (Anticipated) | Interventional | 2012-05-31 | Terminated (stopped due to Sponsor decision due to recommendation of the IDMC.) | ||
| A Phase I/II Study of Oblimersen in Combination With Cisplatin and Fluorouracil in Patients With Advanced Esophageal, Gastro-Esophageal Junction and Gastric Cancer[NCT00064259] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2003-06-30 | Terminated (stopped due to Discontinued development of G3139 (oblimersen)) | ||
| Impact of Widths After Gastric Tube Reconstruction on Quality of Life for Patients With Esophagogastric Cancers[NCT01911832] | Phase 3 | 60 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| A Phase II Study of Daily Low-Dose of Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum) and Continuous Infusion of 5-FU Combined With Radiation for the Treatment of Esophageal Cancer[NCT00197444] | Phase 2 | 33 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System[NCT02662348] | Phase 1 | 6 participants (Anticipated) | Interventional | 2016-02-29 | Enrolling by invitation | ||
| A Phase I/II Trial of Preoperative Oxaliplatin, Docetaxel, and Capecitabine With Concurrent Radiation Therapy in Localized Carcinoma of the Esophagus or Gastroesophageal Junction[NCT00193128] | Phase 1/Phase 2 | 59 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Randomized Phase II Open-Label Controlled Study of EMD 72000 (Matuzumab), in Combination With the Chemotherapy Regimen ECX or the Chemotherapy Regimen ECX Alone as First-line Treatment in Subjects With Metastatic Esophago-Gastric Adenocarcinoma[NCT00215644] | Phase 2 | 72 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| A Phase Ⅱ Study on Low-expression and High-expression of ERCC1 in Recurrent or Metastastic Esophageal Cancer Patients Treated With Biweekly Paclitaxel and Cisplatin[NCT01444547] | Phase 2 | 92 participants (Anticipated) | Interventional | 2007-01-31 | Recruiting | ||
| [NCT02603159] | Phase 3 | 200 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy[NCT02644408] | Phase 3 | 184 participants (Actual) | Interventional | 2014-10-01 | Completed | ||
| A Phase II Study to Compare Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus[NCT02586753] | Phase 2 | 2 participants (Anticipated) | Interventional | 2015-12-31 | Not yet recruiting | ||
| Use of PET/MR Radiomics to Evaluate the Clinical Phenotypes, Response Status of Neoadjuvant Chemotherapy and Long-term Prognosis of Breast Cancer: a Preliminary Study[NCT05466760] | 120 participants (Anticipated) | Observational [Patient Registry] | 2018-07-06 | Recruiting | |||
| A Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Pediatrics With Myeloproliferative Neoplasms[NCT03121599] | 3 participants (Actual) | Interventional | 2017-06-11 | Terminated (stopped due to Delayed study materials, poor recruitment) | |||
| A Study of 18F-FLT Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Cases of Prefibrotic/Early Primary Myelofibrosis (PMF) and Essential Thrombocythemia (ET)[NCT03116542] | 21 participants (Anticipated) | Interventional | 2017-05-07 | Recruiting | |||
| A Phase II Trial of Perioperative Chemotherapy With Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Patients With Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma[NCT04999332] | Phase 2 | 58 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| A Phase II Study Of Paclitaxel-Based Chemoradiotherapy Regimen With Selective Surgical Salvage For Resectable Locoregionally Advanced Carcinoma Of The Esophagus[NCT00069953] | Phase 2 | 43 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG): The Heidelberg Imaging Program in Cancer of the Oesophago-gastric Junction During Neoadjuvant Treatment:[NCT01271322] | Phase 2 | 0 participants | Interventional | 2010-10-31 | Terminated | ||
| A Phase II Study of Weekly Paclitaxel and Capecitabine in Patients With Metastatic or Recurrent Esophageal Cancer[NCT00453323] | Phase 2 | 33 participants (Actual) | Interventional | 2006-06-30 | Active, not recruiting | ||
| Oxaliplatin (NSC-266046) Plus Protracted Infusion 5-Fluorouracil And Radiation For Potentially Curable Esophageal Cancer: A Phase II Trial With Molecular Correlates[NCT00086996] | Phase 2 | 98 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Impacts of Oral Supplement With L-Glutamine on the Radiation-induced Toxicity and Nutritional Status of Head and Neck Cancer Patients Under Radiotherapy[NCT03015077] | 59 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| "Study on Indications of Bard PowerPort Isp Implantable Port: Image Accuracy in Resectable Esophageal Cancer Patients"[NCT02887261] | 100 participants (Actual) | Interventional | 2016-05-31 | Completed | |||
| A Single Arm, Phase II Study of TNFerade™ Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer[NCT00051480] | Phase 2 | 0 participants | Interventional | Completed | |||
| Multicenter, Open Lable Phase II Study to Evaluate the Safety and Efficacy of a Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine in Patients With Gastric Adenocarcinoma, Adenocarcinoma of the Gastro-esophageal Junction or the Distal E[NCT00865982] | Phase 2 | 50 participants (Anticipated) | Interventional | 2008-09-30 | Active, not recruiting | ||
| A Prospective, Phase II Study of Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy in Patients With Esophageal Squamous Cell Carcinoma[NCT04380480] | Phase 2 | 63 participants (Actual) | Interventional | 2020-02-01 | Completed | ||
| A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres[NCT00450203] | Phase 2/Phase 3 | 1,103 participants (Anticipated) | Interventional | 2007-10-31 | Recruiting | ||
| Apatinib Plus XELOX Regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With Lymph Node Metastasis[NCT03229096] | Phase 2 | 35 participants (Anticipated) | Interventional | 2017-02-01 | Recruiting | ||
| A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination With AMG 386 or Placebo in Subjects With Metastatic Gastric, Gastroesophageal Junctio[NCT00583674] | Phase 2 | 171 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| A Phase I Study of Capecitabine, Cisplatin and Imatinib in Patients With Unresectable or Metastatic Gastric Cancer.[NCT00601510] | Phase 1 | 38 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Trastuzumab Plus XELOX for HER2-positive Stage III Gastric Cancer After D2 Gastrectomy：Prospective Observational Study.[NCT02250209] | Phase 2 | 40 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Could Positon Emission Tomography With Radiolabelled 3'-Deoxy-3'-(18)F-Fluoro-L-Thymidine be a Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patients ?[NCT02069418] | Phase 2 | 80 participants (Anticipated) | Interventional | 2014-02-28 | Active, not recruiting | ||
| A Prospective, Phase Ⅱ Study of S-1 Plus Moderately Hypofractionated Conformal Radiation for Esophageal Squamous Cell Carcinoma[NCT03660449] | Phase 2 | 58 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Combination Treatment of S-1 With Paclitaxel Versus Paclitaxel+Cisplatin and 5-Fu+Cisplatin as First-line Treatment in Advanced Esophageal Cancer[NCT01704690] | Phase 2/Phase 3 | 4 participants (Actual) | Interventional | 2012-08-31 | Terminated (stopped due to The enrollment of the study is much slower than expected.) | ||
| Multi-center Prospective Randomized Controlled Clinical Trial of Postoperative Adjuvant Chemotherapy, Adjuvant Radiotherapy, or Surgery Alone for High-risk Histological Node Negative Patients With Thoracic Esophageal Squamous Cell Carcinoma[NCT02891083] | Phase 3 | 486 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| A PHASE III INTERGROUP RANDOMIZED COMPARISON OF COMBINED MODALITY THERAPY FOR CARCINOMA OF THE ESOPHAGUS: HIGH-DOSE VS CONVENTIONAL-DOSE RADIATION THERAPY[NCT00002631] | Phase 3 | 298 participants (Anticipated) | Interventional | 1995-06-30 | Completed | ||
| The Application of Novel Oncolytic Virus in Late Stage Solid Tumors[NCT06080984] | Phase 1 | 24 participants (Anticipated) | Interventional | 2023-10-15 | Recruiting | ||
| Phase I /II Study of Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma[NCT02446574] | Phase 1/Phase 2 | 33 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Phase II Study of Oxaliplatin and Capecitabine in Patients With Measurable Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia[NCT00040859] | Phase 2 | 48 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| A Phase II Study Of Docetaxel And Capecitabine In Patients With Measurable Metastatic Adenocarcinoma Of The Stomach And Gastroesophageal Junction[NCT00054457] | Phase 2 | 46 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| An Open Label, Sequential Multi-Center Multi Dose Study Of G17T Immunogen In Combination With Cisplatin (CDDP) And 5-Fluorouracil (5-FU) In Subjects With Metastatic Or Locally Recurrent Gastric Or Gastroesophageal Cancer Previously Untreated With Chemothe[NCT00020787] | Phase 3 | 8 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| Morbidity In Open Versus Minimally Invasive Hybrid Esophagectomy[NCT03035071] | 26 participants (Actual) | Interventional | 2010-05-01 | Completed | |||
| Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection for Clinical Stage II or III Gastric Cancer[NCT02572050] | Phase 2 | 87 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| The Clinical Efficacy of Patient-derived Organoid-based Drug Sensitive Neoadjuvant Chemotherapy Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer: a Prospective Multi-center Randomized Controlled Study[NCT05351398] | 54 participants (Anticipated) | Observational | 2022-04-30 | Not yet recruiting | |||
| Neoadjuvant Transcatheter Arterial Chemoinfusion and Embolism (TACiE) for Patients With Locally Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction: a Pilot Study[NCT05396326] | Phase 1 | 20 participants (Anticipated) | Interventional | 2022-06-01 | Not yet recruiting | ||
| The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma.[NCT00674167] | Phase 2 | 21 participants (Actual) | Interventional | 2007-05-31 | Active, not recruiting | ||
| A RANDOMISED, CONTROLLED TRIAL OF PRE- AND POST-OPERATIVE CHEMOTHERAPY IN PATIENTS WITH OPERABLE GASTRIC CANCER[NCT00002615] | Phase 3 | 500 participants (Anticipated) | Interventional | 1994-06-30 | Completed | ||
| Approximation to the Therapeutic Individualization in Patients With Locally Advanced Gastric and Gastroesophageal Cancer Through Modelling and Generation of Predictive Gene Signatures[NCT02454673] | 121 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination With Epirubicin, Cisplatin and Capecitabine (ECX) Versus ECX Alone in Subjects With Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction.[NCT01234324] | Phase 2 | 171 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Neoadjuvant Transcatheter Arterial Chemoinfusion and Embolism (TACiE) for Patients With Locally Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction: a Prospective, Phase 2, Single Arm Trial.[NCT05346874] | Phase 2 | 37 participants (Anticipated) | Interventional | 2022-06-01 | Not yet recruiting | ||
| Phase III Multicenter Randomized Controlled Trial of Adjuvant Chemoradiotherapy vs Chemotherapy for Radical Resected Advanced Gastric Carcinoma Concurrent With Lymph Node Metastasis and Lymphovascular Invasion[NCT03680261] | Phase 3 | 556 participants (Anticipated) | Interventional | 2018-10-01 | Not yet recruiting | ||
| Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) During Laparoscopic Resection in High-risk Gastric Cancer Patients: A Multicentre Phase-I Study (the PIPAC-OPC4 Study)[NCT04047004] | Phase 1 | 20 participants (Actual) | Interventional | 2020-03-11 | Completed | ||
| Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy in R0 Gastric Cancer[NCT02640898] | 500 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| A Randomized, Double-blind, Placebo-controlled Phase Ib/II Clinical Study of Anti-pd-l1 Monoclonal Antibody Injection (ZKAB001) Combined Albumin Binding Paclitaxel, Cisplatin in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma.[NCT04460066] | Phase 1/Phase 2 | 70 participants (Anticipated) | Interventional | 2020-11-18 | Active, not recruiting | ||
| Randomized Phase Ⅱ Trial of Induction Chemotherapy Using Gemcitabine and Cisplatin in Concurrence With Intensity-modulated Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma[NCT01417390] | Phase 2 | 80 participants (Anticipated) | Interventional | 2011-11-30 | Recruiting | ||
| Randomized Trial of Comparing One Cycle With Three Cycles Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Locoregionally Advanced Nasopharyngeal Carcinoma[NCT02096380] | 120 participants (Anticipated) | Observational [Patient Registry] | 2014-05-31 | Not yet recruiting | |||
| Prospective Randomized Clinical Trial on Delay Phenomenon Utility in Preventing Oesophagogastric Anastomotic Dehiscence After Ivor-Lewis Esophagectomy. Pilot Study.[NCT02432794] | 44 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib as Adjuvant Therapy for Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas[NCT01143545] | Phase 1 | 10 participants (Actual) | Interventional | 2010-12-07 | Terminated (stopped due to Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same population.) | ||
| A Phase 3, Open-Label, Randomized Study to Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxaliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer Patients at Stage IIIB and IV (M0) (Based on AJCC Ed. 6) Who Received Radical Resecti[NCT01935778] | Phase 3 | 286 participants (Anticipated) | Interventional | 2013-10-02 | Recruiting | ||
| A Phase II Trial of Preoperative Radiation and Chemotherapy (Paclitaxel, Carboplatin, and Continuous Infusion 5-FU) for Locally Advanced Esophageal Cancer[NCT00022139] | Phase 2 | 56 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| Randomized Study of Adjuvant Radiochemotherapy After Surgery Versus Radiochemotherapy Alone in Patients With Locally Advanced Esophageal Cancer[NCT00416858] | Phase 3 | 40 participants (Anticipated) | Interventional | Completed | |||
| Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study[NCT02114359] | Phase 3 | 111 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Phase I / II Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in the Second-line Treatment of Advanced Gastric Cancer[NCT04286711] | Phase 1/Phase 2 | 52 participants (Anticipated) | Interventional | 2020-03-31 | Not yet recruiting | ||
| Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma[NCT02289547] | Phase 3 | 184 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| A Prospective, Multicenter Clinical Study of Apatinib Plus Irinotecan as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junctional Adenocarcinoma[NCT03116555] | Phase 2 | 37 participants (Anticipated) | Interventional | 2017-04-05 | Recruiting | ||
| Pazopanib With 5-Fluorouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line Treatment in Advanced Gastric Cancer; a Randomized Phase-II-study of the Arbeitsgemeinschaft Internistische Onkologie[NCT01503372] | Phase 2 | 75 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Prospective Randomized Phase III Trial Comparing Trimodality Therapy (Cisplatin, 5-FU, Radiotherapy, and Surgery) to Surgery Alone for Esophageal Cancer[NCT00003118] | Phase 3 | 56 participants (Actual) | Interventional | 1997-10-31 | Completed | ||
| Monitoring Efficacy of Radiotherapy Based on Next Generation Sequencing Liquid Biopsy Technique in Lung Cancer and Esophageal Cancer: a Prospective Study[NCT04014465] | 150 participants (Anticipated) | Observational | 2019-02-01 | Recruiting | |||
| Diagnostic Value of Intraoperative Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases During Staging Laparoscopy for Gastric Adenocarcinoma: a Prospective, Multicentric Study.[NCT05687617] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-12-15 | Recruiting | ||
| A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer[NCT01396707] | Phase 2 | 55 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Clinical Trial Of Safety Of Robot-assisted Thoracic Approach Verus Open Transthoracic Esophagectomy in Esophageal Cancer.[NCT04652180] | 108 participants (Anticipated) | Interventional | 2020-11-06 | Recruiting | |||
| An Open-labeled Study to Evaluate Efficacy of Combining Erbitux Plus Concurrent Chemo-radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)[NCT00815308] | Phase 2 | 55 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.[NCT03562897] | Phase 2 | 40 participants (Actual) | Interventional | 2018-10-25 | Completed | ||
| A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer[NCT01137123] | Phase 3 | 301 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| RANDOMIZED STUDY OF PREOPERATIVE CHEMOTHERAPY VERSUS SURGERY ALONE IN ESOPHAGUS CANCER[NCT00002897] | Phase 3 | 240 participants (Anticipated) | Interventional | 1992-07-31 | Completed | ||
| Phase Ⅲ Study of Prophylactic Postoperative Intensity Modulated Radiation Therapy in Stage T2-3N0M0 Disease of Thoracic Esophageal Squamous Cell Carcinoma;[NCT01745107] | Phase 3 | 240 participants (Anticipated) | Interventional | 2012-10-31 | Active, not recruiting | ||
| Phase II Study of High-dose （86 Gy）Intensity Modulated Radiotherapy and Concurrent Paclitaxel and Cisplatin in Locoregionally Advanced Esophageal Cancer[NCT03535207] | 50 participants (Anticipated) | Interventional | 2018-04-01 | Recruiting | |||
| Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Cisplatin and Paclitaxel in Patients With Esophageal Cancer[NCT03082586] | 31 participants (Actual) | Interventional | 2016-11-20 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants who were PD-L1 CPS ≥10." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) |
|---|---|
| Pembrolizumab + SOC | -1.73 |
| Placebo + SOC | 0.04 |
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants who had ESCC." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) |
|---|---|
| Pembrolizumab + SOC | -2.00 |
| Placebo + SOC | -1.94 |
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants who had ESCC and who were PD-L1 CPS ≥10." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) |
|---|---|
| Pembrolizumab + SOC | -2.36 |
| Placebo + SOC | -0.40 |
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) |
|---|---|
| Pembrolizumab + SOC | -1.74 |
| Placebo + SOC | -1.64 |
For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR, and were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 10.4 |
| Placebo + SOC | 5.6 |
For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR, and who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 9.1 |
| Placebo + SOC | 6.1 |
For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR, and who had ESCC and were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 10.4 |
| Placebo + SOC | 4.4 |
For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 8.3 |
| Placebo + SOC | 6.0 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued any study drug due to an AE was reported for each treatment arm. (NCT03189719)
Timeframe: Up to approximately 27 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + SOC | 90 |
| Placebo + SOC | 74 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that experienced at least one AE was reported for each treatment arm. (NCT03189719)
Timeframe: Up to approximately 28 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + SOC | 370 |
| Placebo + SOC | 368 |
ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized). (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + SOC | 45.0 |
| Placebo + SOC | 29.3 |
ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + SOC | 51.1 |
| Placebo + SOC | 26.9 |
ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized) who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + SOC | 43.8 |
| Placebo + SOC | 31.0 |
ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized) who had ESCC and who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + SOC | 51.0 |
| Placebo + SOC | 28.0 |
Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the ITT population (all randomized). (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 12.4 |
| Placebo + SOC | 9.8 |
Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 13.5 |
| Placebo + SOC | 9.4 |
Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the ITT population (all randomized) who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 12.6 |
| Placebo + SOC | 9.8 |
Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the Intent-To-Treat (ITT) population (all randomized) who had ESCC and who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 13.9 |
| Placebo + SOC | 8.8 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by the investigator, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, PFS is reported here for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 6.3 |
| Placebo + SOC | 5.8 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by the investigator, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, PFS is reported here for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 7.5 |
| Placebo + SOC | 5.5 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by the investigator, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, PFS is reported here for all participants of the ITT population (all randomized) who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + SOC | 6.3 |
| Placebo + SOC | 5.8 |
"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores representing a higher (worse) level of symptoms. Change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for participants who were PD-L1 CPS≥10 in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) | ||
|---|---|---|---|
| Dysphagia subscale | Pain subscale | Reflux subscale | |
| Pembrolizumab + SOC | -7.18 | -3.51 | -0.52 |
| Placebo + SOC | 1.02 | 0.07 | 4.25 |
"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores representing a higher (worse) level of symptoms. Change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for participants with ESCC in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) | ||
|---|---|---|---|
| Dysphagia subscale | Pain subscale | Reflux subscale | |
| Pembrolizumab + SOC | -1.18 | -4.03 | -0.40 |
| Placebo + SOC | 3.32 | -2.33 | 1.09 |
"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores representing a higher (worse) level of symptoms. Change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for participants with ESCC who were PD-L1 CPS≥10 in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) | ||
|---|---|---|---|
| Dysphagia subscale | Pain subscale | Reflux subscale | |
| Pembrolizumab + SOC | -5.11 | -2.55 | -0.16 |
| Placebo + SOC | 3.57 | -0.42 | 4.94 |
"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores represent a higher (worse) level of symptoms. Per protocol, change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for all participants in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18
| Intervention | Score on a Scale (Least Squares Mean) | ||
|---|---|---|---|
| Dysphagia subscale | Pain subscale | Reflux subscale | |
| Pembrolizumab + SOC | -3.18 | -4.78 | -0.22 |
| Placebo + SOC | 2.36 | -1.85 | 0.71 |
Chireac tumour regression grade (NCT01362127)
Timeframe: Therapy followed in 14-16 weeks before surgery. After surgery the patients will be followed until 60 weeks after completed therapy.
| Intervention | Participants (Count of Participants) |
|---|---|
| Radiochemotherapy | 22 |
| Chemotherapy | 7 |
Safety profile of carrying out radical surgery after respective neoadjuvant therapy. (NCT01362127)
Timeframe: Five years follow up
| Intervention | Participants (Count of Participants) |
|---|---|
| Radiochemotherapy | 79 |
| Chemotherapy | 81 |
The European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 and disease specific questionnaires (QLQ-OES24/OG25). All items included in the questionnaires are analysed and also separate analysis of dysphagia questionnaires for oesophageal cancer were used, both clinically and psychometrically validated. All questions have four response alternatives (1, not at all; 2:a little, 3: quite a bit, 4: very much), except global scales which comprise seven response alternatives from poor to excellent. Questionnaire responses were transformed lineraly into scores ranging from 0 to 100 according to the EORTC scoring manual. A higher score indicates either more symotoms or better function, depending on the question. (NCT01362127)
Timeframe: Entry study up to Five years follow up
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Mean global QoL | Dysphagia score all | |
| Chemotherapy | 69 | 31 |
| Radiochemotherapy | 67 | 27 |
"Clinical benefit rate is the percentage of combined patients who have achieved complete response (CR), partial response (PR), and stable disease (SD)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters~SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 33 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 22 |
Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 5.8 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 10.5 |
"Objective response (defined as complete response (CR) + partial response (PR) by RECIST 1.1 criteria)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 25 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 22 |
Overall survival is defined as the time interval from date of diagnosis to date of death from any cause. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 15.5 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 19.6 |
Duration of time from start of treatment to time of progression or death, whichever occurs first. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 8.4 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 13.8 |
Duration of time from start of treatment to time of progression. Progression is defined as At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 8.0 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 13.9 |
(NCT01928290)
Timeframe: 30 days after completion of treatment (estimated to be 5 months)
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia | Febrile neutropenia | Anal Fistula | Diarrhea | Hematemesis | Nausea | Peripheral ischemia | Vomiting | Fatigue | Laparoscopy surgery | Pain | Sepsis | Lung infection | Pneumonia | Hypernatremia | Neutrophil count decreased | Platelet count decreased | Anorexia | Dehydration | Hypokalemia | Back pain | Peripheral sensory neuropathy | Syncope | Dyspnea | Pleural embolism | Skin infection | Thromboembolic event | Abdominal pain | Enterocolitis | Hemorrhoids | G-tube infection | Neutropenic entercolitis | Alkaline phosphatase increased | |
| Arm A: FOLFIRINOX (HER2-negative) | 1 | 2 | 1 | 4 | 1 | 2 | 1 | 3 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 19 | 3 | 3 | 4 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 0 | 0 | 0 | 5 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 8.0 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.7 |
DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 8.3 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 10.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.8 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE is presented. (NCT03675737)
Timeframe: Up to 33.7 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 257 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 204 |
An AE was defined as any untoward medical occurrence, in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one AE is presented. (NCT03675737)
Timeframe: Up to 36.7 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 776 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 771 |
ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 51.3 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 42.0 |
ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 52.1 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 42.6 |
ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 60.6 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 43.0 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 45.9 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 12.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 11.5 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 45.9 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 13.0 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 11.4 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 45.9 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 15.7 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 11.8 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 6.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 6.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 8.1 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
The primary endpoint of this study is the percentage of PET/CT non-responders within each induction treatment group reporting a pCR. A pCR is defined as having no tumor found on pathology review at surgery in all resected lymph nodes and tissue. All tissues sampled must have NO viable tumor. (NCT01333033)
Timeframe: Up to 5 years
| Intervention | percentage of participants with a pCR (Number) |
|---|---|
| FOLFOX Non-Responder | 17.95 |
| CP Non-Responder | 20 |
"A Complete Pathological Response (pCR) is defined as having no tumor found on pathology review at surgery in all resected lymph nodes and tissue. All tissues sampled must have NO viable tumor. A non-responder was defined as having a PET/CT SUV (standard uptake value) decrease of less than 35% after induction.>~>>>~>~>>> Among the patients who completed induction therapy and did not respond, the percentage of patients reporting a pCR in each arm were compared." (NCT01333033)
Timeframe: Up to 5 years
| Intervention | percentage of participants with a pCR (Number) |
|---|---|
| FOLFOX Regimen Non-Responders | 17.95 |
| CP (Carboplatin + Paclitaxel + Radiation) Non-Responders | 20 |
"A PET/CT response to induction therapy is defined as metabolic activity of the tumor decreasing by >=35%, as>~>>~>>~>> measured by maximum standardized uptake value (SUVmax). A pCR is defined as having no tumor found on pathology review at surgery in all resected lymph nodes and tissue. All tissues sampled must have NO viable tumor." (NCT01333033)
Timeframe: Up to 5 years
| Intervention | percentage of participants with a pCR (Number) |
|---|---|
| FOLFOX Responder | 40.28 |
| CP (Carboplatin + Paclitaxel + Radiation) Responder | 14.06 |
A PET/CT response to induction therapy is defined as metabolic activity of the tumor decreasing by >=35%, as measured by maximum standardized uptake value (SUVmax). (NCT01333033)
Timeframe: Up to 5 years
| Intervention | percentage of patients with a response (Number) |
|---|---|
| FOLFOX Regimen | 64.86 |
| CP (Carboplatin + Paclitaxel + Radiation) | 56.14 |
"A non-responder was defined as having a PET/CT SUV (standard uptake value) decrease of less than 35% after induction.~Among the patients who completed induction therapy and did not respond, the progression free survival in each arm were compared. PFS will be measured from study entry until documented progression or death from any cause. PFS will be estimated using the method of Kaplan and Meier." (NCT01333033)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| FOLFOX Regimen Non-Responder | NA |
| CP Non-Responder | 33.4 |
Pathologic Complete Response rate: percentage of participants with response reported as Pathologic complete response (pathCR) following surgery. Once surgery performed, response to therapy judged in surgical specimen with three possible categories reported: 1) Pathologic complete response (no residual cancer in the specimen); 2) <50% of residual cells in the surgical specimen; or 3) >50% of cells in the surgical specimen. Upon recovery from chemoradiation (Chemo), surgery follows approximately 5-6 weeks later with response assessment. Arm A schedule consists of 6 weeks of Chemo +XRT, followed by 5-6 weeks of rest, followed by surgery. Arm B schedule consist of 8 weeks of Chemo, followed by 6 weeks of Chemo +XRT, followed by 5-6 weeks of rest, followed by surgery. In particular, Arm B is 8 weeks longer than Arm A. (NCT00525915)
Timeframe: Surgery post chemotherapy (approximately 10-11 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A: Chemo With Radiation Treatment | 13 |
| Arm B: Pre-Op Chemo + Chemo With Radiation Treatment | 26 |
DOR is defined as the time from date of first documented confirmed objective response to date of first documented progressive disease (PD). Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated. (NCT01191697)
Timeframe: 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | months (Median) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 14.9 |
Overall survival based on the Kaplan-Meier method is defined as the time from randomization to death. Participants alive are censored at the last date of contact (including lost-to-follow-up) or at the date of withdrawal of consent, if relevant. (NCT01191697)
Timeframe: 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | months (Median) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 23.2 |
PFS is defined as the duration of time from study entry to documented disease progression (PD) requiring removal from the study or death. Participants alive without PD were censored at the earliest of the date of the last disease evaluation or start of new anticancer therapy. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated. (NCT01191697)
Timeframe: Patients received a median of 19 cycles of therapy (Interquartile range (IQR): 8 - 34.5 cycles). Median duration of follow up of 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | months (Median) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 14.0 |
ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions. (NCT01191697)
Timeframe: Patients received a median of 19 cycles of therapy (Interquartile range (IQR): 8 - 34.5 cycles). Median duration of follow-up of 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | percentage of patients (Number) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 81 |
Duration of complete or partial response with 95% confidence intervals in gastric cancer population. (NCT02318329)
Timeframe: 16 weeks on average
| Intervention | Weeks (Median) |
|---|---|
| Part 1/2: FPA144 Dose Expansion Gastric or Other Solid Tumors | 14.1 |
Number of Participants with AEs and clinical laboratory abnormalities (Parts 1B and 2 only) (NCT02318329)
Timeframe: 16 weeks on average
| Intervention | Participants (Count of Participants) |
|---|---|
| Part 1B: FPA144 Dose Escalation Gastric Cancer 3mg/kg | 1 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 6 mg/kg | 1 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 10 mg/kg | 6 |
| Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors | 48 |
Number of participants with grade 3 and grade 4 adverse events (AE) and clinical laboratory abnormalities defined as dose limiting toxicities (DLTs) (NCT02318329)
Timeframe: 4 weeks on average
| Intervention | Participants (Count of Participants) |
|---|---|
| Part 1A: FPA144 Dose Escalation Solid Tumors 0.3 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 1 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 3 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 6 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 10 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 15 mg/kg | 0 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 3mg/kg | 0 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 6 mg/kg | 0 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 10 mg/kg | 0 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT02318329)
Timeframe: 16 weeks on average
| Intervention | Participants (Count of Participants) |
|---|---|
| Part 1A: FPA144 Dose Escalation Solid Tumors 0.3 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 1.0 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 3.0 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 6.0 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 10 mg/kg | 0 |
| Part 1A: FPA144 Dose Escalation Solid Tumors 15 mg/kg | 0 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 3mg/kg | 0 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 6mg/kg | 1 |
| Part 1B: FPA144 Dose Escalation Gastric Cancer 10mg/kg | 1 |
| Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors | 4 |
"Sampling following the first dose in Part 1, pre and post-dose at selected cycles, and at the end of treatment for both Part 1 and Part 2.~• Summary of area under serum concentration-time curve, maximum serum concentration," (NCT02318329)
Timeframe: 16 weeks on average
| Intervention | ug*day/ml (Mean) |
|---|---|
| Phase 1a Dose Escalation 1 mg/kg | 1.288 |
| Phase 1a Dose Escalation 3 mg/kg | 1.547 |
| Phase 1a Dose Escalation 6 mg/kg | 1.427 |
| Phase 1a Dose Escalation 10 mg/kg | 1.863 |
| Phase 1a Dose Escalation 15 mg/kg | 1.697 |
| Phase 1b Dose Escalation in Gastric Cancer 3 mg/kg | 2.69 |
| Phase 1b Dose Escalation in Gastric Cancer 6 mg/kg | 1.59 |
| Phase 1b Dose Escalation in Gastric Cancer 10 mg/kg | 1.648 |
| Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors | 1.867 |
"Sampling following the first dose in Part 1, pre and post-dose at selected cycles, and at the end of treatment for both Part 1 and Part 2.~• Summary of area under serum concentration-time curve, maximum serum concentration," (NCT02318329)
Timeframe: 16 weeks on average
| Intervention | ug/ml (Mean) |
|---|---|
| Phase 1a Dose Escalation 1 mg/kg | 0.2483 |
| Phase 1a Dose Escalation 3 mg/kg | 0.3117 |
| Phase 1a Dose Escalation 6 mg/kg | 0.2873 |
| Phase 1a Dose Escalation 10 mg/kg | 0.4097 |
| Phase 1a Dose Escalation 15 mg/kg | 0.3847 |
| Phase 1b Dose Escalation in Gastric Cancer 3 mg/kg | 0.4900 |
| Phase 1b Dose Escalation in Gastric Cancer 6 mg/kg | 0.232 |
| Phase 1b Dose Escalation in Gastric Cancer 10 mg/kg | 0.2990 |
| Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors | 0.3145 |
Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient was randomized).
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 6.5 |
| 5-FU/Cisplatin | 5.8 |
Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient. (NCT00400179)
Timeframe: The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 8.6 |
| 5-FU/Cisplatin | 7.9 |
The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient randomized).
| Intervention | Percentage of patients in each group (Number) |
|---|---|
| S-1/Cisplatin | 29.1 |
| 5-FU/Cisplatin | 31.9 |
The time from randomization to date of first documented PD or date of death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 4.8 |
| 5-FU/Cisplatin | 5.5 |
The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 3.8 |
| 5-FU/Cisplatin | 3.8 |
"DCR - complete response, partial response, and stable disease~Complete response - disappearance of all target and non-target lesions~Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter~Stable disease - neither sufficient shrinkage to qualify for partial response not sufficient increase to qualify for progressive disease" (NCT00515216)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Oxaliplatin/Leucovorin/5-FU | 95.7 |
"ORR = complete response + partial response~Complete response - disappearance of all target and non-target lesions~Partial response - at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter" (NCT00515216)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Oxaliplatin/Leucovorin/5-FU | 39.1 |
(NCT00515216)
Timeframe: 4 years
| Intervention | months (Median) |
|---|---|
| Oxaliplatin/Leucovorin/5-FU | 11.4 |
Progressive disease - at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT00515216)
Timeframe: 4 years
| Intervention | months (Median) |
|---|---|
| Oxaliplatin/Leucovorin/5-FU | 6.2 |
This outcome looks at what genotypes of the ERCC1 c.354C>T (rs11615) gene had a partial tumor response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| C/C | C/T | T/T | |
| Oxaliplatin/Leucovorin/5-FU | 2 | 4 | 3 |
This outcome looks at what genotypes of the ERCC2 c.2251A>C (rs13181) gene had a partial response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | A/C | C/C | |
| Oxaliplatin/Leucovorin/5-FU | 5 | 3 | 1 |
This outcome looks at what genotypes of the GSTP1 c.313A>G (rs1695) gene had a partial response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | A/G | G/G | |
| Oxaliplatin/Leucovorin/5-FU | 4 | 3 | 2 |
This outcome looks at what genotypes of the MDR1 c.3435C>T (rs1045642) gene had a partial response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| C/C | C/T | T/T | |
| Oxaliplatin/Leucovorin/5-FU | 0 | 9 | 0 |
This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had a partial tumor response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | |
|---|---|---|
| +6 bp/+6 bp | +6 bp/-6 bp | |
| Oxaliplatin/Leucovorin/5-FU | 5 | 4 |
This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G>C (rs34743033) gene had a partial tumor response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| TYMS, TSER*2/*2 | TYMS, TSER*2/*3 (G) | TYMS, TSER*2/*3 (C) | |
| Oxaliplatin/Leucovorin/5-FU | 5 | 2 | 2 |
This outcome looks at what genotypes of the XRCC1 c.1196G>A (rs25487) gene had a partial response. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | G/A | G/G | |
| Oxaliplatin/Leucovorin/5-FU | 1 | 6 | 2 |
This outcome looks at what genotypes of the ERCC1 c.354C>T (rs11615) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| C/C | C/T | T/T | |
| Oxaliplatin/Leucovorin/5-FU | 1 | 8 | 2 |
This outcome looks at what genotypes of the ERCC2 c.2251A>C (rs13181) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | A/C | C/C | |
| Oxaliplatin/Leucovorin/5-FU | 3 | 6 | 2 |
This outcome looks at what genotypes of the GSTP1 c.313A>G (rs1695) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | A/G | G/G | |
| Oxaliplatin/Leucovorin/5-FU | 8 | 2 | 1 |
This outcome looks at what genotypes of the MDR1 c.3435C>T (rs1045642) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| C/C | C/T | T/T | |
| Oxaliplatin/Leucovorin/5-FU | 1 | 6 | 4 |
This outcome looks at what genotypes of the TYMS 3'-UTR 1494delTTAAAG(6 bp) (rs34489327) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | |
|---|---|---|
| +6 bp/+6 bp | +6 bp/-6 bp | |
| Oxaliplatin/Leucovorin/5-FU | 6 | 5 |
This outcome looks at what genotypes of the TYMS 5'-UTR TSER + G>C (rs34743033) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| TYMS, TSER*2/*2 | TYMS, TSER*2/*3 (G) | TYMS, TSER*2/*3 (C) | |
| Oxaliplatin/Leucovorin/5-FU | 1 | 4 | 6 |
This outcome looks at what genotypes of the XRCC1 c.1196G>A (rs25487) gene had stable disease. (NCT00515216)
Timeframe: 4 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| A/A | G/A | G/G | |
| Oxaliplatin/Leucovorin/5-FU | 6 | 5 | 0 |
Disease recurrence will be defined as radiographic tumor evidence detected by surveillance imaging. Confirmation of recurrence by biopsy will be at the discretion of the treating physician. This study closed early on June 18, 2020. It was earlier than one planned because of the lack of accrual. (NCT03515941)
Timeframe: From the end of completion of assigned therapy, subjects undergo follow-up every 3 months for a total of 36 months(planned) after the date of surgery or until the study closure
| Intervention | months (Median) |
|---|---|
| Arm 1: Adjuvant Chemotherapy | NA |
| Arm 2: Adjuvant Chemoradiation | NA |
The number of patients who complete the recommended therapy will be counted for each arm. (NCT03515941)
Timeframe: From date of assigned therapy up to 17 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1: Adjuvant Chemotherapy | 3 |
| Arm 2: Adjuvant Chemoradiation | 2 |
Overall survival (OS) was defined as the time from study entry to death of any cause. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 11.6 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 8.6 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 11.8 |
Progression free survival (PFS) was defined as the time from study entry to progression or death of any cause. The median PFS with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 7.1 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 4.9 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 6.8 |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs in participants with adenocarcinoma who have received at least one cycle of therapy. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 61 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 45 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 54 |
Time to treatment failure (TTF) was measured from study entry until documented progression, death resulting from any cause, or end of protocol therapy because of unacceptable toxicity. The median TTF with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 5.6 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 4.3 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 6.7 |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs in participants with squamous cell carcinoma who have received at least one cycle of therapy. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A: Squamous Cell Carcinoma (ECF + Cetuximab) | 67 |
| Arm B: Squamous Cell Carcinoma (IC + Cetuximab) | 13 |
| Arm C: Squamous Cell Carcinoma (FOLFOX + Cetuximab) | 60 |
Duration of response was defined using RECIST v. 1.1 criteria as the time from the date criteria were met for the first objectively recorded CR or PR until the first date criteria for PD were met or death from any cause. CR was the disappearance of all lesions and pathological lymph node reduction in the short axis to <10 mm. PR was a ≥30% decrease in the sum of the diameters of target lesions. PD was a ≥20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of ≥5 mm; the appearance of ≥1 new lesions or unequivocal progression of non-target lesions. Participants who were not known to have died and who did not have PD were censored at the date of the last tumor assessment prior to the date of any subsequent systemic anticancer therapy. (NCT01246960)
Timeframe: Time of first response to measured PD (up to Month 23.0)
| Intervention | months (Median) |
|---|---|
| Ramucirumab and mFOLFOX6 | 7.4 |
| Placebo and mFOLFOX6 | 5.8 |
Participants with treatment-emergent anti-ramucirumab antibodies were participants with a 4-fold increase (2 dilution increase) in immunogenicity titer over baseline titer, or participants who tested negative at baseline and positive post-baseline (at titer of ≥1:20). (NCT01246960)
Timeframe: Months 1, 2, 4, 6, and 8
| Intervention | participants (Number) |
|---|---|
| Ramucirumab and mFOLFOX6 | 0 |
| Placebo and mFOLFOX6 | 1 |
OS was defined as the time from randomization to death due to any cause. OS was censored at the date of the last follow-up visit for participants who were alive or lost to follow-up. (NCT01246960)
Timeframe: Randomization to date of death from any cause (up to Month 28.3)
| Intervention | months (Median) |
|---|---|
| Ramucirumab and mFOLFOX6 | 11.7 |
| Placebo and mFOLFOX6 | 11.5 |
The percentage of participants who achieved a best overall response of partial response (PR) or complete response (CR) is reported. Response was defined using RECIST, v. 1.1 criteria. CR was the disappearance of all lesions and pathological lymph node reduction in the short axis to <10 mm. PR was a ≥30% decrease in the sum of the diameters of target lesions. The percentage of participants with objective response=(number of participants whose best overall response achieved was CR or PR/number of participants treated)*100. (NCT01246960)
Timeframe: Randomization to measured PD (up to Month 23.0)
| Intervention | percentage of participants (Number) |
|---|---|
| Ramucirumab and mFOLFOX6 | 45.2 |
| Placebo and mFOLFOX6 | 46.4 |
PFS was defined using Response Evaluation Criteria in Solid Tumors [RECIST version (v.) 1.1] as the time from randomization to the first observation of progressive disease (PD) or death due to any cause, whichever came first. PD was a ≥20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of ≥5 millimeters (mm); the appearance of ≥1 new lesions or unequivocal progression of non-target lesions. If a participant did not have a baseline disease assessment, PFS time was censored at the randomization date, regardless of whether or not PD or death was observed. Participants not known to have died or have objective PD were censored at the last post-baseline radiological assessment date. (NCT01246960)
Timeframe: Randomization to measured PD or date of death from any cause (up to Month 25.0)
| Intervention | months (Median) |
|---|---|
| Ramucirumab and mFOLFOX6 | 6.4 |
| Placebo and mFOLFOX6 | 6.7 |
TTP was defined using RECIST v. 1.1 as the time from study randomization to the first date of PD. PD was a ≥20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of ≥5 mm; the appearance of ≥1 new lesions or unequivocal progression of non-target lesions. TTP was censored at the date of last adequate tumor assessment if death was due to causes other than PD. (NCT01246960)
Timeframe: Randomization to measured PD (up to Month 25.0)
| Intervention | months (Median) |
|---|---|
| Ramucirumab and mFOLFOX6 | 8.7 |
| Placebo and mFOLFOX6 | 7.1 |
Reported are the number of participants who had ramucirumab/placebo-related: AEs, serious AEs (SAEs), AEs based on common terminology criteria for adverse events (CTCAE) ≥Grade 3, AEs = CTCAE Grade 5, as well as, AEs leading to treatment discontinuation and AEs resulting in death. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module. (NCT01246960)
Timeframe: Baseline through study completion (up to Month 28.3)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any Ramucirumab/Placebo-Related AE | Any Ramucirumab/Placebo-Related SAE | Any Ramucirumab/Placebo-Related ≥Grade 3 AE | Any Ramucirumab/Placebo-Related Grade 5 AE | Any AE Leading to Treatment Discontinuation | Any AE with Outcome of Death | |
| Placebo and mFOLFOX6 | 64 | 12 | 33 | 3 | 5 | 2 |
| Ramucirumab and mFOLFOX6 | 64 | 10 | 36 | 0 | 18 | 5 |
"Per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and by Spiral CT assessment:~Complete Response (CR) is the disappearance of all target lesions; Partial Response (PR) is a >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR" (NCT00573131)
Timeframe: Screening and Week 12
| Intervention | percentage of patients (Number) |
|---|---|
| Group 1 | 12.5 |
| Group 2 | 20.0 |
Adverse events were evaluated according to the National Cancer Institute Common Toxicity Criteria (version 2.0). DLT was defined as grade 3 to 4 hematologic toxicity lasting more than 1 week after 5-FU/cisplatin, grade 3 to 4 nausea or vomiting occurring later than 11 days after cisplatin, grade 3 to 4 diarrhea occurring later than 10 days after 5-FU, and grade 3 to 4 mucositis at the beginning of the next cycle. (NCT00064259)
Timeframe: 21 days
| Intervention | mg/kg/d (Number) |
|---|---|
| Oblimersen + Cisplatin + 5-FU | 5 |
Defined as the interval between the start date of treatment and the date of occurrence of progressive disease or death from any cause. (NCT00193128)
Timeframe: 18 months
| Intervention | months (Median) |
|---|---|
| Oxaliplatin/Docetaxel/Capecitabine/Radiation (Cohort 2) | 16.3 |
Length of time, in months, that patients were alive from their first date of protocol treatment until death. (NCT00193128)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Oxaliplatin/Docetaxel/Capecitabine/Radiation (Cohort 2) | 24.1 |
The absence of any residual tumor cells in a histologic evaluation of a tumor specimen following surgery is defined as a complete pathologic response (NCT00193128)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Oxaliplatin/Docetaxel/Capecitabine/Radiation (Cohort 2) | 24 |
Objective response was defined as having a CR or a PR. Response assessment was performed using modified WHO criteria. CR: disappearance of all index and non-index lesions, without appearance of any new lesion. PR: >50% decrease from baseline in sum of product of diameters of index lesions, without appearance of any new lesion. Duration of objective response was defined as time from first appearance of CR or PR to time of PD (PD: >25% increase in one or more lesions, or appearance new lesions) or death. Duration of objective response was to be assessed using Kaplan-Meier analysis. (NCT00215644)
Timeframe: From first documented objective response to PD or death due to any cause (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | NA |
| ECX Only | NA |
OS was defined as the duration from randomization to death (due to any cause). OS was estimated using Kaplan-Meier analysis. (NCT00215644)
Timeframe: Baseline until death due to any cause (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 9.4 |
| ECX Only | 12.2 |
Objective response was defined as having a complete response (CR) or a partial response (PR). Response assessment was performed using modified World Health Organization (WHO) criteria. CR: disappearance of all index and non-index lesions, without appearance of any new lesion. PR: greater than (>) 50 percent (%) decrease from baseline in sum of product of diameters of index lesions, without appearance of any new lesion. (NCT00215644)
Timeframe: Baseline up to PD or death due to any cause (up to approximately 3 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 31 |
| ECX Only | 58 |
PFS was defined as the time from randomization to the first documentation of PD or to death due to any cause, whichever occurred first. PD: >25% increase in one or more lesions, or appearance new lesions. PFS was estimated using Kaplan-Meier analysis. (NCT00215644)
Timeframe: Baseline up to PD or death due to any cause (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 4.8 |
| ECX Only | 7.1 |
EORTC QLQ-C30 included GHS/QoL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from EORTC QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL was linearly transformed and ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). EORTC QLQ-C30 GHS/QoL score at baseline and best overall change from baseline (throughout study) are reported. (NCT00215644)
Timeframe: Baseline (Day 1), Post Baseline (Up to 3 Years)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Post-Baseline | |
| ECX Only | 67.9 | -10.0 |
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 53.3 | 0.0 |
One-year survival estimate is reported. Survival time is defined as time from registration to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at date of last contact. This analysis was planned to occur when all patients had been potentially followed for 1 year. On the basis of a 1-year survival rate of 60% from the Radiation Therapy Oncology Group (RTOG) esophageal database, 38 analyzable patients with a 1-year survival rate of 77.5% or better was needed for this trial to be deemed promising enough for development of a Phase III protocol (type I error of 0.05 and type II error of 0.20). (NCT00069953)
Timeframe: From registration to date of death or last follow-up. Analysis occurs after all patients have been potentially followed for 1 year.
| Intervention | percentage of participants (Number) |
|---|---|
| ChemoRT and Selective Surgery | 71 |
Measured from time of registration to death, or last contact date (NCT00086996)
Timeframe: 0-5 years
| Intervention | months (Median) |
|---|---|
| Chemo Plus RT, Surgery, Chemo | 28.3 |
Complete pathologic response assessed after chemoradiotherapy and surgery, defined as no evidence of residual disease on path review. Patients who did not receive surgery are assumed to have not responded. (NCT00086996)
Timeframe: 10-16 weeks after beginning study treatment
| Intervention | participants (Number) |
|---|---|
| Chemo Plus RT, Surgery, Chemo | 26 |
measured from date of registration to time of first documentation of progression by Response Evaluation Criteria in Solid Tumors (RECIST), death, or last contact date. (NCT00086996)
Timeframe: 0-3 years
| Intervention | months (Median) |
|---|---|
| Chemo Plus RT, Surgery, Chemo | 19.7 |
Only adverse events that are possibly, probably or definitely related to study drug are reported. (NCT00086996)
Timeframe: Up to 3 years
| Intervention | Participants (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adult respiratory distress syndrome (ARDS) | Anorexia | CNS cerebrovascular ischemia | Calcium, serum-low (hypocalcemia) | Cardiac troponin T (cTnT) | Cardiac-ischemia/infarction | Chyle or lymph leakage | Confusion | Cough | Creatinine | Dehydration | Diarrhea | Distention/bloating, abdominal | Dysphagia (difficulty swallowing) | Dyspnea (shortness of breath) | Esophagitis | Fatigue (asthenia, lethargy, malaise) | Febrile neutropenia | Fever in absence of neutropenia, ANC lt1.0x10e9/L | Fistula, GI - Oral cavity | Gastrointestinal-Other (Specify) | Glucose, serum-high (hyperglycemia) | Heartburn/dyspepsia | Hemoglobin | Hypotension | Hypoxia | Inf (clin/microbio) w/Gr 3-4 neuts - Lung | Inf w/normal ANC or Gr 1-2 neutrophils - Blood | Inf w/normal ANC or Gr 1-2 neutrophils - Lung | Inf w/normal ANC or Gr 1-2 neutrophils - Perit cav | Inf w/normal ANC or Gr 1-2 neutrophils - Wound | Infection with unknown ANC - Blood | Infection with unknown ANC - Lung (pneumonia) | Infection with unknown ANC - Wound | Leak (including anastomotic), GI - Esophagus | Leukocytes (total WBC) | Lymphopenia | Mood alteration - anxiety | Mucositis/stomatitis (clinical exam) - Esophagus | Mucositis/stomatitis (clinical exam) - Oral cavity | Mucositis/stomatitis (functional/symp) - Esophagus | Mucositis/stomatitis (functional/symp) - Oral cav | Muscle weakness, not d/t neuropathy - body/general | Nausea | Necrosis, GI - Stomach | Neutrophils/granulocytes (ANC/AGC) | Obstruction, GI - Esophagus | Pain - Abdomen NOS | Pain - Pain NOS | Pericardial effusion (non-malignant) | Platelets | Pleural effusion (non-malignant) | Pneumonitis/pulmonary infiltrates | Potassium, serum-low (hypokalemia) | Pulmonary/Upper Respiratory-Other (Specify) | Renal failure | SVT and nodal arrhythmia - Atrial fibrillation | SVT and nodal arrhythmia - Sinus tachycardia | Skin breakdown/decubitus ulcer | Sodium, serum-low (hyponatremia) | Stricture/stenosis (incl anastomotic), Esophagus | Syncope (fainting) | Thrombosis/thrombus/embolism | Typhlitis (cecal inflammation) | Vomiting | Weight loss | Wound complication, non-infectious | |
| Chemo Plus RT, Surgery, Chemo | 4 | 15 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 12 | 1 | 4 | 3 | 3 | 14 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 1 | 6 | 1 | 2 | 3 | 1 | 4 | 1 | 2 | 1 | 1 | 2 | 10 | 1 | 1 | 4 | 5 | 2 | 1 | 11 | 1 | 1 | 1 | 1 | 1 | 4 | 2 | 3 | 3 | 4 | 3 | 1 | 2 | 1 | 1 | 5 | 2 | 1 | 2 | 1 | 7 | 13 | 1 |
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
DNA was extracted from tumor specimens.Screened for the presence of KRAS codon 12 and 13 mutations using a PCR clamping and melting curve technique. PCR amplification of the wild-type KRAS sequence was suppressed in this process by the incorporation in the reaction mix of a locked nucleic-acid oligomer16 spanning codons 12 and 13 of the KRAS gene. Post-PCR hybridization and melting curve analysis using fluorescently tagged oligonucleotides incorporated in the original PCR reaction permitted the identification and discrimination of distinct KRAS codon 12 and 13 missense mutations. (NCT00815308)
Timeframe: 07/29/2010-09/30/2010
| Intervention | participants (Number) |
|---|---|
| Cetuximab, Concurrent Chemo-radiotherapy | 53 |
The overall response rate was defined as the numbers of patients with a complete response (CR) or partial response (PR). CR was defined as no target lesion at follow-up computed tomography scan and barium swallow examination 3-6 weeks after completion of chemo-radiation. PR was defined at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT00815308)
Timeframe: 1 to 3 month after therapy
| Intervention | participants (Number) |
|---|---|
| Cetuximab, Concurrent Chemo-radiotherapy | 44 |
All patients were regularly monitored for possible adverse events, which were graded according to National Cancer Institute Common Toxicity Criteria version 3.0. (NCT00815308)
Timeframe: Every week during treatment and 1 month after therapy
| Intervention | participants (Number) |
|---|---|
| Cetuximab, Concurrent Chemo-radiotherapy | 55 |
Local failure will be assessed radiographically using endoscopy with biopsy, CT scan, and a positron emission computed tomography-CT scan. which was defined as persistence /recurrence of the tumor in the radiation therapy field. (NCT03082586)
Timeframe: 15 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1: Radiochemotherapy 1 | 0 |
| Arm 2: Radiochemotherapy 2 | 1 |
| Arm 3: Radiochemotherapy 3 | 1 |
| Arm 4: Radiochemotherapy 4 | 0 |
| Arm 5: Radiochemotherapy 5 | 0 |
| Arm 6: Radiochemotherapy 6 | 0 |
The DLTs were defined as grade >/=4 esophatitis, any other grade >/=3 nonhematological toxicity (except nausea and vomiting), or grade >/=4 hematological toxicity lasting more than 7 days, which are possibly, probably, or definitely associated with protocol treatment occurring during and after completion of the HFRT boost treatment. (NCT03082586)
Timeframe: 15 months
| Intervention | dose limiting toxicity (Number) |
|---|---|
| Arm 1: Radiochemotherapy 1 | 0 |
| Arm 2: Radiochemotherapy 2 | 0 |
| Arm 3：Radiochemotherapy 3 | 0 |
| Arm 4: Radiochemotherapy 4 | 1 |
| Arm 5: Radiochemotherapy 5 | 0 |
| Arm 6: Radiochemotherapy 6 | 2 |
123 reviews available for fluorouracil and Cancer of Esophagus
| Article | Year |
|---|---|
Molecular mechanisms associated with chemoresistance in esophageal cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Cisplatin; Drug Resistance, Neoplasm; Esophag | 2022 |
Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Fluorouracil; Humans; Leukopen | 2022 |
Docetaxel, Cisplatin, and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal | 2023 |
Neoadjuvant Management of Adenocarcinoma of the Esophagus and Esophagogastric Junction: Review of Randomized Evidence and Definition of Optimum Treatment Algorithm.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Eso | 2023 |
FLOT or CROSS for gastroesophageal junction cancers-is the debate over yet?
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Esophagogastric Jun | 2023 |
Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Fluo | 2023 |
Gastrointestinal malignancy in cystic fibrosis.
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 2020 |
[Hyperammonemia with Disturbance of Consciousness during 5-FU plus Nedaplatin Therapy for Esophageal Cancer-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Consciousness; Esophageal Neoplasms; Fluoroura | 2020 |
[Neoadjuvant and perioperative treatment of gastric cancer, current studies and new biomarkers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Esophageal Neoplasms; Esophagogastric Ju | 2021 |
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug C | 2017 |
Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.
Topics: Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Deglut | 2017 |
A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cluster Analysis; Disease | 2017 |
Chemoradiotherapy for Solitary Skeletal Muscle Metastasis from Oesophageal Cancer: Case Report and Brief Literature Review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous | 2017 |
The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neoplasms; | 2017 |
Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2018 |
Gastroesophageal Cancer During Pregnancy: a Case Report and Review of the Literature.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemoradiotherapy; Do | 2019 |
A network meta-analysis of the treatments for esophageal squamous cell carcinoma in terms of survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Carcinoma, Squamous Cell | 2018 |
The role of oxaliplatin in the management of upper gastrointestinal tract malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Esophageal Neopl | 2003 |
[Brachytherapy for oesophageal cancer].
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Chemoradiotherapy; Clinical Trials, Phase II as Topi | 2013 |
Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2014 |
Treatment options for esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
Capecitabine in the treatment of esophageal and gastric cancers.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Chemoradiotherapy; Deoxycytidine; | 2013 |
[Esophageal carcinosarcoma treated with surgery and chemoradiotherapy-a report of 4 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemoradiotherapy; Cisplatin; | 2013 |
[A case of consciousness disorder induced by the syndrome of inappropriate secretion of antidiuretic hormone following cisplatin and 5-fluorouracil chemotherapy in a patient with esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Consciousness Disorders; Esophageal | 2013 |
[Current perspective of treatment for advanced esophageal squamous cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvan | 2014 |
[Current status and future direction of definitive chemoradiotherapy for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Dose Fractionation, Ra | 2014 |
[Current surgical treatment and perspectives for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Mod | 2014 |
Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Adenosqu | 2015 |
[A case of syndrome of inappropriate antidiuretic hormone secretion in a patient with esophageal carcinoma possibly induced by cisplatin in neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Fluorouracil; Human | 2014 |
Chemoradiotherapy and surgery for T4 esophageal cancer in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Ther | 2015 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, | 2015 |
[Three cases of esophageal carcinoma achieved a pathological complete response after neoadjuvant chemotherapy with cisplatin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 2015 |
Preoperative chemotherapy for resectable thoracic esophageal cancer.
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Hum | 2015 |
Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradio | 2015 |
Resection of a Submucosal Tumor-Like Superficial Carcinoma in Middle Thoracic Esophagus Concomitant with Mucosal Adenocarcinoma and Submucosal Squamous Cell Carcinoma: A Case Report and Review of Literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2015 |
Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvan | 2016 |
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin | 2016 |
Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2017 |
[Review of medical or combined treatment of local or locally advanced oesophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neoplasms; Flu | 2016 |
The Asian Perspective on the Surgical and Adjuvant Management of Esophagogastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Digestive Sys | 2017 |
Biomarkers of response to therapy in oesophago-gastric cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; DNA Repair; DNA, Neoplasm; Esophageal Neoplasms; | 2009 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms | 2009 |
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2009 |
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2009 |
Solitary subcutaneous metastasis from squamous cell carcinoma of the esophagus: a case report and brief review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2011 |
[A case of long-term survival after resection for postoperative solitary adrenal metastasis from esophageal adenocarcinoma].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antimetabolites, Antineoplastic; Antin | 2010 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorour | 2011 |
Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capecitabine; Cisplatin; C | 2011 |
Multimodal treatment for resectable esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neopla | 2011 |
[A case report of long-term survival of endocrine cell carcinoma of the esophagus with chemo-radiation therapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; End | 2011 |
Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dia | 2012 |
[A case report of primary small cell esophageal carcinoma responding successfully to radiochemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemoradiotherapy; Cisplatin; | 2012 |
Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Fluorour | 2012 |
[Progress of postoperative adjuvant therapies for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neopla | 2002 |
[A patient with stage IVb small cell carcinoma of the esophagus who survived 23 months after systemic cancer chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality | 2003 |
[Chemoradiotherapy for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Esophageal | 2003 |
COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2003 |
Definitive and neoadjuvant therapies for esophageal and gastroesophageal junction tumors: a look back and toward the future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Fluo | 2003 |
[Chemotherapy for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Esophageal Neoplasms; Fluorour | 2003 |
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplat | 2004 |
Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2004 |
Neoadjuvant treatment of oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 2004 |
[Chemoradiation: an alternative to surgery for the curative treatment esophageal cancer?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neo | 2005 |
[The role of radiotherapy in the management of esophageal cancer].
Topics: Antineoplastic Agents; Brachytherapy; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Fluor | 2005 |
Docetaxel in the treatment of esophageal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap | 2005 |
[Neoadjuvant therapy for resectable esophageal cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
Radiation and chemoradiation therapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2005 |
Primary combined-modality therapy for esophageal cancer.
Topics: Algorithms; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; | 2006 |
Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2006 |
Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doceta | 2006 |
[Meta-analysis of postoperative adjuvant chemotherapy for localized esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2006 |
[Complications of surgical resection of esophageal cancer].
Topics: Adenocarcinoma; Age Factors; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Endosc | 2006 |
[Progress in the treatment of gastrointestinal cancers due to introduction of neoadjuvant concept].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Ci | 2006 |
Capecitabine: in advanced gastric or oesophagogastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Eso | 2007 |
Combined-modality therapy for esophageal and gastroesophageal junction cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neo | 2007 |
Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Flu | 2007 |
Salvage oesophagectomy after local failure of definitive chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophagea | 2007 |
Docetaxel: in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Do | 2007 |
[Gemcitabine and digestive carcinomas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 2007 |
Medical treatment for advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2007 |
[Angiogenesis targeting in gastro-intestinal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Chemotherapy of esophageal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorub | 1984 |
Combined-modality therapy of esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Dox | 1984 |
Systemic chemotherapy for advanced gastrointestinal cancer.
Topics: Antineoplastic Agents; Apudoma; Biliary Tract Neoplasms; Colonic Neoplasms; Drug Therapy, Combinatio | 1980 |
Possibilities and limitations of the cytostatic treatment of gastrointestinal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Es | 1982 |
Prolonged infusion of fluorinated pyrimidines in gastrointestinal malignancies: a review of recent clinical trials.
Topics: Carcinoma, Squamous Cell; Circadian Rhythm; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasm | 1994 |
[Chemotherapy and multimodality therapy in the treatment of esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A | 1995 |
[Current perspectives in the treatment of epidermoid cancer of the esophagus].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1995 |
Chemotherapy and combined-modality therapy for esophageal cancer.
Topics: Chemotherapy, Adjuvant; Clinical Trials as Topic; Esophageal Neoplasms; Fluorouracil; Humans; Radiot | 1995 |
Sequential chemotherapy and radiotherapy for patients with squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
High dose external beam radiation therapy with or without concomitant chemotherapy for esophageal carcinoma.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Esophageal Neoplasms; Fluorouracil; Humans; Radiother | 1994 |
The use of mitomycin in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1993 |
Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1996 |
Preoperative concomitant radiochemotherapy in squamous cell carcinoma of the esophagus: results of a study of 56 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1996 |
Combined infusional chemotherapy and radiation for esophageal carcinoma: a review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clinica | 1995 |
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: the Royal Marsden Hospital experience.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Esophageal Neoplasms; Fluorouracil; Gastroint | 1997 |
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience.
Topics: Ambulatory Care; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Clinical Trials as Topic; | 1996 |
[Neoadjuvant chemotherapy and concurrent radiochemotherapy for advanced esophageal carcinoma potentially invading adjacent structures].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials a | 1997 |
[Salvage surgery for the T4 esophageal cancer following downstaging by neoadjuvant chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Mo | 1997 |
[Esophagectomy combined resection of invaded neighboring organs for T4 esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Esop | 1997 |
[Chemoradiation therapy for esophageal carcinoma].
Topics: Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Adminis | 1997 |
Paclitaxel pharmacology and other tumor types.
Topics: Alkylating Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols | 1997 |
Treatment of patients with upper gastrointestinal carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Therapy, Com | 1997 |
[Current status of combined modality therapy for esophageal cancer: from the standpoint of medical oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neo | 1998 |
[Treatment of patients with recurrent esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
[Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 2000 |
[Current trends in surgical treatment of esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Endoscopy; Eso | 2000 |
A case of chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma.
Topics: Esophageal Neoplasms; Fluorouracil; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic | 2000 |
Recent developments in the chemotherapy of advanced esophageal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin | 2000 |
[Postoperative adjuvant therapies for esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neopla | 2000 |
[Analysis of cases of complete response (CR) in esophageal and gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Esophageal | 2000 |
Irinotecan in esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trial | 2000 |
New adjuvant therapies for esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Dig | 2001 |
Neoadjuvant chemoradiation therapy in patients with surgically treated esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
[A patient with small-cell carcinoma of the esophagus with synchronous liver metastasis surviving 48 months after surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Adminis | 2001 |
[Chemotherapy for the patients with esophageal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Ce | 2002 |
[Chemoradiation therapy for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Fluorouracil; Human | 2002 |
Progress report. Cytotoxic therapy for gastrointestinal carcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bleomycin; Carcinoma, | 1976 |
Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedu | 1992 |
Chemotherapy and radiation therapy before transhiatal esophagectomy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1990 |
[Combined radiotherapy and pre-radiation chemotherapy with cisplatin and 5-fluorouracil for advanced esophageal carcinoma. II. Clinical evaluation in cases with higher than T2 stage].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Eval | 1990 |
Combination of cytostatics and radiation--a new trend in the treatment of inoperable esophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Combined Modality Therapy; Doxorubicin; Epirubicin; E | 1985 |
[Inoperable cancer of the esophagus: preliminary results of combined chemotherapy (5-fluorouracil-cisplatin) and radiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
514 trials available for fluorouracil and Cancer of Esophagus
| Article | Year |
|---|---|
Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial-EPOC 2 (JFMC49-1601-C5).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorour | 2021 |
Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study.
Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Japan; Neoplasm Recu | 2022 |
Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy.
Topics: Antibodies, Neoplasm; Antigens, Neoplasm; Cancer Vaccines; Cisplatin; Esophageal Neoplasms; Esophage | 2022 |
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; D | 2022 |
The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neopla | 2022 |
A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophageal Squamous Cell | 2022 |
Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial.
Topics: Cisplatin; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Neoplastic Cells, Circulat | 2022 |
Safety and efficacy of the FLOT regimen in the Polish population - an analysis of the prospective trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric J | 2022 |
Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Do | 2022 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Stomach Neo | 2023 |
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri | 2023 |
Updates of perioperative multidisciplinary treatment for surgically resectable esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Fluorouracil; Human | 2023 |
Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; F | 2023 |
Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined | 2019 |
Health-related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy, Adj | 2019 |
Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2019 |
Palliative short-course hypofractionated radiotherapy followed by chemotherapy in esophageal adenocarcinoma: the phase II PALAESTRA trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2020 |
Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neopla | 2019 |
Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA-Binding Proteins | 2020 |
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progress | 2020 |
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II t
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neo | 2020 |
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2020 |
Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esopha | 2020 |
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as | 2020 |
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as | 2020 |
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as | 2020 |
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as | 2020 |
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Esophageal Ne | 2020 |
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Pr | 2020 |
An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Comb | 2020 |
Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; | 2020 |
Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast in advanced esophageal squamous cell carcinoma: Phase I/II study (TNAC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dose | 2020 |
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2021 |
Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.
Topics: Aged; Chemoradiotherapy; China; Cisplatin; Confidence Intervals; Dose Fractionation, Radiation; Drug | 2021 |
Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analys | 2021 |
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2021 |
Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2021 |
The efficacy of adjuvant chemotherapy with capecitabine and cisplatin after surgery in locally advanced esophageal squamous cell carcinoma: a multicenter randomized phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Dis | 2022 |
Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial.
Topics: Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Induction | 2022 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2021 |
Impact of neoadjuvant chemotherapy and chemoradiotherapy on postoperative cardiopulmonary complications in patients with esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2017 |
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Disea | 2017 |
A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2017 |
Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Squamous | 2017 |
Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neopla | 2018 |
Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, | 2017 |
A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2018 |
Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Chemoradiotherapy | 2018 |
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Fre | 2018 |
Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2019 |
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva | 2019 |
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva | 2019 |
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva | 2019 |
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva | 2019 |
Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; China; Cisplatin; Cl | 2018 |
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous | 2019 |
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2019 |
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doub | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, S | 2019 |
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2019 |
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Clinical Protocols; | 2019 |
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction aden
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Ag | 2019 |
Quality Assurance of Dose-Escalated Radiation Therapy in a Randomized Trial for Locally Advanced Oesophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Cancer Care Facilities; Carcinom | 2019 |
Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fe | 2019 |
A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esoph | 2020 |
Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Fre | 2014 |
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2013 |
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2013 |
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 2013 |
Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.
Topics: Adult; Aged; Bayes Theorem; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esophageal Neop | 2013 |
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.
Topics: Adult; Aged; Bayes Theorem; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esophageal Neop | 2013 |
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.
Topics: Adult; Aged; Bayes Theorem; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esophageal Neop | 2013 |
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.
Topics: Adult; Aged; Bayes Theorem; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esophageal Neop | 2013 |
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.
Topics: Adult; Aged; Bayes Theorem; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esophageal Neop | 2013 |
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.
Topics: Adult; Aged; Bayes Theorem; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esophageal Neop | 2013 |
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.
Topics: Adult; Aged; Bayes Theorem; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esophageal Neop | 2013 |
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.
Topics: Adult; Aged; Bayes Theorem; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esophageal Neop | 2013 |
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.
Topics: Adult; Aged; Bayes Theorem; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esophageal Neop | 2013 |
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2013 |
Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2013 |
Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Fr | 2014 |
Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2013 |
Randomized study of antiinflammatory and immune-modulatory effects of enteral immunonutrition during concurrent chemoradiotherapy for esophageal cancer.
Topics: Adult; Aged; Arginine; C-Reactive Protein; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; E | 2014 |
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2014 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2016 |
Adding preoperative radiotherapy plus cetuximab to perioperative chemotherapy for resectable esophageal adenocarcinoma: a single-center prospective phase II trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2014 |
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2014 |
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2014 |
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2014 |
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2014 |
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2014 |
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2014 |
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2014 |
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2014 |
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2015 |
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cisplatin; Combined Modality | 2014 |
Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradioth | 2014 |
Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradioth | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; | 2014 |
Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2014 |
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Biomarkers, Tumor; Ca | 2014 |
Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols | 2017 |
A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesoph
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2014 |
Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of (18)FDG-PET scans: a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2014 |
Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Sur | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2015 |
Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18)FDG-PET/CT for esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2015 |
Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2015 |
A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods o
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docet | 2015 |
Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2015 |
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2015 |
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2015 |
Feasibility and efficacy of concurrent chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: a respective study of 116 cases from a single institution.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2015 |
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2015 |
Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2015 |
Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2015 |
Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2015 |
Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female | 2015 |
Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adeno | 2015 |
A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Doce | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Disease | 2015 |
Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; | 2016 |
18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compoun | 2015 |
Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; C | 2015 |
Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Fre | 2015 |
Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationsh | 2015 |
Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients.
Topics: Acetic Acid; Adult; Aged; Aged, 80 and over; Cisplatin; Docetaxel; Endpoint Determination; Esophagea | 2017 |
Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2017 |
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; | 2016 |
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; | 2016 |
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; | 2016 |
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; | 2016 |
First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Bone Neoplasms; C | 2016 |
Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Disease-Free Survival; | 2016 |
Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2016 |
Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2016 |
Phase I Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Local or Metastatic Esophageal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel | 2016 |
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Fr | 2017 |
Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Sur | 2016 |
Preoperative chemotherapy in patients with resectable esophageal carcinoma: a single center Phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2016 |
Early Response of Esophageal Cancer to Neoadjuvant Chemotherapy with Docetaxel-Cisplatin-5-Fluorouracil Represents Sensitivity: A Phase II Study.
Topics: Abdomen; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Endoscop | 2016 |
Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2016 |
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer: A Supplementary Analysis of JCOG0303.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2016 |
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem | 2016 |
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2016 |
Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2017 |
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2016 |
Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2016 |
A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2017 |
EUS-guided paclitaxel injection as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation before surgery for localized or locoregional esophageal cancer: a multicenter prospective randomized trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2017 |
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2017 |
Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidi | 2017 |
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2008 |
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2008 |
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2008 |
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2008 |
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2008 |
Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2008 |
Phase II trial of neoadjuvant cisplatin, 5-fluorouracil and interferon-alpha in operable squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2008 |
Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2008 |
Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2009 |
Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal N | 2008 |
A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2009 |
[Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
A phase I trial of 5-fluorouracil with cisplatin and concurrent standard-dose radiotherapy in Japanese patients with stage II/III esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2009 |
Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2009 |
A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophage | 2009 |
[Impact of different extents of lymph node dissection on the survival in stage III esophageal cancer patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Squamous Cell | 2008 |
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Dige | 2009 |
Death-associated protein kinase (DAPK) promoter methylation and response to neoadjuvant radiochemotherapy in esophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Prot | 2009 |
Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboxylesterase; Combine | 2009 |
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2008 |
A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Carcinoma, Squamous C | 2009 |
Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality The | 2009 |
Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality The | 2009 |
Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality The | 2009 |
Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality The | 2009 |
Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality The | 2009 |
Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality The | 2009 |
Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality The | 2009 |
Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality The | 2009 |
Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality The | 2009 |
Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Anticoagulants; Antimetabolites, Antine | 2009 |
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2009 |
Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2010 |
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2009 |
Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2009 |
Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2009 |
Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2009 |
A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Combination; E | 2010 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2009 |
A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2010 |
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2010 |
Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Confidenc | 2010 |
Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Squamous Cell; Circad | 2010 |
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2010 |
A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2010 |
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2010 |
Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2010 |
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2010 |
Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2010 |
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Es | 2011 |
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherap | 2010 |
Feasibility study of sentinel lymph node biopsy in esophageal cancer with conservative lymphadenectomy.
Topics: Adenocarcinoma; Aged; Antimony; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2011 |
A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2010 |
Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2010 |
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2011 |
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2011 |
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2011 |
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2011 |
Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2010 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
[Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2010 |
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2011 |
[Evaluation of efficacy and safety of first-line docetaxel/cisplatin/5-FU combined therapy for advanced esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neopla | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2011 |
A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2012 |
Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2012 |
Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemoradiother | 2012 |
Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2011 |
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dise | 2011 |
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxyc | 2011 |
Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemor | 2012 |
Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemor | 2012 |
Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemor | 2012 |
Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemor | 2012 |
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2011 |
Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2012 |
Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, | 2011 |
Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dietary Supplement | 2012 |
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Triple induction chemotherapy and chemoradiotherapy for locally advanced esophageal cancer. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel | 2011 |
FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease P | 2011 |
A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-F | 2012 |
[Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycyt | 2011 |
Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel | 2012 |
The effect of neoadjuvant chemoradiotherapy on airway colonization and postoperative respiratory complications in patients undergoing oesophagectomy for oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchoalveolar Lavage; Bronchoscopy; Chemoradiother | 2012 |
Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2012 |
Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neopla | 2012 |
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2012 |
Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Ant | 2013 |
Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2012 |
Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplasti | 2013 |
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Doce | 2012 |
Long-term follow-up of a randomized Phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophagea | 2012 |
Prospective phase II study of neoadjuvant therapy with cisplatin, 5-fluorouracil, and bevacizumab for locally advanced resectable esophageal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chem | 2012 |
Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2013 |
Toward semi-automated assessment of target volume delineation in radiotherapy trials: the SCOPE 1 pretrial test case.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradioth | 2012 |
Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma: a final report on a prospective trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2012 |
Docetaxel-based preoperative chemoradiation in localized gastric cancer: impact of pathological complete response on patient outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisp | 2013 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetax | 2013 |
Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Administration Schedul | 2012 |
Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabin | 2012 |
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: correlation between response to treatment and outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2013 |
[Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2012 |
Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female | 2013 |
Assessment and comparison of recovery after open and minimally invasive esophagectomy for cancer: an exploratory study in two centers.
Topics: Activities of Daily Living; Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemoth | 2013 |
The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2013 |
A phase II study on continuous infusional paclitaxel and 5-Fu as first-line chemotherapy for patients with advanced esophageal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; E | 2012 |
Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasm | 2013 |
A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
The clinical efficacy of neoadjuvant chemotherapy in squamous esophageal cancer: a prospective nonrandomized study of pulse and continuous-infusion regimens with Cisplatin and 5-Fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2002 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2002 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2002 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2002 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2002 |
A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2002 |
A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2002 |
Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2002 |
Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2002 |
Preoperative chemoradiotherapy in cancer of the thoracic esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2003 |
Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2003 |
[Concurrent chemotherapy and radiation therapy for unresectable locally advanced carcinoma of the esophagus. Phase II study and clinical review on literature].
Topics: Adult; Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 2003 |
Mitomycin C, carboplatin and protracted venous infusion 5-fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Fema | 2003 |
A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combi | 2003 |
Efficacy of neoadjuvant chemoradiotherapy in resectable esophageal squamous cell carcinoma--a single institutional study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2003 |
[A prospective study of combined chemoradiotherapy followed by surgery in the treatment of esophageal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2003 |
Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cis | 2003 |
Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2003 |
Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; C | 2003 |
Treatment of oesophageal cancer with preoperative chemoradiotherapy may increase operative mortality.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2003 |
Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2003 |
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2003 |
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2003 |
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2003 |
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2003 |
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2004 |
Definitive chemoradiation in patients with inoperable oesophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 2004 |
EMR combined with chemoradiotherapy: a novel treatment for superficial esophageal squamous-cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2004 |
Post-operative chemotherapy improves disease-free survival, but not overall survival in people with oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2004 |
Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2004 |
Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Doxorubici | 2004 |
Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Deglutitio | 2004 |
Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chi-Square Distribution; Eso | 2004 |
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus].
Topics: Adenoviridae; Adenovirus E1B Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
[What to expect from the neoadjuvant therapy of the oesophageal carcinoma?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Fluorouracil; Human | 2004 |
[Phase I study of the combination of nedaplatin (NED), adriamycin (ADM), and 5-fluorouracil (5-FU) (NAF) for treatment of unresectable advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dose-Response Relati | 2005 |
Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2004 |
Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free | 2004 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2005 |
Prospective non-randomized trial comparing esophagectomy-followed-by-chemoradiotherapy versus chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2005 |
Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2005 |
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squam | 2005 |
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area | 2005 |
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2005 |
A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2005 |
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Cisplatin | 2005 |
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Cisplatin | 2005 |
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Cisplatin | 2005 |
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Cisplatin | 2005 |
Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; | 2005 |
Clinical evaluation of low-dose cisplatin and 5-fluorouracil as adjuvant chemoradiotherapy for advanced squamous cell carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2005 |
Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2005 |
Induction chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus: impact of increased dosage on long-term results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2005 |
Chemoradiotherapy for T3 and T4 squamous cell carcinoma of the esophagus using low-dose FP and radiation: a preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2005 |
Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2006 |
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2006 |
Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modal | 2006 |
Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Esoph | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2006 |
Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Brach | 2006 |
Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neoplasm | 2006 |
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cis | 2006 |
Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study.
Topics: Adenocarcinoma; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2006 |
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2006 |
Pilot study of preoperative combined modality treatment for locally advanced operable oesophageal carcinoma: toxicities and long-term outcome.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplas | 2006 |
Symptomatic responses to neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophagogastric junction: are they worth measuring?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2006 |
Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Anemia; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
[Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
[Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca | 2006 |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2007 |
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Celecoxib; Cisplatin; Combined Modality Therapy; | 2007 |
Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy | 2007 |
Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Endoscopy, | 2006 |
A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 2006 |
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
[Phase II clinical trial of home-produced Nedaplatin in treating advanced esophageal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Ne | 2006 |
A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine | 2007 |
[Evaluation of docetaxel, CDDP and 5-FU combined therapy as second-line chemotherapy for esophagus cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, | 2007 |
[Simultaneous radiochemotherapy and endoluminal HDR brachytherapy in esophageal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cispl | 2007 |
A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneity.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2007 |
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Pr | 2007 |
Combined modality chemoradiation in elderly oesophageal cancer patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2007 |
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution | 2007 |
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution | 2007 |
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2007 |
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2007 |
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2007 |
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2007 |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2007 |
A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squam | 2007 |
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2008 |
Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carbop | 2007 |
A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2008 |
Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Combined Modal | 2007 |
The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus.
Topics: Adult; Aged; Ataxia Telangiectasia Mutated Proteins; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, S | 2007 |
Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality | 2007 |
Acute respiratory disease syndrome with preoperative chronomodulated chemoradiotherapy in patients with esophageal cancer. Early termination of a phase I trial.
Topics: Adult; Aged; Chronotherapy; Cisplatin; Combined Modality Therapy; Demography; Esophageal Neoplasms; | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2008 |
Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagea | 2007 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase I trial of escalating-dose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2008 |
Selective dose escalation of chemoradiotherapy for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2008 |
Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
The value of two combined chemoradiotherapy approaches in the treatment of inoperable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca | 1984 |
[Multidisciplinary therapy for esophageal carcinoma. Cooperative Study Group for Esophageal Carcinoma].
Topics: Alcohol Drinking; Bleomycin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; | 1984 |
Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, Combination; Esophageal | 1980 |
Quantitative effect of combined chemotherapy and fractionated radiotherapy on the incidence of radiation-induced lung damage: a prospective clinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Small Cell; Combined Modality | 1994 |
Split-course accelerated radiation therapy combined with carboplatin and 5-fluorouracil for palliation of metastatic or unresectable carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 1995 |
Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1994 |
Preoperative chemoradiotherapy for locoregional esophageal cancer: preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Chemotherapy rapidly alternating with twice-a-day accelerated radiation therapy in carcinomas involving the hypopharynx or esophagus: an update.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1995 |
Neoadjuvant chemotherapy with etoposide, leucovorin, 5-fluorouracil and cisplatin for advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1995 |
Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aust | 1995 |
Treatment of advanced esophageal cancer by means of irradiation, cisplatinum and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; E | 1995 |
A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
[Clinico-pathological study of preoperative chemotherapy of esophageal cancer by combined use of three drugs--cisplatin, 5-FU and leucovorin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal | 1995 |
Treating esophageal cancer with a combination of chemotherapy, radiation, and excision.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
Management of adenocarcinoma of the esophagus with chemoradiation alone or chemoradiation followed by esophagectomy: results of sequential nonrandomized phase II studies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1995 |
Sequential chemotherapy and radiotherapy for patients with squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy for inoperable squamous cell carcinoma of the esophagus potentially followed by surgery.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1995 |
Preoperative high-dose radiation and chemotherapy in adenocarcinoma of the esophagus and esophagogastric junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Eso | 1994 |
Concurrent radiotherapy and chemotherapy with protracted continuous infusion of 5-fluorouracil in inoperable esophageal squamous cell carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Feasibility Studies | 1995 |
Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1995 |
Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 1994 |
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chi- | 1994 |
Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
[Surgical adjuvant therapy of carcinoma of the thoracic esophagus].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 1993 |
High-dose folinic acid with 5-fluorouracil bolus and continuous infusion in the treatment of advanced gastric and oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Dr | 1993 |
Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1993 |
Postoperative pulmonary complications in patients with esophageal cancer.
Topics: Aged; Brachytherapy; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Esophageal Neopl | 1993 |
The use of mitomycin in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1993 |
Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophage | 1995 |
[Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 1995 |
Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined Modality Therapy; Esop | 1995 |
Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1996 |
Preoperative concomitant radiochemotherapy in squamous cell carcinoma of the esophagus: results of a study of 56 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1996 |
5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1996 |
Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1996 |
Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; | 1996 |
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
Phase II trial of 5-fluorouracil, leucovorin, interferon-alpha-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 1996 |
Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1996 |
Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG)
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1996 |
Phase II study of chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus: nine Japanese institutions trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1996 |
Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1996 |
[Effects and efficacy of preoperative administration of cisplatin and 5-fluorouracil in excision of cancer of the thoracic esophagus].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administrati | 1996 |
[Improvement in the surgical outcome in esophageal cancer by multidisciplinary treatment--evaluation of pre-operative combined administration of CDDP and 5FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neo | 1996 |
Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ Cooperative Group, Spain.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1996 |
Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 1996 |
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; C | 1997 |
Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 1997 |
Concurrent chemoradiation for oesophageal cancer: factors influencing myelotoxicity.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Ther | 1996 |
Integration of surgery in multimodality therapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1997 |
Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 1997 |
Progress in treating esophageal adenocarcinoma.
Topics: Adenocarcinoma; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Pr | 1997 |
A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 1997 |
Sequential chemotherapy and radiotherapy for squamous cell esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1997 |
Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for Stages IIB and III esophageal carcinoma: results of a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Combined Moda | 1997 |
Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1997 |
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 1997 |
Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Car | 1997 |
[Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors--nationwide questionnaire survey].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration | 1997 |
Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1997 |
First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1997 |
Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1997 |
Clinical evaluation of adjuvant chemoradiotherapy with CDDP, 5-FU, and VP-16 for advanced esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1998 |
Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1998 |
Accelerated hyperfractionated radiation therapy and concurrent 5-fluorouracil/cisplatin chemotherapy for locoregional squamous cell carcinoma of the thoracic esophagus: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1998 |
Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Membrane Permeability; Cisplatin; Combined Moda | 1998 |
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1998 |
Chemoradiotherapy for esophageal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1998 |
Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 1998 |
Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: a long-term analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1998 |
A phase II trial of cisplatin and 5-fluorouracil in adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 1998 |
[Cisplatin, 5-FU and preoperative radiotherapy in esophageal epidermoid cancer. Multicenter phase II FFCD 8804 study].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; F | 1998 |
A randomized study of radiotherapy alone versus radiotherapy plus 5-fluorouracil and platinum in patients with inoperable, locally advanced squamous cancer of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1998 |
Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Comb | 1998 |
5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
A phase II trial of preoperative mitomycin, cisplatin and 5-fluorouracil in adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplasti | 1998 |
Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1999 |
Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 1999 |
Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1999 |
[Biochemical modulation of 5-FU--effect of low dose CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin | 1999 |
Pre-operative chemoradiation therapy with 5-fluorouracil and low-dose daily cisplatin for esophageal cancer: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 1999 |
Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
[Clinical study on effect of kang' aibao oral liquid in treating 103 malignant tumor patients].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1997 |
[No improvement of prognosis by neoadjuvant chemotherapy alone in operable esophageal carcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1999 |
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Epirubicin; Esophageal Neopl | 1999 |
Does preoperative chemotherapy cause adverse effects on the perioperative course of patients undergoing esophagectomy for carcinoma?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophage | 1999 |
Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85-01?
Topics: Adenocarcinoma; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Black Pe | 1999 |
Simultaneous chemotherapy and radiotherapy with escalating doses of chemotherapy in patients with advanced esophageal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; D | 1999 |
Phase I-II study of 5-fluorouracil, recombinant interferon alpha2a, and cisplatin in combination with external beam radiation therapy followed by surgery in patients with locally advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1999 |
[Concurrent chemoradiotherapy using protracted infusion of low-dose CDDP and 5-FU and radiotherapy for esophageal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1999 |
North Central Cancer Treatment Group Phase II study of 5-fluorouracil and high-dose levamisole for gastric and gastroesophageal cancer using survival as the primary endpoint of efficacy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Esop | 1999 |
A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Esophageal Neoplasms; Fluorouracil; | 1999 |
[Neoadjuvant treatment of operable esophageal cancers].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1999 |
Postoperative complications in patients of esophageal cancer after neoadjuvant chemotherapy.
Topics: Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Esophage | 1999 |
Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
Aggressive multimodality therapy for stage III esophageal cancer: a phase I/II study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality T | 2000 |
Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Com | 2000 |
A prospective trial of short-course radiotherapy plus chemotherapy for palliation of dysphagia from advanced esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2000 |
Effect of neoadjuvant chemotherapy for lymph node micrometastasis and tumor cell microinvolvement in the patients with esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2000 |
Preoperative chemotherapy for esophageal carcinoma with intramural metastasis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Sq | 2000 |
[Chemoradiotherapy with low-dose cisplatin and 5-FU for advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Esophageal | 2000 |
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2000 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Comb | 2001 |
The role of neoadjuvant radiochemotherapy using low-dose fraction cisplatin and 5-fluorouracil in patients with carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi-Square Distributio | 2001 |
Adjuvant chemotherapy for gastro-oesophageal cancer with epirubicin, cisplatin and fluorouracil: a single-centre experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous | 2001 |
Preoperative hyperfractionated radiotherapy with concurrent chemotherapy in resectable esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 2001 |
Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2001 |
Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2001 |
Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2001 |
Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2001 |
[Percutaneous radiotherapy plus brachytherapy and concurrent chemotherapy for patients with localized esophageal carcinoma--Radiation Oncology Group Study 9207].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Brachytherapy; Carcinoma, Squamous Cell; Combined M | 2001 |
Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 2001 |
Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2001 |
A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
[Clinical results of concurrent chemoradiation therapy for primary highly advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 2001 |
Combined results from three phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2001 |
A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Dig | 2001 |
A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2001 |
Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 2001 |
Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2001 |
[Clinical observation on effect of yiqi huoxue decoction in comprehensive treatment on advanced stage of esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progressio | 2001 |
[Preliminary clinical evaluation of continuous infusion of 5-FU and low-dose Cisplatin (LFP) therapy alone and combined with radiation therapy for treatment of advanced or recurrent esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 2002 |
Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cisp | 2001 |
Squamous cell carcinoma of the esophagus: multimodal therapy in locally advanced disease.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combine | 2002 |
Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C | 2002 |
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Esophageal Neopl | 2002 |
[The preventive effect of allopurinol spray on stomatitis induced by anti-cancer drugs].
Topics: Aerosols; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplas | 2002 |
Phase II trial of continuous infusion carboplatin, 5-fluorouracil, and radiotherapy for localized cancer of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2002 |
Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2002 |
Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
[Squamous cell cancer of the esophagus. Treatment concept at the Houston M.D. Anderson Cancer Center].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Carcinoma, Squamous Cell; Ch | 1992 |
[Randomized study of preoperative chemotherapy in squamous cell cancer of the esophagus. CAO Esophageal Cancer Study Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1992 |
Severe complications of 5-fluorouracil and cisplatin with concomitant radiotherapy in inoperable non-metastatic squamous cell oesophageal cancer after intubation--early termination of a prospective randomised trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
A phase II study of 5-fluorouracil and leucovorin in advanced carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evaluati | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
[Chemotherapy for advanced and recurrent cancer patients--the effect of combination chemotherapy using cisplatin, peplomycin, mitomycin C, adriamycin, and 5-fluorouracil].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Colorectal Neopla | 1990 |
A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1991 |
[Randomized trial of combined chemotherapy including high dose cisplatin and radiotherapy for esophageal cancer].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carci | 1991 |
Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug | 1992 |
Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Breast | 1991 |
The role of intraluminal radiotherapy and concurrent 5-fluorouracil infusion in the management of carcinoma esophagus: a pilot study.
Topics: Adult; Aged; Brachytherapy; Brain Neoplasms; Combined Modality Therapy; Deglutition Disorders; Esoph | 1991 |
[Combined radiotherapy and pre-radiation chemotherapy with cisplatin and 5-fluorouracil for advanced esophageal carcinoma. I. Clinical evaluation in cases with distant metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1990 |
[Preoperative chemotherapy of esophageal cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Combined | 1986 |
Radiation therapy alone and in combination with bleomycin and 5-fluorouracil in advanced carcinoma esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1989 |
1214 other studies available for fluorouracil and Cancer of Esophagus
| Article | Year |
|---|---|
Structure-activity studies on the anti-proliferation activity of ajoene analogues in WHCO1 oesophageal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Proliferation; Disulfides; | 2012 |
Potent hydrazone derivatives targeting esophageal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Esop | 2018 |
Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous | 2022 |
Clinico-epidemiological profile and treatment outcomes in patients with squamous cell carcinoma of the esophagus following docetaxel-based neoadjuvant chemotherapy: experience from a cancer care center in Northeast India.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neop | 2021 |
PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma.
Topics: B7-H1 Antigen; Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Esophageal Neoplasms; Esophageal Squa | 2022 |
Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorour | 2022 |
Galangin Enhances Anticancer Efficacy of 5-Fluorouracil in Esophageal Cancer Cells and Xenografts Through NLR Family Pyrin Domain Containing 3 (NLRP3) Downregulation.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2021 |
Beyond Front-Line Therapy for Unresectable Gastroesophageal Adenocarcinoma: Are There Differences in Subsequent Therapy Sequencing?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2022 |
Pre-operative Carboplatin/Paclitaxel
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neo | 2022 |
ypN0 in Patients With Definitive cN-positive Status After Preoperative Treatment Is a Prognostic Factor in Esophageal Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant | 2022 |
[Effect of Biweekly-DCF Neoadjuvant Chemotherapy on Skeletal Muscle Mass of Esophageal Cancer Patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female; Fluorouraci | 2022 |
Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Esophageal Neoplasms | 2022 |
Long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous | 2022 |
Folinic Acid, Fluorouracil, and Oxaliplatin Therapy for Recurrent Esophageal Cancer with Syndrome of Inadequate Antidiuretic Hormone Secretion (SIADH) After Preoperative Cisplatin/5-Fluorouracil Therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Fluorouracil; | 2022 |
Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2022 |
Correlation between magnesium pre-loading and cisplatin-induced nephrotoxicity in 5-fluorouracil/cisplatin combination therapy for esophageal cancer.
Topics: Aged; Antineoplastic Agents; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; Kidney Diseases; | 2022 |
Definitive Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil for Advanced Cervical Esophageal Cancer: A Medium-Term Outcome.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; | 2022 |
Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Ci | 2022 |
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophagogastric Jun | 2022 |
HIF-1α stimulates the progression of oesophageal squamous cell carcinoma by activating the Wnt/β-catenin signalling pathway.
Topics: beta Catenin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Esophageal Neoplasms; | 2022 |
Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Filgrast | 2022 |
Efficacy of thoracotomy and thoracoscopic-assisted esophageal surgery in conversion and salvage surgeries: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Esophageal Neoplasms; Eso | 2022 |
Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasm | 2023 |
Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans | 2022 |
Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2022 |
Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Es | 2023 |
Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2022 |
Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinom | 2022 |
Single-Center Analysis of Pegfilgrastim-induced Aortitis Using a Drug Prescription Database and CT Findings.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aortitis; Breast Neoplasms; Cisplatin; Docetax | 2022 |
Tolerability of neoadjuvant chemotherapy for esophageal cancer in elderly patients over 76 years of age.
Topics: Aged; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; Neoadjuvant Therapy; Retrospective Stud | 2022 |
Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neopl | 2023 |
Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Tumor-derived extracellular vesicles confer 5-fluorouracil resistance in esophageal cancer via long noncoding RNA AC116025.2 delivery.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Esophageal Neoplasms; Extracellular Vesicles; | 2022 |
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cost-Benefit Analysis; Deliv | 2022 |
Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri | 2023 |
[A Case of Perforation of Unresectable Esophageal Cancer during Nivolumab Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophageal Perforation; Fluoro | 2022 |
AGR2 expression as a predictive biomarker for therapy response in esophageal squamous cell carcinoma.
Topics: Biomarkers; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagecto | 2022 |
Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Eso | 2023 |
Chemoradiation for elderly patients (≥ 65 years) with esophageal cancer: a retrospective single-center analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neo | 2022 |
Chemoradiation for elderly patients (≥ 65 years) with esophageal cancer: a retrospective single-center analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neo | 2022 |
Chemoradiation for elderly patients (≥ 65 years) with esophageal cancer: a retrospective single-center analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neo | 2022 |
Chemoradiation for elderly patients (≥ 65 years) with esophageal cancer: a retrospective single-center analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neo | 2022 |
Chemoradiation for elderly patients (≥ 65 years) with esophageal cancer: a retrospective single-center analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neo | 2022 |
Chemoradiation for elderly patients (≥ 65 years) with esophageal cancer: a retrospective single-center analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neo | 2022 |
Chemoradiation for elderly patients (≥ 65 years) with esophageal cancer: a retrospective single-center analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neo | 2022 |
Chemoradiation for elderly patients (≥ 65 years) with esophageal cancer: a retrospective single-center analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neo | 2022 |
Chemoradiation for elderly patients (≥ 65 years) with esophageal cancer: a retrospective single-center analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Esophageal Neo | 2022 |
Predictive Factors of Febrile Neutropenia After Primary Prophylactic Pegfilgrastim With DCF Chemotherapy for Esophageal Cancer.
Topics: Aged; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorour | 2022 |
Predictive Factors of Febrile Neutropenia After Primary Prophylactic Pegfilgrastim With DCF Chemotherapy for Esophageal Cancer.
Topics: Aged; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorour | 2022 |
Predictive Factors of Febrile Neutropenia After Primary Prophylactic Pegfilgrastim With DCF Chemotherapy for Esophageal Cancer.
Topics: Aged; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorour | 2022 |
Predictive Factors of Febrile Neutropenia After Primary Prophylactic Pegfilgrastim With DCF Chemotherapy for Esophageal Cancer.
Topics: Aged; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorour | 2022 |
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Topics: B7-H1 Antigen; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluor | 2023 |
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Topics: B7-H1 Antigen; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluor | 2023 |
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Topics: B7-H1 Antigen; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluor | 2023 |
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Topics: B7-H1 Antigen; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluor | 2023 |
Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2023 |
Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2023 |
Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2023 |
Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2023 |
Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluor | 2023 |
Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esop | 2023 |
Long-term results of chemoradiotherapy with elective nodal irradiation for resectable locally advanced esophageal cancer in three-dimensional planning system.
Topics: Aged; Aged, 80 and over; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma | 2023 |
Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers.
Topics: Aged; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; East A | 2023 |
Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2023 |
[A Case Report of Stage Ⅳb Thoracic Esophageal Cancer Responding to Multidisciplinary Treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Sq | 2022 |
[A Case of Long-Term Survival by Multidisciplinary Surgical Treatment for Metastatic Multi-Organ Metastasis after Radical Resection of Esophageal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagectomy; Fluoroura | 2022 |
Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Febrile | 2023 |
Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Eso | 2023 |
Risk Factors for Muscle Loss During Neoadjuvant Therapy for Esophageal Cancer.
Topics: Aged; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Muscles; Neoadjuvant Therapy | 2023 |
Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Fluo | 2023 |
Long noncoding RNA SNHG6 silencing sensitized esophageal cancer cells to 5-FU via EZH2/STAT pathway.
Topics: Cell Line, Tumor; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; Esophageal Neoplasms; Flu | 2023 |
Therapeutic strategy aiming at R0 resection for borderline-resectable esophageal squamous cell carcinoma using induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2023 |
[A Case of Esophageal Cancer with Consciousness Disorder Due to Hyperammonemia during FP Treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Consciousness Disorders; Esophageal Neoplasms; Fluor | 2023 |
Efficacy and Cost-effectiveness of Pegfilgrastim for Preventing Febrile Neutropenia During Docetaxel, Cisplatin, and 5-Fluorouracil Therapy for Esophageal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Docetaxel; Esophag | 2023 |
Treatment burden and cost-effectiveness analysis of the neoadjuvant CROSS regimen in esophageal squamous cell carcinoma: a multicenter retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Cost-Effectiveness Ana | 2023 |
Association of immune-related expression profile with sensitivity to chemotherapy in esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
Induction of Kallikrein-Related Peptidase 13 and TET2/3 by Anticancer Drugs and Poor Prognosis of Patients with Esophageal Squamous Cell Carcinoma After Preoperative Treatment.
Topics: Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Dioxygenases; DNA-Binding Proteins; Esophageal | 2024 |
[A Case of Esophageal Cancer with Multiple Lung Metastases Resected after Stent Placement and Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 2023 |
Customizing Therapy for Esophageal Cancer: CROSS vs. FLOT.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri | 2024 |
Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2019 |
Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxe | 2019 |
Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; | 2019 |
[Preoperative Chemotherapy with DCF for Advanced Esophageal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female; Fluor | 2019 |
[Successful Multidisciplinary Treatment Accomplished by Collaboration of Multiple Clinical Departments for Synchronous Quadruple Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Fluorouracil; Human | 2019 |
Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophagea | 2019 |
Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies | 2019 |
Tex10 promotes stemness and EMT phenotypes in esophageal squamous cell carcinoma via the Wnt/β‑catenin pathway.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Pro | 2019 |
MicroRNA-338-5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id-1.
Topics: Adult; Aged; Animals; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Esophageal Neoplas | 2019 |
DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2019 |
Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neu | 2020 |
The mechanism of PDA/PEI/5-Fu coated esophageal stent material on inhibiting cancer associated pathological cells.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Coated Materials, Biocomp | 2020 |
Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophage | 2020 |
YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2020 |
Combined use of
Topics: Andrographis; Animals; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Cisplatin; Esop | 2019 |
Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; | 2020 |
Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer.
Topics: Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2020 |
Adaptive radiotherapy in locally advanced esophageal cancer with atelectasis: a case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Ci | 2020 |
Anti-EGFR plus chemotherapy in unselected advanced oesophageal squamous cell carcinoma: less POWERful than expected.
Topics: Cisplatin; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; H | 2020 |
Metabolic response assessment and PET-guided treatment of esophageal cancer.
Topics: Adenocarcinoma; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Positron-Emission | 2020 |
USP9X mRNA expression predicts clinical outcome for esophageal squamous cell carcinoma treated with cisplatin-based therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2020 |
Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri | 2021 |
GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cel | 2020 |
Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2020 |
[Neoadjuvant Triplet Combination Chemotherapy(UDON Therapy)in Esophageal Cancer Patients with Impaired Renal Function-A Retrospective Study].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2019 |
[A Case of Esophageal Cancer Achieving a Pathological Complete Response after Preoperative Docetaxel, Cisplatin, and 5-Fluorouracil Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Es | 2019 |
[A Case of Lymph Node Recurrence with Invasion to the Trachea after the Resection of Esophageal Cancer Treated by Multidisciplinary Treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Sq | 2019 |
[A Case of Far-Advanced Esophageal Cancer with Multiple Metastases Showing Long-Term Survival after Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Fluorouracil; | 2019 |
Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2020 |
Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Down-Regulation; | 2020 |
Definitive chemoradiotherapy for squamous cell carcinoma of the esophagus: outcomes for borderline-resectable disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carcinoma, Sq | 2020 |
Nicotinamide N-methyltransferase decreases 5-fluorouracil sensitivity in human esophageal squamous cell carcinoma through metabolic reprogramming and promoting the Warburg effect.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cellular | 2020 |
Survival of esophageal and gastric cancer patients with adjuvant and palliative chemotherapy-a retrospective analysis of a register-based patient cohort.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, | 2020 |
Morphine Stimulates Migration and Growth and Alleviates the Effects of Chemo Drugs via AMPK-Dependent Induction of Epithelial-Mesenchymal Transition in Esophageal Carcinoma Cells.
Topics: AMP-Activated Protein Kinases; Analgesics, Opioid; Antineoplastic Agents; Apoptosis; Cell Line, Tumo | 2020 |
[A Case of Local Remnant Esophageal Cancer after Chemotherapy Getting Complete Response by Radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Esophageal Neoplasms; Femal | 2020 |
RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma: A Large-cohort Observational Study (KSCC1307).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Chemoradiother | 2022 |
A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2020 |
Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; D | 2021 |
Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2020 |
LncRNA HOTAIR-mediated MTHFR methylation inhibits 5-fluorouracil sensitivity in esophageal cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; DNA Meth | 2020 |
Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2020 |
ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2020 |
Long-Term Outcome of Patients with Locally Advanced Clinically Unresectable Esophageal Cancer Undergoing Conversion Surgery after Induction Chemotherapy with Docetaxel Plus Cisplatin and 5-Fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorour | 2021 |
Neoadjuvant Chemoradiotherapy Using Cisplatin and 5-Fluorouracil (PF) Versus Carboplatin and Paclitaxel (CROSS Regimen) for Esophageal Squamous Cell Carcinoma (ESCC): A Propensity Score-matched Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemora | 2020 |
Five-year Outcomes of Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Oesophagectomy in Oesophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel | 2020 |
Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemora | 2021 |
Three-dimensional printed 5-fluorouracil eluting polyurethane stents for the treatment of oesophageal cancers.
Topics: Antimetabolites, Antineoplastic; Drug-Eluting Stents; Esophageal Neoplasms; Fluorouracil; Humans; Po | 2020 |
A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel | 2021 |
Silencing of long non-coding RNA LINC01270 inhibits esophageal cancer progression and enhances chemosensitivity to 5-fluorouracil by mediating GSTP1methylation.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Cell Proliferation; | 2021 |
[Tolerability of Definitive Chemoradiotherapy in Elderly Patients with Esophageal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2020 |
Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri | 2021 |
Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cancer-Associated Fibroblasts; Cell Proliferati | 2021 |
The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2021 |
Melatonin sensitizes esophageal cancer cells to 5‑fluorouracil via promotion of apoptosis by regulating EZH2 expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dru | 2021 |
Diethylhexyl phthalate (DEHP) regulates the proliferation and chemosensitivity of esophageal squamous cell carcinoma cells via regulation of PTEN.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Diethylhexyl Phthalate; Dise | 2021 |
CROSS or FLOT in Distal Esophageal and Gastroesophageal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Fluo | 2021 |
Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as a Neoadjuvant Chemotherapy for Non-metastatic Esophageal Cancer (nMEC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fl | 2021 |
Rare presentation of subglottic soft-tissue swelling following FOLFOX therapy in a patient with metastatic oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Esophageal Neoplasms; Fluorour | 2021 |
NOTCH3 limits the epithelial-mesenchymal transition and predicts a favorable clinical outcome in esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2021 |
Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous | 2021 |
Clinical outcome of definitive radiation therapy for superficial esophageal cancer.
Topics: Aged; Aged, 80 and over; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouraci | 2017 |
Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Topics: Acute Kidney Injury; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineopla | 2017 |
All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma.
Topics: Angiopoietin-1; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Mov | 2017 |
Safety and feasibility of thoracoscopic esophagectomy after neoadjuvant chemotherapy for esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2017 |
A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resista | 2017 |
The adjuvant value of Andrographis paniculata in metastatic esophageal cancer treatment - from preclinical perspectives.
Topics: Adjuvants, Pharmaceutic; Andrographis; Animals; Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumo | 2017 |
EGFR Expression in Patients with Esophageal Squamous Cell Carcinoma and its Association with Pathologic Response to Preoperative Chemoradiotherapy: A Study in Northeastern Iran.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; ErbB Receptors; Esophageal | 2017 |
Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Area Under Curve; Blood Platelets; Cisplatin; Doc | 2017 |
Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of 18FDG-PET scans: A long follow-up results of phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluo | 2017 |
Treatment of esophageal cancer with radiation therapy -a pan-Chinese survey of radiation oncologists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvan | 2017 |
Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Cisp | 2017 |
Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2017 |
A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2017 |
[Multimodal therapy for gastric or gastroesophageal junction adenocarcinoma -ECF vs. FLOT].
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagogastri | 2017 |
Survival comparison between radical surgery and definitive chemoradiation in 267 esophageal squamous cell carcinomas in a single institution: A propensity-matched study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2017 |
Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Squamous Cell; Ci | 2017 |
A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Es | 2018 |
[Subacute cutaneous lupus erythematosus induced by 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Car | 2017 |
Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Cisplatin; Esoph | 2017 |
Usefulness of computed tomography density of a tumor in predicting the response of advanced esophageal cancer to preoperative chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neo | 2017 |
Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2018 |
Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2018 |
Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemora | 2017 |
Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Fluorouracil; Hum | 2017 |
Appropriate timing for surgery after neoadjuvant chemoradiation for esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 2017 |
Toxicity and Outcomes in Patients With and Without Esophageal Stents in Locally Advanced Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2017 |
Long-term Clinical Results of Concurrent Chemoradiotherapy for Patients with Cervical Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2017 |
C-reactive protein to albumin ratio is a prognostic factor for patients with cStage II/III esophageal squamous cell cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Squamous Cell; | 2017 |
Nano Let‑7b sensitization of eliminating esophageal cancer stem‑like cells is dependent on blockade of Wnt activation of symmetric division.
Topics: AC133 Antigen; Aged; Aldehyde Dehydrogenase 1 Family; Cell Line, Tumor; Docetaxel; Esophageal Neopla | 2017 |
Is There Merit for MET-Targeted Therapies in Gastroesophageal Cancer?
Topics: Adenocarcinoma; Antibodies, Monoclonal; Esophageal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxal | 2018 |
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Consolida | 2018 |
A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; | 2017 |
Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2018 |
Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2018 |
α-solanine enhances the chemosensitivity of esophageal cancer cells by inducing microRNA‑138 expression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Resistan | 2018 |
Concurrent chemoradiotherapy alone is feasible for esophageal squamous cell carcinoma patients not suitable for surgery.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Esophageal Neopl | 2018 |
Consolidation chemotherapy after definite concurrent chemoradiation in patients with non-operable esophageal cancer: Is it useful?
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Esophageal Neopl | 2018 |
Adverse Prognostic Factors of Advanced Esophageal Cancer in Patients Undergoing Induction Therapy with Docetaxel, Cisplatin and 5-Fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Disease-Free Surviv | 2018 |
Effects of Neoadjuvant 5-Fluorouracil and Cisplatin Therapy in Patients with Clinical Stage II/III Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2018 |
[Case Report of an Acute Focal Bacterial Nephritis Associated with Adjuvant Chemotherapy in Esophageal Cancer Patient].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Do | 2017 |
[A Case of Advanced Esophageal Cancer Successfully Treated with DCF Chemotherapy Followed by Conversion Surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fl | 2017 |
[A Case of Metachronous Resection for Advanced Esophageal Cancer with Pheochromocytoma].
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; | 2017 |
[Outcome of Patients with Pathological Complete Response after Neoadjuvant Chemotherapy in Advanced Esophageal Cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel | 2017 |
[A Case of Emergency Resection of Esophageal Cancer Which is on the Brink of Perforation after Neoadjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Emergency Medical Services; Es | 2017 |
[Three-Year Survival after Lymphadenectomy for Residual Lymph Node Metastasis of Esophageal Cancer with Invasion into the Trachea and Carotid Artery after Chemoradiotherapy - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carotid Arteries; Chemoradiotherapy; Cisplatin | 2017 |
[A Case of Myocardial Metastasis of Esophageal Squamous Cell Carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2018 |
The Prognostic Nutrition Index Predicts the Development of Hematological Toxicities in and the Prognosis of Esophageal Cancer Patients Treated with Cisplatin Plus 5-Fluorouracil Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2018 |
[Outcome of postoperative adjuvant chemotherapy and surgery alone for patients with stage pT1b-3N0M0 squamous cell carcinoma of the thoracic esophagus].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Es | 2018 |
Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Che | 2018 |
Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female | 2018 |
Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2018 |
Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Esoph | 2018 |
Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Case-Control Studie | 2018 |
Perioperative ECX chemotherapy in older adults with gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2018 |
Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2018 |
Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma.
Topics: Aged; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Esophageal Squamou | 2018 |
Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esoph | 2018 |
Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2018 |
Dose escalated neoadjuvant chemoradiotherapy with dose-painting intensity-modulated radiation therapy and improved pathologic complete response in locally advanced esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; | 2017 |
Low-dose hyperthermia enhances the antitumor effects of chemotherapy in squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; bcl-2-Ass | 2017 |
Experience of Definitive Chemoradiation for Oesophageal Cancer Within a Large Regional Cancer Treatment Centre: Improving Outcomes and Tolerability.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Cap | 2018 |
Drug-induced coma after chemotherapy in intensive care unit: How to make the right diagnosis?
Topics: Adenosine Triphosphate; Adult; Antineoplastic Combined Chemotherapy Protocols; Coma; Esophageal Neop | 2018 |
Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2018 |
Correlation between high FBXW7 expression in pretreatment biopsy specimens and good response to chemoradiation therapy in patients with locally advanced esophageal cancer: A retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cell Line, T | 2018 |
The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Mod | 2018 |
Efficacy of pegfilgrastim administration in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fe | 2018 |
Long noncoding RNA LINC00261 induces chemosensitization to 5-fluorouracil by mediating methylation-dependent repression of DPYD in human esophageal cancer.
Topics: Animals; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); DNA Methylation; DNA, Neoplasm; Drug | 2019 |
[Definitive Radiotherapy for Esophageal Squamous Cell Carcinoma after Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning of Total Body Irradiation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; | 2018 |
Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamo | 2018 |
Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2018 |
Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells.
Topics: Animals; Autophagy; Biopsy; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemoradiotherapy; Drug Resi | 2019 |
High-dose versus standard-dose radiation therapy for cervical esophageal cancer: Retrospective single-institution study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2019 |
"Sentinel lymph node imaging with sequential SPECT/CT lymphoscintigraphy before and after neoadjuvant chemoradiotherapy in patients with cancer of the oesophagus or gastro-oesophageal junction - a pilot study".
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Colloids; | 2018 |
[Impact of Primary Prophylaxis with Pegfilgrastim on Clinical Outcomes in Patients with Advanced Esophageal Cancer Receiving Chemotherapy with Docetaxel, Cisplatin ,and 5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Filgrast | 2018 |
Oral cryotherapy for prophylaxis of oral mucositis caused by docetaxel, cisplatin, and fluorouracil chemotherapy for esophageal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cryotherapy; | 2019 |
Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chem | 2019 |
Effect of 5-fluorouracil on cellular response to proton beam in esophageal cancer cell lines according to the position of spread-out Bragg peak.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Survival; Dose-Response Relationship | 2019 |
Tetrahydrocurcumin, Curcumin, and 5-Fluorouracil Effects on Human Esophageal Carcinoma Cells.
Topics: Antineoplastic Agents; Cell Proliferation; Curcumin; Dose-Response Relationship, Drug; Drug Screenin | 2019 |
[A Case of Advanced Esophageal Cancer Successfully Treated with Neoadjuvant Chemotherapy Containing 5-FU, Docetaxel. and Nedaplatin Combination Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2018 |
[Successful Treatment of Advanced Esophageal Cancer with DCF Chemotherapy and Pegfilgrastim].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fi | 2019 |
The heart's exposure to radiation increases the risk of cardiac toxicity after chemoradiotherapy for superficial esophageal cancer: a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Cardiotoxicity; Chemoradi | 2019 |
Gypenoside L Inhibits Proliferation of Liver and Esophageal Cancer Cells by Inducing Senescence.
Topics: beta-Galactosidase; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cellular Senescenc | 2019 |
The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2019 |
Identification of miR-29c and its Target FBXO31 as a Key Regulatory Mechanism in Esophageal Cancer Chemoresistance: Functional Validation and Clinical Significance.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Esophageal Neoplasms; F-Box Proteins; Fluorouracil | 2019 |
Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Esophageal Neoplasms; | 2019 |
miR-145 Regulates the sensitivity of esophageal squamous cell carcinoma cells to 5-FU via targeting REV3L.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding P | 2019 |
Successful Stenting Followed by Surgery for Perforated Esophageal Cancer Due to Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2019 |
Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 2020 |
Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer.
Topics: Adult; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Comb | 2019 |
Impact of Perioperative Chemotherapy on Prognosis of Patients with Esophageal Carcinoma Undergoing Pulmonary Metastasectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; | 2019 |
Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2019 |
Gastric mucosal injury and hemorrhage after definitive chemoradiotherapy for locally advanced esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2019 |
S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combination | 2019 |
Safety of thoracoscopic esophagectomy after induction chemotherapy for locally advanced unresectable esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Ca | 2020 |
Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer.
Topics: Adult; Age Factors; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Ch | 2020 |
A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy.
Topics: Aged; Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoxazines; Chemor | 2020 |
Reply to A. Adenis et al.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; | 2019 |
Definitive Chemoradiotherapy for Esophageal Squamous Cell Cancer: A Matter of Standard.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Fluorouracil; Humans; | 2019 |
Is Concurrent Chemotherapy With Radiotherapy for Esophageal Cancer Beneficial in Patients Aged 80 Years or Older?
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Com | 2019 |
Long-term Esophageal Cancer Survivor Treated by Bypass for Esophagobronchial Fistula After Chemoradiotherapy: A Case Report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bronchial Fistula; Chemoradiotherapy; Cisplat | 2019 |
Notch1 is a 5-fluorouracil resistant and poor survival marker in human esophagus squamous cell carcinomas.
Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Transformation, Vi | 2013 |
Lymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Card | 2013 |
Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Data Interpretation, S | 2013 |
Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2013 |
[A case of reversible encephalopathy syndrome caused by hyponatremia during neoadjuvant 5-FU+CDDP therapy for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
[A case of squamous cell carcinoma of the esophagogastric junction with bulky no.7-metastatic node successfully treatedby chemoradiation followed by surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2013 |
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy, | 2013 |
Endoscopic ultrasound in staging esophageal cancer after neoadjuvant chemotherapy--results of a multicenter cohort analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2013 |
Ring-enhancing lesion associated with radiation-induced liver disease.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2013 |
Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinosarcom | 2014 |
Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
Involvement of ribonucleotide reductase-M1 in 5-fluorouracil‑induced DNA damage in esophageal cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; C | 2013 |
Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Cel | 2013 |
REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; C | 2013 |
Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
Survival in patients treated with definitive chemo- radiotherapy for non-metastatic esophageal cancer in north- west iran.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2014 |
Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, A | 2013 |
Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2013 |
Significance of GSTP1 for predicting the prognosis and chemotherapeutic efficacy in esophageal squamous cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemotherapy, Adj | 2013 |
[Pathological complete response in a case of advanced esophageal cancer invading aorta treated by preoperative chemotherapy with docetaxel and cisplatin plus 5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Combined Modality Therapy; Docetax | 2013 |
Diffusion-weighted magnetic resonance imaging for predicting and detecting the early response to chemoradiotherapy of advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, A | 2013 |
Impact of postoperative chemoradiotherapy and chemoradiotherapy alone for esophageal cancer in North-West Iran.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Multimodal treatment strategy for clinical T3 thoracic esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case | 2013 |
Pretreatment patient comorbidity and tobacco use increase cost and risk of postoperative complications after esophagectomy at a high-volume cancer center.
Topics: Adenocarcinoma; Adult; Aged; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Cance | 2013 |
Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2013 |
ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Endonuclease | 2013 |
Clinical and oncological effects of triplet chemotherapy followed by radical esophagectomy for resectable esophageal cancer associated with unfavorable prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
Stem cell-like side populations in esophageal cancer: a source of chemotherapy resistance and metastases.
Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; ATP Binding Cassette Transporter, S | 2014 |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2013 |
Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell L | 2013 |
[A case of advanced esophageal cancer revealed a pathological complete response and survived more than 8 years, treated by radiation therapy combined with nedaplatin and 5-FU chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Esophageal Neoplasms; Female; Flu | 2013 |
Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance.
Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Bridged-Ring Compounds; Chemoradiotherapy; Combined Mo | 2013 |
Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Blood Cell Count; Chemoradioth | 2013 |
Autocrine extra-pancreatic trypsin 3 secretion promotes cell proliferation and survival in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Apoptosis; Autocrine Communication; Barrett Esophagus; Cell Line, Tumor; Cell Membra | 2013 |
TNF-α -857C>T genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug-Related Side Effects and | 2013 |
The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Longitudinal assessments of quality of life and late toxicities before and after definitive chemoradiation for esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Esophageal Neoplasms | 2014 |
Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case.
Topics: Adenocarcinoma; Aged; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2014 |
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemothera | 2014 |
Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Cooperative inhibitory effect of sinomenine combined with 5-fluorouracil on esophageal carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Carc | 2013 |
The potential of photodynamic therapy to treat esophageal candidiasis coexisting with esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Candidiasis; Endoscopy; Esophageal Neoplasms | 2014 |
[Current status of neoadjuvant chemotherapy for advanced esophageal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esoph | 2013 |
[A case of esophageal squamous cell carcinoma with submucosal tumor-like tumor due to direct invasion of the gastric wall].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; E | 2013 |
[Study of decreased oral intake in patients receiving neoadjuvant chemotherapy for esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Eating; Esophageal Neopl | 2013 |
[Successful treatment of locally advanced squamous cell carcinoma of the esophagus by combination chemotherapy with 5-fluorouracil plus nedaplatin following tracheal stent tube placement-a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms | 2013 |
[A case of cytomegalovirus colitis during chemotherapy for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cisplatin; Colitis; Cytomegaloviru | 2013 |
[A case of primary esophageal carcinoma treated with 5-fluorouracil plus cisplatin and curatively resected after complete response].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 2013 |
[Pathological complete response in 2 patients with cT4 esophageal cancer treated with neoadjuvant chemoradiation therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neopl | 2013 |
Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2013 |
Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad | 2014 |
Complete pathological response in a patient with metastatic esophageal cancer treated with a regimen of capecitabine, oxaliplatin and docetaxel: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal N | 2014 |
The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplati | 2016 |
A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2014 |
A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; C | 2014 |
Bronchoscopic finding determined outcome after chemoradiotherapy in esophageal cancer patients with airway invasion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Chemoradiotherapy; Cisplatin; Esophage | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therap | 2014 |
Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Asian People; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Esophageal Squamous C | 2014 |
Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2014 |
Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antime | 2014 |
High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2014 |
Clinical results of preoperative CDDP/5-FU chemotherapy followed by surgery for patients with clinical stage II/III thoracic esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal | 2013 |
Patterns of recurrence after trimodality therapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemot | 2014 |
Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2014 |
5-FU induced acute toxic leukoencephalopathy: early recognition and reversibility on DWI-MRI.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Diffusion Magnetic Resonance Imaging; Esophag | 2014 |
The usefulness of neoadjuvant chemoradiation therapy for locally advanced esophageal cancer with multiple lymph-node metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2014 |
High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2014 |
The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2014 |
Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Squamous Cell; Ci | 2014 |
The novel HDAC inhibitor OBP-801/YM753 enhances the effects of 5-fluorouracil with radiation on esophageal squamous carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Growth Processes; Cel | 2014 |
Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blot | 2014 |
Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Co | 2015 |
Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2016 |
Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2014 |
Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; | 2014 |
Definitive radiotherapy for early-stage hypopharyngeal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Su | 2015 |
Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2014 |
Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU: more than 20 years' experience at a single institution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvan | 2014 |
Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2015 |
Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2015 |
p38δ MAPK phenotype: an indicator of chemotherapeutic response in oesophageal squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cel | 2015 |
[A case of esophageal squamous cell carcinoma with an adenocarcinoma component that dedifferentiated after chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell | 2014 |
Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma?
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Esophag | 2014 |
High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (DCF) combination chemotherapy for locally advanced esophageal and junctional cancer.
Topics: Adult; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Fem | 2014 |
Assessment of insulin-like growth factor 1 receptor as an oncogene in esophageal squamous cell carcinoma and its potential implication in chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; C | 2014 |
Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Ce | 2014 |
Synergistic effects of puerarin combined with 5-fluorouracil on esophageal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2014 |
Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Doxorub | 2015 |
Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; D | 2014 |
O-MAX chemotherapy: high activity in metastatic esophagogastric adenocarcinoma and possible relation to subclinical hemolysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2014 |
Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2014 |
ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, | 2015 |
Combination of SNX-2112 with 5-FU exhibits antagonistic effect in esophageal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Drug Antagonism | 2015 |
Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway.
Topics: Androstadienes; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance | 2014 |
A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2015 |
Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity.
Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; DNA Methylation; Drug Resi | 2015 |
MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor | 2014 |
Radio(chemo)therapy for locally advanced squamous cell carcinoma of the esophagus: long-term outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2015 |
Radiochemotherapy for esophageal squamous cell carcinoma in elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2014 |
Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2015 |
Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine | 2015 |
Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2015 |
A case of metachronous development of esophageal squamous cell carcinoma in the patient with esophageal carcinosarcoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Carcinosarcoma; Cisplatin; Drug Therapy, Combinatio | 2014 |
Local control may be the key in improving treatment outcomes of esophageal squamous cell carcinoma undergoing concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2014 |
MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance.
Topics: Adenocarcinoma; Anoikis; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cell Proliferati | 2014 |
Effectiveness of proton beam therapy on liver metastases of esophageal cancer: report of a case.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; | 2015 |
Concurrent radiotherapy and weekly chemotherapy of 5-fluorouracil and platinum agents for postoperative locoregional recurrence of oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Administration | 2015 |
Perfusion computed tomography in predicting treatment response of advanced esophageal squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Semi-radical chemoradiotherapy for 53 esophageal squamous cell carcinomas with supraclavicular lymph node metastasis in a single institutional retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; D | 2014 |
[Pulmonary embolism in esophageal cancer patients receiving neoadjuvant chemotherapy with CDDP and 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Venous Catheters; Cisplatin; Esophagea | 2014 |
[A case of pneumatosis cystoides intestinalis after neoadjuvant chemotherapy for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Fluorouracil; Human | 2014 |
[Evaluation of esophageal cancer treatment for patients aged over 80 years].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Eso | 2014 |
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2015 |
Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcin | 2015 |
Long-term results of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer (T1bN0M0).
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherap | 2015 |
Relief of dysphagia during neoadjuvant treatment for cancer of the esophagus or gastroesophageal junction.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adj | 2016 |
Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2015 |
Tumor recurrence and in-field control after multimodality treatment of locally advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neopl | 2015 |
High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
[Strategies to minimize toxicities during chemoradiotherapy for esophageal cancer].
Topics: Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Clinical Trials as Topic; Esophageal Neoplasms; | 2015 |
Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy.
Topics: Aged; Chemoradiotherapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Hyperthe | 2015 |
Paclitaxel or 5-fluorouracil/esophageal stent combinations as a novel approach for the treatment of esophageal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neopl | 2015 |
Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; D | 2015 |
Induction Chemotherapy Using FAP for Patients with Stage II/III Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2015 |
Aortic pseudoaneurysm formation following concurrent chemoradiotherapy and metallic stent insertion in a patient with esophageal cancer.
Topics: Aneurysm, False; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aortic Diseases; Chemoradio | 2015 |
Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Ch | 2015 |
Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2015 |
Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2015 |
Invited Commentary.
Topics: Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Postoperative Care; Taxoids | 2015 |
Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2015 |
Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neopla | 2015 |
Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2015 |
Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
[A Successfully Treated Case of Central Venous Catheter-Related Suppurative Thrombophlebitis of the Right Jugular Vein to the Superior Vena Cava Associated with Esophageal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheter-Related Infections; Central Venous Catheter | 2015 |
Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
[Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2015 |
Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cognition; Cognition Disord | 2015 |
Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control | 2015 |
Lithium Modulates Autophagy in Esophageal and Colorectal Cancer Cells and Enhances the Efficacy of Therapeutic Agents In Vitro and In Vivo.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; E | 2015 |
Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2015 |
Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers: a single institutional retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; D | 2015 |
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Baculoviral IAP Rep | 2015 |
ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer.
Topics: Adaptor Proteins, Signal Transducing; Aniline Compounds; Animals; Antineoplastic Agents; Antineoplas | 2015 |
Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Lin | 2015 |
Salvage pharyngolaryngectomy with total esophagectomy following definitive chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44(+) cancer stem cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cel | 2015 |
The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Clinical Study on Lobaplatin Combined with 5-Fu and Concurrent Radiotherapy in Treating Patients with Inoperable Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamous Cell | 2015 |
[A Case of Early Recurrence after Esophagectomy for Cancer Following Neoadjuvant Chemotherapy Resulting in a Complete Response of the Primary Lesion].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagectomy; Fatal Out | 2015 |
[Complete Response in Far-Advanced Esophageal Cancer Treated with Induction Chemotherapy Followed by Definitive Chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal | 2015 |
Serum Transforming Growth Factor-β1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compoun | 2015 |
Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance.
Topics: Binding, Competitive; Carcinoma, Squamous Cell; Cdc20 Proteins; Cell Line, Tumor; Cell Proliferation | 2016 |
Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Wester | 2016 |
Pneumatosis intestinalis due to 5-fluorouracil chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Oxygen carrier YQ23 can enhance the chemotherapeutic drug responses of chemoresistant esophageal tumor xenografts.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cisplatin | 2015 |
Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2016 |
[A Case of Severe Bradycardia Induced by Combination Chemotherapy with Cisplatin and 5-Fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bradycardia; Cisplatin; Combined Modality Ther | 2015 |
Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2016 |
A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Dialysis Solutions; Esoph | 2016 |
Changes in Total Lesion Glycolysis Evaluated by Repeated F-18 FDG PET/CT as Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Preoperative Chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 2016 |
Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Car | 2016 |
[A Case of Salvage Chemoradiotherapy for Regional Recurrence after Curative Esophagectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neopl | 2015 |
[A Case of Solitary Brain Metastasis from Stage 0 Esophageal Carcinoma after Neoadjuvant Chemotherapy Followed by Surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Cell; Cisplatin | 2015 |
[A Case of Advanced Esophageal Cancer Patient with Schizophrenia Successfully Treated with Chemoradiation Therapy with S-1 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neopl | 2015 |
[A Case of Penetrating Diverticulum of the Small Intestine that Occurred during Chemotherapy for Esophageal Cancer].
Topics: Abdominal Abscess; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcin | 2015 |
Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Plasma ghrelin levels as a predictor of adverse renal events due to cisplatin-based chemotherapy in patients with esophageal cancer.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Do | 2016 |
DESC1, a novel tumor suppressor, sensitizes cells to apoptosis by downregulating the EGFR/AKT pathway in esophageal squamous cell carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Dow | 2016 |
MiR-193b promotes autophagy and non-apoptotic cell death in oesophageal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Drug Resistance, Neopl | 2016 |
Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Second-Line Modified FOLFOX6 Regimen in The Patients with Metastatic Esophagus Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 2015 |
Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Admin | 2017 |
Identification of a predictive factor for distant metastasis in esophageal squamous cell carcinoma after definitive chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2016 |
Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
Herpes simplex virus-1 encephalitis induced by chemoradiotherapy and steroids in an esophageal cancer patient: a case report.
Topics: Acyclovir; Aged; Chemoradiotherapy; Cisplatin; Dexamethasone; Encephalitis, Herpes Simplex; Esophage | 2016 |
Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2017 |
Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review.
Topics: Ablation Techniques; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2016 |
Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, S | 2017 |
Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy | 2016 |
The impact of neoadjuvant chemotherapy on cardiopulmonary physical fitness in gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anaerobic Threshold; Antineoplastic Combined Chemotherapy Protocols; Cardiores | 2016 |
Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Auraptene Attenuates Malignant Properties of Esophageal Stem-Like Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Coumarins; Cyclin-Dependent Kinase In | 2017 |
Inhibition of autophagosome-lysosome fusion by ginsenoside Ro via the ESR2-NCF1-ROS pathway sensitizes esophageal cancer cells to 5-fluorouracil-induced cell death via the CHEK1-mediated DNA damage checkpoint.
Topics: Animals; Apoptosis; Autophagosomes; Autophagy; Cell Cycle; Cell Survival; Checkpoint Kinase 1; Chlor | 2016 |
Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2017 |
Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2016 |
ypN0: Does It Matter How You Get There? Nodal Downstaging in Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2016 |
miR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Culture Techniques; Disease Models, A | 2016 |
Dosimetric predictors of acute haematological toxicity in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chemoradiotherapy; Cisplat | 2016 |
Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2016 |
Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Esophageal | 2016 |
β-Carotene synergistically enhances the anti-tumor effect of 5-fluorouracil on esophageal squamous cell carcinoma in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; beta Carotene; Carcinoma, Squamous Cell; Cell Line, Tumor | 2016 |
Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dige | 2016 |
The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Carcinoma, | 2017 |
Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN.
Topics: Animals; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Gene Expression Regu | 2016 |
AFP-producing adenocarcinoma of the esophagogastric junction: report of a case with atypical immunohistochemical findings responding to palliative chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT regime).
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esoph | 2016 |
Radiation field size and dose determine oncologic outcome in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2016 |
Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Drug-Related Side Effects and Adverse Reactions; Esophageal N | 2017 |
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; B7-H1 Antigen; Barrett Esophagus; Biopsy; Cell Line | 2016 |
Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease Pro | 2016 |
Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway.
Topics: Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Syne | 2016 |
Feasibility of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus Adriamycin, Cisplatin, and 5-Fluorouracil for Resectable Advanced Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Doxorubicin; Esophageal | 2017 |
Target volume delineation for radical radiotherapy of early oesophageal carcinoma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squam | 2017 |
A prospective study of nutritional supplementation for preventing oral mucositis in cancer patients receiving chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Esophageal Neoplasms; Fe | 2017 |
Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2017 |
[Preoperative Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2016 |
[Pathological Complete Response in 3 Patients with Esophageal Cancer Treated with Neoadjuvant Chemoradiation Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neopl | 2016 |
[CR of All Target Lesions in a Patient with Metastatic Esophageal Cancer and Generalized Weakness Treated with Systemic Chemotherapy after Nutritional Support].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2016 |
[A Case of Heterochronic Cervical Esophageal Cancer with a Subcutaneous Abscess Showing a Complete Response to Chemoradiation Therapy].
Topics: Abscess; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ch | 2016 |
[Salvage Surgery after CRT for Advanced Esophageal Cancer Resulting in a Pathological Complete Response and More Than Five Years' Survival].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; | 2016 |
[Pathological Complete Response in a Case of Advanced Esophageal Cancer with Widespread Lymph Node Metastases Treated Using Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-FU(DCF therapy)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fe | 2016 |
[A Case of Neuroendocrine Carcinoma of the Esophagus Treated with Neoadjuvant Chemotherapy Comprising 5-Fluorouracil plus Cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Esophage | 2016 |
[Long-Term Complete Response in Postoperative Multiple Lung and Mediastinal Lymph Node Metastases of Esophageal Cancer Using Systemic Chemotherapy with DCF Treatment - A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esop | 2017 |
Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluo | 2017 |
UBE2L6/UBCH8 and ISG15 attenuate autophagy in esophageal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Su | 2017 |
Continuous infusion of a large dose of CF (folinic acid) and 5-FU combined with CDDP in the treatment of advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Di | 2017 |
The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2017 |
Effect of Intensity Modulated Radiation Therapy With Concurrent Chemotherapy on Survival for Patients With Cervical Esophageal Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined | 2017 |
The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy | 2017 |
[A Case of Resected Advanced Esophageal Cancer That Responded to Combination Therapy Comprising Docetaxel, Cisplatin, and 5-Fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fl | 2017 |
Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2008 |
[Curcumin promotes apoptosis of esophageal squamous carcinoma cell lines through inhibition of NF-kappaB signaling pathway].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Curcumin; Eso | 2008 |
Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
Preventive wrapping of the fragile tracheobronchial wall using a flap of latissimus dorsi muscle during esophagectomy after chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchi; Cisplatin; Combined Modality Therapy; | 2008 |
Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Stud | 2008 |
VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2008 |
Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcium-Binding Proteins; C | 2008 |
[A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Docetaxel; Esophageal | 2008 |
Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2009 |
Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; E | 2008 |
Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cis | 2009 |
Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2008 |
[Successful treatment with 5-fluorouracil and cis-dichlorodiammineplatinum combined with 60Gy of radiation in a case of advanced esophageal cancer complicated with chronic renal failure treated with hemodialysis].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2008 |
[Diagnosis and treatment of basaloid squamous cell carcinoma of the esophagus].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Basosquamous; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
REG I enhances chemo- and radiosensitivity in squamous cell esophageal cancer cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Dos | 2008 |
Overall survival with cisplatin and 5-fluorouracil neoadjuvant treatment in patients with esophageal cancer: single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophagea | 2008 |
Fluorouracil should continue to be incorporated in the treatment of localized esophageal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasm | 2009 |
[A case of esophageal cancer with recurrent lymph-node metastasis successfully treated with chemo-radiotherapy after mediastinoscopy-assisted transhiatal esophagectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neoplasms; Eso | 2008 |
Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2009 |
Efficacy of chemoradiotherapy with low-dose cisplatin and continuous infusion of 5-fluorouracil for unresectable squamous cell carcinoma of the esophagus.
Topics: Aged; Antimetabolites, Antineoplastic; C-Reactive Protein; Carcinoma, Squamous Cell; Cisplatin; Esop | 2009 |
[A case of elderly esophageal adenocarcinoma successfully treated with daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2009 |
Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxyc | 2009 |
Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car | 2009 |
Neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: prognostic value of circumferential resection margin and stratification of N1 category.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2009 |
Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2009 |
High orotate phosphoribosyltransferase gene expression predicts complete response to chemoradiotherapy in patients with squamous cell carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2009 |
Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2009 |
Development of gastro-lymphatic fistula during chemoradiotherapy for advanced esophageal cancer: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Fatal Outcome; Fluorouracil; G | 2009 |
Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2009 |
[A long-term recurrence-free survivor after chemotherapy with 5-FU plus CDDP and surgery for small cell carcinoma of the esophagus].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Small Cell; Cisplatin; Esophageal | 2009 |
Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemother | 2010 |
Retrospective review of surgery and definitive chemoradiotherapy in patients with squamous cell carcinoma of the thoracic esophagus aged 75 years or older.
Topics: Aged; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil | 2009 |
Comparison of cisplatin and 5-fluorouracil chemotherapy protocols combined with concurrent radiotherapy for esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclopho | 2009 |
Gene expression changes in a chemoresistant model with human esophageal cancer xenografts using cDNA microarray.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell | 2009 |
Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemo-radiotherapy for esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous | 2009 |
Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2009 |
[A case of double advanced cancer with esophageal and hypopharyngeal carcinoma responding completely to combination chemotherapy of docetaxel/5-fluorouracil and nedaplatin with radiation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Esophage | 2009 |
[A case of pathologic complete response of primary esophageal carcinoma treated with 5-FU/CDDP as neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophagoscopy | 2009 |
Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin | 2009 |
Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2009 |
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; E | 2009 |
Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2010 |
Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2009 |
[A case of the oldest old patient with advanced esophageal cancer responding completely to the combination chemotherapy of docetaxel/5-fluorouracil/nedaplatin with radiation].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined C | 2009 |
[Clinical analysis of 22 cases of esophageal adenosquamous carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Adenosquamou | 2009 |
Sustained complete response following combined nedaplatin+ adriamycin+5-fluorouracil therapy in a patient with superficial esophageal cancer -case report-.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2009 |
A retrospective comparison of clinical outcomes and quality of life measures between definitive chemoradiation alone and radical surgery for clinical stage II-III esophageal carcinoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2009 |
Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2009 |
Quantitative analysis of survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer.
Topics: Actins; Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Squamous Cell | 2009 |
High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcome.
Topics: Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Cohort Studies; Disease-Free Survival; Esophageal | 2010 |
Influence of irradiated lung volumes on perioperative morbidity and mortality in patients after neoadjuvant radiochemotherapy for esophageal cancer.
Topics: Acute Lung Injury; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplat | 2010 |
[A case of severe electrolytic disorder after adjuvant chemotherapy for esophageal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2009 |
Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Female; Fl | 2009 |
Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2009 |
Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Circadian Rhythm; Ci | 2009 |
[A case of small cell undifferentiated carcinoma of the esophagus successfully treated by chemoradiotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Small Cell | 2009 |
Chemoradiotherapy for cancer of the esophagus: contribution of the leucovorin, 5-fluorouracil bolus, and infusion-cisplatin-radiotherapy schedule starting with two neoadjuvant chemotherapy cycles: results from a pilot study.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Admi | 2010 |
p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2010 |
p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doxorubic | 2010 |
[Feasibility and short-term efficacy of simplified intensity-modulated radiotherapy and concurrent chemotherapy for neck and upper thoracic esophageal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchitis; Carcinoma, Squamous Cell; Cisplati | 2009 |
Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassett | 2010 |
TaqMan low-density arrays and analysis by artificial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Combined Modality Th | 2010 |
EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Carcinoma, S | 2010 |
[PSK-mediated growth suppression and enhancement of 5-FU/docetaxel-induced cytotoxicity in human esophageal cancer cell lines].
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 2009 |
[Concurrent chemoradiotherapy with nedaplatin and 5-fluorouracil (5-fu) for locally advanced squamous cell carcinoma of the esophagus].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2009 |
[A case of a 14-month survival patient on advanced esophageal cancer with uncontrolled brain metastasis completely responding to nedaplatin, adriamycin, plus 5-FU (NAF) therapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2009 |
[Two case reports of metastatic liver carcinoma with the effective treatment of radiofrequency ablation and intraarterial chemotherapy].
Topics: Aged; Catheter Ablation; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Infu | 2009 |
[A case of stage IV advanced esophageal cancer with a long term survival by radiation therapy combined with nedaplatin and 5-FU chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
[A case of esophageal cancer associated with colon cancer successfully treated with combination chemotherapy of FOLFOX and concurrent radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Esopha | 2009 |
[A case of advanced esophageal cancer that has come back eight years after combined modality therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2009 |
[Usefulness of induction chemotherapy followed by chemo-radiotherapy for patients with advanced cervical esophageal cancer].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineopl | 2010 |
[A case of small cell carcinoma of the esophagus with SIADH].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplas | 2010 |
Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-F | 2010 |
Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Che | 2010 |
A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2010 |
The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells.
Topics: Autophagy; Carboplatin; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combinat | 2010 |
Radiotherapy with or without concurrent chemotherapy for lymph node recurrence after radical surgery of thoracic esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; C | 2010 |
Targeted HER2 treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2010 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; | 2010 |
Pre- and post-therapy nodal status equally affects survival of patients with oesophageal squamous cell carcinoma receiving preoperative chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Successful treatment of esophageal squamous cell carcinoma in a patient with Fanconi anemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Carcinom | 2010 |
Predictors of sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarker | 2010 |
High-dose chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer: a retrospective cohort study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2010 |
Therapy-related leukemia following chemoradiotherapy for esophageal cancer.
Topics: Aged; Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 5; Combined Modality T | 2010 |
Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Lin | 2010 |
Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach - a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2010 |
Chemoradiation for esophageal cancer: institutional experience with three different regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2011 |
Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2010 |
High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, M | 2010 |
Prognostic significance of age in the radical treatment of oesophageal cancer with surgery or chemoradiotherapy: a prospective observational cohort study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2010 |
TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2010 |
Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, S | 2011 |
Combinatory cytotoxic effects produced by E1B-55kDa-deleted adenoviruses and chemotherapeutic agents are dependent on the agents in esophageal carcinoma.
Topics: Adenoviridae; Adenovirus E1B Proteins; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cel | 2010 |
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcin
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2010 |
High-dose preoperative chemoradiotherapy in esophageal cancer patients does not increase postoperative pulmonary complications: correlation with dose-volume histogram parameters.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Di | 2010 |
Retrospective study of photodynamic therapy vs photodynamic therapy combined with chemotherapy and chemotherapy alone on advanced esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2010 |
Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Dose Fract | 2011 |
[A case of SIADH developed during neoadjuvant chemotherapy using nedaplatin and 5-fluorouracil in a patient with esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Esophageal Neoplasms; Fluorouracil; Hu | 2010 |
New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; De | 2011 |
Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; C | 2010 |
Interleukin-10 and -12 predict chemotherapy-associated toxicity in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisp | 2010 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, | 2011 |
Early detection of 5-FU-induced acute leukoencephalopathy on diffusion-weighted MRI.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Brain; Diffusion Magnetic Resonance Imaging; Early D | 2011 |
[A successful resected case of far-advanced cancer at the esophagogastric junction by chemoradiotherapy with docetaxel, nedaplatin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Docetaxel; | 2010 |
[Syndrome of inappropriate antidiuretic hormone secretion following adjuvant CDDP and 5-FU administration in a patient with esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neopla | 2010 |
Outcomes from chemoradiotherapy for patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Insulin-like growth factor 1 mediates 5-fluorouracil chemoresistance in esophageal carcinoma cells through increasing survivin stability.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Casein | 2011 |
[Four resected cases with basaloid carcinoma of esophagus--comparison of 5-FU-related enzymes (thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT)) between basaloid carcinoma and squamous cell carcin
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dihydrouraci | 2010 |
Submucosal tumor appearance is a useful endoscopic predictor of early primary-site recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Early Detection of Canc | 2011 |
[Promoting effect of all-trans retinoic acid on the chemosensitivity of esophageal cancer EC9706 cells].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cy | 2010 |
Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2011 |
Esophageal adenocarcinoma after laparoscopic gastric band placement for obesity.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bariatric Surgery; Deglutition | 2011 |
TS gene tandem repeats in esophageal cancer patients receiving chemoradiotherapy.
Topics: Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; | 2011 |
Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco | 2011 |
Defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
[Mechanism of apoptosis of esophageal cancer EC9706 in nude mice induced by all-trans retinoic acid].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tu | 2010 |
[A case of recurrent esophageal cancer with tracheal invasion treated by chemo-radiotherapy (CRT) after placement of tracheal stent that maintained complete response (CR) for two years].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2010 |
[Successfully treated case of hypopharyngeal and cervical esophageal squamous cell carcinoma with laryngeal preservation].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2010 |
[ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2010 |
[A case of recurrent esophageal cancer successfully treated by combined therapies].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophage | 2010 |
[A case successfully treated with subtotal esophagectomy after preoperative second-line chemotherapy for cT4 esophageal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2010 |
[Regional treatment of esophageal liver metastasis by intra-arterial low-dose 5-FU therapy].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Esophageal Neoplasms; Female; Fluorouracil | 2010 |
Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Su | 2011 |
Esophageal adenocarcinoma presenting as pseudo-achalasia in a patient with juvenile polyposis syndrome: an enemy out of the blue.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antin | 2011 |
Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Pro | 2011 |
Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; | 2011 |
Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Com | 2011 |
Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Squamous Cell; | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
[A curative resected case of pathological complete response of esophageal carcinoma treated with 5-FU/CDDP as neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophagoscopy; Fluo | 2011 |
[A case of advanced esophageal carcinoma with nephrotic syndrome completely responding to chemotherapy of docetaxel, nedaplatin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Docetaxel; Esophageal Neoplasms; Fluor | 2011 |
COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2011 |
Primary lung cancer surgery after curative chemoradiotherapy for esophageal cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2011 |
VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Cycloox | 2011 |
Minimally invasive esophagectomy is safe and effective following neoadjuvant chemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Role of preoperative chemotherapy in squamous cell carcinoma of esophagus in kashmir, a cancer belt - a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2011 |
Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2011 |
[A case of advanced esophageal cancer with multiple liver metastases accompanying poorly general conditions and serious liver dysfunctions, successfully treated using concurrent radiotherapy and chemotherapy with low-dose nedaplatin and 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2011 |
Minimally invasive esophagectomy with two-field lymphadenectomy.
Topics: Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality | 2011 |
Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Weight; | 2012 |
Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chromosomes, Human, Pair 2; | 2012 |
Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carci | 2012 |
Correlation between tumor-associated proteins and response to neoadjuvant treatment in patients with advanced squamous-cell esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Blotting, W | 2011 |
Inhibition of nuclear factor-κB activity by small interfering RNA in esophageal squamous cell carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prolife | 2011 |
Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2012 |
Cervical nodal metastases of unresectable thoracic esophageal squamous cell carcinoma: characteristics of long-term survivors after concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Di | 2011 |
Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2011 |
Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2011 |
Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2011 |
Endoscopic ultrasonography is useful for monitoring the tumor response of neoadjuvant chemoradiation therapy in esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2012 |
Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials as Topic; Combined M | 2011 |
Linear correlation between patient survival and decreased percentage of tumor [(18)F]fluorodeoxyglucose uptake for late-course accelerated hyperfractionated radiotherapy for esophageal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; China; Dose Fractionation, R | 2012 |
A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma.
Topics: Animals; Apoptosis; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Esophageal Neop | 2011 |
Complete response to chemoradiotherapy in a patient with synchronous double gastric and esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophage | 2011 |
Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Combined Modality Therapy; | 2011 |
Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2011 |
Chemotherapy-induced modification of microRNA expression in esophageal cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Esophageal Neoplasms; | 2011 |
Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; | 2012 |
[A case of metastatic esophageal cancer - endoscopic resection of the primary site following systemic chemotherapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Endoscopy; Eso | 2011 |
Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, A | 2011 |
The amount of neoadjuvant chemotherapy for Barrett's carcinoma does not correlate with long-term survival.
Topics: Aged; Antineoplastic Agents; Barrett Esophagus; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cohort | 2011 |
The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CD8-Positive T-Lymph | 2012 |
[A case of a patient with stage IVa esophageal cancer surviving over 4 years by combination chemotherapy with docetaxel,5 -FU and cisplatin, without operation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorour | 2011 |
Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Weekly Taxotere and cisplatin with continuous-infusion 5-fluoruracil for the treatment of advanced gastric and esophageal cancer: a prospective, observational, single-institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetax | 2012 |
Nonsurgical management of esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
[Analysis of the factors related to esophageal injuries in radiotherapy of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2011 |
Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; C | 2012 |
Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Carcinoma, Squamou | 2011 |
Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Sq | 2011 |
Anastomotic complications after Ivor Lewis esophagectomy in patients treated with neoadjuvant chemoradiation are related to radiation dose to the gastric fundus.
Topics: Adult; Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherap | 2012 |
Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2012 |
Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for esophageal carcinoma.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squam | 2012 |
Long-term results of radiochemotherapy for solitary lymph node metastasis after curative resection of esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Esophageal Neopl | 2012 |
Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2012 |
Prognostic factors in definitive radiochemotherapy of advanced inoperable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Che | 2012 |
Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer.
Topics: Abnormal Karyotype; Adenocarcinoma; Antineoplastic Agents; Capecitabine; Clinical Trials, Phase II a | 2012 |
A small interfering RNA targeting NF-κB p65 alone or combined with 5-FU inhibits growth of esophageal squamous cell carcinoma in nude mice.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; Dow | 2012 |
[Elental prevented and reduced oral mucositis during chemotherapy in patients esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female; Fluor | 2011 |
[Efficacy of combined chemotherapy with nedaplatin, adriamycin, and 5-FU (NAF), and clinical factors affecting its effect in patients with advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Esophageal Neoplasms; Female; Flu | 2011 |
[A case of advanced esophageal cancer patient surviving more than 7 years treated with chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Esophageal Neoplasms; Fluorouraci | 2011 |
[A case of advanced esophageal cancer invaded to the trachea with PCR after preoperative chemoradiotherapy, which relapsed at the time of three years and seven months after resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; | 2011 |
[Two cases of complete response of primary esophageal carcinoma treated with 5-FU/CDDP as neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Fluorouracil; | 2011 |
Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2012 |
Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Aurora Kinases; Chemor | 2012 |
The BH3 mimetic HA14-1 enhances 5-fluorouracil-induced autophagy and type II cell death in oesophageal cancer cells.
Topics: Autophagy; Benzopyrans; Cell Death; Cell Line, Tumor; Esophageal Neoplasms; Fluorouracil; Humans; Ni | 2012 |
Impact of radiotherapy, chemotherapy and surgery in multimodal treatment of locally advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2011 |
Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Esophageal Neoplasm | 2012 |
Overexpression of Cks1 increases the radiotherapy resistance of esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CDC2-CDC28 Kinases; | 2012 |
Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2012 |
Prognostic factors in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiation therapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Esop | 2013 |
Acute cardiac impairment associated with concurrent chemoradiotherapy for esophageal cancer: magnetic resonance evaluation.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradioth | 2012 |
Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2012 |
[Chemotherapy for esophageal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2011 |
Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryo | 2012 |
[A successful resected case of advanced esophageal cancer with early gastric cancer responding to neoadjuvant chemotherapy of docetaxel, CDDP and 5-FU].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Ce | 2012 |
Comparison of the effect of p65 siRNA and curcumin in promoting apoptosis in esophageal squamous cell carcinoma cells and in nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell L | 2012 |
Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy | 2012 |
Efficacy analysis of simplified intensity-modulated radiotherapy with high or conventional dose and concurrent chemotherapy for patients with neck and upper thoracic esophageal carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neop | 2012 |
Clinical outcome of endoscopic mucosal resection for esophageal squamous cell cancer invading muscularis mucosa and submucosal layer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherap | 2013 |
Low morbidity after palliation of obstructing gastro-oesophageal adenocarcinoma to restore swallowing function.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Argon Plasma Coagulation; Capecitabi | 2012 |
Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer.
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free S | 2012 |
Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function.
Topics: Acetylcholinesterase; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2012 |
Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheter Ablation; Chemoth | 2013 |
Clinical significance of chemoradiotherapy and surgical resection for cT4 esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophage | 2012 |
Aldehyde dehydrogenase 1 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma.
Topics: Aged; Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2013 |
Results of chemoradiotherapy for stage I esophageal cancer in medically inoperable patients compared with results in operable patients.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemora | 2013 |
Identification and characterization of stemlike cells in human esophageal adenocarcinoma and normal epithelial cell lines.
Topics: Adenocarcinoma; Animals; Antigens, CD; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription F | 2012 |
Curcumin potentiates the antitumor effects of 5-FU in treatment of esophageal squamous carcinoma cells through downregulating the activation of NF-κB signaling pathway in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, T | 2012 |
The oncoprotein and stem cell renewal factor BMI1 associates with poor clinical outcome in oesophageal cancer patients undergoing preoperative chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2012 |
[Long-term survival of a case of advanced cancer of the esophagogastric junction with complete response to low-dose 5-fluorouracil and cisplatin chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophagogastric Jun | 2012 |
[Multimodality therapy containing hepatic arterial infusion chemotherapy for liver metastasis of esophageal cancer-a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cisplatin; Combined Modality Therap | 2012 |
Mediastinal extravasation of oxaliplatin.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Central | 2012 |
[The role of neoadjuvant therapy in the treatment of locally advanced squamous cell cancer of the cervical oesophagus].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Treatment strategy for superficial pharyngeal squamous cell carcinoma synchronously combined with esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2013 |
THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcino | 2012 |
[A case of pathologically complete response of esophageal carcinoma treated with low-dose 5-FU/CDDP as neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female; Fluor | 2012 |
VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2012 |
[Efficacy of docetaxel and nedaplatin combined with concurrent intensity modulated radiation therapy in the treatment of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2012 |
Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamou | 2013 |
Evaluation of 5-FU plasma concentration by 13C breath test in patients treated with oral 5-FU analogs.
Topics: Acetates; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breath Tests; Carbon Isotopes | 2012 |
5-FU-induced cardiac toxicity--an underestimated problem in radiooncology?
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Cardiotoxins; Chemoradiotherapy; Electrocardiograp | 2012 |
[A case of lung metastasis from esophageal cancer resistant to fluorouracil and cisplatin combination therapy but responsive to radiation therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; | 2012 |
[Two cases of complete response for cStage I( T1bN0M0) esophageal carcinoma treated with chemoradiation therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2012 |
[A case of Barrett's esophageal carcinoma treated with combined therapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Chemoradio | 2012 |
[Esophageal cancer: outcome according to therapeutic strategy].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2013 |
Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2013 |
Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2013 |
The telomere/telomerase binding factor PinX1 is a new target to improve the radiotherapy effect of oesophageal squamous cell carcinomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Cycle Protei | 2013 |
Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2013 |
Outcomes of patients with stage IVA esophageal cancer (Japanese classification) treated with definitive chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemoradiotherapy; | 2013 |
COX-2 overexpression Induced by gene transfer reduces sensitivity of TE13 esophageal carcinoma cells to 5-fluorouracil and cisplatin.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prolifera | 2013 |
Adjuvant concurrent chemoradiation using intensity-modulated radiotherapy and simultaneous integrated boost for resected high-risk adenocarcinoma of the distal esophagus and gastro-esophageal junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherap | 2013 |
Complete regression of esophageal cancer with concomitant liver metastasis achieved by concurrent chemoradiation therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2002 |
Preoperative chemotherapy and radiation for advanced esophageal carcinoma: comparison between once a day radiation and hyperfractionation, a single-institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; E | 2002 |
Preoperative therapy for patients with resectable squamous cell carcinoma of the esophagus: are we still confused?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2002 |
[Salvage operation for esophageal cancer after radical chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2002 |
[A case of advanced esophageal cancer with multiple lymph node metastases successfully treated with induction chemotherapy consisting of nedaplatin and 5-FU followed by chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu | 2002 |
Prognostic value of TP53 transcriptional activity on p21 and bax in patients with esophageal squamous cell carcinomas treated by definitive chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carcinoma, | 2002 |
Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2002 |
[Superficial esophageal carcinoma successfully treated with combined chemotherapy and radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2002 |
Surgical resection with and without chemotherapy in oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2002 |
Surgical resection with and without chemotherapy in oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2002 |
Surgical resection with and without chemotherapy in oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2002 |
Surgical resection with and without chemotherapy in oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2002 |
Early changes in [18F]FLT uptake after chemotherapy: an experimental study.
Topics: Antineoplastic Agents; Artifacts; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Deoxycytidine; | 2002 |
[A trial of continuous and biweekly low-dose cisplatin and 5-FU with UFT chemotherapy for esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Resp | 2002 |
A case of advanced esophageal cancer with extensive lymph node metastases successfully treated with multimodal therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2002 |
[Clinical study of the combination of small amount of nedaplatin (CDGP)/5-FU with radiation for the treatment of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2002 |
Effects of preoperative chemotherapy on metastatic lymph nodes in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cel | 2002 |
DNA-PKcs expression in esophageal cancer as a predictor for chemoradiation therapeutic sensitivity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; Combined Modality Thera | 2002 |
[Chemoradiotherapy using platinum analogs/5-FU for advanced esophageal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2002 |
[A case of esophageal cancer successfully treated by chemoradiotherapy after resection for multiple liver metastasis of sigmoid colon cancer].
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Infus | 2002 |
Clinical markers of hypoxia and other predictive factors of survival in conservative therapy of squamous-cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Hypoxia; | 2003 |
[Cisplatin, 5-fluorouracil, and high-dose leucovorin for advanced esophageal cancer].
Topics: Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 2003 |
Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 2003 |
Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 2003 |
Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 2003 |
Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 2003 |
Expression of copper-transporting P-type adenosine triphosphatase in human esophageal carcinoma.
Topics: Adenosine Triphosphatases; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cation T | 2003 |
Cutaneous recall reactions with systemic fluorouracil.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Drug Eruptions; Esophageal Neoplasms | 2003 |
[Complete remission of esophageal undifferentiated carcinoma with nedaplatin and 5-FU chemotherapy and endoesophageal brachytherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; Combined Modality Th | 2003 |
Synchronous occurrence of glioblastoma multiforme and esophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplat | 2003 |
Adjuvant chemotherapy after radical resection of squamous cell carcinoma in the thoracic esophagus: who benefits? A retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2003 |
Basaloid-squamous carcinoma of the esophagus treated by preoperative chemotherapy: report of two cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2003 |
Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: activation of the thymidine phosphorylase as active principle?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxy | 2003 |
[Effect of nedaplatin, 5-FU, and leucovorin combined with radiation therapy in unresectable esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 2003 |
Relapse patterns after chemo-radiation for carcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2003 |
The significance of cardiac doses received during chemoradiation of oesophageal and gastro-oesophageal junctional cancers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2003 |
Plummer-Vinson syndrome associated with celiac disease and complicated by postcricoid carcinoma and carcinoma of the tongue.
Topics: Anemia, Iron-Deficiency; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Celiac Diseas | 2003 |
[The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells].
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Drug Interactions; Esophageal Neoplasms; Etoposide | 2003 |
Response to preoperative chemotherapy affects prognosis in esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control | 2003 |
[Renal metastasis after curative resection of an epidermoid carcinoma of the esophagus].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined C | 2003 |
[Nedaplatin and 5-fluorouracil combined with radiotherapy for advanced esophageal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2003 |
Concurrent chemoradiotherapy with protracted infusion of 5-FU and cisplatin for postoperative recurrent or residual esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Clinical benefit of chemosensitivity test for patients with regional lymph node-positive esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2003 |
Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2003 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
[A case report of an advanced esophageal carcinoma (stage II) without signs of recurrence in 5 years after chemoradiotherapy. With reference to p53 immunohistochemistry as an indicator for prognostic evaluation of chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2003 |
Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mism | 2003 |
[A case of multiple advanced esophageal carcinomas with abdominal LN metastases showing complete response after chemoradiotherapy with concurrent cisplatin, 5-FU and adriamycin chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2003 |
Combined modality therapy in esophageal cancer: the Memorial experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; | 2003 |
[Resection of esophageal cancer infiltrating the left main bronchus following complete response to preoperative radiochemotherapy--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cispl | 2003 |
[Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Sche | 2003 |
Response of neoplastic meningitis from solid tumors to oral capecitabine.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcin | 2003 |
Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Aged; bcl-2-Associated X Protein; Cisplatin; Combined Modality Therapy; Disease-Free | 2003 |
Choroidal metastasis from adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Choroid Neoplasms | 2003 |
[Neoadjuvant chemoradiotherapy for advanced squamous cell carcinoma of thoracic esophagus].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2004 |
Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cis | 2004 |
Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2004 |
A rare life-threatening complication of migrated nitinol self-expanding metallic stent (Ultraflex).
Topics: Adenocarcinoma; Aged; Alloys; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther | 2004 |
Outcome of surgery for oesophageal carcinoma in a low volume centre, with and without preoperative chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Combined Modalit | 2004 |
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2004 |
Sustained complete remission of metastatic oesophageal adenocarcinoma using long-term therapy with 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Doxorubicin; Esophageal Neoplasms; Fluorourac | 2004 |
Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Combined Modality Th | 2004 |
Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2004 |
Use of LeVeen pleuroperitoneal shunt for refractory high-volume chylothorax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chylothorax; | 2004 |
Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ci | 2004 |
Complete remission with long-term survival in a patient with esophageal carcinoma and a tracheoesophageal fistula after treatment with the AIO regimen and bi-weekly cisplatin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survi | 2004 |
Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dise | 2004 |
[The radiochemotherapy of the oesophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Degl | 2004 |
Experimental gene therapy using p21Waf1 gene for esophageal squamous cell carcinoma by gene gun technology.
Topics: Animals; Biolistics; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Prolifera | 2004 |
Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2004 |
[A resected case of thoracic esophageal cancer in which pCR was obtained using low-dose of nedaplatin (CDGP)/5-FU and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2004 |
[Preoperative chemoradiation in esophageal cancer: experience of a single center in 102 patients].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2004 |
Impact of chemoradiotherapy-induced anemia on survival in uniformly staged patients with locally advanced squamous cell carcinoma of the esophagus.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2004 |
Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemot | 2004 |
Cardiotoxicity and neurotoxicity of high-dose continuous fluorouracil as a result of degradation compounds in the drug vials.
Topics: Acetaldehyde; Aged; Antimetabolites, Antineoplastic; Brain Diseases; Carcinoma; Chemistry, Pharmaceu | 2004 |
[Radio-chemotherapy for non-resectable primary esophageal malignant melanoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal | 2004 |
Coronary artery spasm induced by 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Coronary Angiograph | 2005 |
Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Cisplatin; Combined Mod | 2005 |
Correlation between histological effects on the main tumors and nodal status after chemoradiotherapy for squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2005 |
Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc | 2005 |
[Role of an exclusive concomitant radio-chemotherapy treatment in non operable esophageal cancer: results of a 10-year experience in Antoine-Lacassagne Center].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cispl | 2005 |
Two cases of retroperitoneal hematoma caused by combination of anticoagulant therapy and 5-fluorouracil.
Topics: Aged; Anticoagulants; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Interactions; Esophag | 2005 |
Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2005 |
Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Biopsy; Calibration; Carcinom | 2005 |
Delayed radiation myelopathy after concurrent chemoradiation for hypopharyngeal-esophageal carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Degluti | 2005 |
High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2005 |
[Effect of steroid on antiemetic for side effect of anticancer chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dexamethasone; Drug Administration S | 2005 |
[Local failure-related factors of esophageal carcinoma after concurrent chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female | 2005 |
Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal N | 2005 |
Iris metastasis of esophageal cancer.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorouracil; Humans; Iris Neoplasms; Male; Middle A | 2005 |
Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2005 |
[Phase I study of CM-Na combined with concurrent radiochemotherapy for advanced esophageal carcinoma].
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2005 |
[Long-term results of neoadjuvant radiochemotherapy in squamous carcinoma of the thoracic esophagus].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2005 |
Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Circadian Rhythm; CLOCK Proteins; Esophageal Neoplasms; Fluor | 2005 |
[A case of T4 esophageal squamous cell carcinoma in esophagogastric junction effectively treated by neoadjuvant FAP therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Dr | 2005 |
[Multivariate prognostic analysis for patients with unresectable esophageal carcinoma after concurrent chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 2005 |
[The value of postoperative arterial infusion chemotherapy in patients with T3 esophageal squamous carcinoma after radical surgery].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2005 |
Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Predictive value of p53 and 14-3-3sigma for the effect of chemoradiation therapy on esophageal squamous cell carcinoma.
Topics: 14-3-3 Proteins; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, | 2005 |
Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi-Sq | 2005 |
[Pathologic complete response of thoracic esophageal cancer developing after gastrectomy to neoadjuvant low-dose nedaplatin (CDGP), 5-fluorouracil and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2005 |
[Chemotherapy for an esophageal cancer patient undergoing continuous ambulatory peritoneal dialysis for chronic renal failure and measurement of plasma concentration of the drug].
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Dose-Response Relations | 2005 |
Unbiased estimation of tumor regression rates during chemoradiotherapy for esophageal carcinoma using CT and stereology.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2005 |
Neoadjuvant chemoradiotherapy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2005 |
An audit of postoperative radiotherapy after non-curative resection for cancer of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality The | 2005 |
Activated nuclear factor-kappa B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 2005 |
Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; | 2005 |
Efficacy and toxicity of fluorouracil, doxorubicin, and cisplatin/nedaplatin treatment as neoadjuvant chemotherapy for advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Doxo | 2005 |
Invited commentary.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2005 |
[Hyperfractionated radiotherapy with concurrent chemotherapy for advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deglutit | 2005 |
[A case of complete response after neoadjuvant chemotherapy for advanced esophageal cancer with low-dose FP therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response R | 2005 |
The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2005 |
Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation.
Topics: 3' Untranslated Regions; Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; | 2006 |
Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
Topics: Analysis of Variance; Camptothecin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorou | 2006 |
Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Calm | 2005 |
The experience of concurrent chemoradiation for Japanese patients with superficial esophageal squamous cell carcinoma: a retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2005 |
Presentation of esophageal cancer with solitary splenic metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carcinoma, Squamous Cell; Cispl | 2005 |
High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squa | 2005 |
Vitamin C enhances chemosensitization of esophageal cancer cells in vitro.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antioxidants; Ascorbic Acid; Cell Proliferat | 2005 |
The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma.
Topics: 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; Antineoplastic Agents; Combined Modality | 2006 |
Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Es | 2005 |
Cardiac function after chemoradiation for esophageal cancer: comparison of heart dose-volume histogram parameters to multiple gated acquisition scan changes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dose Fra | 2005 |
Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-kappaB.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Eso | 2006 |
Quantification and reduction of cardiac dose in radical radiotherapy for oesophageal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modalit | 2005 |
Radiation therapy combined with cis-diammine-glycolatoplatinum (nedaplatin) and 5-fluorouracil for Japanese stage II-IV esophageal cancer compared with cisplatin plus 5-fluorouracil regimen: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Esophageal Ne | 2006 |
Pharmacogenetics in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Esophage | 2005 |
[A case of successful treatment by low-dose 5-fluorouracil and cisplatin for liver metastases of esophageal adenosquamous carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Cisplatin; Dose-Response R | 2006 |
Palliative ethanol injections of unresectable advanced esophageal carcinoma combined with chemoradiation.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophage | 2006 |
Long-term survival after three-field lymph-adenectomy for an adenocarcinoma in Barrett's esophagus with metastasis to Virchow's node.
Topics: Abdomen; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Ci | 2006 |
Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation.
Topics: Animals; Antineoplastic Agents; Carbon; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; C | 2006 |
[Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Li | 2006 |
Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2006 |
P53, COX-2, iNOS protein expression changes and their relationship with anti-oxidant enzymes in surgically and multi-modality treated esophageal carcinoma patients.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western | 2006 |
[Experimental chemotherapy against human esophageal carcinoma xenografts with TS-1, cisplatin and docetaxel].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Dr | 2006 |
Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, | 2006 |
Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal | 2006 |
Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Treatment results of preoperative concurrent chemoradiotherapy followed by surgery for stage III or IV esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2006 |
Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2006 |
[HPV-infection in esophageal cancer as possible predictive factor after neoadjuvant therapy].
Topics: Antineoplastic Agents; Blotting, Southern; Chemotherapy, Adjuvant; Cisplatin; DNA, Viral; Esophageal | 2006 |
Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc | 2006 |
Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 2006 |
Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2006 |
[Bcl-XL antisense oligodeoxynucleotide sensitizes human esophageal cancer cell line to 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Dru | 2006 |
[Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; DNA Pr | 2004 |
[Hand-foot syndrome with capecitabine therapy].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neopl | 2007 |
[A case of advanced esophageal cancer with suspected tracheoesophageal fistula that responded to chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 2006 |
A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Dru | 2006 |
[Long-term results of chemoradiation therapy for the patients with locally advanced (T4) esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 2006 |
Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Ther | 2006 |
Successful outcome after combined chemotherapeutic and surgical management in a case of esophageal cancer with breast and brain relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Squamo | 2006 |
Preoperative chemoradiotherapy for esophageal cancer enhances the postoperative systemic inflammatory response.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 2006 |
[Perioperative chemotherapy vs. surgery alone in resectable gastroesophageal carcinomas. Results of the MAGIC study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 2006 |
[Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients--a report of 43 cases].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2006 |
Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2007 |
Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2006 |
Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2007 |
Bazex syndrome (acrokeratosis paraneoplastica).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Ear, External; | 2007 |
Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Bronchi; Carcinoma, Sq | 2007 |
Left ventricular thrombus in a patient with esophageal carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Diagnosis, Differential; Esophageal Neoplasms; Fluo | 2007 |
Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Yoon-Koo Kang.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Hu | 2007 |
Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Sai-Hong Ignatius Ou and Randall F. Holcombe.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Es | 2007 |
Long-term results of chemoradiotherapy for locally advanced esophageal cancer, using daily low-dose 5-fluorouracil and cis-diammine-dichloro-platinum (CDDP).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 2007 |
[A case of carcinosarcoma of the esophagus treated by the chemoradiotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Combin | 2007 |
Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Es | 2007 |
Pretreatment with insulin enhances anticancer functions of 5-fluorouracil in human esophageal and colonic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Colonic Neo | 2007 |
Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2007 |
The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus.
Topics: Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Esophageal Neoplasms; Fluo | 2007 |
Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Sq | 2007 |
Exclusive chemoradiotherapy for patients with medically inoperable early-stage oesophageal cancer.
Topics: Cisplatin; Combined Modality Therapy; Disease Progression; Esophageal Neoplasms; Fluorouracil; Human | 2007 |
Salvage lymphadenectomy of the right recurrent nerve node with tracheal involvement after definitive chemoradiation therapy for esophageal squamous cell carcinoma: report of two cases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2007 |
XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cisplatin; | 2007 |
[A case of recurrent esophageal cancer successfully treated with concurrent radiochemotherapy with low-dose docetaxel plus 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2007 |
Comparison of pretherapeutic and posttherapeutic expression levels of chemotherapy-associated genes in adenocarcinomas of the esophagus treated by 5-fluorouracil- and cisplatin-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transport | 2007 |
Results of the 1999 2001 Japanese patterns of care study for patients receiving definitive radiation therapy without surgery for esophageal cancer.
Topics: Aged; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Combined Modality T | 2007 |
The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 2007 |
Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 2007 |
Successful treatment with low-dose capecitabine for disseminated esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progress | 2007 |
Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2007 |
Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Doce | 2007 |
[An elderly case of advanced cervical esophageal cancer successfully treated with UFT after chemoradiotherapy with docetaxel/5-FU/CDDP].
Topics: Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2007 |
[An effective treatment by chemoradiation therapy after stent insertion for advanced esophageal cancer with esophago-pulmonary fistula--report of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2007 |
Evaluation of prognostic factors of esophageal squamous cell carcinoma (stage II-III) after concurrent chemoradiotherapy using biopsy specimens.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squa | 2007 |
Metastatic esophageal adenocarcinoma presenting in the iris.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deo | 2007 |
Perfusion CT can predict the response to chemoradiation therapy and survival in esophageal squamous cell carcinoma: initial clinical results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2007 |
The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases.
Topics: Brain Diseases; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorouracil; Humans; Hypera | 2008 |
Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cape | 2007 |
Prospective cohort comparison of neoadjuvant chemoradiotherapy versus chemotherapy in patients with oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Epirubicin; | 2007 |
Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2008 |
Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2007 |
Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cispl | 2007 |
[Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Comb | 2007 |
[Cost effectiveness of chemoradiotherapy with cisplatin/fluorouracil and nedaplatin/fluorouracil for patients with esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Drug Adminis | 2007 |
Salvage esophagectomy following definitive chemoradiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Esopha | 2007 |
Concurrent chemoradiotherapy or endoscopic stenting for advanced squamous cell carcinoma of esophagus: a case-control study.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Co | 2008 |
[A case of thoracic esophageal cancer with invasion of the main bronchus in which long-term survival with high quality of life was achieved through chemoradiotherapy, esophageal bypass and then additional chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Cisplatin; Combined Modality Th | 2007 |
Visualisation of metastatic oesophageal and gastric cancer and prediction of clinical response to palliative chemotherapy using 18FDG PET.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Female; Fluorodeo | 2007 |
A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cisplatin; Combined Modality T | 2007 |
Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dihydrouracil Dehy | 2008 |
Selection of a novel drug-response predictor in esophageal cancer: a novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response.
Topics: Antigens, Differentiation; Antineoplastic Agents; Biomarkers, Tumor; Chemistry, Pharmaceutical; Cisp | 2008 |
Concurrent chemoradiotherapy for esophageal cancer with malignant fistula.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2008 |
Scoring system for predicting response to chemoradiotherapy, including 5-Fluorouracil and platinum, for patients with esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2008 |
Changes in antioxidant defense status in response to cisplatin and 5-FU in esophageal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antioxidants; Cisplatin; Esopha | 2008 |
Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Dose-Response Relationship | 2008 |
[Evaluation of efficacy and influence factors of transarterial interventional therapy in patients with liver metastasis from malignancy of alimentary tract].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, T | 2007 |
[A case of advanced esophageal cancer with large liver metastasis successfully treated with FAP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Esophageal Neoplasms; | 2008 |
[Complete response in a case of advanced esophageal cancer treated with docetaxel/5-FU/CDDPand S-1/docetaxel as neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Esophageal | 2008 |
Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2008 |
Adjuvant chemotherapy of cisplatin, 5-fluorouracil and leucovorin for complete resectable esophageal cancer: a case-matched cohort study in east China.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China; Cisplati | 2008 |
Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Stu | 2008 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Drug Costs; | 2008 |
A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Dr | 2008 |
Correlation between pretherapeutic d-dimer levels and response to neoadjuvant chemotherapy in patients with advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Doxorubicin; Esophageal Neoplasms; Female; Fibrin Fib | 2008 |
A pilot study of combined radiotherapy and chemotherapy for esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neoplasm | 1984 |
[Chemotherapy of esophageal cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorub | 1984 |
Infusional 5-fluorouracil and X-ray therapy for non-resectable esophageal cancer.
Topics: Bone Marrow; Drug Tolerance; Esophageal Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Male | 1980 |
Multidisciplinary treatment for esophageal carcinoma.
Topics: Adult; Age Factors; Aged; Bleomycin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middl | 1983 |
[Asymptomatic electrocardiographic abnormalities during antiblastic chemotherapy].
Topics: Aged; Antineoplastic Agents; Arrhythmias, Cardiac; Breast Neoplasms; Cardiac Complexes, Premature; C | 1983 |
Combined modality therapy for esophageal squamous cell carcinoma.
Topics: Abdomen; Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Esophageal Neoplasms; Eso | 1983 |
Combined preoperative chemotherapy and radiation therapy for cancer of the esophagus: the Wayne State University, Southwest Oncology group and Radiation Therapy Oncology Group experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1984 |
[Cooperative phase II study of releasing tegafur (SF-SP) against advanced digestive cancers].
Topics: Administration, Oral; Adult; Aged; Colonic Neoplasms; Delayed-Action Preparations; Digestive System | 1984 |
Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1984 |
Multimodality approach to treatment of carcinoma of the esophagus.
Topics: Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; | 1984 |
Fluorouracil (F), Adriamycin (A), and cisplatin (P) (FAP): combination chemotherapy of advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 1983 |
Correlation between the level of urinary D-glucaric acid and the degree of activation of masked compound (FT-207) in cancer patients.
Topics: Adult; Aged; Biotransformation; Cytochrome P-450 Enzyme System; Esophageal Neoplasms; Female; Fluoro | 1981 |
[A case of inoperable esophageal carcinoma responding to adriamycin and FT 207 suppository for more than one year (author's transl)].
Topics: Aged; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, Combination; Esophageal Neoplasms; Female | 1981 |
Chemotherapy of carcinomas of the digestive tract.
Topics: Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Esop | 1982 |
[Treatment of advanced epidermoid carcinoma of the oesophagus with combined 5-fluorouracil, adriamycin and cis-platinum (FAP)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 1982 |
Chemotherapy in gastric and oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, Combinat | 1982 |
Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sch | 1982 |
Eradication and palliation of squamous cell carcinoma of the esophagus with chemotherapy, radiotherapy, and surgical therapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagus; Femal | 1981 |
[Treatment of marked epithelial dysplasia of esophagus. II. Microspectophotometric studies on DNA content in epithelial cells of esophagus treated with antitumor B III or tilorone (author's transl)].
Topics: Antineoplastic Agents, Phytogenic; DNA, Neoplasm; Drug Combinations; Drugs, Chinese Herbal; Epitheli | 1981 |
[Therapy of severe epithelial dysplasia of esophagus. I. Therapeutic effects of Antitumor B III, Antitumor B and tilorone (author's transl)].
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Drug Combinations; Drugs, Chinese Herbal; Esophag | 1980 |
Chemotherapy for gastrointestinal malignancy.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Esophageal Neoplasms; Fluoroura | 1980 |
[A case of advanced esophageal cancer made resectable by preoperative combination therapy with 5-FU and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Mo | 1995 |
[Nursing care of esophageal carcinoma treated by local chemotherapy injection and microwave local heating].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1993 |
[Establishment and application of transplantable models of human esophageal carcinoma in nude mice].
Topics: Animals; Bleomycin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Disease Models, Animal; Esop | 1993 |
Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma. The MRC Gastric Cancer Working Party and the British Stomach Cancer Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Esophageal Neoplasms; Fluorou | 1995 |
Pre-operative induction chemotherapy for small cell carcinoma of the oesophagus: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality | 1995 |
Combined radiochemotherapy for postoperative recurrence of oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1995 |
Radiotherapy alone compared with radiotherapy and chemotherapy in patients with squamous cell carcinoma of the esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1995 |
[Preoperative neoadjuvant chemotherapy with a combination of 5-fluorouracil, adriamycin and cisplatin (FAP) for advanced esophageal cancer invading trachea or main bronchus].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Chemotherapy, Adjuvant; C | 1995 |
[A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1995 |
[The experience of concurrent radiotherapy and chemotherapy for advanced or recurrent esophageal cancers--continuous infusion of 5-FU and low dose cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 1995 |
Cytomegalovirus enteritis after treatment with 5-fluorouracil, leukovorin, cisplatin, and alpha-interferon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytomegalovirus Infections; Enteritis; Es | 1995 |
Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1995 |
[Postoperative abdominal lymph node recurrence of intrathoracic esophageal cancer with a long-term complete response to radiation and split CF therapy (CDDP and 5-FU)--a case report].
Topics: Abdomen; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esoph | 1995 |
The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line; Cisplatin; DNA Damage; Esophageal Neop | 1995 |
[Clinicopathological evaluation of high-range hyperthermia for advanced thoracic esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Esophageal Neoplasms; Female; | 1993 |
Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
Multimodality therapy for adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1995 |
[Cisplatin, 5-fluorouracil and leucovorin combination chemotherapy-added radiation therapy for advanced esophageal cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Esophageal | 1995 |
5-Fluorouracil, adriamycin, and mitomycin C in adenocarcinoma of the esophagus or gastroesophageal junction tumors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Esophageal | 1994 |
Patterns of failure in carcinoma of the upper esophagus after alternating chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1994 |
Evolution of treatment strategies for adenocarcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 1994 |
[Concomitant radiotherapy and chemotherapy with protracted low dose continuous infusion of 5-fluorouracil and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1994 |
[Neoadjuvant chemoradiotherapy in esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
[Cancer of the cervical esophagus: integrated therapy and surgical treatment].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; E | 1994 |
Chemoradiotherapy of esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1994 |
Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens.
Topics: Carboplatin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Drug Evaluation; Drug Stabi | 1994 |
[Histopathological criteria for the effects of neoadjuvant chemotherapy for carcinoma of the esophagus--comparison of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Admini | 1994 |
Concurrent radiotherapy and continuous 5-fluorouracil infusion in the management of locally advanced esophageal cancer.
Topics: Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenou | 1993 |
[Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1993 |
[Nocturnal infusion of 5-fluorouracil in advanced digestive tract cancer--two case reports].
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Circadian Rhythm; Drug Administration Schedule; Eso | 1994 |
[Results of preoperative radio-chemotherapy in locally advanced squamous epithelial cancer of the esophagus].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1993 |
Small cell carcinoma of the esophagus with an esophago-mediastinal fistula successfully treated by chemoradiation therapy and intubation: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cobalt Radioisotop | 1993 |
[Multidisciplinary treatment of cancer of the esophagus].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 1993 |
[Multimodality treatment of thoracic esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 1993 |
[Multimodality treatment of esophageal carcinoma: evaluation of preoperative (neoadjuvant) chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1993 |
[A case of nonresectable esophageal cancer treated by the combination of cisplatin, 5-fluorouracil and THP-adriamycin].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1993 |
[Clinical efficacy of cis-diamminedichloroplatinum [II] and 5-fluorouracil (UFT) in advanced cancer of the alimentary tract].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1993 |
Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemothera | 1993 |
Preoperative chemotherapy and radiotherapy for cancer of the esophagus.
Topics: Adult; Aged; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Human | 1993 |
[A case report of an advanced esophageal carcinoma treated by neoadjuvant chemotherapy (CDDP + 5-FU) and evaluation of effect on metastatic lymph nodes].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1993 |
Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1993 |
High dose rate intraluminal radiation in a combined modality treatment plan for carcinoma of the esophagus.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous C | 1993 |
Long-term follow-up of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and possible postoperative radiotherapy and/or chemotherapy in squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1993 |
Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1993 |
Irradiation of carcinoma of the esophagus containing a tracheoesophageal fistula.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1993 |
[A case of advanced esophageal cancer showing good partial response by combination therapy of low dose 5-FU and low dose CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Cisplatin; Drug Admi | 1996 |
Prolonged survival follows resection of oesophageal SCC downstaged by prior chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1996 |
Management for patients with advanced T4 epidermoid carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1996 |
Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 1996 |
Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
[A case report of small cell carcinoma of the esophagus with remarkable response to neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cispl | 1996 |
[CF/5-FU-DDP therapy for esophageal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Es | 1995 |
[Radiotherapy of inoperable esophageal cancer. Retrospective analysis apropos of 108 cases].
Topics: Actuarial Analysis; Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplast | 1990 |
5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Drug Therapy, Combination; | 1996 |
Paradoxical clinical deterioration despite near-complete pathological response to neoadjuvant chemotherapy for locally advanced gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1995 |
[Effective combined injection method of fluoropyrimidine and platinum--application for advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Cisplatin; Doxoru | 1996 |
Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Esophageal Neoplasms; Fluorouracil; Gas Chromatography-Mass Sp | 1997 |
[Preoperative synchronized chemoradiation therapy for advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 1997 |
[A case of advanced esophageal cancer successfully treated by concurrent use of radiotherapy and low-dose CDDP and continuous infusion of 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1997 |
Carcinoma of the esophagus treated with radical chemoradiation 19 years after irradiation for recurrent breast cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamou | 1997 |
[Inoperable esophageal carcinoma managed by combined chemotherapy (CBDCA, 5-FU and VDS) and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Catheterization; Combined Modalit | 1997 |
Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1997 |
[Split-course concomitant radiochemotherapy plus surgery vs. surgery alone in squamous cell carcinoma of the esophagus. A non-randomized retrospective study of 184 patients].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1997 |
Esophageal intramural pseudodiverticulosis with esophageal cancer improved by target rotation irradiation: case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1997 |
Accelerated fractionation in esophageal cancers: a multivariate analysis on 88 patients.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemothera | 1997 |
Multimodality treatment in the management of esophageal cancer: neoadjuvant chemoradiotherapy followed by transhiatal esophagectomy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemothera | 1997 |
[A case of local advanced cervical esophageal cancer treated with concurrent radiochemotherapy followed by surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1997 |
[A case of far-advanced gastric cancer treated with continuous 5-fluorouracil injection and intrahepatic arterial infusion of low-dose cisplatin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasm | 1997 |
Neoadjuvant chemotherapy followed by concurrent chemotherapy and radiotherapy for locally advanced esophageal carcinoma with bulky upper abdominal lymphadenopathy. Case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neopla | 1997 |
Clinical results of treatment of advanced esophageal carcinoma with hyperthermia in combination with chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 1997 |
Surgical treatment for carcinoma of the thoracic esophagus with major involvement in the neck or upper mediastinum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neo | 1998 |
[Epidermoid cancer of the esophagus: role of radiotherapy and chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1998 |
[A case report of esophageal carcinoma with grade 3 response by preoperative chemotherapy using CDDP/5-FU/LV].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1998 |
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Dih | 1998 |
[A case of left main bronchus obstruction due to recurrent esophageal cancer successfully treated by Nd-YAG laser followed by radiotherapy, low-dose CDDP and continuous infusion of 5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Diseases; Bronchial Neoplasms; Carcinoma, | 1998 |
Pre-operative sequential chemo- and radiochemotherapy in locally advanced carcinomas of the lower oesophagus and gastro-oesophageal junction.
Topics: Adenocarcinoma; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1998 |
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcino | 1998 |
Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma.
Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, A | 1998 |
[Probable choroid metastasis of an esophageal adenocarcinoma that regressed with chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Choroid Neoplasms; Cisplatin; | 1998 |
[Adenocarcinoma of the Barrett esophagus. Apropos of 44 resected cases].
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; | 1997 |
[A case of stage IV (N4) esophageal cancer successfully treated with concurrent chemoradiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophage | 1998 |
Nedaplatin and 5-FU combined with radiation in the treatment for esophageal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 1998 |
Neurological complications of 5-fluorouracil chemotherapy: case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Brain; Bulbar Palsy, Progressive; Colonic Neoplasms; Esophageal Neo | 1998 |
Complete response of esophageal cancer achieved by combination therapy with 5-fluorouracil, low-dose cisplatin, and radiation: report of a case.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 1998 |
Supraventricular arrhythmia: a complication of 5-fluorouracil therapy.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atr | 1998 |
Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 1999 |
[Treatment with 5-FU modulated by low-dose CDDP for advanced cancers and recurrent cases of metastasis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic N | 1999 |
Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1999 |
A comparison of conventional and conformal radiotherapy of the oesophagus: work in progress.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Esophageal Neoplasms; Feasibility Studies; Fluorouracil; | 1998 |
Complete regression of recurrent esophageal carcinoma with reduced expression of glutathione S-transferase-pi by treatment with continuous infusion of 5-fluorouracil and low-dose cisplatin infusion.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1999 |
Role of preoperative chemoradiation in the management of upper third thoracic esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1999 |
[A case report of esophageal small cell carcinoma responding well to chemotherapy of 5-FU and cisplatin combined with radiotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 1999 |
Neoadjuvant chemotherapy before surgery for resectable carcinoma of the lower esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 1999 |
[Chemoradiation therapy for advanced esophageal cancers--report of 3 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1999 |
[Usefulness of combination therapy with expandable metallic stent replacement and FLEP chemotherapy (consisting of 5-FU, leucovorin, etoposide and cisplatin) for advanced esophageal cancer invading the bronchus: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cispl | 1999 |
Preoperative chemotherapy for advanced esophageal cancer and relation with histological effect.
Topics: Actuarial Analysis; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Agen | 1999 |
High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 1999 |
Comparison between chemoradiation protocol intended for organ preservation and conventional surgery for clinical T1-T2 esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cause of Death; Cisp | 1999 |
The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1999 |
Causes for increased myelosuppression with increasing age in patients with oesophageal cancer treated by chemoradiotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplat | 1999 |
Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
[Chemotherapy and surgery compared to surgery alone in localized cancer of the esophagus].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1999 |
[Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1999 |
[Palliative chemo-radiotherapy for abdominal recurrence of esophageal carcinoma--case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 1999 |
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
[Curative treatment of non-metastatic esophageal cancer: concomitant chemoradiotherapy and high-dose-rate endoluminal curietherapy boost].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 1999 |
Current trends in the surgical treatment of esophageal and cardia adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cardia; Chemother | 1999 |
Analysis of postoperative complications after esophagectomy for esophageal cancer in patients receiving neoadjuvant therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophagectomy; Fluo | 1999 |
[Effective and low toxicity chemoradiotherapy for distant metastatic esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 1999 |
[A case of stage IV esophageal cancer successfully treated by chemoradiation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Fluorouracil; Human | 1999 |
[A case of stage IV (A3) cervical and upper thoracic esophageal adenocarcinoma successfully treated with concurrent chemoradiotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1999 |
Fluorouracil-induced neurotoxicity.
Topics: Aged; Antimetabolites, Antineoplastic; Ataxia; Confusion; Esophageal Neoplasms; Fluorouracil; Humans | 2000 |
Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2000 |
Primary chemo-radiotherapy and selective oesophagectomy for oesophageal cancer: goal of cure with organ preservation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2000 |
[Palliative surgical treatment of thoracic esophageal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 1999 |
Induction chemotherapy followed by concurrent chemotherapy and high-dose radiotherapy for locally advanced squamous cell carcinoma of the upper-thoracic and midthoracic esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell | 2000 |
Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Bone Marrow; Bon | 2000 |
[A case of advanced esophageal carcinoma successfully treated with chemoradiation therapy with low-dose cisplatin and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2000 |
Feasibility of daily concurrent chemoradiation therapy as nonsurgical management for esophageal cancer: our experience and theoretical background.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose Fractionation, Radiation; Drug | 2000 |
Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; | 2000 |
[Hepatic arterial infusion chemotherapy for liver metastasis from esophageal squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2000 |
A case of inoperable esophageal carcinoma with hepatic and nodal metastases which showed a long-term survival after chemoradiotherapy including nedaplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu | 2000 |
Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2000 |
CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers.
Topics: Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Squamous Cell; cdc25 Phosphatases; Cell Cycle; C | 2000 |
Impact on survival of surgery after concomitant chemoradiotherapy for locally advanced cancers of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; E | 2001 |
Assessment of the predictive value of clinical and histopathological factors as well as the immunoexpression of p53 and bcl-2 proteins in response to preoperative chemotherapy for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2000 |
Late esophageal toxicity using a combination of external beam radiation, intraluminal brachytherapy and 5-fluorouracil infusion in carcinoma of the esophagus.
Topics: Brachytherapy; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagus; Female; Fluorouracil; Huma | 2000 |
Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Esophageal Neo | 2001 |
[Chemotherapy with cisplatinum, carboplatin and 5FU-folinic acid, followed by concomitant chemo-radiotherapy in unresectable esophageal carcinomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modali | 2001 |
The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Bindin | 2001 |
Localized squamous-cell cancer of the esophagus: retrospective analysis of three treatment schedules.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cause of Death; Cisplatin; | 2001 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Com | 2001 |
Pretreatment surgical lymph node staging predicts results of trimodality therapy in esophageal cancer.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Moda | 2001 |
The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Mo | 2001 |
[A case of esophageal carcinoma with multiple liver metastases successfully treated with nedaplatin (NDP) and 5-fluorouracil (5-FU) combined with radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration | 2001 |
Does neoadjuvant chemoradiation downstage esophageal carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2001 |
Neoadjuvant radio-chemotherapy of adenocarcinoma of the oesophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2001 |
[Neoadjuvant treatment in surgery of esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2000 |
Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer.
Topics: Aged; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squa | 2001 |
Second primary cardiac B-cell lymphoma after radiation therapy and chemotherapy--a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cisp | 2001 |
Esophagectomy and hepatic arterial chemotherapy following hepatic resection for esophageal cancer with liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neo | 2001 |
Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal | 2001 |
[Chemoradiotherapy and salvage surgery in a patient with advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administra | 2001 |
[Tissue platinum distribution and the effect following intra-arterial injection of cisplatin to metastatic liver cancer--a case report].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2001 |
Squamous cell carcinoma of the oesophagus treated with radiation and 5-fluorouracil, with and without mitomycin C.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as T | 2001 |
5-fluorouracil-induced balanitis in a patient with oesophageal carcinoma.
Topics: Antimetabolites, Antineoplastic; Balanitis; Carcinoma; Esophageal Neoplasms; Fluorouracil; Humans; M | 2001 |
[Hyperfractionated radiation therapy and concurrent continuous cisplatin/5-fluorouracil chemotherapy for esophageal cancer--preliminary experience].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose Fractionati | 2001 |
A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2001 |
Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene increases the sensitivity of esophageal cancer cells to 5-fluorouracil.
Topics: Adenoviridae; Animals; Drug Synergism; Escherichia coli; Esophageal Neoplasms; Fluorouracil; Mice; M | 2001 |
Endoscopic Nd:YAG laser therapy combined with local chemotherapy of superficial carcinomas of the oesophagus and gastric cardia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardia; Combined Modality Th | 2001 |
[Immunohistochemical study of dihydropyrimidine dehydrogenase (DPD) and p53 in biopsied specimens of esophageal cancer before chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Dihydrouracil Dehydrogenase (NADP | 2001 |
[Significant role of cisplatin and 5-FU combination chemotherapy for first-line intensive treatment for advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2001 |
[A case of postoperative multiple hepatic metastasis from esophageal cancer successfully treated by surgical resection and hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2001 |
[A patient with esophageal cancer with subcutaneal abscess and esophago-tracheal fistula who survived more than 2 years following treatment by drainage and chemoradiation therapy].
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Draina | 2001 |
[Severe interstitial pneumopathy due to herpes virus after radiochemotherapy for esophageal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2001 |
Spontaneous and inducible apoptosis in oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cisplatin; Combined | 2001 |
Telomerase activity in esophageal squamous cell carcinoma: down-regulation by chemotherapeutic agent.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Case-Control Studies; DNA-Binding P | 2002 |
[Cisplatin plus 5-fluorouracil combination therapy in the treatment of advanced esophageal cancer: a report of 156 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female | 1999 |
Larynx-preserving pharyngo-esophagectomy after chemoradiation in the treatment of cancer of the pharyngo-esophageal junction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dose Fractio | 2001 |
[Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Combined Modality | 2001 |
Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Cisplatin; Combined Modality Therapy; Cyclin D1; Dihydrouracil Dehyd | 2002 |
[A complete response after neoadjuvant chemotherapy for advanced gastric cancer with esophageal invasion].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dihydrouracil Dehydrogenase (NADP); | 2002 |
Surgical and oncological advances in the treatment of esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bleomycin; Cisplatin; Combined Moda | 2002 |
Bi-modality (chemo-radiation) versus tri-modality (chemo-radiation followed by surgery) treatment for carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; Chi-Sq | 2001 |
Advanced esophageal cancer with esophago-bronchial fistula successfully treated by chemoradiation therapy with additional endoscopic resection: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Fistula; Carcinoma, Squamous Cell; Cisplat | 2002 |
Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Esophageal Neoplasms; Fluorou | 2002 |
Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2002 |
Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2002 |
A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, S | 2002 |
Esophageal carcinoma. The value of staging in long-term survival.
Topics: Administration, Oral; Cyclophosphamide; Esophageal Neoplasms; Esophagus; Female; Fluorouracil; Follo | 1975 |
Combined treatment with by-pass operation, irradiation and immunochemotherapy for advanced thoracic esophageal cancer.
Topics: Adult; Aged; Bleomycin; Drug Therapy, Combination; Esophageal Neoplasms; Esophagoplasty; Fluorouraci | 1979 |
[Chemotherapy for digestive carcinomas. Results of a phase II clinical trial (author's transl)].
Topics: Bile Duct Neoplasms; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Esophageal Neopl | 1979 |
Recent trends in chemotherapy of solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Breast Neopl | 1975 |
Walter Hubert lecture Chemotherapy of upper gastrointestinal carcinoma.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, S | 1976 |
The screening test of various chemotherapeutic drugs in primary malignant melanoma cells and human malignant melanoma cell line (TM-1).
Topics: Aged; Antineoplastic Agents; Cell Line; Cells, Cultured; Dactinomycin; Drug Evaluation, Preclinical; | 1979 |
[Experiences with radiotherapy of malignant tumors in the head-neck-esophagus area using the synchronization effect of 5-FU].
Topics: Esophageal Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans; Remission, Spontaneous | 1978 |
[Critical reflections to the problem of timing in the synchronization therapy of human malignant tumors. Mitotic-index determination, cytophotometric and radioautographic studies (author's transl)].
Topics: Autoradiography; Cell Division; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Hu | 1977 |
[Contribution to the radiation therapy of malignant tumors in the regions of the head and neck using the synchronization effects of fluorouracil (author's transl)].
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal | 1978 |
Synergistic combination therapy of 5-fluorouracil, vitamin A and cobalt-60 radiation upon head and neck tumors.
Topics: Cobalt Radioisotopes; Drug Therapy, Combination; Esophageal Neoplasms; Fluorouracil; Head and Neck N | 1978 |
["MFC" therapy for advanced gastrointestinal cancer (author's transl)].
Topics: Cytarabine; Drug Therapy, Combination; Esophageal Neoplasms; Fluorouracil; Gastrointestinal Neoplasm | 1975 |
[Intra-arterial infusion chemotherapy for recurrent cervical lymph nodes after surgery in esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug | 1992 |
Neoadjuvant chemotherapy in multiple synchronous head and neck and esophagus squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchial Neoplasms; Carcinoma, Squamous | 1992 |
[The percutaneous-endocavitary irradiation of esophageal carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; Cisplatin; Combined Modali | 1992 |
[A case of locally advanced esophageal cancer effectively treated with concurrent chemotherapy and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1992 |
Preoperative chemotherapy for cancer of the oesophagus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neopla | 1992 |
[Experimental study of biochemical modulation of 5-fluorouracil with l-leucovorin against human esophageal cancer].
Topics: Colonic Neoplasms; Drug Screening Assays, Antitumor; Drug Synergism; Esophageal Neoplasms; Fluoroura | 1992 |
Curative non-surgical combined treatment of squamous cell carcinoma of the oesophagus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1992 |
Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1992 |
The pre-operative treatment of oesophageal carcinoma with synchronously administered chemotherapy and radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1992 |
[Chemotherapy-associated hemolytic uremic syndrome--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1992 |
Prolonged chemotherapy for localised squamous carcinoma of the oesophagus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Role of chemotherapy in oesophageal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
[Radio-chemotherapy combination in cancer of the esophagus. The radiotherapist's point of view].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neoplasms; Flu | 1992 |
[Pharmacokinetic studies on fluorinated pyrimidine in cancer cell and tissue].
Topics: Animals; Carcinoma, Ehrlich Tumor; Colonic Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Gl | 1992 |
[Predictive factors of response to chemotherapy in epidermoid cancer of the esophagus. Study apropos of 60 patients and evaluation of a response score].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1992 |
[Analysis of cellular DNA content by flow cytometry in epidermoid carcinoma of the esophagus].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cispl | 1992 |
Preoperative chemotherapy and radiotherapy for esophageal carcinoma.
Topics: Actuarial Analysis; Adenocarcinoma; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Com | 1992 |
[Treatment of advanced cancer of the alimentary tract with cisplatin and 5-fluorouracil (UFT)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Administration Sc | 1992 |
Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery .
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1992 |
[Comparative evaluation of radiotherapy and chemoradiotherapy in inoperable cancer of the esophagus].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1990 |
[Evaluation of multidisciplinary treatment involving chemotherapy with cis-diamminedichloroplatinum, bleomycin (peplomycin) and 5-fluorouracil for advanced esophageal carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1990 |
Subrenal capsule assay as a chemosensitivity test for primary esophageal squamous cell carcinoma.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; | 1991 |
Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 1991 |
[The combined radio-chemotherapy of inoperable esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1990 |
Cisplatin and 5-FU combined with radiotherapy and surgery in the treatment of squamous cell carcinoma of the esophagus. Palliative effects and tumor response.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1991 |
[Clinico-pathological studies on the effects of preoperative hyperthermo-chemoradiotherapy of advanced esophageal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1991 |
Concurrent preoperative chemotherapy and radiation therapy in localized esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; | 1992 |
A phase II study of 5-fluorouracil, adriamycin and mitomycin-C in adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dox | 1991 |
Preoperative concurrent chemotherapy and radiotherapy for local-regional and advanced squamous cell carcinoma of the thoracic oesophagus: preliminary results of a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1991 |
[Regional immunochemotherapy for liver metastasis of esophageal cancer in a patient with variant hepatic artery].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1991 |
[Study of intermittent intra-arterial infusion chemotherapy in liver metastases from squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doxorubic | 1991 |
Chemo-irradiation induced aortoesophageal fistula.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Aortic Diseases; Cisplatin; Combine | 1991 |
A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1991 |
Chemosensitivity correlation between the primary tumors and simultaneous metastatic lymph nodes of patients evaluated by DNA synthesis inhibition assay.
Topics: Breast Neoplasms; Carbazilquinone; Cisplatin; Colorectal Neoplasms; DNA, Neoplasm; Doxorubicin; Drug | 1990 |
[Clinical studies of in vitro chemosensitivity test evaluated by ATP assay of gastrointestinal cancer].
Topics: Adenosine Triphosphate; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Scree | 1990 |
[A case of esophageal carcinoma with the lung and liver metastases surviving more than 3 years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Cell; Ci | 1990 |
Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin.
Topics: Arrhythmias, Cardiac; Carcinoma, Squamous Cell; Chest Pain; Cisplatin; Electrocardiography; Esophage | 1990 |
Intramural myocardial infarction under combined radiochemotherapy of an oesophageal carcinoma.
Topics: Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; | 1990 |
Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1990 |
[Endoscopic laser recanalization in the chemo- and radiotherapy of stenosing cancer of the esophagus].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Esophageal Neoplasms; Esophageal | 1990 |
Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; F | 1990 |
[Intratumoral administration of 5-fluorouracil and bleomycin in inoperable cancer of the cardioesophageal region].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cardia; Combined Modality Th | 1985 |
Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1986 |
[A study of sensitivity to anticancer agents in esophageal cancer].
Topics: Animals; Bleomycin; Cisplatin; Colony-Forming Units Assay; Esophageal Neoplasms; Fluorouracil; Human | 1986 |
Nonoperative therapy for squamous-cell cancer of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1987 |
Inoperable esophageal carcinoma: results of aggressive synchronous radiotherapy and chemotherapy. A pilot study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1987 |
Nonsurgical management of esophageal cancer: report of a study of combined radiotherapy and chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1987 |
Concomitant 5-fluorouracil infusion, mitomycin C and radical radiation therapy in esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; | 1989 |
Cisplatin, 5-fluorouracil, mitomycin C, and concurrent radiation therapy with and without esophogectomy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1989 |
[120-hour continuous 5-FU infusion and cisplatin in the treatment of advanced esophageal carcinoma--clinical analysis of 19 cases].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1989 |
Neoadjuvant therapy of squamous cell carcinoma of the esophagus: role of resection and benefit in partial responders.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
[5-FU intra-arterial infusion and simultaneous irradiation in the treatment of esophageal cancer and metastatic lung cancer].
Topics: Adult; Aorta, Thoracic; Combined Modality Therapy; Esophageal Neoplasms; Esophagus; Female; Fluorour | 1989 |
Ischaemic pancolitis: a serious complication of chemotherapy in a previously irradiated patient. Case report.
Topics: Carcinoma, Squamous Cell; Cisplatin; Colitis; Combined Modality Therapy; Dysgerminoma; Esophageal Ne | 1989 |
[Observations on 32 cases of advanced carcinoma of the esophagus and the proventriculus treated by the MOF III plan in combination with fu zheng kang ai tang].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cardia; Esoph | 1985 |
Watery diarrhea-hypokalemia-achlorhydria syndrome and carcinoma of the esophagus.
Topics: Achlorhydria; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; | 1985 |
Adenoid cystic carcinoma of the esophagus. Complete response to combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Adenoid Cystic; Cisplati | 1986 |
Clinical evidence of feasibility and efficacy of simultaneous irradiation and chemotherapy in advanced squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinom | 1986 |
Prediction of individual tumor chemosensitivity in subrenal capsule assay.
Topics: Animals; Antineoplastic Agents; Cisplatin; Colony-Forming Units Assay; Cyclophosphamide; Doxorubicin | 1986 |
Esophageal carcinoma: modest benefits from combined modality therapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1987 |
Preliminary experience with a combined-modality approach to the management of oesophageal cancer.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1988 |
[Simultaneous radio- and chemotherapy of squamous cell carcinoma of the esophagus].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1988 |
Chemo/radiation with and without surgery in the thoracic esophagus: the Wayne State experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1988 |
Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac | 1988 |
[Inhibition of thymidylate synthetase and antiproliferative effect by 1-hexylcarbamoyl-5-fluorouracil].
Topics: Animals; Antineoplastic Agents; Cell Division; Esophageal Neoplasms; Fluorouracil; Mice; Mice, Inbre | 1988 |
Respiratory tract fistulae in recurrent aerodigestive cancers after chemotherapy.
Topics: Bronchial Fistula; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Etoposide; Fluorouraci | 1988 |
Preoperative radiation and chemotherapy for localized squamous cell carcinoma of the esophagus: a RTOG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1988 |
Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Eso | 1988 |
[Chemotherapy of esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neo | 1988 |
Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1988 |
[Epidermoid cancers of the esophagus: combined chemotherapy, surgery and radiotherapy. Preliminary results in 50 cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1988 |
Systemic chemotherapy with cisplatin, 5-fluorouracil and allopurinol in the management of advanced epidermoid esophageal cancer.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1988 |
Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1987 |
Acute myelocytic leukemia following radiation and chemotherapy for esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therap | 1987 |
Cisplatin, high dose folinic acid and 5-fluorouracil in squamous cell carcinoma of the esophagus. A pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 1987 |
Sequential infusional 5-fluorouracil followed by concomitant radiation for tumors of the esophagus and gastroesophageal junction.
Topics: Aged; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Stomach N | 1987 |
Comparison of three treatment strategies for esophageal cancer within a single institution.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1987 |
[A case of esophageal cancer of superficial depressive type in an advanced age successfully treated with HCFU].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluo | 1987 |
[Radiochemotherapy of inoperable esophageal cancer with 5-FU infusions].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil | 1987 |
Preoperative chemotherapy followed by surgery with possible postoperative radiotherapy in squamous cell carcinoma of the esophagus: evaluation of the chemotherapy component.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1986 |
[Multidisciplinary treatment of the head and neck cancer--FAR therapy and its modification and application].
Topics: Adult; Aged; Combined Modality Therapy; Drug Resistance; Drug Therapy, Combination; Esophageal Neopl | 1986 |
[Comparison of in vitro assays for the cytotoxic effect of anticancer drugs].
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Count; Cell Line; Colony-Forming Units Assay; Diterpenes | 1986 |
Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
The use of 5-FU in treating advanced esophageal carcinoma.
Topics: Adult; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Ag | 1986 |
Synergistic combination therapy of 5-fluorouracil, vitamin A, and cobalt-60 radiation for head and neck tumors--antitumor combination therapy with vitamin A.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cobalt Radioisotopes; Combined Modality | 1985 |
Chemoradiation therapy and resection for carcinoma of the esophagus: short-term results.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 1985 |
Combined treatment approach in surgical management of carcinoma of the esophagus: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1985 |
Radical radiation therapy with 5-fluorouracil infusion and mitomycin C for oesophageal squamous carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1985 |
Esophageal carcinoma.
Topics: Adult; Aged; Alkylating Agents; Carcinoma, Squamous Cell; Diagnosis, Differential; Esophageal Neopla | 1972 |
[Esophageal tumors--therapeutic problems].
Topics: Adenocarcinoma; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cobalt Isotopes; Esophageal Neoplasm | 1972 |
Value of cytotoxic infusion in dyspnoea and dysphagia due to cancer.
Topics: Antineoplastic Agents; Cyclophosphamide; Deglutition Disorders; Dyspnea; Esophageal Neoplasms; Fluor | 1973 |
[Comparison of several different methods of antiblastic therapy in advanced carcinomas of the digestive system].
Topics: Antineoplastic Agents; Bleomycin; Cyclophosphamide; Drug Therapy, Combination; Esophageal Neoplasms; | 1974 |
The roles of radiotherapy and cytotoxic drugs in the management of carcinoma of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Esophageal Neoplas | 1973 |
[Palliative radiotherapy of cancer in the Karl Bremer Hospital, 1963-1968].
Topics: Black People; Cobalt Isotopes; Colonic Neoplasms; Esophageal Neoplasms; Fluorouracil; Humans; Neopla | 1969 |
Chemotherapy of gastrointestinal cancer.
Topics: Antineoplastic Agents; Colonic Neoplasms; Esophageal Neoplasms; Floxuridine; Fluorouracil; Gastroint | 1972 |
[Characteristics of the cell mitotic cycle and the possibility of enhancing the effect of radiotherapy].
Topics: Animals; Cell Survival; Cells, Cultured; Chromosome Aberrations; Deoxyuridine; DNA, Neoplasm; Esopha | 1974 |
[Antibodies to sarcolysine and 5-fluorouracil].
Topics: Animals; Antibody Formation; Basophils; Cross Reactions; Dysgerminoma; Erythrocytes; Esophageal Neop | 1974 |
[The reactivity of the RES in cancer of the gastrointestinal tract and during treatment with fluorofur].
Topics: Achlorhydria; Adult; Aged; Colonic Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Furans; Go | 1972 |
[Graphic assessment of esophageal cancer regression].
Topics: Carcinoma, Squamous Cell; Colchicine; Esophageal Neoplasms; Fluorouracil; Humans; Mathematics; Metho | 1972 |
[Serum complement activity of oncologic patients].
Topics: Complement System Proteins; Esophageal Neoplasms; Fluorouracil; Humans; Immunologic Deficiency Syndr | 1973 |
[Effects of 5-FU (5-fluorouracil) in 4.3MeV Linac x-ray treatment of advanced cancer].
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fl | 1968 |
Combined parenteral hyperalimentation and chemotherapy in the treatment of disseminated solid tumors.
Topics: Amino Acids; Analgesics; Appetite; Body Weight; Breast Neoplasms; Carcinoid Tumor; Colonic Neoplasms | 1971 |
Chemotherapy as the definitive form of therapy in esophageal carcinoma.
Topics: Anemia, Hypochromic; Anti-Bacterial Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Esophageal N | 1972 |
[The functional state of the liver during conservative treatment of oncologic patients].
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Esophageal Neoplasms; Fluorouracil; H | 1972 |
[Possibilities of treating cancer relapse after proximal gastric resection and gastrectomy].
Topics: Esophageal Neoplasms; Fluorouracil; Gastrectomy; Gastroenterostomy; Humans; Stomach Neoplasms | 1969 |
Esophageal metastases and dysphagia in patients with carcinoma of the breast.
Topics: Adrenalectomy; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Deglutition Disorders; Dilatation; E | 1969 |
[Combined drug and radiation therapy with cancer of the esophagus].
Topics: Colchicine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Radiotherapy Dosa | 1970 |
Combined intra-arterial infusion and radiotherapy for the treatment of advanced cancer of the head and neck.
Topics: Aged; Brain Neoplasms; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorouracil; Follow-Up Studi | 1969 |